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The Substance Abuse and Mental Health Services Administration (SAMHSA) is the U.S. Department of 
Health and Human Services agency that leads public health efforts to reduce the impact of substance 
abuse and mental illness on America’s communities. An important component of SAMHSA’s work is 
focused on dissemination of evidence-based practices and providing training and technical assistance to 
healthcare practitioners on implementation of these best practices. 
The Treatment Improvement Protocol (TIP) series contributes to SAMHSA’s mission by providing science-
based, best-practice guidance to the behavioral health feld. TIPs refect careful consideration of all 
relevant clinical and health services research, demonstrated experience, and implementation requirements. 
Select nonfederal clinical researchers, service providers, program administrators, and patient advocates 
comprising each TIP’s consensus panel discuss these factors, offering input on the TIP’s specifc topics in 
their areas of expertise to reach consensus on best practices. Field reviewers then assess draft content and 
the TIP is fnalized. 
The talent, dedication, and hard work that TIP panelists and reviewers bring to this highly participatory 
process have helped bridge the gap between the promise of research and the needs of practicing 
clinicians and administrators to serve, in the most scientifcally sound and effective ways, people in need of 
care and treatment of mental and substance use disorders. 
My sincere thanks to all who have contributed their time and expertise to the development of this TIP. It is 
my hope that clinicians will fnd it useful and informative to their work. 
Miriam E. Delphin-Rittmon, Ph.D.
Assistant Secretary for Mental Health and Substance Use
U.S. Department of Health and Human Services
Substance Abuse and Mental Health Services Administration 
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Since the 1980s, stimulant use has wreaked havoc on individuals and communities across the United 
States and has prompted strong responses from federal, state, and local governments and organizations. 
For example, the relatively minor problems caused by cocaine use in the 1960s and 1970s have grown to 
become major medical and law enforcement issues. 
Similarly, the increasing use of methamphetamine (MA) has led policymakers, public offcials, and service 
providers to increase efforts to fght its spread. For example, concerns that MA use would become 
epidemic led to passage of the Combat Methamphetamine Epidemic Act of 2005 and the incorporation of 
MA-specifc provisions in the Comprehensive Addiction and Recovery Act of 2016. Misuse of prescription 
stimulants such as methylphenidate has also become a growing concern. 
The explosive growth of stimulant use has also triggered a furry of research. The results are tremendous 
advances in understanding stimulant use disorders, the basic functioning of the brain, and substance use 
disorders (SUDs) in general. Yet reports that describe the fundamentals of stimulant use disorder treatment 
and the success of various treatment interventions are still needed. 
This Treatment Improvement Protocol (TIP) reviews what is currently known about treating the medical, 
psychiatric, and SUD-related problems associated with the use of cocaine and MA and the misuse of 
prescribed stimulants (such as those for the treatment of attention defcit hyperactivity disorder [ADHD]). 
The scientifcally based information in this TIP is presented in a manner that makes it accessible and 
relevant to behavioral health service clinicians and other frontline SUD treatment providers, including 
healthcare service providers (e.g., in primary care settings, in emergency departments). The TIP 
offers recommendations on treatment approaches, strategies for planning and initiating treatment, 
recommendations on how to maximize treatment engagement and retention, and strategies for initiating 
and maintaining abstinence. Also included are recommendations for the medical management of people 
who use stimulants and recommendations regarding special populations and settings. 
The Substance Abuse and Mental Health Services Administration (SAMHSA) frst published this TIP in 
1999. SAMHSA implemented a full-scale review and revision of the original TIP. Content now addresses: 
• Recent research on stimulant use disorders. 
• The increasing number of overdose deaths in the United States attributable to cocaine and MA 
(especially when combined with other substances, like synthetic and semisynthetic opioids). 
• The rise in the use and misuse of prescription stimulants (leading to increased risk and incidence of 
diversion). 
This TIP revision: 
• Uses terminology that is person centered and aligned with language in the latest edition of the 
Diagnostic and Statistical Manual of Mental Disorders. 
• Incorporates fndings from research published since 2010 (and where possible, since 2016). 
• Includes key messages at the beginning of every chapter to guide readers in understanding from the 
outset the core content they are about to read. 
• Updates statistics and related information about stimulant use, treatment, overdose, and legislation in 
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• Provides a more focused discussion of the 
neurobiology of stimulant use disorders than 
the original TIP’s broad primer on the topic. 
• Refects updated empirical evidence that 
supports using contingency management (CM), 
cognitive–behavioral therapy (CBT), community 
reinforcement, and motivational interviewing 
(MI) to treat stimulant use disorders—as well as 
recent evidence for other nonpharmacologic 
treatments with some support (like exercise and 
mindfulness techniques). 
• Includes no discussion of pharmacotherapy 
options, given that all prescribing for stimulant 
use disorders is done off label (that is, no Food 
and Drug Administration [FDA]-approved 
medication for any stimulant use disorder 
currently exists). 
• Expands the discussion of special populations 
with unique treatment needs to cover racial/ 
ethnic minorities, women (including those who 
are pregnant), men who have sex with men 
(MSM), transgender and gender nonbinary 
community members, adolescents, people 
experiencing homelessness/unstable housing, 
rural populations, people involved with the 
criminal justice system, people taking opioid use 
disorder medication, people who inject drugs, 
people with or at risk for HIV/AIDS, people 
with or at risk for hepatitis, and individuals with 
co-occurring mental disorders. 
The purpose of this TIP is to advance the 
understanding of treating the SUDs associated 
with the use of cocaine and MA and the misuse 
of prescription stimulants. This TIP is organized 
to guide behavioral health service providers, 
healthcare service providers, and other addiction 
and allied professionals sequentially through the 
primary components of proper identifcation and 
management of stimulant use disorders. The TIP 
is divided into seven chapters so that readers can 
easily fnd the material they need most. Below 
is a summary of the TIP’s main points and brief 
summaries of the frst six chapters. (The seventh 
chapter is a listing of resources.) 
Overall Key Messages 
Stimulant use disorders are a growing problem in 
the United States, with more than 5 million people 
age 12 and older reporting past-year cocaine use, 
nearly 2 million reporting MA use, and almost 5 
million reporting prescription stimulant misuse in 
2019. Stimulant-related overdose fatalities are also 
on the rise, with the incidence of stimulant-related 
deaths more than tripling between 2010 and 2017. 
Stimulant use disorders have a powerful 
neurobiological basis that includes changes in 
brain chemistry and functioning that in turn help 
drive stimulant use behaviors. But stimulant use 
disorders also have a social and environmental 
component that clinicians need to consider in 
trying to understand patients’ stimulant use 
behaviors, diffculties in achieving and maintaining 
abstinence, and potential unwillingness to engage 
in formal SUD treatment. 
Healthcare providers need to understand the 
medical complications of stimulant use, their 
clinical signs and symptoms, and appropriate 
management approaches. Behavioral health service 
providers should learn to recognize the medical 
complications of stimulant use so they can make 
quick and successful referrals to medical treatment 
as needed. 
Ample research supports the use of CM as the 
primary psychosocial treatment for stimulant 
use disorders. The lack of FDA-approved 
pharmacotherapies for stimulant use disorders 
makes it vital for clinicians to learn about and 
offer psychosocial interventions (e.g., CM, CBT) 
and other nonpharmacologic services that have 
empirical support (e.g., mindfulness practices, 
family/couples counseling, the Matrix model of 
treatment). 
Clinicians should consider a variety of factors in 
assessing why people with stimulant use disorders 
have sought treatment and what their individual 
treatment needs are. Clinicians can make treatment 
engagement—as well as treatment completion— 
more likely by maximizing access; addressing 
treatment ambivalence; training staff on how to 
provide respectful, patient-centered services; 
developing a well-thought-out treatment plan; and 














Certain populations may be at an increased risk for 
stimulant use or, once they start using stimulants, 
may be at higher risk for negative outcomes (like 
contracting HIV). Such populations—including 
women, people living in rural areas, people of 
diverse racial/ethnic backgrounds, MSM, and 
people experiencing homelessness/housing 
instability—may beneft from targeted treatment 
engagement techniques, interventions, and 
monitoring approaches that are tailored to their 
unique needs and challenges. 
Content Overview 
This TIP is divided into seven chapters designed to 
thoroughly cover all relevant aspects of stimulant 
use disorders. 
Chapter 1: Introduction 
This chapter provides a broad introduction to 
stimulant use disorders and trends in stimulant use 
in the United States. The chapter also describes the 
goals and scope of the TIP as well as its intended 
audiences. 
In Chapter 1, readers will learn about: 
• Current rates of stimulant use disorders and 
overdose in the United States, including 
overdose involving the combination of 
stimulants with synthetic opioids (e.g., fentanyl) 
or semisynthetic opioids (e.g., heroin). 
• Recent trends that are making stimulant use 
more lethal, such as the use of stimulants in 
combination with opioids or the increasing 
purity and decreasing price of cocaine and MA. 
• The ongoing unmet treatment needs of people 
with stimulant use disorders, as well as the need 
for efforts to improve treatment retention. 
• Rates of prescription stimulant misuse and how 
prescribers can help combat diversion. 
• Legislation and regulations relevant to patients 
with stimulant use disorders and behavioral 
health and healthcare service providers who 
work with them. 
Chapter 2: How Stimulants Afect the 
Brain and Behavior 
This chapter reviews the ways in which brain 
structures, functions, and neurochemistry are 
altered in the presence of stimulants. The chapter 
also looks at the role of these alterations in the 
development and persistence of a stimulant use 
disorder. 
In Chapter 2, readers will learn that: 
• Neurological reinforcement systems (i.e., the 
reward system, the stress system) and other 
brain structures and mechanisms underlie the 
occurrence of stimulant use disorders and 
infuence key aspects of stimulant use disorders, 
like craving and memory dysfunction. 
• Brain imaging technology has played an 
important role in helping researchers and 
clinicians understand the ways in which short-
and long-term stimulant use can affect the brain. 
• Stimulants alter the dopamine system in ways 
that can affect substance use. For instance, 
increased feelings of pleasure and euphoria 
when using a stimulant can reinforce its use. 
• Providers should be aware of the specifc 
medical and psychological acute and chronic 
effects of each of the three main types of 
stimulants generally used by individuals with 
stimulant use disorders: cocaine, MA, and 
prescription stimulant medication, such as 
methylphenidate for ADHD. 
Chapter 3: Medical Aspects of Stimulant 
Use Disorders 
This chapter describes medical and psychological 
signs, symptoms, and complications associated 
with stimulant use and stimulant use disorders and 
how to best manage common complications. 
In Chapter 3, readers will learn that: 
• The signs, symptoms, and harmful effects of 
stimulant use will vary depending on route 
of administration, dose, drug purity, level 
of intoxication, experience of withdrawal, 



















• Medical complications of stimulant use can be 
serious and in some cases life threatening; these 
complications include cardiovascular disease, 
respiratory effects, cerebrovascular dysfunction, 
muscular and renal toxicity, gastrointestinal 
complaints, infections (including HIV), and 
hepatitis. 
• Psychological complications include psychosis, 
aggression, and violence. 
• People with stimulant use disorders often 
grapple with co-occurring disorders and 
conditions that can complicate diagnosis, 
treatment, and recovery. These disorders 
and conditions are secondary substance use 
(especially co-occurring opioid use), specifc 
mental disorders (e.g., depression, anxiety, 
ADHD), medical conditions (e.g., dental 
problems, vein and nerve damage in the arm, 
cardiovascular disorders), and traumatic injury 
(e.g., due to violence/physical altercations). 
• Patients’ psychological reactions to stimulant 
use, like psychosis and violent behaviors, can 
also result in self-harm or harm to others if not 
managed properly. 
• Coordinated care between medical and SUD 
treatment programs is a major aspect of 
properly identifying and treating co-occurring 
disorders and conditions of people with 
stimulant use disorders. Many patients will frst 
appear for treatment or services in non-SUD 
settings—mainly primary care clinics and 
emergency departments. 
Chapter 4: Approaches to Treatment 
This chapter describes the best supported 
nonpharmacologic approaches to helping patients 
begin and sustain recovery from stimulant use 
disorders. 
In Chapter 4, readers will learn that: 
• There are no FDA-approved medications for 
managing stimulant use disorders. This makes 
understanding available nonpharmacologic 
treatment options imperative. 
Treatment for Stimulant Use Disorders 
• CM is by far the psychosocial treatment with 
the greatest scientifc support. In some studies, 
CM is even more effective when used in 
combination with other psychosocial treatments, 
like community reinforcement. 
• After CM, the three other psychosocial 
interventions with the most support are CBT, 
community reinforcement, and MI. 
• Other forms of psychosocial treatment with less 
but still some support are the Matrix model, 
behavioral family or couples therapy, and case 
management/coordinated care. 
• There is growing evidence that physical 
exercise, mindfulness, and transmagnetic cranial 
stimulation also may help people with stimulant 
use disorders reduce their stimulant use or 
otherwise improve their health and well-being. 
• Not all people with stimulant use disorders will 
be interested in formal SUD treatment. Offering 
harm reduction tools and strategies is critical 
because they can help people who continue 
to use stimulants stay alive. Harm reduction 
involves providing access to or information 
about: 
- Needle/syringe exchanges. 
- Fentanyl test strips (to determine whether 
drugs have been laced with fentanyl). 
- The opioid overdose reversal agent naloxone. 
- HIV prevention education. 
• Rather than using a cookie-cutter approach to 
treatment selection (e.g., sending all patients 
to 60-day residential treatment), clinicians 
should consider each individual’s unique SUD 
history and treatment needs and preferences. 
The American Society of Addiction Medicine’s 
patient placement criteria can help guide the 
treatment selection process. 
Chapter 5: Practical Application of 
Treatment Strategies 
This chapter briefy summarizes techniques 
clinicians can use to help engage patients in SUD 






































In Chapter 5, readers will learn that: 
• People seek treatment for any number of 
reasons, and clinicians will better understand 
how to help their patients engage and stay in 
treatment if they know why their patients are 
entering treatment. 
• Factors that can make treatment engagement 
more likely include: 
- Identifying barriers to treatment engagement. 
- Making treatment highly accessible. 
- Providing support for treatment participation. 
- Offering multiple treatment options. 
- Discussing with patients their expectations 
for treatment and any ambivalence they may 
have about treatment. 
- Working collaboratively with patients to 
develop a clear, fexible treatment framework. 
• Staff should be educated about how to provide 
person-centered, respectful, empathic services, 
which can help encourage patients to stay 
engaged in treatment. 
• To start treatment off “on the right foot,” 
clinicians should work with patients to set 
their treatment goals, fully assess their clinical 
needs, discuss reducing or discontinuing all 
substance use, and help them manage stimulant 
withdrawal symptoms. 
• Treatment retention is critical. Simply put, 
people are less likely to die when in treatment 
than when not in treatment. Any amount of time 
people with stimulant use disorders remain in 
treatment is an opportunity for them to stay 
alive and improve their health. 
• Many strategies can help patients maintain 
progress in recovery, such as teaching functional 
analysis of stimulant use; reinforcing positive 
behaviors with incentives; teaching strategies 
to avoid high-risk situations; offering relapse 
prevention techniques; and promoting 
connections to family, friends, and the community. 
• Other services that can help patients maintain 
recovery are vocational counseling, social skills 
training, relationship counseling, mutual-help 
support programs, and wellness counseling. 
Clinicians should offer referrals for these services 
as needed. 
Chapter 6: Treatment Considerations for 
Special Populations 
This chapter discusses numerous populations 
that may be at increased risk for developing a 
stimulant use disorder or for experiencing negative 
outcomes associated with stimulant use (e.g., 
contracting HIV or hepatitis) and prescription 
stimulant misuse. These populations may require 
tailored assessment, treatments, or education to 
meet their unique needs and circumstances. 
In Chapter 6, readers will learn that: 
• Vulnerable populations are people of diverse
racial/ethnic backgrounds, women (including
those who are pregnant), MSM, transgender and
gender nonbinary communities, adolescents,
people experiencing homelessness/unstable
housing, rural populations, people involved in the
criminal justice system, people taking medication
for opioid use disorder, people who inject drugs,
people with or at risk for HIV/AIDS and hepatitis,
and individuals with co-occurring mental
disorders. 
• Populations that experience health disparities
related to systems of care and engagement
in care may have higher rates of stimulant use
disorder and increased issues accessing care
for stimulant use disorders. They may also be
more likely to experience secondary negative
consequences related to these vulnerabilities
(e.g., trauma or communicable diseases). 
• By understanding the needs, SUD care access
issues, and treatment considerations of these
populations, clinicians will be more likely to
provide patient-centered, effective care that
maximizes rapport and treatment engagement. 
• Services can be tailored to each of these
populations to account for their unique
risk factors, patterns of use, and health
considerations. Clinicians may need to seek
guidance from experts in these populations when
tailoring treatment.
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• Stimulant use disorders are a major public 
health concern in the United States, with 
more than 5 million people age 12 and older 
reporting past-year cocaine use, nearly 2 
million reporting methamphetamine use, 
and almost 5 million reporting prescription 
stimulant misuse in 2019. 
• Overdose deaths from stimulants have been 
increasing over the past 20 years, especially 
deaths attributable to stimulants taken 
with either synthetic opioids (e.g., fentanyl) 
or semisynthetic opioids (e.g., heroin). This 
underscores the importance of (1) having 
behavioral health and healthcare service 
providers understand and educate patients 
about the dangers of stimulant use disorders 
and (2) creating easy access to screening and 
treatment. 
• Effective treatments for stimulant use 
disorders are available, but more behavioral 
health and healthcare service providers 
need to learn about these treatments and 
understand how and why to offer them to 
patients. 
Chapter 1 of this Treatment Improvement Protocol 
(TIP) lays the groundwork for understanding the 
scope and effects of stimulant use disorders in the 
United States. The TIP generally uses the plural 
term “stimulant use disorders”—rather than the 
singular term “stimulant use disorder” found in 
the ffth edition of the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-5; American 
Psychiatric Association [APA], 2013)—to refect 
that patients may well misuse multiple substances 
classifed as stimulants, including nonprescription 
stimulants. The plural term also conveys the 
purpose of this TIP—helping clinicians combat 
stimulant use and stimulant-related problems. 
This chapter will beneft all behavioral health 
and healthcare service providers who encounter 
patients with stimulant use disorders by giving a 
broad overview of why stimulant use disorders are 
so harmful and how information in this TIP can be 
leveraged to bring about more timely and effective 
management of these disorders. 
Purpose of the TIP 
Major U.S. institutions responded slowly to the 
dangers of stimulants throughout the 1970s and 
1980s, partly because researchers and clinicians 
had only a partial picture of the basic biologic 
and psychological effects of these powerful 
psychostimulants. Knowledge gained over the 
past four decades about the properties of these 
substances can help clinicians understand, prevent, 
and treat the problems created by the use of 
cocaine and methamphetamine (MA) and the 
misuse of prescription stimulant medications (e.g., 
methylphenidate). This TIP summarizes the latest 
research as well as frsthand clinical experience 
of substance use disorder (SUD) treatment 
professionals. 
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Since the mid-1980s, there has been an 
explosion of knowledge about the effects of 
stimulants. Because these psychostimulants 
alter the functioning of the body and the brain, 
physicians and physician assistants, nurses and 
nurse practitioners, psychologists, social workers, 
licensed professional counselors, marriage 
and family counselors, SUD counselors, other 
behavioral health service providers, and peer 
recovery support specialists must understand 
the biologic aspects of stimulant use disorders. 
New areas of expertise include pharmacology, 
genomics, neurobiology, psychiatric and 
psychological manifestations, and treatment 
approaches for stimulant use disorders. 
Stimulant use disorders do more than harm the 
people who have them. They can also negatively 
affect the lives of these individuals’ family 
members, friends, neighbors, and coworkers. This 
wider effect makes it all the more important to help 
individuals with stimulant use disorders engage in 
SUD treatments and services. 
This TIP presents current knowledge about the 
nature and treatment of stimulant use disorders. 
Because the Food and Drug Administration (FDA) 
has to date not approved any medications for 
stimulant use disorders, this TIP does not discuss 
pharmacology as a treatment strategy. The TIP 
is designed to provide scientifcally established 
information about the effects of stimulants in a 
manner that makes it available and relevant for 
frontline treatment providers. In addition, the 
document reviews what is known about treating 
the medical, psychiatric, and SUD problems 
associated with the use of cocaine and MA and 
misuse of prescription stimulants. The treatment 
section emphasizes those approaches that have 
empirical support. 
Organization of the TIP 
This TIP opens with a broad overview of the 
current state of stimulant use disorders in the 
United States (Chapter 1) and then moves into the 
neurobiologic aspects (Chapter 2), assessment and 
diagnosis (Chapter 2), and medical management 
(Chapter 3) of stimulant use disorders. Chapter 
4 introduces readers to empirically supported 
nonpharmacologic treatments for stimulant 
use disorders, and Chapter 5 takes an indepth 
look at important clinical factors affecting the 
full continuum of care, including treatment 
initiation and abstinence maintenance. Chapter 6 
discusses stimulant use among a range of special 
populations and specifc considerations to improve 
engagement and treatment for the described 
populations. Finally, Chapter 7 provides a 
compendium of resources, including links to online 
information and tools. 
Exhibit 1.1 defnes important terms used in this 
publication. Also, note that the term “clinician” 
covers all healthcare providers and behavioral 
health service providers who work with people 
with stimulant use disorders and other SUDs. This 
could include psychologists, psychiatrists, national 
certifed addiction counselors, licensed alcohol and 
drug counselors, marriage and family therapists, 
social workers, licensed professional counselors, 
physicians, nurses, and advanced practice 
healthcare providers (e.g., nurse practitioners, 
physician assistants). However, this term does 
not refer to peer recovery support specialists. 
Also, the TIP uses the term “patients” rather than 
“clients” or “consumers” to refer to people who 
are receiving any preventive services or care for 
stimulant use disorders or related conditions. 














EXHIBIT 1.1. Key Terms 
• Craving: A powerful desire for drugs. 
• Designer drug: A synthetic analog of a restricted drug; has psychoactive properties. 
• Drug diversion: The illegal distribution or use of prescription drugs or their use for purposes not 
intended by the prescriber (Centers for Medicare & Medicaid Services, 2016). 
• Physical dependence: An adaptive physiological state that occurs with regular drug use and results in a 
withdrawal syndrome when drug use stops. 
• Stimulant use disorder: According to DSM-5 (APA, 2013), a diagnosis based on the occurrence of at 
least two of the following criteria within a 12-month period (or 12 months before incarceration): (1) taking 
more of the stimulant than intended; (2) failing to reduce or control stimulant use, despite a wish or 
efforts to do so; (3) devoting excessive amounts of time to activities related to stimulant use; (4) having 
cravings or urges for the stimulant; (5) not meeting obligations at home, school, or work; (6) continuing 
to take stimulants, even if this use has led to or increased relationship or social diffculties; (7) forgoing 
or limiting important recreational, social, or job-related activities because of stimulant use; (8) taking 
stimulants in situations where doing so is physically hazardous; (9) continuing to take stimulants despite 
the realization that doing so has probably caused or aggravated a physical or psychological problem; (10) 
developing tolerance to the stimulants; and (11) experiencing withdrawal symptoms when stimulants are 
not taken or taking stimulants to ease or prevent withdrawal symptoms (Substance Abuse and Mental 
Health Services Administration, 2020m). 
• This TIP uses the terms amphetamine use disorder, cocaine use disorder, and methamphetamine use 
disorder (or MA use disorder). Although these terms do not appear in DSM-5, they are used in research 
and survey literature. (Amphetamine use disorder and cocaine use disorder were classifed as separate 
disorders in the previous edition of DSM.) 
• Substance misuse*: The use of any substance in a manner, situation, amount, or frequency that can 
cause harm to users or to those around them. In the case of prescription medications, misuse is any use 
other than as prescribed or directed by a healthcare professional. For some substances or individuals, any 
use would constitute misuse (e.g., injection drug use). 
• Substance use disorder (SUD)*: A medical illness caused by repeated misuse of a substance or 
substances. According to DSM-5 (APA, 2013), SUDs are characterized by clinically signifcant impairments 
in health and social function and by impaired control over substance use. They are diagnosed through 
assessing cognitive, behavioral, and psychological symptoms. SUDs range from mild to severe and 
from temporary to chronic. They typically develop gradually over time with repeated misuse, leading to 
changes in brain circuits governing incentive salience (the ability of substance-associated cues to trigger 
substance seeking), reward, stress, and executive functions like decision making and self-control. DSM-
5 notes that both amphetamine-type and cocaine-type stimulant use disorders can develop as quickly 
as 1 week (APA, 2013). Multiple factors infuence whether and how rapidly a person will develop an SUD, 
including the substance itself; the genetic vulnerability of the user; and the amount, frequency, and 
duration of the misuse. 
• Tolerance: A condition in which higher doses of a drug are required to produce the same effect as 
experienced initially; often leads to physical dependence. 
• Withdrawal: A psychological and/or physical syndrome caused by the abrupt cessation of the use of a 
drug in an habituated individual. 
• Withdrawal management: A process of allowing the body to clear a drug while the symptoms of 
withdrawal are managed; often the frst step in an SUD treatment program. 
* Defnitions of all terms with an asterisk correspond closely to those in Facing Addiction in America: The 
Surgeon General’s Report on Alcohol, Drugs, and Health. This resource provides a great deal of useful 
information about substance misuse and its impact on U.S. public health. The report is available online 
(https://addiction.surgeongeneral.gov). 








Treatment for Stimulant Use Disorders 
Scope of the TIP 
This TIP looks at stimulants derived from the coca 
plant (cocaine hydrochloride and its derivatives) 
and the synthetically produced amphetamines. 
Regarding amphetamines, the TIP focuses on 
MA—the major illicitly produced and misused drug 
in this group—in its various forms. Certainly, there 
are other stimulants that are more widely used 
(e.g., caffeine) or that produce major health and 
social problems (e.g., nicotine); however, discussion 
of these substances is beyond the scope of this 
document. 
Although considered drugs of misuse, MA 
analogs are not included in this document. These 
analogs are compounds with MA-like molecular 
structures but not necessarily effects similar to MA. 
Sometimes called designer drugs, they include 
MDA (3,4-methylenedioxy-amphetamine) and 
MDMA (3,4-methylene-dioxymethamphetamine). 
Current Stimulant Use in the
United States 
Stimulant epidemics of the 1980s and 1990s had 
a devastating impact on American society. The 
impact of illicit stimulant use affected international 
politics, the U.S. legal system, and the U.S. 
healthcare system. 
As the end of the 20th century neared, the 
powerful psychostimulants cocaine and MA and 
their derivatives joined opioids and alcohol as 
primary targets in the efforts to combat SUDs and 
misuse of prescription stimulants. The pressing 
need to effectively address the stimulant epidemic 
and treat people with stimulant use disorders 
produced a tremendous amount of scientifc 
and clinical research. The results of this research 
broadened our knowledge of the human brain and 
expanded our understanding of SUDs. 
Recent statistics demonstrate the scope of 
stimulant use in the United States. For instance 
(Center for Behavioral Health Statistics and Quality 
[CBHSQ], 2020a): 
• Past-month cocaine use by people in the 
United States ages 18 to 25 increased from 
approximately 552,000 in 2016 to 665,000 in 
2017, which then decreased to 524,000 in 2018, 
and increased slightly to 540,000 in 2019. 
• Among people age 26 and older, past-month 
cocaine use increased slightly from 1.3 million 
in 2016 to 1.5 million in 2017, and essentially 
remained level for the next 2 years. 
• Past-year MA use among people ages 18 to 
25 increased moderately from 2016 to 2017 
(approximately 256,000 to 375,000), but then 
leveled out around 275,000 in 2018 and 2019. 
• Past-year MA use among people age 26 and 
older increased each year, from 1.1 million in 
2016 to 1.7 million in 2019. 
• Past-year prescription stimulant misuse was 
steady among people age 26 and older from 
2016 to 2019. However, among people ages 
18 to 25, misuse has decreased, from about 2.5 
million in 2016 and 2017 to 2 million in 2019. 
Stimulant-involved overdose deaths in the United 
States have skyrocketed over the past 20 years. 
From 1999 to 2019, overdose fatalities from 
psychostimulants with misuse potential other than 
cocaine (e.g., MA) grew more than 29-fold, from 
547 deaths in 1999 to 16,167 in 2019 (National 
Center for Health Statistics [NCHS], 2020; National 
Institute on Drug Abuse [NIDA], 2021a). In that 
same time, overdose deaths due to cocaine 
increased from 3,822 in 1999 to 15,883 in 2019 
(NCHS, 2020; NIDA, 2021a). 
More recently, overdose deaths involving cocaine 
increased by 26.5 percent from the 12 months 
ending in June 2019 to the 12 months ending 
in May 2020. Overdose deaths involving other 
psychostimulants (e.g., methamphetamine, 
prescription stimulants, amphetamines) are 
provisionally calculated to have increased by 34.8 
percent across the same comparison periods 
(Centers for Disease Control and Prevention [CDC], 
2020c). 






These patterns appear to be strongly driven by the 
increasingly popular trend of combining cocaine 
or MA with synthetic opioids (e.g., fentanyl) or 
nonsynthetic opioids (e.g., heroin). Most MA in 
the United States is cultivated and produced 
in Mexico, whereas Colombia is the United 
States’ main supplier of cocaine (although the 
Mexico-Southwest border is the primary port of 
entry into the United States; Drug Enforcement 
Administration [DEA], 2019, 2021). Increasing 
amounts of the MA produced by Mexican cartels 
and transported into the United States now contain 
fentanyl in varying amounts. Much of the stimulant 
product sold on the street currently includes 
fentanyl. 
Like MA, cocaine is increasingly being combined 
with fentanyl (or with both heroin and fentanyl, in 
what is known as a super speedball) to help offset 
the steep decline individuals experience when a 
cocaine “high” subsides (DEA, 2019, 2021). Most 
cocaine is adulterated with fentanyl at the “retail” 
level and not the “wholesale” level—that is, after it 
enters the United States (DEA, 2019, 2021). 
The connection of stimulant use to the opioid 
epidemic is very real and very dangerous: 
• The State Unintentional Drug Overdose 
Reporting System found that, from January 
to June 2019, the most common stimulant 
in stimulant–opioid combinations leading to 
overdose death was cocaine (68.5% of cases), 
followed by MA (33.3%; O’Donnell et al., 2020). 
• For both cocaine and MA, the number of 
overdose deaths also involving opioids has 
increased steadily since 2014. For cocaine, 
overdose deaths are primarily due to 
combinations with fentanyl or fentanyl analogs 
specifcally (NIDA, 2021a). 
• Data from the National Vital Statistics System 
found the percentage of cocaine-related 
overdose deaths also involving any opioid 
increased from almost 30 percent in 2000 to 63 
percent in 2015 (McCall Jones et al., 2017). 
Price and purity have likely played a role in the 
changing statistics on U.S. stimulant use, overdose, 
and fatalities. In 2018, the average purity of 
wholesale cocaine bricks analyzed by DEA’s 
Cocaine Signature Program was 85 percent (DEA, 
2019). In the frst half of 2019, the average purity of 
MA was over 97 percent (DEA, 2021). From 2013 
to 2017, the price of MA purchased in the United 
States decreased by more than 17 percent, from 
$68 to $56 per pure gram (DEA, 2019). Like MA, 
domestic purchases of cocaine also became less 
expensive from 2013 to 2017, falling from $213 to 
$153 per pure gram (DEA, 2019). 
Also contributing to the increased lethality of MA 
is the shift toward production using phenyl-2-
propanone as the chemical precursor to synthesis 
rather than ephedrine or pseudoephedrine. 
Using pseudoephedrine has been hindered 
somewhat by reduced access to sales of the 
over-the-counter product as a result of the 
Combat Methamphetamine Act of 2005 (see the 
text box “Legislative and Regulatory Milestones 
Since 2000”). The phenyl-2-propanone method 
bypasses the use of strictly controlled chemicals 
(i.e., ephedrine, pseudoephedrine) and yields a 
highly potent form of MA. More than 99 percent 
of MA samples analyzed in the frst half of 2019 
by the DEA Methamphetamine Profling Program 
were manufactured using the phenyl-2-propanone 
method (DEA, 2021). 
The breakdown of stimulant overdose patterns 
by race/ethnicity underscores differential effects 
among people of color. In 2019, the highest total 
number of psychostimulant-related deaths by race 
occurred among Whites (13,987), but the highest 
crude death rate by race was among American 
Indian/Alaska Native populations, at 8.1 deaths 
per 100,000 people (NCHS, 2020). (Crude death 
rates are a measure of the number of deaths within 
a given population during a specifed period.) For 
cocaine, the highest crude death rate by race was 
among Blacks/African Americans, at 10.9 deaths 
per 100,000 people—more than twice that of the 
next-highest crude death rate (4.3 deaths per 
100,000 Whites) and more than 4 times that of 
American Indian/Alaska Native populations (2.5 
deaths per 100,000; NCHS, 2020). 
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Treatment for Stimulant Use Disorders 
Treatment for stimulant use disorders has been 
increasing recently. From 2015 to 2017, treatment 
admissions (i.e., the formal acceptance of a client 
into SUD treatment) for crack cocaine increased by 
11 percent, for nonsmoked cocaine by 37 percent, 
for amphetamines by 41 percent, and for other 
stimulants by 62 percent (CBHSQ, 2020b). 
But unmet treatment need is pervasive across SUDs 
broadly, with data from the Substance Abuse and 
Mental Health Services Administration’s (SAMHSA) 
2019 National Survey on Drug Use and Health 
indicating that only 10 percent of people age 
12 and older who had a past-year SUD received 
any SUD treatment, and only 1 percent received 
treatment at an SUD specialty facility (CBHSQ, 
2020a). 
Treatment dropout is also a problem. A meta-
analysis of 151 studies looking at SUD treatment 
rates (Lappan et al., 2020) found that the overall 
treatment dropout rate across all SUDs is 30.4 
percent. By comparison, the treatment dropout 
rate is 53.5 percent for MA and 48.7 percent for 
cocaine (Lappan et al., 2020). 
Cocaine 
Both the increase in cultivation and production of 
cocaine from Colombia—which supplies more than 
90 percent of U.S. cocaine seized by DEA—as well 
as the increased purity of cocaine entering the 
United States have made cocaine use, cocaine  
use disorder, and fatal overdose growing concerns 
over the past two decades (DEA, 2017; Kerridge 
et al., 2019). The prevalence of cocaine use among 
U.S. adults in 2019 was 5.5 million for past-year 
use, 2 million for past-month use, and 1 million  
for a stimulant use disorder involving cocaine 
(CBHSQ, 2020a). 
The 2020 Monitoring the Future survey found that 
2.9 percent of 12th graders reported past-year 
use of cocaine (University of Michigan, 2020). 
Cocaine use among adolescents and young adults 
is particularly worrisome given potential long-term 
effects on neurodevelopment, cardiovascular 
functioning, and psychosocial functioning, 
and the association between cocaine use and 
polysubstance use (Ryan, 2019). 
In 2019, almost 65 percent of U.S. adults with 
cocaine use had a history of any mental illness, 
36 percent had a serious mental illness, and 31 
percent had at least one major depressive episode 
(CBHSQ, 2020a). 
Methamphetamine 
The prevalence of MA use among people age 
12 and older in the United States in 2019 was 2 
million for past-year use, 1.2 million for past-month 
use, and 1 million for a stimulant use disorder 
involving MA (CBHSQ, 2020a). From 2015 to 2018, 
approximately 1 million men and almost 600,000 
women took part in past-year MA use (C. M. Jones 
et al., 2020). Of those adults with past-year MA 
use, 53 percent met criteria from the fourth edition 
of DSM for MA use disorder (C. M. Jones et al., 
2020). The number of people age 26 and older 
with past-year MA use rose more than 50 percent 
from 2016 to 2019 (1.1 million in 2016 to 1.7 
million in 2019; CBHSQ, 2020a). 
MA use frequently co-occurs with other substance 
use and with a mental disorder (C. M. Jones et al., 
2020). Among people 12 and older with past-year 
MA use in 2019, an estimated 68 percent engaged 
in past-year cannabis use, 43 percent in past-year 
opioid misuse, and 32 percent in past-year cocaine 
use; 24 percent experienced a past-year major 
depressive episode. Additionally, among adults 
who used MA in 2019, an estimated 27 
percent had past-year serious mental illness 
(CBHSQ, 2020a). 














Prescription Stimulant Misuse 
Stimulant medication is FDA approved for 
treating attention defcit hyperactivity disorder 
(ADHD) and narcolepsy (a disorder of extreme 
sleepiness). Commonly prescribed stimulants 
include dextroamphetamine, dextroamphetamine/ 
amphetamine combination product, and 
methylphenidate. 
The prescribing of these medications has been 
increasing. National prescription stimulant 
dispensing rates grew signifcantly from 2014 to 
2019, from 5.6 prescriptions per 100 persons to 6.1 
per 100 persons, with the growth attributable in 
large part to increases among women and adults 
age 20 and older (Board et al., 2020). Total usage 
of prescription amphetamine, methylphenidate, 
lisdexamfetamine, and prescription MA, including 
extended-release formulations, doubled from 
2006 to 2016 (Piper et al., 2018; Sembower et al., 
2013). Further, from 2007 to 2011, the prevalence 
of children taking medication for ADHD increased 
by 28 percent, from 4.8 to 6.1 percent (Visser et 
al., 2014). Between 2013 and 2015, CDC reported 
a 344-percent increase in ADHD prescription 
medication claims by privately insured women ages 
15 to 44 (K. N. Anderson et al., 2018). 
Rates of nonmedical prescription stimulant use also 
are concerning. In 2019, almost 4.5 million adults 
in the United States reported past-year misuse, 1.4 
million reported past-month misuse, and 492,000 
met criteria for a stimulant use disorder involving 
prescription stimulant misuse (CBHSQ, 2020a). 
Data suggest diversion of stimulant medication is 
increasing among U.S. adolescents and may occur 
out of a desire to enhance academic performance 
(Colaneri et al., 2017). Additionally, among young 
adults, anywhere from 5 to 35 percent of college 
students reportedly misuse prescription stimulants 
not just for enhanced neurocognitive performance 
but for euphoric effects or weight control as well 
(Benson et al., 2015; Kilwein et al., 2016; Weyandt et 
al., 2013, 2016; Wilens et al., 2016). 
Prescribers can help limit diversion of stimulants by 
adhering to DSM-5 criteria when diagnosing ADHD 
so that the medication is appropriately prescribed. 
When a prescription is written, the prescriber 
should cross-reference the prescription information 
with data available in state-run prescription drug 
monitoring programs. Prescribers can also help 
prevent stimulant medication misuse through 
numerous strategies, including (Colaneri et 
al., 2017): 
• Using medication contracts. 
• Educating patients, especially high school and 
college students who are diagnosed with ADHD, 
about the danger of sharing their medication 
with friends and the legal implications of this. 
• Limiting prescriptions to a smaller number of 
pills. 
• Implementing pill counts. 
• Prescribing long-acting instead of immediate-
release formulations. 
Additionally, because overdiagnosis and incorrect
diagnosis can lead to inappropriate prescribing,
primary care providers should not diagnose ADHD
themselves. Rather, they should refer patients to an
appropriate mental health service professional (such
as a psychiatrist or psychologist) for evaluation. 
Prescribing nonstimulant medications for ADHD 
is another option that is particularly relevant for 
patients with a stimulant use disorder and co-
occurring ADHD who want to pursue abstinence. 
Atomoxetine is a norepinephrine reuptake inhibitor 
that is not a DEA-controlled substance because 
it has very low misuse/stimulant use disorder 
potential (Clemow & Walker, 2014). Guanfacine 
and clonidine are alpha2-adrenergic receptor 
agonists that also have demonstrated good effcacy 
in reducing ADHD symptoms but have low misuse 
potential (Clemow & Walker, 2014). To learn more 
about managing ADHD in people with co-occurring 
stimulant use disorder, see Chapter 6. 
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LEGISLATIVE AND REGULATORY MILESTONES SINCE 2000 
The statutory and regulatory landscape of SUD prevention and treatment has changed since the original 
publication of this TIP in 1999. Here are important statutory and regulatory developments related to the 
topics in this TIP: 
• The Drug Addiction Treatment Act of 2000: This legislation, as amended, allows healthcare 
professionals who meet certain qualifcations to offer Food and Drug Administration (FDA)-approved 
narcotic medication treatment for opioid use disorder in settings other than opioid treatment programs. 
(At the time of this publication, buprenorphine is the only approved medication that meets the provisions 
of the act.) This is relevant for patients with stimulant use disorder who are also using opioids and wish 
to initiate buprenorphine treatment. For the law as originally enacted, see Title XXXV here: www.govinfo. 
gov/content/pkg/PLAW-106publ310/pdf/PLAW-106publ310.pdf. For later statutory changes expanding 
buprenorphine prescribing, see www.samhsa.gov/medication-assisted-treatment/statutes-regulations-
guidelines. 
• The Combat Methamphetamine Epidemic Act of 2005: This act requires purchasers to show a 
photographic identifcation card or other acceptable document issued by a state or the federal 
government when buying over-the-counter cold medicines containing ingredients that are commonly 
used to make MA, such as pseudoephedrine. It also limits the amount of these products that can be 
purchased at one time and tracks purchasers. Read more about the act at www.deadiversion.usdoj.gov/ 
meth/. 
• Fair Sentencing Act of 2010: This act reduced the 5-to-10-year “mandatory minimum” prison sentence for 
possession of low-level crack cocaine. It also removed the mandatory minimum for simple possession of 
cocaine. Read more about the act at www.ussc.gov/research/congressional-reports/2015-report-congress-
impact-fair-sentencing-act-2010. 
• The 21st Century Cures Act of 2016: This act was passed to help increase the speed and effciency of the 
discovery, development, and delivery of medical cures. It provided U.S. research and healthcare delivery 
institutions, like FDA and the National Institutes of Health, with funding to improve clinical trials, enhance 
data sharing, increase the recruitment of participants in clinical trials, and launch innovative research 
projects. It also established the State Targeted Response to the Opioid Crisis grant program. For the text 
of the act, see www.congress.gov/114/plaws/publ255/PLAW-114publ255.pdf. 
• The Comprehensive Addiction and Recovery Act (CARA) of 2016: This legislation authorizes grant 
programs designed to expand SUD (especially opioid use disorder) prevention, education, treatment, and 
recovery efforts. The act includes provisions explicitly aimed at supporting such efforts in communities 
facing sudden increases in MA use. For the text of the act, see www.congress.gov/bill/114th-congress/ 
senate-bill/524/text. 
• Confdentiality of Substance Use Disorder Patient Records (42 CFR Part 2): Changes to these 
regulations—which pertain to patient records in federally assisted SUD treatment programs—were made 
in response to the opioid epidemic. For a summary of these revisions, review SAMHSA’s 42 CFR Part 2 
Revised Rule Fact Sheet at www.hhs.gov/about/news/2020/07/13/fact-sheet-samhsa-42-cfr-part-2-revised-
rule.html. 







Importance of Science in Building
Future Treatments 
The original TIP’s consensus panel believed that 
scientifcally derived knowledge should serve 
as the foundation of treatment for stimulant 
use disorders. Findings from basic and clinical 
research efforts funded by NIDA, as well as other 
government and private institutions, have given 
treatment providers a set of strategies and tools to 
assist people with stimulant use disorders. 
At this time, the approaches with the greatest 
empirical support combine psychosocial and 
behavioral strategies delivered in outpatient 
settings (e.g., contingency management, 
cognitive–behavioral therapy/relapse prevention). 
Emerging treatment techniques include exercise 
and mindfulness meditation. As knowledge 
of stimulants and brain functioning rapidly 
increases, thanks to active research funded by 
federal agencies and private foundations, other 
new approaches should soon be forthcoming. 
The development of pharmacotherapies for the 
treatment of stimulant use disorders remains a 
major priority of research efforts, and these efforts 
will likely provide some important new options in 
the near future. 
Summary 
Stimulant use and related deaths in the United 
States are growing problems that are intertwined 
with the current opioid epidemic. Stimulant 
use disorders have direct effects on the health 
and functioning of people with these disorders 
as well as secondary effects on others around 
them. This is partly what makes treatment so 
critical. SUD treatments and services not only 
help individuals with stimulant use disorders, 
but also beneft their entire support system and 
surrounding environment (e.g., family, friends, 
workplace, neighborhood). Treatment rates 
are lower than needed to keep pace with the 
number of individuals using stimulants and 
developing stimulant use disorders each year. 
New knowledge about how these substances 
infuence the basic electrical and chemical 
activity of the human brain has allowed a better 
understanding of how and why stimulants affect 
human behavior, and this knowledge has rapidly 
infuenced the development of new treatment 
efforts. This TIP provides an overview of: 
1. The new knowledge about stimulants. 
2. The treatment efforts to address stimulant use 
disorders. 
3. Other clinical, medical, and social 
interventions developed in response to these 
disorders. 
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Chapter 2—How Stimulants Afect the 
Brain and Behavior 
KEY MESSAGES 
Over the past several decades, research on 
substances of misuse has vastly improved 
understanding of human behavior and physiology 
and the nature of substance use disorders (SUDs). 
Basic neurobiologic research has enhanced 
understanding of the biologic and genetic causes 
of SUDs. These discoveries have helped establish 
SUD as a biologic brain disease that is chronic 
and relapsing in nature (National Institute on 
Drug Abuse [NIDA], 2018c; Volkow et al., 2019). 
By mapping the neural pathways of pleasure 
and pain through the human brain, investigators 
are beginning to understand how psychoactive 
substances, including stimulants, interact with 
various cells and neurochemicals in the brain. 
This new information has also improved 
understanding of appropriate treatment 
approaches for different SUDs. This chapter 
describes the effects that acute and chronic 
cocaine and methamphetamine (MA) use, and 
prescription stimulant misuse, have on a person’s 
brain and behavior. The chapter also discusses 
how to assess for and diagnose stimulant use 
disorders. Knowledge of the neurobiologic effects 
of stimulants will give clinicians greater insight 
into people who use stimulants, how to detect a 
stimulant use disorder in an individual, and why the 
treatment approaches described in Chapter 4 are 
effective. 
• A stimulant use disorder changes a person’s 
brain in two major ways. One is neurotoxic (by 
affecting brain processes such as memory, 
learning, and other cognitive functions). 
The other way is by triggering the addiction 
process, such as by acting on the brain’s 
reward system or through the development of 
craving. This information is critical for clinicians 
to understand because it explains the course 
of symptoms and recovery and underscores 
how diffcult it is to quit using/misusing 
substances without interventions. 
• A host of harmful effects can occur from acute 
and chronic cocaine or methamphetamine 
use, with some evidence from human studies 
suggesting that long-term stimulant exposure 
can cause persistent damage to the brain. 
• The neurobiology of stimulant use disorders 
underscores the biologic aspects of substance 
use disorders as a chronic, relapsing medical 
illness. Understanding the changes in the 
brain that occur as someone becomes 
addicted to stimulants, experiences 
withdrawal, or stops using stimulants can also 
help guide clinicians in their approaches to 
treatment as well as help them understand 
behaviors and moods that a patient may 







Substance Use Disorders 
SUDs are complex phenomena with numerous 
psychological, social, familial, emotional, and 
systemic contributors. SUDs often co-occur, and 
people with stimulant use disorders often also use 
or misuse other substances (Timko et al., 2018). 
However, at the core, SUDs involve a biologic 
process: the effects of repeated exposure to an 
agent (a substance) on a biologic substrate (the 
brain) over time (MacNicol, 2017; Volkow et al., 
2019). Ultimately, adaptations that substance 
exposure elicits in individual neurons alter the 
functioning of those neurons, which in turn alters 
the functioning of the neural circuits and networks 
in which those neurons operate. This eventually 
leads to the complex phenomena that characterize 
SUDs (MacNicol, 2017). 
Chronic substance use results in a complex set of 
physiological and neurologic adaptations. These 
adaptations are the body’s attempt to adjust to 
or compensate for the intermittent or chronic 
presence of substances. Repeated exposure to 
a substance can also lead to adaptations in the 
reward circuitry that oppose and/or neutralize the 
substance’s effects (i.e., counteradaptation). See 
Exhibit 2.1 for the parts of the brain that make up 
the reward circuitry. SUD-related brain activity can 
be characterized in three stages: 
1. Acute intoxication/binge 
2. Withdrawal/negative affect stage 
3. Anticipation/craving 
Each stage has its own complicated and intricate 
neurocircuitry that continues to reinforce the 
seeking and use of a specifc substance (Koob & 
Volkow, 2016). There are more than 18 systems 
of neuromodulation involved in the perpetuation 
of the three stages of SUDs in the brain; three 
important structures and regions are the basal 
ganglia, the amygdala, and the prefrontal cortex 
(Koob & Volkow, 2016). 
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A SIMPLE WAY OF THINKING ABOUT
SUDS 
A helpful way to think about SUDs and the 
processes within the brain that go awry is to think 
of the brain as having a “stop” system and a “go” 
system (Offce of the Surgeon General, 2016). The 
“go” system is the reward-seeking component 
that drives an individual to make decisions and 
achieve goals. The “stop” system inhibits the 
“go” system. In SUDs, the brain’s “go” system is 
activated when an individual seeks substances 
in response to a substance-related cue in the 
environment. The “go” system also helps drive 
habitual behavior, which too can play a role in 
substance seeking. But the “stop” is ineffective in 
controlling these behaviors, because substance-
related changes in the brain can decrease the 
“stop” system’s activity and increase the “go” 
system’s activity. Another way of thinking about 
this is that having an SUD is like driving a car 
without brakes (NIDAnews, 2014), which helps 
explain why people with SUDs cannot easily 
suppress their “go” system to “just stop” using or 
misusing substances. 
With increasing use and development of tolerance 
to the effects of a substance, people will need to 
increase the amount taken to produce the desired 
effects. As substance use increases, so does 
disruption of executive function and of the reward 
and stress pathways. (The stress pathway comprises 
the various neurobiologic mechanisms invoked in 
response to stressful stimuli, such as the “fght or 
fight” response triggered by the hypothalamic– 
pituitary–adrenal axis.) These disruptions result in 
patients continuing to use and seek substances 
despite adverse consequences—the very defnition 
of an SUD (Koob & Volkow, 2016). 
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EXHIBIT 2.1. Brain Structures Involved in the Reward System 
Source: From Telzer (2016). Adapted with permission from Elsevier. 
HOW TO UNDERSTAND A PERSON’S STRUGGLE WITH SUDS 
Over the past three centuries, many theories evolved to explain why some people can use a substance 
with little risk, whereas others have diffculty controlling their use. The most widely accepted term for the 
combination of factors and processes contributing to the development of an SUD is biopsychosocial. This 
term includes the infuence that genetic/biologic, psychological, and sociocultural factors have on short- 
and long-term effects of substance use. In the biopsychosocial model, all of these components are taken 
into account when working to prevent and treat SUDs (Skewes & González, 2013). 
To understand the specifc contribution of biology compared with the contribution of a person’s 
environment, researchers look to monozygotic (i.e., identical) and dizygotic (i.e., nonidentical) twin studies. 
Twin studies often examine siblings who were separated at birth versus those who both remained in 
their family of origin. These studies point to the infuence genes have on the development of SUDs (Ducci 
& Goldman, 2012). Although these genetic/biologic factors are clearly important, gender, development, 
environment, and culture also play a determining role. 
Researchers’ understanding of substance use is continually evolving and thus so are the models society 
uses to explain why some individuals can use substances without harm and others develop SUDs. The 
predominant model from the 18th and 19th centuries focused on morals. This “moral model” defned an 
SUD as a sin driven by the person’s desires and wrongful choices. This model led to harsh treatment of 
people with SUDs, and its effects can still be seen in the stigma people with SUDs still encounter. 
Continued on next page 
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Continued 
Stigma and associated feelings of shame persist despite the fact that, by the mid-1900s, the disease model 
of SUDs had emerged, supported by research fndings that there was no one type of person predisposed 
to alcohol use disorder. Additionally, advances in brain imaging allowed researchers to visualize neurologic 
changes in specifc brain regions and neurotransmitters, highlighting the infuence and primary 
importance of the reward systems involved. 
These biologically driven fndings led to the current understanding of SUDs as brain diseases, 
propelling clinical researchers to develop medicines to counter the physiologic effects on the brain (e.g., 
pharmacotherapies like methadone and naltrexone). 
Although the basic neurologic structures are fairly consistent across humans, there is a considerable 
amount of neuroplasticity and researchers learned that the brain is both static and dynamic throughout the 
lifespan. In the 1970s, the social learning model emerged, highlighting the infuence of social interactions 
and behaviors on SUDs (Giovazolias & Themeli, 2014). In this model, any person using a substance could 
become dependent through the infuence of conditioning, modeling others, thinking about substance use, 
and still using despite the negative consequences. 
An offshoot of the social learning model is the sociocultural model, which describes the effects of society 
on the individual’s behaviors and takes into account differences across cultures, races, and ethnicities. 
This model aligns well with our newer understanding of social determinants of health, including food 
and housing insecurities, adverse childhood experiences, and generational trauma—all of which may be 
associated with more prevalent substance use. 
Current SUD research suggests that clinicians and researchers need to take into account both physiologic 
components (e.g., genetics, neurobiology, neuroplasticity) and biopsychosocial aspects of the human 
experience (e.g., culture, environment and socialization, human development and behaviors throughout 
the lifespan) to develop a full conceptualization of the origin and severity of SUDs. 
Neurobiology 
The human nervous system is an elegant 
communication system, and the brain is the control 
center. The brain processes sensory information 
from throughout the body, guides muscle 
movement and locomotion, regulates a multitude 
of bodily functions, forms thoughts and feelings, 
modulates perception and moods, and essentially 
controls all behavior. Neurotransmitters (chemicals 
that transfer information between neurons and 
help neurons communicate with one another) also 
play a key role in the neurobiology of SUDs. 
The Reward System or Positive
Reinforcement 
The brain circuit that is considered essential to 
neurologic reinforcement is called the limbic 
reward system (also called the dopamine 
reward system or the brain reward system). 
This neural circuit extends across the ventral 
tegmental area, the nucleus accumbens, and 
the prefrontal cortex. 
Substances of misuse—including stimulants—affect 
the reward system (Volkow et al., 2019). Normal 
functioning of the brain’s circuitry results in 
inhibition and stimulation of neurotransmitters 
at multiple sites in the brain’s reward systems. 
However, neuroadaptation and neuroplasticity 
that occur when substances are present can result 
in multiple neurotransmitters disrupting this 
normal circuitry, resulting in prolonged phases of 
withdrawal/negative affect and anticipation/craving 
(Koob & Volkow, 2016). 
The neurotransmitter dopamine, which helps to 
regulate the feelings of pleasure (euphoria and 
satisfaction), is both directly and indirectly affected 
by stimulants (Volkow et al., 2019). Dopamine also 
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plays an important role in the control of movement, 
cognition, motivation, and reward (Bromberg-
Martin et al., 2010; Volkow et al., 2019). In 
addition, stimulant use causes the brain to release 
norepinephrine, which helps regulate mood, 
attention, learning, memory, and arousal and may 
play a role in substance withdrawal (Offce of the 
Surgeon General, 2016). The neurotransmitter 
serotonin affects reinforcement, motivation, 
learning, and memory, and may play a role in SUDs 
by making people more susceptible to compulsive 
(rather than controlled) substance use, especially 
people with genetic vulnerabilities to SUDs (Müller 
& Homberg, 2015). 
Activities such as eating, drinking, and sex 
activate the reward system, inducing considerable 
communication among this structure’s neurons. 
This internal communication leads to the release 
of dopamine. But substance use causes a surge 
of dopamine release that is far beyond that of 
natural activities, like eating and sex. The released 
dopamine produces immediate, but short-lived, 
feelings of pleasure and elation. 
As dopamine levels subside, so do the feelings 
of pleasure. But if the activity is repeated, then 
dopamine is again released, and more feelings of 
pleasure and euphoria are produced. The release 
of dopamine and the resulting pleasurable feelings 
positively reinforce such activities and motivate 
the repetition of these activities. Moreover, with 
substance use, the person needs more and more 
of the substance to achieve the same level of 
pleasure. 
Dopamine is believed to play an important 
role in the reinforcement of and motivation for 
repetitive actions (Daw & Tobler, 2013; Nutt et 
al., 2015; Volkow et al., 2019). An increasing 
amount of scientifc evidence suggests that 
neuroadaptations to the reward and stress systems 
play a considerable role in the development of 
compulsive use behaviors (Koob & Volkow, 2016). 
When the nucleus accumbens is functioning 
normally, communication among its neurons occurs 
in a consistent and predictable manner (Koob & 
Volkow, 2016). First, an electrical signal within a 
stimulated neuron reaches its point of connection 
(i.e., the synapse) with the target (postsynaptic) 
neuron. The electrical signal in the transmitting 
(presynaptic) neuron triggers the release of 
dopamine into the synaptic gap (Koob & Volkow, 
2016). Dopamine travels across the synaptic gap 
until it reaches the postsynaptic neuron. It then 
binds to the postsynaptic neuron’s dopamine-
specifc receptors. The binding of dopamine to the 
receptor has an excitatory effect that generates 
an internal electrical signal within this neuron. 
However, not all of the released dopamine binds 
to the target neuron’s receptors. Extra dopamine 
may be chemically deactivated, or it may be quickly 
reabsorbed by the presynaptic neuron through a 
system called the dopamine reuptake transporter 
(see Exhibit 2.2). 
The postsynaptic neuron receives messages in 
the form of neurotransmitters released from the 
presynaptic neuron, resulting in depolarization 
or hyperpolarization of the postsynaptic neuron 
membrane. If the membrane is depolarized to a 
certain degree, an action potential occurs that 
causes the neuron to release a neurotransmitter 
(i.e., to “send a message”). 
To learn more about the reward circuit in 
stimulant use disorders, see the NIDA video 
“The Reward Circuit: How the Brain Responds to 
Cocaine” (https://www.drugabuse.gov/videos/ 
reward-circuit-how-brain-responds-to-cocaine). 
The Stress System or Negative
Reinforcement 
In addition to positive reinforcement through the 
brain’s reward system, negative reinforcement 
can play a key role in the development and 
maintenance of chronic, compulsive substance 
use (Wise & Koob, 2014). The motivation to use 
a substance to avoid discomfort is an example 
of negative reinforcement. This motivation 
to continue using a substance occurs in the 
withdrawal/negative affect stage of substance use 
and also in the anticipation/craving stage. 
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EXHIBIT 2.2. Normal Dopamine Transmission 
As people experience negative withdrawal 
symptoms from not using a substance, their 
brain circuitry causes further dysregulation of 
executive function and other cognitive processes. 
This dysregulation creates negative effects in 
the absence of the substance, further driving the 
precontemplation/craving phase to reinforce the 
compulsive seeking and taking of the substance 
(Koob & Volkow, 2016). 
Experimental evidence supports the theory 
that stimulants and other commonly misused 
substances imitate, facilitate, or block the 
neurotransmitters (especially dopamine) involved 
in brain reinforcement systems (Ashok et al., 
2017; dela Peña et al., 2015; Nutt et al., 2015; 
Volkow et al., 2019). Negative reinforcement 
through overactivation of the stress system or the 
anti-reward system could also play a role in the 
perpetuation of chronic recurrent use to alleviate 
negative effects (Koob & Volkow, 2016). 
Drug Craving and Memory 
The degree to which learning and memory 
sustain the addictive process has also been 
addressed. Researchers believe that each time 
a neurotransmitter like dopamine foods across 
a synapse, circuits that trigger thoughts and 
memories and that motivate action become more 
strongly activated in the brain. Moreover, activation 
of the reward system creates a very powerful 
association between the euphoric and other 
rewarding effects of the substance and whatever 
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people, objects, or places the individual is exposed 
to at the time; these people, objects, or places 
then can become cues for substance use (Offce of 
the Surgeon General, 2016). 
Craving, a central aspect of SUDs, is a very strong 
learned response with powerful motivational 
properties often associated with specifc 
memories (i.e., conditioned cues and triggers; 
Carmack et al., 2017). Cues—any stimuli (e.g., 
drug paraphernalia, moods, friends who use 
substances, locations associated with substance 
use) repeatedly paired with substance use over the 
course of a patient’s SUD—can become so strongly 
associated with the substance’s effects that the 
associated (conditioned) stimuli can later trigger 
arousal and an intense desire for the substance 
and lead to recurrent use (Carmack et al., 2017). 
High recurrence rates are common in people 
with stimulant use disorders even after treatment 
(Brecht & Herbeck, 2014). 
Brain imaging studies have shown that cue-
induced drug craving may be linked to distinct 
brain systems involved in memory (Moreno-Rius & 
Miquel, 2017; Perry et al., 2014). Brain structures 
involved in memory and learning, including the 
dorsolateral prefrontal cortex, amygdala, and 
cerebellum, have been linked to cue-induced 
craving (Moreno-Rius & Miquel, 2017; Sinha, 
2013). A network of these brain regions integrates 
emotional and cognitive aspects of memory 
and triggers craving when it reacts to cues and 
memories. These cues and memories also play 
an important role in reinforcing substance use 
(Carmack et al., 2017). In contrast, negative 
experiences (e.g., violence, trauma, paranoia) that 
occur during acute intoxication do not seem to 
reinforce avoidance of intoxication. 
Most SUD treatment approaches recognize the 
power of these factors in triggering recurrent use 
and warn patients to avoid everything previously 
associated with their substance use. Treatment 
approaches that address these learning and 
memory issues of SUDs may prove effective. For 
example, cue exposure therapy uses extinction 
(i.e., breaking the individual’s association 
between the trigger or cue—like seeing drug 
paraphernalia—and the conditioned response— 
such as experiencing feelings of craving) to 
help decrease physiologic reactions to triggers 
and decrease cravings (Carmack et al., 2017; 
Torregrossa & Taylor, 2013). 
Researchers have examined other methods of 
similarly reducing physiologic responses to triggers 
and thereby reducing craving, such as inhibiting 
memory reconsolidation (i.e., the process of 
stabilizing newly formed memories so they can 
be stored long term) and using pharmacologic 
agents (e.g., propranolol) to enhance the 
extinction process used in cue exposure therapy 
(Torregrossa & Taylor, 2013). People with SUDs may 
further beneft from cue exposure therapy that is 
combined with other psychosocial interventions, 
like cognitive therapy and motivational 
enhancement (Kaplan et al., 2011). 
Role of Technologies 
The development of noninvasive brain imaging 
(e.g., positron emission tomography [PET] scans) 
has created a powerful new tool for demonstrating 
not only the short-term effects of substance use 
but also the longer term consequences of chronic 
substance use and SUDs. These tools have allowed 
researchers to go where they previously could 
not—literally into a living human brain. However, 
this research is still maturing, and many questions 
remain about whether and how these technologies 
might inform clinicians’ care of people with 
stimulant use disorders. 
Such noninvasive techniques can depict higher 
or lower activity levels of different brain areas by 
measuring metabolic activity (e.g., glucose use; 
Fakhoury, 2014). They can identify substance-
induced structural changes and physiologic 
adaptations (Fakhoury, 2014). Through a 
combination of techniques, researchers and 
clinicians can observe the altered processing of 
information in various circuits as the brain responds 
to substance use. 
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Using noninvasive imaging techniques, 
investigators have been able to identify brain 
structures involved in craving, map the emotions 
of people who use substances, and plot the 
neurobiologic basis of substance-induced euphoria. 
For example, researchers have used functional 
magnetic resonance imaging to predict substance 
use relapse and maintenance of abstinence (S. J. 
Moeller & Paulus, 2018). Additional neuroimaging 
studies have demonstrated signifcant changes in 
gray matter and in neurochemistry and have also 
predicted long-term effects of substance use  
and potential for recurrent use (S. J. Moeller & 
Paulus, 2018). 
PET has revealed subtle alterations in the 
dopamine receptors in the brains of people who 
use stimulants (Solingapuram Sai et al., 2019). A 
review of some PET studies has demonstrated not 
just reductions in dopamine receptor availability 
and sensitivity associated with cocaine and MA 
use, but also increased dopamine release (Wiers 
et al., 2016). Combining PET with the radiotracer 
[18F]-fuorodeoxyglucose—which is used to visualize 
brain glucose metabolism—has helped researchers 
understand changes in the brain’s metabolic 
activity associated with craving, alterations in 
cognition, self-regulation, and intoxication (Wiers 
et al., 2016). 
PET imaging has also provided insight into 
stimulant-related effects on neurofunction 
such as identifying infammation in the brain, 
understanding the infuence of cocaine on 
mu-opioid receptor binding, and pinpointing 
increases in norepinephrine in the synapses due  
to blockage of its reuptake (Wiers et al., 
2016). Single photon emission computerized 
tomography—a form of PET that uses a 
different type of radiotracer—may prove to be 
a useful diagnostic and classifcation tool (e.g., 
differentiating people at high risk of recurrent use 
from those who are not). 
Structural magnetic resonance imaging studies 
of people with MA use have shown clear gray 
matter defcits in cortical areas (i.e., frontal, 
insular, cingulate, temporal, and occipital cortices) 
and in the hippocampus, along with an increase 
in volume in the parietal lobe and the striatum 
(Hall et al., 2015; Jan et al., 2012). White matter 
enhancement appears to occur in the temporal 
and occipital lobes, accompanied by widespread 
white matter hyperintensities and aberrations in 
the corpus callosum (Jan et al., 2012). Structural 
changes documented in people with cocaine and 
amphetamine use include reduced gray matter 
in the insula, ventromedial prefrontal cortex, 
inferior frontal gyrus, pregenual anterior cingulate 
gyrus, and anterior thalamus (Ersche et al., 2013; 
Hall et al., 2015). Research is ongoing to better 
understand what these patterns mean and how 
structural defcits and changes affect substance use 
behaviors and outcomes. 
Imaging research is also providing important 
evidence about changes that can take place in 
the brain with abstinence and SUD treatment. For 
instance, exercise training for people in treatment 
for MA use disorder (and who were abstinent) 
was associated with recovery of certain striatal 
dopamine receptors that are known to become 
defcient with MA exposure—although it should 
be noted that abstinence plus education did not 
produce these benefts (C. L. Robertson et al., 
2016). Nonetheless, such research suggests that 
healing in the brain can occur, providing additional 
evidence for the importance of promoting 
abstinence and recovery. 
Although mapping brain activity during stimulant 
use and withdrawal may allow researchers 
to further document substance-induced 
neuropsychological impairments, not much of 
this research has been conducted in humans. 
Animal models suggest stimulant withdrawal is 
accompanied by a reduction in modularity—the 
ability of independent and functionally separate 
networks within the brain to interact with one 
another, somewhat like an electric circuit board 
with independent circuits that can connect to 
one another (Kalvar & Medaglia, 2018). Reduced 
modularity appears to occur in thalamic regions 
for MA and in a combination of midbrain-cortico-
thalamic-hypothalamic-amygdalar brain regions for 
cocaine (Kimbrough et al., 2019). 
Chapter 2 18 
TIP 33Chapter 2—How Stimulants Affect the Brain and Behavior 
The continuing development and application 
of new technologies such as noninvasive brain 
imaging will allow researchers to improve their 
understanding of how stimulants affect the human 
brain. Greater understanding of the underlying 
neuronal impairments of stimulant use will aid 
in the development of new and more effective 
treatment approaches. 
Stimulant Use and the Brain 
To better understand underlying drivers for 
substance use, it is important to learn the effects 
of any particular substance on a given person. For 
instance, someone with long-term stimulant use 
who is taking a stimulant and an opioid at the same 
time will be affected differently by that stimulant 
than someone taking a stimulant alone and for the 
frst time. How stimulants affect individuals (both 
universal effects as well as person-specifc effects) 
can provide helpful information to providers to 
assess, treat, and prevent recurrent use of the 
substance (Volkow et al., 2017). 
Once a substance enters the bloodstream, it is 
transported throughout the body to various organs 
and organ systems, including the brain. To enter 
the brain, a substance’s molecules must frst get 
through its chemical protection system, which 
consists mainly of the blood–brain barrier. Tight 
cell-wall junctions and a layer of cells around the 
blood vessels keep large or electrically charged 
molecules from entering the brain. However, small 
neutral molecules like those of cocaine and MA 
easily pass through the blood–brain barrier and 
enter the brain (Kousik et al., 2012; Turowski & 
Kenny, 2015). Once inside the brain, substances 
begin to exert psychoactive effects. 
Stimulants’ Mechanisms of Action 
On a short-term basis, stimulants exert their 
effects by disrupting or modifying the normal 
communication that occurs among brain neurons 
and brain circuits. Cocaine and MA have both been 
shown to disrupt the dopamine neurotransmitter 
system—cocaine indirectly and MA both directly 
and indirectly (Ashok et al., 2017). Both cocaine 
and MA can inhibit the reuptake and release of 
dopamine by the presynaptic neuron, resulting in 
excess dopamine in the synaptic gap. 
The two common forms of prescription 
stimulants—methylphenidate and amphetamine— 
affect the dopamine system differently, but, 
like cocaine and MA, both result in increased 
extracellular dopamine. Methylphenidate inhibits 
the reuptake of dopamine, as does amphetamine; 
but amphetamine also increases the amount of 
dopamine initially released into the synaptic gap 
(Yanofski, 2011). 
Whereas the mechanism of action of prescription 
stimulants is not drastically different from that 
of cocaine and MA, differences in effects can 
occur based on who is taking the substance (e.g., 
someone with attention defcit hyperactivity 
disorder [ADHD] versus someone without it), the 
dose taken, and how it is administered. These 
differences infuence whether the prescription 
stimulant is a helpful therapy or a drug that can 
change the brain at the cellular and structural 
levels. Specifcally, if a person has ADHD and takes 
a prescription stimulant, the medication is provided 
at a dose that increases dopamine to a level that 
provides relief from ADHD. When taken as directed 
(i.e., orally at the prescribed dosage and according 
to schedule), it provides a constant blood level of 
the medication. People with ADHD will feel more 
focused and productive as a result. But when MA, 
cocaine, or prescription stimulants are injected or 
smoked (or, in the case of medications, taken in 
higher-than-prescribed amounts or taken by people 
without ADHD), they can lead to brain changes and 
stimulant use disorder. 
The use of stimulants increases the amount of 
available dopamine in the brain (Paulus & Stewart, 
2020). High levels of available dopamine in the 
brain generally enhance mood and increase body 
movement (i.e., motor activity) and motivation, but 
too much dopamine may produce symptoms that 
approximate positive symptoms of schizophrenia 
(e.g., delusions, hallucinations, paranoia; Kesby 
et al., 2018; Klein et al., 2019). With cocaine, the 
effects are generally short-lived, whereas with MA, 
the duration of effect is much longer. 
As the stimulant level in the brain decreases, 
the dopamine levels subside to normal, and the 
pleasurable feelings dwindle. With repeated 
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stimulant use, dopamine stores in the brain 
become temporarily depleted (Ashok et al., 
2017), resulting in the depressive and exhaustive 
symptoms associated with stimulant withdrawal. 
Although the neurochemical pathways of chronic 
stimulant use disorders are not defnitively 
established, a few researchers have found evidence 
of changes in the structure and function of brain 
neurons after chronic stimulant use in humans. 
Some researchers propose that the changes 
may come from dopamine depletion, changes in 
neurotransmitter receptors or other structures, 
or changes in cellular components or other brain 
messenger pathways that could cause the changes 
in mood, behavior (e.g., compulsivity, decision 
making), and cognitive function associated with 
chronic stimulant misuse (Ashok et al., 2017; Jan 
et al., 2012). (The medical aspects of stimulant use 
disorders are discussed in Chapter 3.) 
General Efects of Stimulants 
Stimulants affect the normal functioning of the 
dopamine neurotransmitter system (Volkow et al., 
2019). Stimulants appear to increase the brain’s 
levels of free dopamine (Ashok et al., 2017; dela 
Peña et al., 2015; MacNicol, 2017; Volkow et al., 
2019). The higher the substance dose, the greater 
the individual’s feelings of wakefulness, mania, and 
euphoria. As the dopamine levels and pleasurable 
feelings subside, the individual experiences an 
intense desire to replicate the feelings of pleasure 
by administering another dose of the substance. 
As with substance use generally, this tendency 
toward repeated administration is characteristic of 
stimulant use disorders and underlies most of the 
other effects of stimulants, as well as most other 
addictive substances. 
Half-lives of stimulants vary by drug. Cocaine, 
being naturally derived, has a much shorter half-life 
(around 60 minutes), whereas MA, being synthetic, 
has a half-life of around 10 hours (Coe et al., 
2018; Cruickshank & Dyer, 2009). The half-lives 
of prescription stimulants also vary by drug and 
by formulation (e.g., short-acting versus long-
acting). For example, short-acting prescription 
amphetamine has a half-life of approximately 9 
hours, whereas the long-acting formulation has a 
half-life in the range of 10 to 13 hours (Pradeep & 
Standeven, 2019). 
Continued use often leads to adverse 
consequences, which may include 
neuropsychologic impairment, mental health 
issues, and diminished physical health. Work 
performance and social and family relations can 
be adversely affected, and the risk of arrest and 
criminal/legal involvement increases (McKetin et 
al., 2020). 
It is important to note that in small and measured 
doses, stimulants may serve a clinical purpose to 
heighten wakefulness, help focus attention, and 
enhance cognition (see Exhibit 2.3). This could 
explain why some people who misuse prescription 
stimulants—especially adolescents in high school 
and young adults in college—often do so to 
improve their concentration and alertness, which 
they perceive as helping with their studying 
and academic performance (Clemow & Walker, 
2014; Weyandt et al., 2018). Increasing doses, 
higher potency, and more frequent use increase 
psychostimulation and may eventually result in 
the cognitive impairments often correlated with 
stimulant use disorder (Wood et al., 2014). In 
very high doses, stimulant use can lead to serious 
medical complications, including coma and 
circulatory collapse, or even death (Wood et 
al., 2014). 
For patients with a stimulant use disorder, 
impairments in the brain’s reward systems that lead 
to problems with cognition and neuropsychiatric 
functioning may persist even after cessation of 
stimulant use (Taylor et al., 2013). Cravings for 
the stimulant’s effects tend to linger, even after 
abstinence has been achieved, and the potential 
for recurrent use is high. 
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EXHIBIT 2.3. Continuum of Psychostimulant Activation 
Increasing cognitive activation as stimulant dose increases initially produces increased wakefulness 
and cognitive enhancement. These are the benefcial effects. As dose or potency increases, a 
sense of power and euphoria can ensue. These are the effects people with SUD seek. Such effects 
are accompanied by cognitive defcits. Higher doses can result in overdose, psychosis, coma, and 
eventual circulatory collapse 
Source: Wood et al. (2014). Adapted with permission. 
Efects of Combining Psychostimulants 
With Opioids 
Psychostimulant-related overdose deaths involving 
opioids have been increasing over the past 20 
years, with heroin and synthetic opioids (like 
fentanyl) largely accounting for psychostimulant-
associated fatalities since 2010 (McCall Jones 
et al., 2017). Polysubstance use, specifcally 
the co-consumption of synthetic opioids and 
psychostimulants, like cocaine and MA, was largely 
responsible for the increases in cocaine- and MA-
related overdose deaths observed from 2012 to 
2017 (Kariisa et al., 2019). 
Opioids can lead to potentially lethal respiratory 
depression. This is especially true of fentanyl 
and fentanyl analogs, which are rapid acting and 
are increasingly being taken in combination with 
cocaine or MA, by accident or on purpose (LaRue 
et al., 2019). Fentanyl can induce fatal respiratory 
depression in as little as 2 minutes (Kuczyńska et 
al., 2018). Even if nonfatal, respiratory depression 
is dangerous and can lead to hypoxic brain injury 
(Kiyatkin, 2019). Because people naïve to opioids 
lack opioid tolerance, they may be at an increased 
risk of unintentional overdose when combining 
stimulants, like cocaine, with fentanyl or other 
synthetic and nonsynthetic opioids (LaRue et 
al., 2019). 
















































Efects of Route of Administration 
The fve most common routes of administering
psychoactive (mood-changing) substances are: 
• Oral consumption (i.e., swallowing, gumming
[rubbing the substance on the gums]). 
• Intranasal consumption (i.e., insuffation). 
• Inhalation into the lungs (i.e., smoking). 
• Intravenously (i.e., injection). 
• Vaginal or anal insertion. 
Cocaine and MA can be smoked, snorted, 
injected, ingested orally, or absorbed intrarectally 
or intravaginally. Prescription stimulants can be 
taken orally or crushed and snorted. The route of 
administration affects the amount (i.e., the dosage) 
of stimulant delivered to the brain, the speed at 
which it is delivered, and the resulting intensity of 
the stimulant’s effects—which in turn may affect 
the course of an SUD. Because a person’s preferred 
route of administration affects the extent and 
depth of chronic effects, it has implications for 
treatment decisions (see Chapter 5). (For specifc 
information on drug use and peak effects, see 
Chapter 3, Exhibit 3.2.) 
The long plateau effect and the much longer half-life 
of MA versus cocaine suggest considerable dangers 
in repeated use of MA (Cruickshank & Dyer, 2009). 
Because stimulants exert their effects in a dose-
dependent manner, the route of administration 
has serious neurologic, physical, psychiatric, and 
neurocognitive implications for the person using the 
stimulant. Prolonged high doses of stimulants (e.g., 
during binges or chronic use) may cause greater and 
longer lasting neurologic damage, which in turn may 
lead to greater and longer lasting cognitive defcits. 
The onset of stimulants’ chronic effects varies across 
individuals, and although there are few data to 
predict how long it will take for any person to begin 
experiencing the chronic effects of stimulant use, 
onset is probably related to: 
• The amount of stimulant used. 
• The frequency of use. 
• The route of administration. 
• Signifcant medical comorbidities. 
• Co-occurring mental disorders. 
• Co-administration of other substances. 
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• The environment in which the substance is taken. 
• Genetics and metabolic factors. 
However, in general, higher, more frequent doses
of stimulants used in combination with other
substances result in more rapid transition to
the effects of chronic stimulant exposure. (For a
discussion of route-of-administration effects on
toxicity and adverse reactions, see Chapter 3.) 
Psychological and Neurocognitive
Efects 
The immediate psychological effects of stimulant
administration include a heightened sense of well-
being, euphoria, excitement, and alertness, and
increases in motor activity, similar to what would
be seen in a manic state. Stimulants also reduce
appetite and may result in insomnia. Stimulants may
also enhance focus and libido (Volkow et
al., 2007). 
High doses, particularly in the setting of sleep
deprivation, may result in restlessness, agitation, and
more profound psychiatric presentation, including
altered perceptions of reality and hallucinations.
Chronic psychological effects of stimulant use
and withdrawal may include paranoia, psychosis,
depression, and/or suicidal ideation. 
Cocaine 
Routes of Administration 
Cocaine is most commonly taken by nasal
insuffation (snorting), intravenous injection, or
inhalation of smoke vapors (smoking/inhalation).
Less often, it is taken orally, vaginally, rectally, or
sublingually. The half-life of cocaine is about 60
minutes (Coe et al., 2018) but can range from 40 to
90 minutes (ARUP Laboratories, 2019). 
Pharmacology 
Cocaine has two main pharmacologic actions. It is
both a local anesthetic and a central nervous system
(CNS) stimulant (NIDA, 2016a). Cocaine exerts its
local anesthetic actions by blocking the conduction
of sensory impulses within nerve cells. This effect
is most pronounced when cocaine is applied to
the skin or to mucous membranes. Cocaine has
approved medical use as a local anesthetic in some
surgery of the eye, ear, and throat (NIDA, 2016a). 






































Chapter 2—How Stimulants Affect the Brain and Behavior 
As a CNS stimulant, cocaine affects a number
of neurotransmitter systems, but it is through its
interaction with the dopamine and the limbic reward
system that cocaine produces some of its most
important effects, including positive reinforcing
effects (NIDA, 2016a). The major infuence of
cocaine on the dopamine system is its ability to
block the synaptic reuptake of dopamine. 
Cocaine does not directly stimulate the dopamine
system; rather, it causes the system to be stimulated
by preventing dopamine from being removed
from the synaptic gap. Cocaine’s blockade of
the dopamine reuptake transporter extends the
availability of dopamine in the synaptic space, where
it continues to occupy the dopamine receptors and
causes the postsynaptic neurons to fre for a longer-
than-normal period (NIDA, 2016a). (See Exhibit 2.4.) 
Acute Physiologic Efects 
Acute cocaine use can lead to narrowing of the
blood vessels and an increase in body temperature,
pulse, and blood pressure (NIDA, 2016a) as well as
fatigue (Ciccarone, 2011). In some cases, tremors,
dizziness, and muscle twitching can occur (NIDA,
2016a).
Acute Psychological Efects 
The extended fring of the postsynaptic neurons
resulting from prolonged dopamine receptor activity
is initially experienced subjectively by people using
cocaine as a positive sensation involving increased
energy, arousal, and stimulation (NIDA, 2016a).
The effects experienced during the initial period
of cocaine use are generally mood altering in a
positive manner. For most individuals, the subjective
experience of the acute effects includes a generalized
state of euphoria in combination with feelings of
increased energy, talkativeness, mental alertness, and
hypersensitivity to sight, sound, and touch (NIDA,
2016a). 
Many people feel more intensely involved in their
interactions with others and more playful and
spontaneous when using cocaine. As patients use
more, they may experience unpleasant adverse



































effects including increased anxiety, irritability,
paranoia, and restlessness (NIDA, 2016a). As cocaine
use subsides, particularly among patients with a
stimulant use disorder, withdrawal symptoms will be
present, including depressive symptoms and mood
lability (Ciccarone, 2011). 
With continued escalating use of cocaine, the
individual becomes progressively tolerant to the
positive effects and sensitized to the negative effects,
which can increase the risk of unintentional overdose
(NIDA, 2016a). People report that the positive
effects of cocaine use are not as profound and that
the rebound negative and adverse effects may
increase over time, leading to a dysphoric, depressed
state. This constant cycle of seeking additional
positive effects and eliminating negative effects may
perpetuate the cocaine use disorder. (For details
on the medical aspects of acute cocaine use, see
Chapter 3.) 
Chronic Physiologic Efects 
Initial experimental cocaine use often progresses to 
more steady use, requiring larger and larger doses to 
achieve the desired effects (NIDA, 2016a). Someone 
with regular cocaine use may become obsessed 
with the rituals of cocaine use and fnd that many 
common items or situations trigger cravings for 
the drug. Cocaine use disorder can develop, with 
overwhelming urges and cravings for cocaine, and an 
inability to self-limit or abstain from use. 
The person addicted to cocaine will continue  
use despite the negative consequences. At this stage, 
the adverse consequences of cocaine use disorder 
have probably affected all aspects of the person’s life. 
There are no data that indicate how long it will take 
for any individual to begin to experience the chronic 
effects of cocaine use. Some individuals report an 
ability to use for extended periods with few signs 
of negative consequences. Others report a very 
dramatic onset of severe detrimental effects as soon 
as a few weeks or months after initiation of cocaine 
use. In general, however, similar to the effects of 
MA, the higher the doses and the more frequently 
the doses are administered, the more quickly the 
chronic effects of cocaine use will appear. In addition, 
intranasal administration (snorting) is associated 
with slower onset of chronic effects than is smoking 
cocaine (freebasing or smoking crack) or injecting it 
intravenously (Ciccarone, 2011). 
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Physically, the person with cocaine use disorder 
may appear thin or even emaciated. Personal 
hygiene and self-care may be neglected, and 
medical and dental needs may go unmet. Because 
cocaine suppresses appetite, the person fails to 
eat properly and may suffer from weight loss and 
nutritional defciencies (Ciccarone, 2011). People 
with severe cocaine use disorder may ignore food, 
clothing, shelter, and sexual needs. Continued 
cocaine use can lead to erectile dysfunction and 
menstrual irregularities (Ciccarone, 2011), as well as 
anorexia, chest pain, and extreme fatigue. 
Chronic Psychological Efects 
Psychologically, cocaine’s chronic effects oppose 
the often-desired initial effects. Chronic cocaine 
use increases paranoia and confusion (Ciccarone, 
2011). The same substance that produced a mild 
sensation of arousal and decreased fatigue now 
causes insomnia and episodic depression. 
Chronic use of cocaine may cause 
neuropsychological impairments (Quednow & 
Vonmoos, 2017; Spronk et al., 2013). Cocaine-
induced cognitive defcits may affect multiple 
domains, but they appear to be reversible in 
patients with a mild or moderate cocaine use 
disorder within 1 year of cessation of use (Vonmoos 
et al., 2014). 
The physical, psychological, and cognitive effects 
of chronic cocaine use refect the underlying 
neurobiologic changes from cocaine’s impact 
on the neurotransmitter dopamine. Spronk and 
colleagues (2013) found a strong association 
between the long-term use of cocaine and 
defciencies in the following cognitive domains: 
attention, response inhibition (i.e., the ability to 
inhibit one’s impulse to respond to a stimulus), 
working memory, cognitive fexibility, and 
psychomotor performance. 
Although clinicians may easily pick up on the 
extensive health-compromising effects of 
cocaine use when examining the behavioral and 
psychological profle of patients entering SUD 
treatment, patients may need additional education 
to understand the correlation between their 
substance use and its negative health effects. 
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Methamphetamine 
Routes of Administration 
MA is typically taken orally, nasally (snorting/ 
insuffation), intravenously, or by inhaling smoke 
vapors (smoking/inhalation). Less often, MA is 
taken vaginally, rectally, or sublingually. The half-
life of a single dose of MA is about 10 hours 
across routes of administration (Cruickshank & 
Dyer, 2009). 
Pharmacology 
The course of MA use disorder development
is similar to that of cocaine use disorder. The
underlying neurologic effects of MA are similar
to the effects produced by cocaine: essentially,
it increases levels of free dopamine in the brain’s
limbic reward system. (Exhibit 2.5 illustrates some of
the acute effects of MA on dopamine transmission.) 
Research has demonstrated that MA has 
neurotoxic effects, but the mechanism of action 
of neurotoxicity is still being studied, although 
it seems to be multifactorial. Oxidative stress, 
excitotoxicity, and neuroinfammation have all 
produced signals related to the neurotoxic effects 
of MA (Paulus & Stewart, 2020; Yang et al., 2018). 
Because MA crosses neuronal cell membranes and 
enters the microscopic sacs (called vesicles) where 
neurons store dopamine, it is believed that damage 
to the storage sacs and the neurons’ axonal 
endings causes dopamine to leak uncontrollably 
into the synapse. MA can also cause neurotoxicity 
indirectly by moving dopamine out of the storage 
sacs and into the neuron’s cytoplasm (i.e., the cell’s 
internal material), where it is converted to toxic 
and reactive chemicals. (Exhibit 2.5 shows some of 
these processes.) 
Exhibit 2.6 includes key terms discussed in this 
chapter. 
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Excitotoxicity: A complex process in which 
excessive activation of excitatory amino acid 
receptors causes the death of nerve cells in the 
nervous system. Excitotoxicity can lead to the 
production of free radicals and oxidative stress. 
Neuroinfammation: The infammation of tissue 
in the nervous system resulting from a cascade of 
immune responses to injury or illness. 
Oxidative stress: Injury to tissues in the body due 
to an imbalance between free radicals that cause 
damage and antioxidants that repair damage. 
Free radicals are molecules produced during 
metabolic reactions or after exposure to certain 
environmental agents. 
Additionally, glutamate accumulation and 
microglial activity changes associated with MA 
use may be related to MA’s neurotoxic effects. 
Medications that block the infammatory effects 
of microglial activation may help prevent MA’s 
neurotoxicity (Yang et al., 2018). 
Numerous animal studies have demonstrated 
that MA can damage both dopamine and 
serotonin systems (Chiu & Schenk, 2012; Shin et 
al., 2017; Yang et al., 2018). MA toxicity occurs 
after repeated high-dose administration, and it is 
selective for certain neuronal systems, particularly 
those in the limbic reward system (e.g., striatum, 
substantia nigra, nucleus accumbens). Within 
these brain circuits, MA has been shown to 
reduce the number of nerve fbers, impair normal 
physiologic functioning, and destroy both axons 
and axon terminals (i.e., synaptic junctions). These 
studies have also shown that MA toxicity is highly 
dependent on dose, route of administration, and 
the frequency with which the drug is taken. 
Long-term use of MA may deplete dopamine 
levels, decrease dopamine receptors, and 
lower dopamine transporter levels (Yang et al., 
2018). Some postmortem studies have shown 
that even recreational doses of MA signifcantly 
expend dopamine levels (Boileau et al., 2016). A 
review on the neurotoxicity of MA (Yang et al., 
2018) implicates dopamine in numerous harmful 
effects of MA exposure, including increased 
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oxidative stress (i.e., an imbalance of free radicals 
and antioxidants in the body), impairments in 
mitochondrial metabolism, and infammatory 
processes within the brain. 
Prolonged or heavy use of MA decreases the 
brain’s ability to manufacture dopamine. This 
impairment may persist for months or even 
years after one stops taking MA (Yang et al., 
2018). Researchers believe that those changes 
in dopamine levels and the damage done to 
dopamine and serotonin neurons are responsible 
for the chronic effects of MA use (Shin et al., 2017). 
Compared with cocaine, which is rapidly 
metabolized by plasma and tissue enzymes, MA is 
metabolized at a much slower rate, which results 
in a longer duration of action (NIDA, 2019a). 
Although the half-life of cocaine is about 1 hour, a 
single dose of MA may produce an effect for about 
10 hours (Coe et al., 2018; Cruickshank & Dyer, 
2009). MA’s slower rate of metabolism extends the 
duration of its neurotoxic effects. 
Acute Physiologic Efects 
The acute physiologic effects of MA are generally 
similar to those of cocaine: increased heart 
and respiratory rates, elevated blood pressure 
and body temperature, and pupillary dilation 
(Matsumoto et al., 2014). Other acute effects 
include increased vigor, irregular heart rate, 
and damage to small blood vessels in the brain 
(Ciccarone, 2011; Kevil et al., 2019). Dangerously 
elevated body temperature and severe damage to 
the liver occur with high-dose MA (Matsumoto et 
al., 2014). If not treated immediately, these effects 
can result in death (Matsumoto et al., 2014). 
Acute Psychological Efects 
MA’s psychological effects, like those of 
cocaine, include a heightened sense of well-
being or euphoria, and increased alertness 
(Ciccarone, 2011). High doses may produce 
repetitive and compulsive acts and may cause 
irritability; excitement; visual, auditory, or tactile 
hallucinations; and altered perceptions of 
reality, characterized by delusions and psychosis 
(Bramness et al., 2012; Glasner-Edwards & Mooney, 
2014; Wearne & Cornish, 2018). People using MA 
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may engage in protective behaviors in response to 
irrational fears brought on by altered perceptions 
of reality. Mood lability secondary to elevated 
dopamine levels is common. With continued use, 
tolerance develops to the behavioral effects, and 
repeated exposure may produce sensitization. 
MA withdrawal is like that of cocaine, but because of 
the longer effects of MA, withdrawal may be more 
intense and protracted (Courtney & Ray, 2014). 
Over the course of 1 to 14 days after last use, the 
person using MA experiences a drastic drop in 
mood and energy levels. Sleep—which may be 
promoted by the use of secondary substances such 
as alcohol, barbiturates, and benzodiazepines— 
fnally begins and may last more or less 
uninterrupted for several days. Upon awakening, 
the individual may experience mild to severe 
depression (Zorick et al., 2010), perhaps lasting for 
several weeks. While in this depressed state, the 
person has an increased risk of suicide (Lerner & 
Klein, 2019). 
Chronic Physiologic Efects 
Understanding the chronic physiologic effects 
of MA use is essential for treatment providers 
who serve this population. Chronic use of MA 
may result in multiple dysfunctions of the heart 
(e.g., hypertension, aortic dissection, acute 
coronary syndromes, pulmonary hypertension, 
cardiomyopathy [Kevil et al., 2019; Paratz et 
al., 2016; Paulus & Stewart, 2020; Petit et al., 
2012]) and, among people who inject the drug, 
skin abscesses (Yasaei & Saadabadi, 2021) 
and damaged blood vessels at the injection 
site. Chronic use may also lead to episodes of 
protective behaviors, paranoia, anxiety, confusion, 
and insomnia (Glasner-Edwards & Mooney, 2014). 
Heavy use is linked to progressive social and 
occupational deterioration. Psychotic symptoms 
may sometimes persist for months or years after 
use has ceased (Wearne & Cornish, 2018). 
Some of the most concerning research fndings 
about MA suggest that its prolonged use not 
only modifes behaviors, but changes the brain in 
fundamental and long-lasting ways. MA impairs the 
functioning of both the dopamine system and the 
serotonin system (serotonin is another important 
CNS neurotransmitter; Thomas et al., 2010) and 
possibly other neurotransmitter systems (Ferrucci 
et al., 2019). MA-induced neuronal toxicity is 
specifc to certain brain regions (primarily the 
limbic reward system), and this toxicity is refected 
both biochemically and anatomically. Finally, these 
impairments in brain functioning may underlie 
the cognitive and emotional defcits seen in many 
people who use MA. 
Chronic Psychological Efects 
One of the potential negative effects of chronic MA 
use is psychosis. Patients with persistent psychosis 
are often treated with medications to return their 
brain functions to normal, and many antipsychotic 
medications work by affecting the activity of the 
dopamine and serotonin neurons. Current protocol 
in treating persistent MA psychosis is to manage 
the patient’s symptoms—potentially through 
second-generation antipsychotics like olanzapine 
and risperidone—to try and improve overall quality 
of life and reduce the risk for recurrent use (Wearne 
& Cornish, 2018). 
Characteristics of neurocognitive decline in people 
with MA use disorder are similar to those seen in 
patients with a cocaine use disorder. The changes 
to cognition are usually across multiple domains, 
including attention, psychomotor activity, memory, 
and decision making (Hart et al., 2012). Unlike 
with cocaine, the duration of the neurocognitive 
defciencies has not been well described, but 
neuroimaging would suggest more long-lasting 
neurocognitive defciencies likely related to the 
longer duration of action of MA itself and its more 
profound effect on the neuroplasticity of the brain. 
Depletion of dopamine in the brains of people 
who use MA is similar to the loss of dopamine 
seen in patients with Parkinson’s disease. Research 
has yet to defne a clear correlation between MA 
use disorder and the Parkinson-like symptoms 
described by clinicians and patients (Christine et 
al., 2010; Granado et al., 2013; Kish et al., 2017). 
Determining the lasting effects of prolonged 
exposure to MA on the dopamine reward system 
may help clinicians better support patients entering 
recovery from MA use. Additionally, understanding 
how these Parkinsonian symptoms develop may 
reveal additional pathways for treatment of the 
condition and MA use disorder. 








Routes of Administration 
Prescription stimulants are typically taken orally 
but, when misused, can also be taken intranasally 
(snorted; Yanofski, 2011). Half-lives vary by drug 
and by formulation (e.g., short acting versus long 
acting). For example, short-acting amphetamine 
has a half-life of approximately 9 hours, whereas 
the long-acting formulation has a half-life in the 
range of 10 to 13 hours (Pradeep & Standeven, 
2019). 
Pharmacology 
Stimulant medications (e.g., d-amphetamine, 
mixed enantiomers/mixed salts amphetamine, 
lisdexamfetamine) exert their effect in much the 
same way that cocaine and MA do—by increasing 
levels of dopamine in the brain (NIDA, 2014). 
The prescription stimulants methylphenidate 
and d-amphetamine increase dopamine 
signaling—methylphenidate by blocking dopamine 
transporters and d-amphetamine by enhancing 
dopamine release from nerve terminals (Lakhan 
& Kirchgessner, 2012). Prescription stimulants 
are prescribed in such a way that, when taken 
appropriately, they produce slow and steady 
increases in dopamine (NIDA, 2014). 
Acute Physiologic Efects 
Acute adverse physiologic effects of stimulant 
medications include loss of appetite, insomnia, 
weight loss, headache, nausea, vomiting, 
abdominal cramps, increased blood pressure and 
heart rate, and, potentially, worsening of motor tics 
(Craig et al., 2015; Heal et al., 2013). 
Chronic Physiologic Efects 
Ongoing exposure to stimulants—such as 
repeatedly taking even the same doses of stimulant 
medication—can lead to tolerance to the stimulant, 
as well as tolerance to the brain’s endogenous 
dopamine (Yanofski, 2011). This tolerance to 
dopamine means the brain becomes less sensitive 
to it; thus, it could become less sensitive to the 
medication’s effects over time (Yanofski, 2011). 
Treatment for Stimulant Use Disorders 
Other long-term effects of stimulant medication 
in children and adults are unclear, in part because 
of the lack of longitudinal treatment studies and 
poor long-term adherence to treatment (Molina 
& Swanson, 2020). For instance, it is unknown 
whether brain changes that occur with acute 
stimulant medication exposure (e.g., increased 
activation of areas of the prefrontal cortex that are 
normally underactive in ADHD) persist with chronic 
exposure (Molina & Swanson, 2020; Weyandt et 
al., 2013). There seems to be no link between 
prescription stimulants taken in adolescence and 
later development of SUDs (Quinn et al., 2017; 
Wilens et al., 2011). Appetite loss, headache, and 
digestive distress appear to continue with chronic 
use, but, again, few studies of long-term effects 
exist (Craig et al., 2015). 
Acute Psychological Efects 
Prescription stimulants are known to improve 
alertness, attention, and energy (NIDA, 2018b). 
Thus, much of the research on the short-term 
effects of these medications concerns cognitive 
functioning, including enhancement of several 
cognitive processes, such as attention, vigilance, 
response inhibition, memory, and working memory 
(D. M. Dougherty et al., 2016; Molina & Swanson, 
2020; Swanson et al., 2011). People misusing 
prescription stimulants often do so because of the 
perceived neurocognitive beneft—largely that of 
improved concentration and alertness, such as for 
studying and academic performance (Clemow & 
Walker, 2014; Marraccini et al., 2016; Weyandt et 
al., 2013)—and not necessarily solely as a result  
of craving. 
Chronic Psychological Efects 
Research suggests that long-term use results 
in continued alleviation of ADHD symptoms, 
including inattention, hyperactivity, and impulsivity, 
but only while the medication is being taken (Craig 
et al., 2015). 
Assessment and Diagnosis 
Diagnosis can be based on criteria established in the
ffth edition of the Diagnostic and Statistical Manual
of Mental Disorders (DSM-5; American Psychiatric
Association [APA], 2013) for a stimulant use disorder
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involving amphetamine or cocaine. For treatment
reimbursement, the diagnosis may also need to
refect criteria according to the most recent version
of the International Classifcation of Diseases, Clinical
Modifcation (ICD–CM) found under “Coding” at
https://www.cms.gov/Medicare/Medicare (the current
version at the time of this Treatment Improvement
Protocol [TIP] update’s publication was ICD-10-
CM). Arriving at a diagnosis is simplifed by having
information available from a relevant and accurate
patient history, a urine toxicology screen or similar
laboratory tests, and clinical observations of physical
signs and mental status. 
WHAT TO DO IF A PATIENT SCREENS POSITIVE FOR STIMULANT USE 
• Primary care providers are on the front lines of identifying and helping manage SUDs in patients. Regular 
screening can help hasten diagnosis and referral for treatment. But once a patient screens positive for 
stimulant use, what should primary care physicians do? Best practices include the following (Substance 
Abuse and Mental Health Services Administration [SAMHSA], 2011): 
• Leverage screening, brief intervention, and referral to treatment (SBIRT) techniques to get a better sense 
of the patient’s symptoms and severity, substance-related problems (e.g., with work, with relationships, 
legal problems), and treatment needs. (For more information about SBIRT, see the text box “Screening, 
Brief Intervention, and Referral to Treatment for SUDs: What Primary Care Providers Need to Know” in 
Chapter 3.) 
• For mild or moderate stimulant use, a brief SBIRT intervention centered on education and motivational 
interviewing may be helpful in guiding patients toward acknowledging their problem behaviors and 
committing to behavior change. Using trained peer recovery support specialists can offer patients 
additional support and resources from people with lived experience with SUDs. 
• For severe stimulant use, refer patients to qualifed licensed mental health service providers and SUD 
treatment providers in the co-occurring disorders feld for treatment and supportive services (e.g., for 
outpatient services, intensive outpatient programs, partial hospitalization services, residential programs, 
12-Step programs such as Crystal Meth Anonymous). 
• Use warm handoffs and other active referral linkages, rather than simply disseminating contact 
information, to increase the likelihood that patients will enter treatment. Providers should also have 
follow-up discussions with patients to ensure the referral was used. If the patient did not follow through, 
providers should talk with the patient to determine the reason and discuss how barriers to access can be 
overcome. 
• Offer education about the dangers of taking stimulants laced with synthetic or nonsynthetic opioids— 
particularly cocaine with fentanyl, which is an increasingly popular and highly lethal combination. 
Educate patients and family members about the purpose of naloxone (to reverse opioid overdose) and 
how and when to administer it, and ensure that interested patients have a prescription for naloxone. 
• For patients who inject drugs, also offer education about the importance of safer injection practices, how 
to obtain new needles and syringes, simple wound care techniques, and signs and symptoms of infection 
that warrant further medical intervention. 
• For patients ambivalent about treatment, provide harm-reduction strategies and education. Providers 
should prescribe prevention medications like postexposure prophylaxis (nPEP) or pre-exposure 
prophylaxis (PrEP), screen for asymptomatic infections, provide overdose and overamping education, and 
create a plan for how to access treatment when the patient is ready. 
• Where appropriate (e.g., when patients have a supportive family network), consider including family in 
the recovery process to give patients additional emotional support and resources to help with stopping 
stimulant use. (See SAMHSA’s TIP 39, Substance Use Disorder Treatment and Family Therapy [https:// 
store.samhsa.gov/product/treatment-improvement-protocol-tip-39-substance-use-disorder-treatment-
and-family-therapy/PEP20-02-02-012], for more guidance about the role of families in SUD treatment.) 
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History 
An appropriate substance use history should 
include the substance(s) and medications used 
during the past 30 days; the specifc substance(s) 
or combinations typically used with the usual 
dose, frequency, and route of administration; the 
duration of use; and the time and amount of last 
use (Substance Abuse and Mental Health Services 
Administration [SAMHSA], 2020l). If the patient 
has been bingeing, a brief description of this and 
previous episodes is helpful. In addition, the history 
should include information about any previous 
seizures, delirium tremens, heart and pulmonary 
problems, paranoid reactions (with or without 
altered perceptions of reality and hallucinations), 
and other serious medical and psychological 
conditions and psychiatric diagnoses and if they 
occurred pre- or post-stimulant use, as well as all 
medications the patient is taking. Additionally, 
check to see if there are substance use or 
psychiatric problems within the person’s family 
(SAMHSA, 2020l). 
For most patients presenting in an emergency 
department, the substance use and medical 
history will, of necessity, be brief and focus on 
the potential causes for the observed symptoms 
and complaints and any potential medical 
or psychological problems that are likely to 
complicate treatment and the patient’s response. 
Emergency department personnel should stabilize 
the patient medically and assess potential danger 
to self and others before trying to take a history. 
Patients in a heightened state of arousal and 
experiencing persecutory perceptions may not 
give an accurate accounting of their current and 
past substance use. Information from signifcant 
others or from a reliable source can help clarify 
the patient’s history. In situations where the 
patient is delirious, psychotic, or unable to 
respond, information from accompanying friends 
or signifcant others about the antecedents of the 
problem is particularly important. Sometimes, the 
substance use history must await symptomatic 
management. 
The history may be supplemented by a variety of 
SUD screening instruments, although these are not 
notably reliable if used with individuals who are 
intoxicated or acutely psychotic. 
A number of these screening instruments are 
described in detail in Appendix B of SAMHSA’s 
TIP 42, Substance Use Disorder Treatment for 





A urine screen or toxicology test can be used to 
identify which substances the patient has used 
recently (Jaffe et al., 2016). This testing is vital 
to confrm clinicians’ clinical assessments and 
observations. Some emergency departments have 
bedside or patient-side urine immunoassay testing 
kits (dipstick tests) that can be used for a quick 
turnaround without waiting on more formal assays. 
The kit’s results can be validated by additional 
laboratory studies. 
The results of either dipstick or Enzyme 
Multiplied Immunoassay Technique (EMIT) tests 
are appropriate to use for medical purposes. 
Alternative techniques for determining substance 
use are analyses of hair, blood, sweat, or tissue 
samples (Jaffe et al., 2016). In general, however, 
urine has become the standard method of 
determining substance use in an individual, and 
tests are readily available in the medical setting, 
whereas other types of testing are not (Jaffe et al., 
2016). Urine screens are relatively inexpensive, with 
fve-panel tests (i.e., tests for fve different drugs) 
costing on average $4 and 14-panel tests costing 
about $7 (Jaffe et al., 2016). Both qualitative and 
quantitative urine assays are usually needed to 
verify use and time/amount taken. Repeated assays 
can be used to track elimination of stimulants from 
the system if large amounts have been detected. 
Because no standard set of substances is tested 
in a urine substance screen, medical personnel 
should make certain that assays for suspected 
substances are included. Also, no toxicology 
screen can determine with certainty whether 
someone used any particular substance—or any 
substances at all. The detection limitations may be 
too broad or the specifc substance may have been 
completely metabolized before a urine specimen 
was collected. A positive report will not necessarily 
indicate when the substance was last used. 
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Metabolites for some substances are detectable 
for days or weeks after last use but take some time 
after substance administration to be detectable in 
urine (K. E. Moeller et al., 2017). 
MA can be detected in urine for approximately 48 
hours following use, and cocaine metabolites may 
be detected for as long as 2 to 4 days following 
use (K. E. Moeller et al., 2017). Many prescription 
and over-the-counter medications (e.g., diet aids, 
cold remedies) contain phenylpropanolamine 
or ephedrine that may yield positive EMIT or 
radioimmunoassay tests for amphetamines. Certain 
agents (e.g., phenylpropanolamine, ephedrine) 
can produce cross-reactivity in amphetamine 
tests, causing immunoassays for the analysis of 
amphetamine-type substances to potentially 
produce false positives (K. E. Moeller et al., 2017). 
Urine screening tests are not confrmation of 
patient substance use but rather are one piece 
of information to help guide clinical decision 
making. Many substances may interact with an 
amphetamine screening test. For this reason, the 
preferred method for determination of stimulant 
substance use is confrmatory urine testing in the 
form of gas chromatography/mass spectrometry. 
Physical Signs and Mental Status 
Signs and symptoms of cocaine use can include 
extreme happiness or being very energetic; 
hypersensitivity to sight, sound, and touch; 
irritability; paranoia; and, in large amounts, bizarre 
and violent behavior (NIDA, 2016a). Signs of MA 
use can include increased attention, decreased 
fatigue, increased activity and wakefulness, 
decreased appetite, euphoric mood, (NIDA, 
2019a) and, in large amounts, fever, sweating, 
tremors, a rapid heart rate, stroke, aggression, 
and paranoia (Radfar & Rawson, 2014). Increased 
sensitivity to noise, nervous physical activity like 
scratching, irritability, dizziness, confusion, extreme 
anorexia, convulsions, and blood pressure are also 
potential harmful effects of MA use (SAMHSA, 
2018c). Prescription stimulant misuse can manifest 
as feelings of euphoria, but in large amounts 
can result in restlessness, tremors, overactive 
refexes, rapid breathing, confusion, aggression, 
hallucinations, panic, high fever, muscle pains, and 
weakness (NIDA, 2018b). 
Data acquired from monitoring vital signs 
(temperature, blood pressure, pulse rate, 
respiration rate) can be used to document 
physical indicators of stimulant use. In addition, 
observations of physical manifestations related 
to acute or chronic stimulant use and to 
withdrawal can be documented. Similarly, a 
variety of instruments exists to determine mental 
status, although observational data regarding 
psychological and mental status may be adequate 
(see Appendix B of TIP 42, Substance Use Disorder 
Treatment for People With Co-Occurring Disorders 
at https://store.samhsa.gov/product/tip-42-
substance-use-treatment-persons-co-occurring-
disorders/PEP20-02-01-004. [SAMHSA, 2020l]). 
ASSESSING FOR COGNITIVE DEFICITS 
Profound cerebrovascular dysfunctions can occur 
among people who use stimulants. Clinicians 
must remain vigilant for neurocognitive 
disorders, like delirium, as well as signs and 
symptoms of those disorders, like changes in 
memory or orientation, in patients with stimulant 
use because such disorders can hinder recovery. 
They do so by negatively affecting outcomes like 
abstinence and treatment retention and certain 
cognitive domains, like motivation and decision 
making (Copersino et al., 2012; Perry & Lawrence, 
2017). 
For indepth cognitive assessment, referral to 
a neuropsychologist or neuropsychiatrist may 
be warranted. For older adults with past or 
current stimulant use who are experiencing 
cognitive diffculties, also consider referring to a 
geriatrician. 
Diferential Diagnosis 
In the diagnostic process, other disorders and 
conditions with similar or identical presentations 
must be considered. Many people with stimulant 
use disorder have coexisting mental illnesses such 
as bipolar disorder and borderline personality 
disorder, which share some symptoms with 
stimulant use disorders (SAMHSA, 2020l). A  
heart attack, seizure, or other type of adverse 
medical event that can be brought on by stimulant 
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toxicity may instead have a different cause. The 
cause of the symptoms or adverse events must 
be determined for optimal continuing care and 
medical management. 
Before a differential diagnosis of a coexisting 
mental disorder can be made, the patient must 
be abstinent for at least 4 weeks following 
cessation of withdrawal or severe intoxication 
(APA, 2013). The presenting psychiatric syndrome 
and symptoms can be treated meanwhile, and a 
diagnosis of unspecifed schizophrenia spectrum 
and other psychotic disorders can be given. More 
information regarding the diagnostic process for 
patients with symptoms that indicate coexisting 
substance use and mental disorders can be found 
in TIP 42, Substance Use Disorder Treatment for 




New forms of brain imaging techniques could 
offer a promising approach for making certain 
differential diagnoses—for example, if current 
research determines that these techniques are 
useful for distinguishing among drug-induced 
and other forms of psychosis. 
Summary 
Research has shown how stimulants such as 
cocaine, MA, and prescription stimulants exert 
their effects on the nervous system and affect 
feelings, emotional response, and behavior. There 
is now a greater understanding of neurologic 
systems related to reward and reinforcement, 
the development of stimulant use disorders, 
and the roles that craving and memory play in 
sustaining SUDs. Existing research can also help 
guide treatment approaches. Although more 
research is needed on the long-term neurologic, 
medical, psychiatric, and neurocognitive effects 
of stimulants in humans, animal studies have 
demonstrated cocaine’s and MA’s ability to disrupt 
normal brain function and cause long-lasting and 
perhaps permanent neurologic impairments. 
Continuing research and emerging imaging 
technologies will assist in the development of new 
and improved approaches for treating stimulant 
use disorders. Assessment of people with stimulant 
use should involve taking a thorough history, 
complemented by urine toxicology and data from 
physical observations. For less severe stimulant 
use, clinicians can use screening, brief intervention, 
and referral to treatment techniques to help guide 
patients toward behavior change. Patients with 
severe stimulant use disorder should be referred 
for specialized SUD treatment. 
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Chapter 3—Medical Aspects of Stimulant Use 
Disorders 
KEY MESSAGES 
• Healthcare service providers need to learn the 
medical signs, symptoms, and consequences 
of stimulant use to understand how best to 
medically manage patients with stimulant use 
disorders. Behavioral health service providers 
should also learn the medical aspects of 
stimulant use disorders so they can refer 
patients for medical intervention quickly and 
appropriately. 
• The physical effects of stimulants will vary 
by the type of stimulant taken, route of 
administration, dose, purity of the substance, 
the individual’s pattern of use, other 
substances the individual may be using, and 
any medical or psychiatric comorbidities the 
individual may have. 
• Common medical complications of stimulant 
use disorders are cardiovascular conditions, 
respiratory problems, cerebrovascular 
events, muscular and renal dysfunction, 
gastrointestinal problems, infections including 
HIV/AIDS, and hepatitis C. 
• Common psychological complications of 
stimulant use disorders include psychosis, 
depression, hypervigilance, and anxiety. 
• People with stimulant use disorders often have 
co-occurring conditions that, if untreated, can 
exacerbate their substance use or otherwise 
make recovery more diffcult. Co-occurring 
conditions of note are polysubstance use, co-
occurring mental illness, medical conditions, 
and traumatic injury. 
This chapter addresses the psychological 
symptoms and other medical consequences 
commonly seen in people using various forms of 
stimulants (e.g., powder cocaine, crack cocaine, 
methamphetamine [MA]) who appear at hospital 
emergency departments (EDs) and other medical 
settings or who need specialized medical care 
while participating in residential or outpatient 
substance use disorder (SUD) programs. The 
purpose of the chapter is to assist medical 
personnel in recognizing and treating problems in 
people with stimulant use that may arise secondary 
to acute/chronic intoxication, during withdrawal, or 
in various stages of recovery and in differentiating 
these problems from similar presentations of 
other medical and psychiatric conditions. The 
information in this chapter may also be useful to 
nonmedical treatment providers to help them 
recognize physical symptoms that would warrant 
medical attention and follow-up. Another emphasis 
is the need for establishing and ensuring linkages 
between medical facilities and appropriate, 
comprehensive SUD treatment/rehabilitation 
programs. 
People who use psychostimulants typically 
present with acute medical problems such as 
cerebrovascular accidents (i.e., stroke), acute 
myocardial ischemia, heart failure, hyperthermia, 
or seizures. Other major symptoms manifest as 
altered mental status, including confusion, altered 
perceptions of reality (e.g., delusions), paranoid 
ideation, hallucinations, and suicidal ideation. 
Cardiovascular disease is the third leading cause 
of death, behind overdose and accidents, among 
people who use MA (Kevil et al., 2019). 
Because this chapter discusses medical topics and 
concepts that may not be familiar to all readers, 
Exhibit 3.1 defnes key terms that will be used. 
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EXHIBIT 3.1. Key Terms 
Altered perception of reality: A phenomenon in which the way that an individual understands or 
interprets external stimuli or internal sensations is distorted. The term is used in Chapter 3 specifcally 
to refer to a delusion, which is a false belief based on an incorrect interpretation of reality, that is frmly 
believed despite evidence to the contrary, and that is not part of one’s culture or religious beliefs (e.g., 
believing that a fickering light bulb is a sign that one is being spied on, believing that one is pregnant 
despite no medical indication that this is true) (Shahrokh et al., 2011). Hallucination, another altered 
perception of reality, is defned separately. 
Alveolar rupture: A condition of the respiratory system in which pressure changes between the alveoli (air 
sacs) and the interstitium (a fuid flled space around the air sacs) cause a tear in the wall of the air sac that 
allows air to enter the interstitial space. Alveolar rupture can lead to breathing problems and lung damage. 
Anticholinergic: A substance that inhibits the parasympathetic nervous system by interfering with 
the action of the neurotransmitter acetylcholine, which regulates neural impulses that control muscle 
movement. It is often used to describe the mechanism of action for a drug (e.g., anticholinergic 
medications). 
Aortic dissection: An aortic dissection is a potentially life-threatening condition in which tears in the inner 
layer of the aorta, the large blood vessel that exits the heart and supplies blood to the rest of the body, 
lead to blood loss and separation of the layers of the aorta’s wall, which can block blood fow, resulting in 
impaired perfusion throughout the body. Severe tears that extend all the way through to the outermost 
layer of the aorta are usually fatal (Mayo Clinic, 2017b). 
Arrythmia: A condition in which a person’s heart rate or rhythm is abnormal due to malfunctions in 
electrical impulses. The heartbeat can be too fast, too slow, or irregular. 
Barotrauma: An injury caused by a change in air or water pressure resulting in physical damage to body 
tissue, frequently affecting the ears or the lungs. 
Bronchospasm: A tightening of the muscles that line a person’s airway. 
Bruxism: A condition in which people unconsciously or consciously grind or clench their teeth. 
Catecholamine: A type of hormone that is produced by the adrenal glands or brain. 
Choreoathetoid: Related to choreoathetosis, which is a movement disorder characterized by rapid or slow 
involuntary twitching or writhing of the body. 
Conditioning: A learning process in which one stimulus signals the occurrence of a second stimulus 
either through pairing stimuli (classical conditioning) or applying a consequence after a behavior (operant 
conditioning). 
Corticostriatal: Refers to the connection between the cortex and the striatum in the brain, which facilitates 
the fow of sensory, motor, and limbic information along a pathway to regulate motor control, action 
selection, and reward (W. Li & Pozzo-Miller, 2020). 
Depersonalization: A sense of experiencing one’s own thoughts, feelings, and behaviors from a distance, as 
if observing or dreaming. 
Derealization: A sense of feeling detached from one’s surroundings, such that the environment appears 
distorted and not real. 
End organ: Any organ fed by the circulatory system (e.g., heart, kidneys, brain, eyes) that can sustain 
temporary or permanent damage when circulation is disrupted. 
Euphoria: A mental and emotional condition characterized by an intense feeling or state of pleasure, 
happiness, and excitement. 
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Continued 
GABA system: The network of brain receptors that respond to the inhibitory neurotransmitter gamma-
aminobutyric acid. 
Glomerular fltration: The process that takes place in the kidneys to flter the blood and eliminate excess 
fuid and waste from the body through the production of urine. The physiologic process is often expressed 
as a rate and used to determine the stage of kidney disease (if present). 
Granulomatosis: A condition stemming from infammatory processes that cause nodules made up of 
immune cells, known as granulomas, to form and affect various organs throughout the body. 
Hallucination: A false sensory perception that occurs despite the fact that no sensory stimulus is present 
(Shahrokh et al., 2011). This could include experiences like seeing things that aren’t really present (i.e., 
visual hallucinations), hearing voices that aren’t really there (i.e., auditory hallucinations), or feeling tactile 
sensations that are not real (e.g., feeling like bugs are crawling under one’s skin). 
Hypertension: Blood pressure that is elevated above the normal range. 
Hypomania: A state defned by abnormal elevations in mood, activity, or energy, typically lasting for at least 
4 days. Hypomania is less extreme than mania and does not cause signifcant impairment in functioning. 
Hyponatremia: A condition characterized by abnormally low levels of sodium in the blood, often caused by 
conditions such as kidney disease, liver disease, and heart failure. 
Ideas of reference: The false belief that casual incidents and external events have a personal signifcance. 
Ischemia: A condition in which blood fow to tissues and other organs is reduced, often resulting from 
damage to blood vessels caused by a blockage. Ischemia can occur anywhere in the body and can be 
classifed as either partial or complete, leading to either reduction in oxygen transport or total impairment 
in oxygenation. 
Kindling: A neurologic response, characterized by increased sensitivity to a substance, that worsens 
withdrawal symptoms following repeated attempts at cessation. 
Metabolic acidosis: An imbalance of electrolytes that disrupts the acid–base pH balance and causes excess 
acid in body fuids. This condition can have severe consequences and become life threatening without 
medical intervention. 
Myocardial infarction: Also known as a heart attack, myocardial infarction occurs when there is impaired 
blood fow to the heart, causing damage to the heart muscle and affecting its ability to pump blood 
effciently and circulate oxygen throughout the body. 
Necrosis: The premature death of cells due to external factors, such as infection or injury. 
Perfusion: The movement of fuid through the circulatory system. 
Perseveration: An uncontrollable persistence or repetition of a particular thought or behavior despite a 
clear reason for ceasing or absence of a stimulus. 
Placental abruption: A sudden complication of pregnancy that occurs when the placenta partially or 
completely separates from the inner wall of the uterus prior to delivery, endangering the mother due to 
bleeding and the baby due to limited oxygen and nutrient transport (Mayo Clinic, 2020). 
Pneumonitis: A condition affecting the lungs that is characterized by tissue irritation and infammation 
that impairs oxygen exchange. Pneumonitis can be caused by infectious or noninfectious agents. 
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Psychosis: A group of symptoms defned by diminished contact with reality. Individuals with psychosis can 
have positive symptoms characterized by odd or unusual thoughts, feelings, or behaviors, including the 
presence of hallucinations, altered perceptions of reality, and disorganized thoughts, speech, and behaviors. 
Alternatively, an individual with psychosis may experience negative symptoms defned by an absence or 
loss of normal behaviors and experiences, including impaired emotional responsiveness, poverty of speech, 
reduced motivation to complete tasks, lack of pleasure, apathy, fat affect, and social withdrawal. (See also 
the entries for “Altered perception of reality” and “Hallucination.”) 
Rhabdomyolysis: The rapid breakdown of skeletal muscle due to injury. Rhabdomyolysis can cause 
permanent disability and become life threatening without medical intervention. 
Sensorium: “The parts of the brain or the mind concerned with the reception and interpretation of sensory 
stimuli” (Merriam-Webster, n.d.-b). A clear sensorium suggests that an individual has a reasonably accurate 
memory and demonstrates appropriate orientation to person, place, and time. 
Status epilepticus: A type of seizure with a specifc duration (i.e., lasts longer than 5 minutes) or frequency 
(i.e., having more than one seizure within a 5-minute period, without returning to a normal level of 
consciousness between episodes; Johns Hopkins University, n.d.-a). 
Stereotypy: Persistent, repetitive acts (e.g., body rocking, hand waving, or working through an elaborate 
process, such as disassembling and reassembling radios or other small gadgets) that seem to offer some 
relief from agitation and anxiety. 
Tachycardia: An elevated resting heart rate, generally greater than 100 beats per minute for adults. In 
children and adolescents, the threshold for tachycardia varies with age. 
Thrombotic microangiopathy: The formation of microscopic blood clots in the small blood vessels that 
can cause the breakdown of red blood cells, low platelet levels, and organ dysfunction, most commonly 
affecting the brain and the kidneys (Johns Hopkins University, n.d.-b). 
Thyrotoxicosis: The presence of excessive concentrations of thyroid hormones in the body, which can 
increase metabolic function at the cellular level. Thyrotoxicosis is characterized by systematic alterations, 
including increased heart rate, sweating, anxiety, shakiness, weight loss, increased appetite, heart 
palpitations, heat intolerance, and diffculty relaxing (A. Sharma & Stan, 2019). 
Tonic-clonic: A term used to refer to the type of seizure in which there is stiffening of the muscles (tonic) 
followed by rhythmic twitching or jerking of the muscles (clonic). 
Urticaria: Also known as hives, urticaria is a skin reaction characterized by red, swollen, itchy bumps. 
Valsalva maneuver: A breathing technique in which an individual tries to blow air (exhale as if one were 
infating a balloon) while the airways are blocked (i.e., pinching the nose and closing the mouth). The 
technique is primarily used to restore heart rhythm when the heart is beating too fast or to diagnose a 
disorder of the autonomic nervous system. People who take cocaine sometimes perform this intentionally 
to increase the drug’s absorption and increase its effects. 
Vasculature: The arrangement of blood vessels in organs within the body. 
Vasoconstriction: A narrowing of blood vessels that reduces blood fow and causes increases in blood 
pressure. 
Vasospasm: An acute or subacute contraction (spasm) of an artery that limits blood fow and reduces 
oxygen transport with the potential to cause ischemia and end-organ damage. 
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Toxicity, Addiction, and Other
Adverse Reactions 
Cocaine use impairs central and peripheral 
nervous system presynaptic nerve uptake of 
catecholamines, which increases catecholamine 
circulation (Bachi et al., 2017) and leads to 
impairment in the regulation of dopaminergic 
systems (Verma, 2015). The increased availability 
of extracellular dopamine as a result of cocaine 
exposure in the brain’s reward centers is 
hypothesized to at least partially account for the 
drug’s strong addiction potential and euphoric 
effects (Verma, 2015). This pattern is also seen in 
MA use, as MA both blocks dopamine reuptake 
and increases dopamine release (National Institute 
on Drug Abuse [NIDA], 2019b). Meta-analyses 
indicate a larger and more consistent dysregulation 
of dopaminergic systems with MA exposure than 
with cocaine (Ashok et al., 2017). The two common 
forms of prescription stimulants—methylphenidate 
and amphetamine—affect the dopamine system 
differently, but, like cocaine and MA, both increase 
extracellular dopamine. Methylphenidate primarily 
inhibits the reuptake of dopamine, whereas 
amphetamine both inhibits dopamine reuptake 
and also increases the amount of dopamine in the 
synapse (Yanofski, 2011). 
The precise clinical effects of cocaine, MA, and 
prescription stimulants depend on a complex 
mixture of the pharmacologic properties and 
purity of the drug used; the dose, frequency of 
use, and route of drug administration; the person’s
state of intoxication or withdrawal and previous
experience with the drug; the context in which the
drug is used; and other concomitant medical and
psychiatric factors, including simultaneous use of
other substances, as well as personality attributes
and expectations regarding drug reactions. All of
these factors not only mediate drug effects, but also
infuence the person’s susceptibility to an SUD and
are an important part of screening and history taking
(American Society of Addiction Medicine, 2015a). 
Route of Administration 
The method by which stimulants are taken—the 
route of administration—determines the dosage 
and the rapidity and intensity of effects. Route 
of administration also affects the potential for 
adverse reactions and the likelihood of developing 
an SUD. The principal routes for cocaine and MA 
use are oral ingestion, nasal insuffation (snorting), 
intravenous injection, and inhalation of smoke 
vapors (smoking/inhalation). These stimulants can 
also be taken vaginally, rectally, or sublingually. 
When taken as prescribed, prescription stimulants 
are taken orally. But when misused, they can be 
taken orally or by snorting, smoking, or injecting. 
In general, smoking and intravenous use rapidly 
evoke similarly intense responses, whereas oral 
ingestion and intranasal administration are slower 
delivery mechanisms, causing lower and more 
gradually rising blood levels and less intense 
subjective responses. The fact that cocaine is 
seldom taken orally may be attributed to the 
reduced systemic bioavailability with this route of 
administration (Coe et al., 2018). 
Smoking crack cocaine rapidly delivers a highly 
concentrated dose to the brain. As the effciency of 
the delivery system increases, so does the intensity 
of both the pleasurable and the adverse effects. 
Subjective reports from people who smoke cocaine 
suggest that this route of administration delivers a 
more intense experience than do the intranasal or 
intravenous routes (Kiluk et al., 2013). Exhibit 3.2 
depicts these general variations in response times 
according to the different routes of administration 
for cocaine, MA, and prescription stimulants. 
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EXHIBIT 3.2. Effects of Route of Use for Cocaine, Methamphetamine, and
Prescription Stimulants 
ROUTE OF USE* FORM OF DRUG 
ONSET OF ACTION FOR  
COCAINE, MA, AND PRESCRIPTION
STIMULANTS 
 
DURATION OF SUBSTANCE 
EFFECTS 
Oral Powder/ pill Approximately 30 minutes 
for cocaine; 15 to 20 minutes 
for MA; 30 to 45 minutes 
for both amphetamine and 
methylphenidate 
45 to 90 minutes for 
cocaine; 6 to 12 hours for 
MA, but can continue for 
up to 24 hours for large 
doses (peak concentration 
3 to 6 hours); depending 
on brand, 4 to 6 hours for 
short-acting formulations of 
prescription amphetamine 
and 8 to 14 hours for long-
acting [extended-release] 
formulations; depending 
on brand, 4 hours for 
short-acting prescription 
methylphenidate and 7 to 
12 hours for long-acting 
formulations 
Intranasal Powder Within 3 minutes for cocaine; 3 to 5 
minutes for MA 
15 to 30 minutes for cocaine; 
5 to 15 minutes (peak 
concentration) for MA 
Intravenous Solution Within 5 to 15 minutes for cocaine 
and MA 
10 to 20 minutes for cocaine; 
4 to 6 hours for MA 
Inhalation Crystalline solid 8 to 12 seconds for crack cocaine; 
within minutes for MA 
2 to 20 minutes for crack 
cocaine; up to 8 to 12 hours 
for MA 
*Limited information is available on the pharmacokinetics of methylphenidate and amphetamine when 
used intranasally or intravenously or when inhaled. 
Sources: Ballester et al. (2017); Cruickshank & Dyer (2009); Drug Enforcement Administration, Diversion Control Division 
(2019a); Hodgkins et al. (2012); National Center for Biotechnology Information (2021); NIDA (2016a, 2019b); Reddy et al. 
(2020); Steingard et al. (2019). 
To some extent, the dangerous consequences and 
addictive potential of stimulants also refect the 
route of drug administration. Routes that facilitate 
more rapid drug delivery are more strongly linked 
to addiction and worse severity of addiction (Allain 
et al., 2015). Inhalation and intravenous injection 
of cocaine or MA are more strongly linked to 
addiction than oral, intranasal, and transdermal 
routes and in some cases are also linked to other 
harms, such as increased risk of overdose and 
more frequent drug use (Allain et al., 2015). 
Intravenous use produces the greatest effect with 
the greatest risk for negative side effects compared 
to intranasal or oral routes. Inhalation is generally 
perceived as a quick form of drug delivery, 
producing the highest peak blood levels and the 
most potent subjective impact without attendant 
hazards from syringe needle use (Cruickshank & 
Dyer, 2009; Kiluk et al., 2013; National Center for 
Biotechnology Information [NCBI], 2021; NIDA, 
2019b; Reddy et al., 2020). 






























 Smoking produces 
a long-lasting high, 
about 8 to 12 hours 
 Approximately 50 
percent is excreted 
in the urine within 12 
hours 
 Limited medical use 
(e.g., attention defcit 
hyperactivity disorder 
[ADHD], narcolepsy, 
and weight loss) 
 Synthetic 
 Depending on brand, short-acting amphetamine 
produces an effect of about 4 to 6 hours and short-
acting methylphenidate produces an effect of 
about 4 hours; depending on brand, long-acting 
amphetamine produces an effect of about 8 to 14 
hours and long-acting methylphenidate produces 
an effect of about 7 to 12 hours 
 50 percent of short-acting methylphenidate is 
eliminated in about 3 hours, and 50 percent of 
short-acting amphetamine is eliminated in about 
7 hours; elimination of amphetamines is highly 
dependent on urine pH 
 Food and Drug Administration approved for 
medical use (e.g., ADHD, narcolepsy) 
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Different routes of drug use also produce different
side effects. People who engage in intravenous
drug use can develop illnesses associated with
the preparation of drugs for use (i.e., mixing/ 
making) and the use or sharing of unsterile needles,
including HIV and hepatitis B and C, loss of vein
functioning (venous sclerosis) and vein scarring, the
formation of blood clots within veins, and skin and
soft tissue infections (Allain et al., 2015; Al-Tayyib
et al., 2017; Ciccarone & Harris, 2015; Hart et al.,
2014; Raiker et al., 2016). Infections introduced
into the bloodstream by contaminated needles can
travel via the circulatory system to any end organ,
including the kidneys, brain, liver, bone, and lungs.
Nasal insuffation is associated with sinusitis, loss of
sense of smell, congestion, atrophy of nasal mucosa,
nosebleeds, perforation or necrosis of the nasal
septum, hoarseness, and problems with swallowing
(Center for Integrated Healthcare, 2013; Nassar &
Ouanounou, 2020). Compared with inhalation, nasal
insuffation of cocaine has also been linked to longer
duration of outpatient treatment, better cocaine
treatment-related outcomes, and less cocaine use
posttreatment (Kiluk et al., 2013). 
People who use MA may recognize these route-
related effects in general and may vary the routes 
of administration because of specifc adverse 
effects. For example, someone may choose to 
insuffate or inject MA because of irritation that 
it potentially causes to the lungs, or people may 
choose to smoke to avoid the risks associated with 
injection use (McCarthy & McClain, 2019). 
Diferences Between Cocaine, 
Methamphetamine, and Prescription 
Stimulants 
The major differences between cocaine, MA, and 
prescription stimulants pertain to the rapidity 
of responses and the duration of their effects 
(Exhibit 3.3). The sought-after effects of MA can 
persist for hours, whereas those from cocaine are 
over in minutes. Effects of prescription stimulants 
vary by formulation (i.e., short acting versus 
long acting). This has important consequences 
for the choice of drug and the patterns of 
administration adopted by individuals. The plasma 
concentration level refers to the amount of a drug 
in the plasma component of a sample of blood. 
Plasma concentration levels are an indicator of 
drug concentration (i.e., the concentration of the 
drug at a cell’s receptor), which is important for 
understanding its pharmacologic effect or toxicity. 







Smoking produces a 
high that lasts up to 
20 minutes; snorting 
produces a high that 
lasts 15 to 30 minutes 
50 percent is 
eliminated from the 
body in 1 hour 
Limited medical 
use; used as a local 
COCAINE MA PRESCRIPTION STIMULANTS 










Sources: Courtney & Ray (2014); Hodgkins et al. (2012); NIDA (2019b, 2021b). 
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The plasma concentration levels of cocaine 
peak and decline rapidly, with a half-life of 
about 60 minutes (Coe et al., 2018). MA plasma 
concentration levels also peak rapidly but remain 
high for much longer, with a half-life of about 10 
hours across routes of administration (Cruickshank 
& Dyer, 2009). Typically, the half-life of cocaine 
is about 60 minutes but can range from 40 to 90 
minutes (ARUP Laboratories, 2019). The plasma 
concentration levels from smoked cocaine both 
peak and decline rapidly, whereas those from 
smoked MA also peak relatively rapidly but decline 
more slowly because metabolism takes longer. 
Regular repeated use may be more common 
among people who use cocaine in an attempt to 
sustain the drug’s effects. 
The half-lives and peak plasma concentrations 
of prescription stimulants vary by type (e.g., 
amphetamine and methylphenidate), brand, and 
formulation (e.g., short acting and long acting). 
Time to peak concentration for short-acting 
formulations of amphetamine ranges from about 
2 to 3 hours; for long-acting formulations, it 
ranges from about 4 to 8 hours (Markowitz & 
Patrick, 2017). Time to peak concentration for 
methylphenidate is about 1 to 2 hours for short-
acting formulations and about 3 to 6 hours for 
long-acting formulations (Mariotti et al., 2013). 
The misuse of long-acting methylphenidate by 
injecting or snorting can lead to a more rapid peak 
concentration level (Spiller et al., 2013). 
Other factors in the preference for smokable 
forms of cocaine and MA include availability and 
price. Crack is generally less expensive and more 
available than powdered cocaine hydrochloride 
and produces, in the initial smoker, a very intense 
but brief rush (Drug Enforcement Administration, 
Diversion Control Division, 2019a). Because 
crystalline MA costs less per dose than other 
forms of MA and because the euphoria attained 
may persist for several hours, this form of MA 
delivery may be preferred. Because potential for 
addiction increases as time before onset of action 
decreases, concern about increased use of cocaine 
and MA pertains both to the smokable crystalline 
preparations and to continuing intravenous use of 
these drugs. 
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Dose 
The incidence and severity of stimulant-induced 
side effects and overdose potential are also dose 
related. As the dose increases, the profle of side 
effects progresses from mild excitement to more 
intense reactions (NIDA, 2016a). Because tolerance 
develops rapidly to the desired euphoric effects, 
people using stimulants nearly always escalate 
dose size and frequency of drug use in pursuit 
of the vanishing rush. Compared with oral or 
intranasal routes, intravenous or inhalation use 
promises more rapid response rates and peak 
plasma concentration levels (Cruickshank & Dyer, 
2009; NIDA, 2016a). People using stimulants 
may often change their route of use, dose, and 
frequency of use to achieve the desired effect 
(NIDA, 2019b). 
Dosing patterns of MA vary by individual and 
pattern of use and can range broadly from 50 mg 
to 2,000 mg per day (Cunha-Oliveira et al., 2013). 
People with chronic MA use may binge in doses up 
to 5,000 mg per day (Cunha-Oliveira et al., 2013). 
Low-to-moderate doses of MA that range from 5 to 
30 mg can induce arousal, euphoric mood, cardiac 
stimulation, and acute improvements in attention 
and psychomotor skills (Cruickshank & Dyer, 2009). 
High doses of MA (50 mg and up) can lead to 
psychosis (Cruickshank & Dyer, 2009). 
A lethal dose of cocaine has been estimated to 
be around 50 mg, with documented cases of 
individuals having died after taking as little as 20 
mg (NCBI, 2021). In low doses, cocaine can result 
in euphoria and agitation (NCBI, 2021). Large 
doses can lead to cardiovascular and respiratory 
dysfunctions, including hyperthermia, arrhythmias 
(irregular heartbeat), high blood pressure, and 
possibly death (NCBI, 2021; NIDA, 2016a). 
However, different routes of use may lead to higher 
concentrations in the blood, indicating a greater 
effect and greater potential for overdose. 
Maximum doses of prescription stimulants depend 
on the age of the patient (i.e., child, adolescent, 
adult up to age 65, and older adult), the type of 
medication (methylphenidate or amphetamine), 
and the medication brand (PDR Network, n.d.). 
Severe tissue damage and necrosis can occur 
with intravascular injection, especially accidental 
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intra-arterial injection (Bruggisser et al., 2011). 
Ingestion of oral doses in mass quantities (e.g., 
approximately 3,000 mg) has been reported and 
can lead to death (Cantrell et al., 2014). Overdose 
of amphetamine is common and contributes to 
signifcant morbidity but is less fatal than other 
drugs (Spiller et al., 2013). The dosage leading 
to overdose depends on the patient’s individual 
tolerance to amphetamine. 
Purity of the Drug 
The purity of the stimulant used also infuences 
the rate and completeness of its absorption 
and effects. The purer the drug, the greater the 
effects. Illicit drugs, however, are seldom entirely 
pure. High drug purity is a public health and 
public policy concern that may be connected 
to overdose, overdose fatalities, and healthcare 
resource use (e.g., ED visits). In 2018, the average 
purity of wholesale cocaine analyzed by the Drug 
Enforcement Administration’s (DEA) Cocaine 
Signature Program was 85 percent (DEA, 2019). 
That same year, the average purity of MA was 90 
percent (DEA, 2019). 
Adulterants are added to cocaine to increase its 
weight by cutting or substituting less expensive 
but similar-tasting and -acting products that will 
maximize profts for the seller while still satisfying 
the consumer. Of cocaine seized and tested by 
the DEA Cocaine Signature Program in 2018, 80 
percent was unadulterated—an almost 36-percent 
increase from 2017 (DEA, 2019). Of the remainder, 
17 percent was adulterated with levamisole (a 
veterinary drug that is not commercially available in 
the United States) and/or levamisole mixtures with 
dexamisole, and 3 percent was mixed with various 
other cutting agents (DEA, 2019). 
A growing trend has been documented in the 
United States of adulterating cocaine (and to an 
extent MA) with fentanyl and fentanyl derivatives 
(e.g., acetyl fentanyl, carfentanil, furanyl fentanyl, 
4-fuoroisobutyrfentanyl). From 2016 to 2017, DEA 
found such substances in more than 180 seized 
cocaine exhibits from the State of Florida. The 
most common adulterant of these was carfentanil, 
which is 10,000 times stronger than morphine 
(DEA, 2018). MA–fentanyl mixtures have been on 
the rise since 2015 and account for 2 percent of all 
reports on MA from DEA and the National Forensic 
Laboratory Information System (DEA, 2019). 
From 2013 to 2018, the number of MA-positive 
urine drug tests also testing positive for fentanyl 
increased by 798 percent, and cocaine-positive 
urine drug screens that also tested positive for 
fentanyl increased by 1,850 percent (Han et al., 
2019). These combinations increase the risk of 
opioid overdose, as patients may not be aware 
that the stimulant they are taking is laced with an 
opioid. From January to June 2019, 32 percent 
of all drug overdose deaths in 24 states and the 
District of Columbia involved an opioid–stimulant 
combination, and of those combination overdose 
deaths, 80 percent involved illegally manufactured 
fentanyl (O’Donnell et al., 2020). This underscores 
the importance of providing people who use 
stimulants access to and education about naloxone 
(the opioid overdose reversal drug). 
The manufacturing processes for illicit MA 
can be crude and involve many impurities 
and contaminants that pose serious health 
consequences. Until recently, most of the MA in 
the United States was manufactured from phenyl-
2-propanone (P2P), a method of synthesis in 
which lead acetate is used as a chemical reagent. 
Production using ephedrine or pseudoephedrine 
as the precursor became popular in the 1990s 
but has decreased in popularity somewhat as 
access to over-the-counter pseudoephedrine 
has become more tightly controlled under the 
Combat Methamphetamine Epidemic Act of 2005. 
The P2P method bypasses the use of ephedrine 
and pseudoephedrine and yields a highly potent 
form of MA; consequently, P2P has become the 
standard production approach. More than 98 
percent of MA samples analyzed in the second half 
of 2018 by the DEA Methamphetamine Profling 
Program were manufactured via P2P (DEA, 2019). 
In 2014, an alternate P2P method was identifed. 
Termed the nitrostyrene method, it uses 
benzaldehyde and nitroethane as precursors 
(DEA, 2019). In the second half of 2018, the older 
P2P method accounted for 48 percent of P2P 
production and the newer nitrostyrene method 
12 percent (DEA, 2019). DEA has identifed an 
even more recent production method using 
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phenyl-acetic acid, benzyl chloride, and sodium 
cyanide (which form an oil called benzylnitrile), 
but no forensic marker currently exists, and it is 
unclear currently how widespread these chemical 
precursors are (DEA, 2019). 
Illicit MA is also likely to contain potentially toxic 
contaminants from unintended reaction byproducts 
and reagent residuals, as well as processing errors. 
Many clandestine laboratories are operated by 
untrained individuals who get instructions from 
unpublished handwritten sources or through the 
Internet. As with cocaine, most of the contaminants 
are intentional fllers used to dilute or cut the 
product. Some examples of fllers are lactose, 
lidocaine, procaine, caffeine, quinine, and sodium 
bicarbonate (Cole et al., 2010). Other impurities in 
illicit MA can cause dangerous toxic reactions. 
Patterns of Use 
The effects of stimulant use also refect the 
temporal pattern of drug administration and the 
individual’s experience history or chronicity of 
use. Some people use stimulants only periodically, 
although most discover that tolerance builds 
rapidly to many of the desired effects, particularly 
euphoria, so increasing doses and increasing 
frequency are needed to achieve similar effects. 
Although serious medical, psychological, and 
social consequences have followed experimental 
low-dose use of stimulants, two other patterns 
of self-administration are of greater concern. 
The ffth edition of the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-5; American 
Psychiatric Association [APA], 2013) characterizes 
these as chronic or episodic, with binges occurring 
intermittently with brief periods of abstinence. 
An estimated 10 to 15 percent of people who use 
cocaine develop an SUD (Simon & Kreek, 2016). 
Exhibit 3.4 lists the range of physiologic and 
behavioral symptoms often seen in stimulant 
intoxication (Paulus & Stewart, 2020; United 
Nations Offce on Drugs and Crime [UNODC], 
2019b). 
















Euphoria, heightened sense of self 
Diaphoresis (profuse sweating)—often with Increased vigor, giddiness, and sense of enhanced 
chills mental acuity and performance 
Hypertension Agitation, restlessness, irritability 
Tachycardia, with or without arrhythmia and Increased alertness 
chest pain Decreased appetite 
Decreased cardiac output Increased sexual libido 
Hyperthermia (elevated temperature) Poor concentration, although some individuals 
Suppressed appetite, weight loss may report improved concentration 
Nausea and vomiting Grandiosity, exaggerated self-esteem, egocentricity 
Abnormal body movements Hypervigilance 
Bruxism Fearlessness 
Insomnia Suspiciousness, psychotic symptoms (e.g., 
Tremors paranoia) 
Headache (occasionally) Clear sensorium, not usually disoriented 
Emotional lability with potential for violence, 
perceptions of persecution 
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Intoxication 
The following paragraphs describe the sequence of
phases that typically occur in a person as he or she
moves from occasional or binge use to daily use and
dependence as well as some of the accompanying
side effects. Knowledge of these phases can help
medical practitioners take a substance use history
and understand what effects are likely to accompany
a particular stage of acute intoxication, withdrawal, or
more chronic use patterns. 
Stimulant use phases 
• Initiation, single-dose phase. Early use of a 
single dose of stimulants results in euphoria and 
increased energy that correspond closely to 
stimulant plasma concentration levels. Higher 
levels of euphoria are achieved by inhalation 
(smoking) or injection routes of administration 
that evoke a rapid rise to peak drug 
concentrations. The rush experienced by people 
who inhale or inject stimulants is profoundly 
rewarding and reinforcing. Classical conditioning 
to the cues associated with drug use may occur 
during this initial phase. 
• Consolidation, dose-frequency escalation 
phase. As tolerance develops to the euphoric 
effects, people tend to increase doses and 
frequency of stimulant administration in an 
attempt to recapture the original and most 
intense sensations. They may also switch the 
route of use to get a more rapid response. 
During this phase, intermittent consumption is 
prolonged with the discovery that higher doses 
produce greater effects and more frequent 
doses prolong those effects. 
• Maintenance phase with bingeing. High-dose 
and high frequent-use patterns often lead 
to even more compulsive bingeing over a 
few hours to days that ceases only when the 
individual is totally exhausted or the stimulant 
supply runs out. Binges typically last 12 to 18 
hours (but may last 2 to 3 days or longer) for 
people who use cocaine and much longer—from 
3 to 15 days—for people who use MA. The 
high and sustained plasma concentration levels 
achieved during binges can have considerable 
pathological effects. The binge is characterized 
by frequent mood swings as plasma 
concentration levels of the stimulant fuctuate. 
Stereotypic behaviors and thinking exclude 
other concerns so that the person focuses 
exclusively on internal sensations and withdraws 
from social activities in pursuit of direct 
pharmacologic effects. Almost all activity is 
directed to acquiring the drug and consuming it. 
Also, the settings in which the person consumes 
drugs become progressively restricted. 
“Crash” and withdrawal syndrome 
phases 
• Acute withdrawal or “the crash” phase. The 
timing of withdrawal phases will vary based on 
the type of stimulant used. Cocaine withdrawal 
will be shorter in duration than MA (Lerner & 
Klein, 2019). Withdrawal from MA use can be 
protracted, lasting several weeks (Courtney & 
Ray, 2014). Withdrawal syndromes should be 
thought of as a direct effect of a withdrawal 
from excessive dopaminergic activity throughout 
the body. A binge terminates with acute 
withdrawal, often called a “crash” (Lerner & 
Klein, 2019). Acute withdrawal is characterized 
by dysphoria, anxiety, and agitation and can 
begin a short time after cessation of stimulant 
use (Lerner & Klein, 2019). Intense cravings 
during the acute withdrawal phase frequently 
lead to recurrent substance use (Lerner & Klein, 
2019). Individuals may exhibit a repetitive cycle 
of bingeing, with an intervening crash, over a 
period of several months. Anxiety and agitation 
are accompanied by a period of fatigue, 
increasing depression, and decreased mental 
and physical energy. An intense desire for 
sleep, often accompanied by insomnia, usually 
replaces the drug craving. During this part of 
the crash, individuals may use “landing gear,” 
such as alcohol, benzodiazepines, cannabis, or 
opioids, to induce and prolong sleep. During 
the acute withdrawal phase, patients may 
continue to experience psychotic symptoms 
related to sleeplessness or prolonged stimulant 
use. Additionally, in the frst 1–2 weeks of 
withdrawal from stimulants, some patients may 
experience suicidality and should be monitored 
appropriately (Lerner & Klein, 2019). 
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• Postacute withdrawal or “the wall.” This 
period is characterized by a profound 
hypersomnolence, fatigue, mood lability, 
and increased appetite. People sometimes 
continue to have cravings during the postacute 
withdrawal period and return to recurrent 
use or a repeat binge during this period. The 
period of postacute withdrawal may extend 
to 2 weeks or more after the patient’s last 
use. During the immediate period after the 
initiation of abstinence, after psychosis subsides, 
patients often report anxiety or worry about 
painful memories lingering from the binge, and 
confusion about which are real and which are 
imagined. These disturbing events, whether 
real or imagined, can be traumatizing. Criminal 
or abusive behaviors that occur during acute 
intoxication, either real or imagined, can lead to 
feelings of remorse or dread and can contribute 
to impulsive self-harm behaviors. 
• Protracted withdrawal. Following acute 
withdrawal, the person may experience 
symptoms that are opposite to those of 
stimulant intoxication: fatigue, loss of physical 
and mental energy, depression, anhedonia, 
and a limited interest in his or her surroundings 
(Lerner & Klein, 2019). Severity and duration 
of protracted withdrawal symptoms is often 
correlated with the duration and severity 
of stimulant use. As in previous phases of 
withdrawal, a severe and persisting depression 
in this phase can result in suicidal ideation 
or suicide attempts and is a major concern. 
Anhedonia and dysphoria can last for months 
in people who use MA (D. Hunt et al., 2006; 
Rawson, 2013). In the protracted withdrawal 
phase, periods of drug craving may reemerge 
or become stronger. These cravings are often 
triggered by conditioned environmental cues 
and can only be extinguished by sustained 
abstinence. Patients may also experience 
breakthrough psychotic episodes during the 
protracted withdrawal phase. 
• The post-crash euphoric phase or “the pink 
cloud.” During the stage sometimes termed 
“the pink cloud,” patients enter a euphoric 
state. This often occurs around the 1-month 
mark following withdrawal and completion of 
detoxifcation, when the brain is overproducing 
dopamine. Patients may express a sense of 
positivity and self-confdence (“I am never 
going to use drugs again!”). However, this 
period quickly subsides as the brain begins to 
underproduce dopamine, and patients typically fall
into a depression at the 3- to 6-month mark, when
they have a high likelihood of return to use. 
Tolerance/Sensitization to Stimulant 
Efects 
People with chronic stimulant use develop 
tolerance to many of the initial effects, often after 
only a few weeks of drug use. This means that a 
higher dose is required to achieve the same effects, 
or markedly diminished effects are attained if the 
same dose is continued (APA, 2013). (Note that this 
is not true of prescription stimulants when taken 
as prescribed.) Most notably, tolerance develops 
rapidly to the euphoric effects of stimulants and 
is the ostensible cause for most dose escalation 
by people who use stimulants, although dose 
increases may also stem from a desire to 
experience more intense effects. Tolerance also 
develops to the anorectic (appetite-reducing) 
effects of MA in humans because weight loss stops 
after several weeks. Tolerance also appears to 
develop to the cardiotoxic effects of large doses 
of MA that many people survive. In fact, many 
of the initial symptoms of stimulant intoxication 
disappear with chronic use: Blood pressure may be 
normal, and nausea and vomiting are seldom seen. 
This tolerance is not the result of increased MA 
metabolism (Cruickshank & Dyer, 2009). 
Interestingly, people with chronic, high-dose 
stimulant use may also become sensitized to the 
drug, a unique phenomenon characteristic of 
psychomotor stimulants. Sensitization is essentially 
the reverse of tolerance and produces undesirable 
effects with lower doses of the drug than were 
required to yield these same reactions in an earlier 
phase of the addiction process. There appears to 
be some sensitization to the psychosis-inducing 
effects of stimulants in humans. After one 
psychotic episode is experienced following chronic, 
high-dose use, a lower minimal dose of cocaine 
or MA may induce another psychotic episode, 
with more rapid onset following drug intake and 
a longer duration than the initial psychosis. The 
sensitization process in stimulant use disorder is 
elaborated on in the “Stimulant-Induced Psychosis” 
section in this chapter. 








































Chapter 3—Medical Aspects of Stimulant Use Disorders 
Some researchers suggest that long-term use of 
stimulant medication may lead to tolerance in 
some patients and thus the need for patients with 
ADHD to increase their dosages over time; but it is 
unclear whether this tolerance and resulting need 
for more medication occur because of the chemical 
properties of the medication itself or because of 
other factors (Yanofski, 2011). 
Clinical Manifestations and
Medical Management 
The intensity and duration of acute manifestations of
stimulant intoxication correlate generally with the rate
of rise and the height of peak blood levels refected
in brain concentrations. Acute intoxication with
stimulants resembles hypomania or a manic state.
In low doses, the libido (sexual drive) is stimulated;
sexual desire and sexual response are enhanced
(Ciccarone, 2011). Agitated states featuring
increased paranoia, fear of persecution, or other
psychotic symptoms may also occur with intoxication,
particularly for MA (UNODC, 2019b). With increasing
doses, impaired judgment, hypersexuality, and
other atypical behaviors or mental alterations are
more likely. Acute stimulant intoxication can result
in seizures, confusion, respiratory depression, chest
pain, or cardiac arrhythmias (UNODC, 2019b; see
Exhibit 3.4). 
Distinctive Characteristics of 
Methamphetamine Intoxication 
• MA intoxication may be indicated by an odor 
of ammonia or stale urine, especially among 
people who smoke MA that has been crudely 
synthesized in illicit laboratories. Smoked MA is, 
however, essentially odorless. 
• The person who uses MA may present 
with tachycardia, which may or may not be 
accompanied by arrhythmia (Richards & Laurin, 
2020). 
• People who use MA may present in the ED as a 
result of trauma from blunt force or penetrating 
injuries or from motor vehicle accidents 
(Richards et al., 2017). 
• Given MA’s longer lasting effects, its use may lead
to more frequent mental impairment, more potent
central nervous system (CNS) effects, and more
overdoses. Chronic use of MA (beyond 2 weeks) is
more hazardous than chronic cocaine use because
of MA’s sustained effects. Moreover, drug-induced
psychoses in people who use MA are likely to last
longer than those of people who use cocaine and,
in addition, may not respond as readily to available
treatments. 
• Stereotyped activity—persistent, repetitive, and 
compulsive activity such as vacuuming the same 
part of the foor over and over again, popping 
knuckles repeatedly, picking at scabs, or taking 
apart and reassembling mechanical devices— 
may appear in people who use MA. 
• People who chronically use MA will likely 
experience increased persecutory perceptions/ 
suspiciousness (Alexander et al., 2017). 
• Increased social avoidance and disorganization 
can occur. 
• Dilated pupils and rapid eye movement can 
occur. 
Distinctive Characteristics of Cocaine 
Intoxication 
• People who have recently used cocaine may 
have increased issues with abstract concepts (as 
measured by problem solving in a card sorting 
task; Mangado & Madoz-Gúrpide, 2009). 
• People who experience cardiovascular effects 
from cocaine are likely to return to baseline 
more readily than people using MA (Newton et 
al., 2005). 
Distinctive Characteristics of Prescription 
Stimulant Intoxication 
• Amphetamine intoxication may be less likely to 
produce cardiovascular problems and seizures 
than cocaine toxicity. Behavioral and psychiatric 
symptoms, such as hallucinations and psychosis, 
are common with amphetamine intoxication 
(Spiller et al., 2013). 
• Rhabdomyolysis (a breakdown of muscle 
tissue that can release protein into the blood 
and damage kidneys) can occur with severe 
amphetamine toxicity and is often preceded 
by psychomotor agitation, hyperthermia, and 
seizures (Spiller et al., 2013). 
• Distinctive signs of prescription stimulant 
misuse in college students can include poor 
psychosocial adjustment, lower academic 
performance (i.e., grade point average), 


















































Treatment for Stimulant Use Disorders 
co-occurring use of alcohol and drugs (e.g., 
cannabis), and increased problems with 
attention (Munro et al., 2017; Rabiner, 2013). 
• Behaviors indicative of prescription medication 
misuse in general that could appear in people 
with prescription stimulant misuse include 
stealing, forging (faking), or selling prescriptions; 
taking more doses than prescribed; repeatedly 
asking for early reflls; continually claiming to 
have lost one’s prescription (and thus needing 
another one); or “prescription shopping” (trying 
to obtain multiple prescriptions from multiple 
doctors; Mayo Clinic, 2018). 
Management of Stimulant Intoxication 
General measures to manage uncomplicated 
intoxication are monitoring vital signs for rising 
pulse rate, temperature, or blood pressure and 
providing a quiet and cool environment that helps 
to diminish agitation and overreaction to external 
stimuli. These measures are continued until 
symptoms subside, usually after several hours. 
Physical exertion and an overheated room can
increase the likelihood of adverse effects because
stimulants affect the body’s heat-regulating
mechanism at the same time that blood vessel
constriction conserves heat. Although verbal
reassurance is usually suffcient for calming the
patient, indications that agitation is escalating and
moving toward paranoia and potential psychosis,
with increasing risk for violence, may warrant talking
with the patient about pharmacologic options (e.g.,
lorazepam or midazolam for severe cases in which
rapid control over the patient is needed). 
Background on Stimulant Overdose 
Because of the rising trend of stimulants being 
combined with opioids, like fentanyl, risk of 
overdose should include the risk for both opioid
overdose and stimulant overdose (Fleming et
al., 2020). Variability in stimulant purity and an
unpredictable and unknown relationship to body
weight means overdose cannot always be predictable
based on the substance used. 
The symptoms of a sublethal stimulant overdose
may include dizziness, tremor, irritability, confusion,
mood lability, hallucinations, panic, headache, skin
fushing, chest pain, palpitations, cardiac arrhythmias,
hypertension, vomiting, cramps, and excessive
sweating (Richards & Laurin, 2020; Richards &
Le, 2020; Vasan & Olango, 2020). High doses of
stimulants may cause high fever, cardiac arrhythmias
and arrest, irregular breathing, seizures, and stroke
(Richards & Laurin, 2020; Richards & Le, 2020; Vasan
& Olango, 2020). The development of hyperpyrexia
(excessively high fever), severe hypertension,
convulsions, and cardiovascular collapse signal a life-
threatening situation (UNODC, 2019b). Prescription
stimulant overdose is associated with pupil dilation,
tremor, agitation, hyperrefexia, combativeness,
confusion, hallucinations, delirium, anxiety, paranoia,
movement disorders, and seizures (Spiller et al.,
2013).
Lethal doses of stimulants produce a predictable
sequence of events culminating in generalized
convulsions and death. Heart rate, blood pressure,
cardiac output, and body temperature rise rapidly,
and a delirium is observed before generalized and
terminal seizures begin (Mash, 2016; UNODC,
2019b). Overdose is more likely to occur when
people have been abstinent for a time rather than
when they have been actively and continuously using.
They are at the highest risk for overdose when they
enter treatment and stop using a substance. 
Management of a Potentially Lethal 
Overdose 
People who use stimulants and present with 
life-threatening medical conditions (e.g., 
arrhythmias, compromised airways, seizure) 
and lethal drug levels should be treated with 
standard life-saving techniques that respond to 
the presenting symptoms (NIDA, 2018b; Vasan 
& Olango, 2020). Acute neurologic symptoms, 
such as seizures or rapidly elevating vital signs, 
require immediate intervention. Non-drug-induced 
causes of any symptoms should be carefully ruled 
out, and the patient should also be evaluated 
for polysubstance use. Stimulant overdose—as 
well as acute intoxication and withdrawal—can 
be managed in hospital settings to help address 
medical complications and prevent symptoms from 
increasing in severity (UNODC, 2019b). 
Management of prescription stimulant overdose
should focus on providing supportive care, including
the cautious use of benzodiazepines and—if












Chapter 3—Medical Aspects of Stimulant Use Disorders 
agitation, delirium, and movement disorders are
unresponsive to benzodiazepines—the possible
use of antipsychotics, central alpha-adrenoreceptor
agonists, or propofol (Spiller et al., 2013). 
For a stimulant overdose in which opioid 
involvement is suspected (including fentanyl 
involvement), administration of the opioid reversal 
agent naloxone by emergency medical service 
personnel in the feld or in the hospital setting is 
critical (Chou et al., 2017). 
No specifc antidotes or antagonists to stimulant 
overdose are available, unlike naloxone for opioids 
and the benzodiazepine antagonist fumazenil. 
However, the following procedures are suggested: 
• Request specialist consultations as needed. 
• Manage hyperthermia by rapidly cooling the 
patient with cooling devices or external cooling 
agents like water misting from convection 
cooling fans or ice (Richards & Le, 2020). 
Aggressive sedation and volume replacement 
may also be indicated. 
• Provide adequate ventilation and oxygenation. 
• Benzodiazepine therapy is generally suffcient 
to alleviate cardiovascular symptoms and signs. 
Otherwise, manage uncontrolled hypertension 
by administration of phentolamine. Non-
dihydropyridine calcium channel blockers (e.g., 
diltiazem, verapamil) may be used to reduce 
hypertension but not tachycardia (Richards & 
Le, 2020). The alpha-blocker phentolamine 
also may be used to manage hypertension but 
is not effective for tachycardia (Richards & Le, 
2020). Labetalol, a mixed beta/alpha blocker, 
has demonstrated safety and effectiveness in 
cocaine-induced hypertension and tachycardia 
(Agrawal et al., 2015; Richards & Le, 2020) and 
is approved by an American Heart Association/ 
American College of Cardiology guideline for 
patients with unstable angina/non-ST elevation 
myocardial infarction who have used cocaine or 
MA (J. L. Anderson et al., 2007). Beta-blockers 
are generally discouraged in the treatment of 
stimulant-induced hypertension (and particularly 
for cocaine), although this is an unresolved 
matter with some guidelines offering mixed 
advice on their use or avoidance. 
• Treat seizures like status epilepticus with 
intravenous lorazepam or midazolam, preferably 
starting frst with lorazepam (H.-Y. Chen, 
Albertson, & Olson, 2016). If intravenous 
access cannot be obtained, intramuscular 
midazolam can be administered (H.-Y. Chen, 
Albertson, & Olson, 2016). Barbiturates 
(typically phenobarbital) are recommended only 
if patients do not respond to benzodiazepines 
(H.-Y. Chen, Albertson, & Olson, 2016). 
• Complaints of chest pain warrant evaluation for 
possible myocardial ischemia and infarction. 
Nitroglycerin is indicated for cocaine-induced 
myocardial ischemia to alleviate coronary 
vasoconstriction and for cocaine-induced chest 
pain (Agrawal et al., 2015). Beta-adrenergic 
blockers such as propranolol should not be used 
because they may enhance vasospasm. Aspirin 
should be administered, unless contraindicated, 
to reduce cocaine-mediated prothrombotic 
effects (Agrawal et al., 2015). 
Correction of abnormal electrolytes, dehydration, 
and metabolic dysfunction should lower the risk 
of isolated arrythmias. If arrythmias occur, use 
standard treatments. Atrial arrhythmias (e.g., 
atrial fbrillation, atrial futter) that do not respond 
to cooling, oxygen, volume resuscitation, and 
sedation may require the calcium-channel blocker 
diltiazem as frontline parenteral (i.e., administered 
by injection, such as intravenous or intramuscular 
injection) treatment; supplemental magnesium 
can also be helpful (Farkas, 2021). Cardioversion is 
unlikely to be successful during acute intoxication. 
Ventricular tachycardia should be treated with 
sodium bicarbonate to reverse antagonism of 
sodium channels; if the arrhythmia is resistant to 
this and electrical cardioversion, lidocaine is the 
next choice to terminate the arrythmia (Farkas, 
2021). Also, management of acute psychiatric 
manifestations of cocaine intoxication by sedation 
appears to have a benefcial effect on emerging 
cardiovascular complications. 
In general, phenothiazines, especially chlorpromazine,
are contraindicated because they may lower the 
seizure threshold (M. M. Dougherty & Marraffa, 
2014). Haloperidol may precipitate or exacerbate 
acute dystonic reactions associated with recent 
cocaine use (K. Lewis & O’Day, 2020). 




































Treatment for Stimulant Use Disorders 
Manifestations of Stimulant Withdrawal/ 
Abstinence 
A characteristic withdrawal syndrome usually 
develops within hours to days after cessation of 
prolonged and heavy stimulant use. The symptoms 
can follow long-term use or much shorter binges 
(Exhibit 3.5). 
Some clinicians distinguish between stimulant 
withdrawal symptoms following a several-day 
binge and complaints that characterize withdrawal 
after more chronic high-dose use. People who 
use stimulants who have binged for 2 to 3 days 
are dysphoric and exhausted, and they sleep 
excessively for 24 to 48 hours. To reduce irritability 
and induce sleep, people may commonly use 
alcohol, cannabis, benzodiazepines, or opioids 
with cocaine or MA (often called “landing gear”). 
Following more chronic and regular stimulant use, 
severe withdrawal symptoms last several days, with 
less severe symptoms (e.g., fatigue, depressed 
mood, anxiety, drug craving, concentration 
diffculties) lasting 1 to 3 weeks (UNODC, 2019b). 
A substantial number of people with chronic 
cocaine use may have subclinical evidence of 
withdrawal symptoms. Some people who use 
cocaine report withdrawal symptoms beginning 1 
to 2 days after the last dose, with the crash lasting 
several days and withdrawal persisting from 1 
to 2 weeks, with waxing and waning of the drug 
craving, although protracted withdrawal may last 
longer (Lerner & Klein, 2019). The mood state of 
the person may return to normal after several days 
to a month. 
For MA, withdrawal symptoms seem to be most 
severe in the initial days following cessation of use 
(UNODC, 2019b). There may be some physical 
manifestations of a withdrawal syndrome when 
MA use is stopped (e.g., headache, increased 
or pounding heartrate, sweating, muscle or joint 
aches; Zorick et al., 2010). Symptoms begin 2 to 4 
days after a person stops use and may persist for 
2 to 4 weeks (Lerner & Klein, 2019). The patient 
initially feels depressed and anxious, with an 
intense craving for MA. This phase is followed 
by fatigue and sleepiness, possibly mixed with 
insomnia. Upon awakening after prolonged 
sleep, the patient may be very hungry and may 
have persistent anhedonia and dysphoria. Other 
symptoms include paranoia and agitation (Lerner & 
Klein, 2019). 
Withdrawal from MA can mimic symptoms of 
depression, which complicates differentiating 
withdrawal from an independent depressive 
disorder (Hellem, Lundberg, & Renshaw, 2015). 
Research on withdrawal from prescription stimulants
is mostly concentrated on adults and suggests that
vomiting, headache/migraine, and light sensitivity can
occur with abrupt discontinuation or dose reduction
EXHIBIT 3.5. Common Signs and Symptoms of Stimulant Withdrawal/ 
Abstinence Syndrome 
PHYSIOLOGIC PSYCHOLOGICAL/BEHAVIORAL 
Weight gain Dysphoric mood that may deepen into clinical 
Dehydration depression and suicidal ideation 
Fatigue and lassitude, with lack of mental or Persistent and intense drug craving 
physical energy Anxiety and irritability 
Dulled sensorium Impaired memory 
Psychomotor lethargy and retardation—may be Anhedonia (i.e., loss of interest in pleasurable 
preceded by agitation activities) 
Hunger Interpersonal withdrawal 
Chills Intense and vivid drug-related dreams 
Insomnia followed by hypersomnia 















Chapter 3—Medical Aspects of Stimulant Use Disorders 
(Krakowski & Ickowicz, 2018). Other withdrawal
symptoms in adults include depression, fatigue,
appetite change, and sleep disturbance (Krakowski &
Ickowicz, 2018). Symptoms of withdrawal in children
are based mostly on case studies and can include
symptoms like headache, depression, and a general
feeling of malaise (Krakowski & Ickowicz, 2018). 
Management of Stimulant Withdrawal 
No consistent physiologic disruptions requiring 
gradual withdrawal have been observed, but some 
medications may attenuate symptoms and provide 
support and comfort throughout withdrawal. 
The greatest risk during stimulant withdrawal is of 
doing harm to self. Because withdrawal-related 
dysphoria and depression can be particularly 
severe in people using stimulants, risk of suicide is 
intensifed and sensitive management is essential 
(Lerner & Klein, 2019). Cocaine-induced depression 
usually dissipates fairly rapidly—in a matter of 
hours to days. The depression is agitated and often 
related to actual situations resulting from drug use 
(e.g., a patient is disturbed that he has spent all his 
savings on the cocaine binge or that his continuing 
SUD jeopardizes his interpersonal relationships). 
Withdrawal-associated depression/suicidality
following high-dose MA use is more prolonged.
During the acute phase of withdrawal, the person
using high-dose MA may exhibit agitated paranoia,
extreme frustration, and the return of intense drug
cravings. Suicidal ideation may be high. People in MA
withdrawal have been known to become violent if
they perceive that they are being persecuted. 
Altered perceptions of reality after acute 
intoxication, particularly in a binge pattern of 
use, may result in patients perceiving caretakers’ 
gestures and comments as persecutory. Stress 
reduction techniques and other approaches to 
prevent harm should be used; medical personnel 
can also use benzodiazepines (e.g., diazepam) to 
control agitation and tachycardia (see the section 
“Aggression and Violence” in this chapter). 
For patients with preexisting diagnosed or 
unrecognized clinical depression, stimulant 
withdrawal worsens symptomatology. These 
individuals are most likely to experience deepening 
dysphoria and/or paranoia after use. 
Medication management of withdrawal symptoms 
has not been well established in major clinical 
trials but might involve short-term use of sleep 
medications to manage insomnia or other sleep 
problems (Wilkerson et al., 2019). Antipsychotics 
are not recommended for MA withdrawal 
(Braunwarth et al., 2016). 
Continuing agitation and persistent inability to 
fall asleep during the acute withdrawal stage 
may also be treated symptomatically by using 
the antidepressant trazodone, which can help to 
sedate the patient. Diphenhydramine is also used 
for its sedating properties and for its effects on the 
dermatologic problems that often accompany MA 
use (e.g., itching and hypersensitivity of the skin). 
However, caution should be exercised in using any 
medications with high potential for misuse. 
During acute withdrawal, the “crash” results 
in patients who sleep several days at a time, 
depending on the dose and duration of the 
binge (Nishino, 2009). This hypersomnolence may 
interfere with assessment of mental status and 
physiologic functioning. Patients experiencing 
hypersomnolence will struggle to meaningfully 
engage in a treatment program and will need to 
be reassessed and referred during the postacute 
withdrawal phase, likely with additional supports. 
Drug craving during stimulant withdrawal has 
been treated with a variety of medications (e.g., 
stimulant-replacement therapy [Stoops & Rush, 
2013]). However, clinical evidence is limited. More 
research is needed in this area. 
“Drug dreams” may occur during this period or 
as late as 6 months or more after termination of 
stimulant use during a protracted withdrawal phase 
(Jiménez-Correa et al., 2020). They usually entail 
vivid recall of actually using and experiencing 
the effects of the substance (Yee et al., 2004). 
The patient may actually sweat and experience 
other symptoms of intoxication while dreaming. 
These intense dreams, which may sometimes 
contain vignettes in which the person loses or 
drops a supply or refuses to smoke, can be used 
therapeutically to educate patients on their 
progress and identify potential triggers to recurrent 
use (Yee et al., 2004). The dreams may enhance 
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drug cravings and intensify a vulnerability for 
recurrent use. These dreams may be especially 
common in patients who have high ratings of drug 
craving and suicidality (Yee et al., 2004). 
People who use stimulants will frequently self-
medicate withdrawal symptoms with alcohol, 
benzodiazepines, or opioids. Patients may 
experience symptoms of withdrawal from these 
other substances if such use was regular or at 
high doses. These withdrawal symptoms require 
specifc management and may potentially require a 
medication titration schedule to alleviate symptoms 
and prevent an acute medical event. 
Withdrawal from prescription stimulants can also 
occur and result in fatigue, depressed mood, and 
sleep diffculties (NIDA, 2018b). Amphetamine 
withdrawal is associated with depression, 
fatigue, sleep problems, agitation, irritability, 
and concentration diffculties (Harro, 2015). 
There is limited research on methylphenidate 
withdrawal, but Food and Drug Administration 
(FDA)-approved labeling suggests withdrawal 
can include depressed mood, fatigue, vivid and 
unpleasant dreams, insomnia, hypersomnia, 
increased appetite, psychomotor retardation, or 
psychomotor agitation (see, for example, Novartis 
Pharmaceuticals, 2019). 
SCREENING, BRIEF INTERVENTION, AND REFERRAL TO TREATMENT FOR SUDS:
WHAT PRIMARY CARE PROVIDERS NEED TO KNOW 
Screening, brief intervention, and referral to treatment (SBIRT) is a highly studied, widely used approach to 
ensure access to comprehensive care that has demonstrated effectiveness in identifying and treating SUDs 
(e.g., alcohol use disorder, tobacco use disorder) as well as depression and anxiety (Hargraves et al., 2017). 
Primary care providers need to be aware of SBIRT and how to implement it in their service settings, because 
people with stimulant use disorders and other SUDs often frst present in primary care settings rather than 
SUD specialty treatment settings. Also, research suggests that primary care providers do not recognize and 
treat (or offer referral for) SUDs as often as needed (Pace & Uebelacker, 2018). Using SBIRT can help close 
these practice gaps. 
SBIRT for SUDs involves (Hargraves et al., 2017; Pace & Uebelacker, 2018): 
• Quick universal screening (using validated measures, such as the NIDA Modifed Alcohol, Smoking, 
and Substance Involvement Screening Test) to determine SUD presence. Quick screening often includes 
items to help assess level of risk (i.e., low, moderate, or severe) for patients who screen positive; 
answers to these items help determine treatment or service needs. 
• A brief motivational intervention that educates patients about substance use and prescription 
stimulant misuse and helps increase their motivation for behavior change. 
• Referral to treatment and service providers for individuals who need specialty services, a higher level of 
care, or both. 
Best practices for primary care providers and clinics wanting to implement SBIRT for SUDs include the 
following (Hargraves et al., 2017; Pace & Uebelacker, 2018): 
• Identify a practice champion or team lead to promote staff buy-in and increase accountability. 
• Use a multidisciplinary team of professionals and nonprofessionals, such as administrative staff and 
information technology experts. 
• Determine a screening strategy, such as which SUD screening measures will be used, who will administer 
them, and how the team will follow up on positive and negative screens. Nursing and intake staff can 
administer basic screening tools, saving time during the clinical encounter. 
• Make sure the team understands the SBIRT components and their individual roles in making SBIRT a 
success. 
Continued on next page 
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Continued 
• Cultivate close relationships with referral partners and maintain lines of communication when patients 
are referred. 
• Lay out a process for the brief intervention, such as identifying which team members will conduct the 
intervention and what key information needs to be conveyed to patients in the short amount of time 
allotted. 
• Implement ongoing SBIRT training so all team members can stay up to date on policies and procedures. 
This includes providing staff education to reduce stigma associated with drug and alcohol addiction and 
to help the team understand the scientifc evidence in support of SBIRT. 
• Make sure SBIRT fts into the natural workfow of the offce, and use visual diagrams to ensure that staff 
understand how and where each step of SBIRT is to take place. 
• Leverage electronic health records to enhance the effectiveness of SBIRT; this will help ensure that 
appointments, billing, screening (e.g., reminders, fags for positive screens), and interventions are 
implemented, tracked, and monitored. Digital technology, such as tablets and mobile phones, can be 
used for screening before an appointment or while in the waiting room (Ramsey et al., 2019). 
• Implement performance management tools and strategies to identify performance goals and 
benchmarks, barriers to implementation and positive outcomes, and potential solutions to these barriers. 
These efforts help organizations ensure continuous quality improvement. 
Manifestations of Chronic Stimulant Use 
Although fatalities from stimulant overdose or 
acute myocardial infarction following administration 
of cocaine by inexperienced people have been 
documented, and other medical and psychiatric 
complications have been observed at all dose 
levels and routes of administration among naïve 
individuals (i.e., people who previously have not 
been exposed to the drug), most serious stimulant-
induced medical and psychological complications 
follow chronic, high-dose use. Potentially serious 
manifestations of chronic stimulant use may also 
be somewhat sensitive to the environment in which 
the person resides. 
Long-term use can lead to stimulant use disorder, 
tolerance, and, upon cessation of use, withdrawal 
(UNODC, 2019b). This is also true for prescription 
stimulants, which are Schedule IIN drugs (DEA, 
Diversion Control Division, n.d.). A wide range of 
psychological and medical issues can arise with 
chronic stimulant exposure, from psychosis to 
depressive and anxiety disorders to numerous 
(potentially life-threatening) cardiovascular and 
respiratory complications (Petit et al., 2012; 
UNODC, 2019b). 
Although the medical consequences of chronic MA 
and cocaine use differ somewhat, the incidence of 
such side effects as chest pain, seizures, paranoid 
reactions, and suicidal thoughts is similar for both 
substances. Some studies indicate an increased 
risk of transient ischemic attack and sudden 
death/ventricular arrhythmia is associated with 
prescription stimulants, although more research 
is needed in this area (Westover & Halm, 2012). 
Exhibit 3.6 summarizes some of the more common 
symptoms and potentially serious complaints 
presented by chronic stimulant use or prescription 
stimulant misuse. Exhibit 3.7 shows the distinctive 
indicators of chronic MA use, cocaine use, and 
prescription stimulant misuse. 
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EXHIBIT 3.6. Common Symptoms of Chronic Stimulant Use or



















Extreme fatigue—with physical exhaustion and disrupted sleep patterns 
Nutritional disorders—extreme weight loss, anemia, anorexia, cachexia (body 
wasting) 
Poor hygiene and self-care 
Skin disorders and secondary skin infections—itching, lesions, hives, urticaria 
Hair loss 
Muscle pain/tenderness—may indicate rhabdomyolysis 
Cardiovascular damage—from lethal doses of the drug and contaminants in 
MA production, with concomitant renal and hepatic problems 
Hypertensive crises with renal damage from sustained hypertension 
Diffculty breathing—may refect pulmonary edema, pneumonitis, obstructive
airway disease, barotrauma, and other complications 
Myocarditis, infarcts 
Headaches, strokes, seizures, vision loss 
Choreoathetoid disorders 
Impaired sexual performance and reproductive functioning 
Cerebrovascular changes, including evidence of cerebral hemorrhages and 










cues, psychosis with 
altered perceptions 




and a fear of 
impending doom 
that resembles panic 
attacks 
Depression—with 






Ischemic bowel, gastrointestinal complaints 
EXHIBIT 3.7. Distinctive Indicators of Chronic Use of Cocaine and
Methamphetamine, and Chronic Misuse of Prescription Stimulants 














Possible physical dependence and 
tolerance 
In adults, increased risk of transient 
ischemic attack and sudden death due to 
ventricular arrhythmia 
Dental problems, including missing teeth, 
bleeding and infected gums, cavities 
Muscle cramping related to dehydration, 
with low magnesium and potassium levels 
Dermatitis around the mouth from 
smoking hydrochloride salt 
Stale urine smell due to ammonia 
constituents used in manufacturing MA 
Various dermatologic conditions, including 
excoriated skin lesions 
Possible physical dependence and 
tolerance 
In adults, increased risk of transient 
ischemic attack and sudden death due 
to ventricular arrhythmia 
Behaviors indicative of prescription 
drug misuse in general, like 
stealing, forging (faking), or selling 
prescriptions; taking more doses than 
prescribed; repeatedly asking for early 
reflls; continually claiming to have lost 
one’s prescription (and thus needing 
another one); or trying to obtain 
multiple prescriptions from multiple 
doctors (sometimes called “doctor 
shopping” or “prescription shopping”) 
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Research on methylphenidate-specifc misuse is 
lacking. However, knowing the signs of prescription 
stimulant misuse in general may be helpful in 
identifying long-term misuse in patients. Such 
signs and symptoms can include anxiety, loss of 
appetite, confusion, depression, irritability, memory 
problems, psychotic symptoms, and, in students, 
worsening academic performance (Greydanus, 
2006). Additionally, behaviors consistent with 
prescription drug misuse in general could appear 
in people with chronic prescription stimulant 
misuse. These include stealing, forging (faking), 
or selling prescriptions; taking more doses than 
prescribed; repeatedly asking for early reflls; 
continually claiming to have lost one’s prescription 
(thus needing another one); or trying to obtain 
multiple prescriptions from multiple doctors 
(also sometimes called “doctor shopping” or 
“prescription shopping”; Mayo Clinic, 2018). 
ROLE OF SOCIAL DETERMINANTS OF HEALTH IN MEDICAL COMPLICATIONS OF
STIMULANT USE DISORDERS 
Nonmedical infuencers of health and well-being—termed “social determinants of health” (SDoH)—can play a
role in the formation or exacerbation of medical conditions in people with stimulant use disorders. Common
SDoH include income, housing status, employment status, education level, and adverse childhood events
(like experiencing abuse or poverty as a child). 
For instance, a person with cocaine use disorder who does not have access to stable housing and hygienic 
food preparation may be more vulnerable to contracting hepatitis A virus. Someone with MA use disorder 
with no job or health insurance who has developed a cardiac arrythmia may not be able to afford (and thus 
adhere to) antiarrhythmic medication, which could lead to poorly controlled cardiac symptoms. When 
assessing patients with stimulant use disorders for possible medical conditions, clinicians should be sure to 
also assess for the presence of adverse SDoH. Where possible, link patients to professionals and resources 
that can help them address these challenges, such as mental health service providers, social workers, 
vocational rehabilitation services, child and family services, and fnancial assistance programs. 
For more information, see the Chapter 6 text box “The Importance of Thinking About Social Determinants 
of Health” and visit the Centers for Disease Control and Prevention website Social Determinants of Health: 
Know What Affects Health (https://www.cdc.gov/socialdeterminants/index.htm). 
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 Identifcation and Management
of Medical Complications 
The following sections briefy describe signs and 
symptoms of and treatments for common medical 
complications of stimulant use and prescription 
stimulant misuse. Certain populations of people 
with stimulant use disorders may be more likely 
than others to exhibit some of the medical 
complications described below (e.g., pregnant 
women exhibiting issues related to reproduction, 
pregnancy, childbirth, and the health of the fetus/ 
newborn). Readers are encouraged to reference 
Chapter 6 for more detailed information about 
these special populations (i.e., people who engage 
in intravenous drug use, men who have sex with 
men, members of the transgender and gender 
nonconforming community, people in opioid 
treatment programs, individuals with co-occurring 
mental illness, people with medical illnesses 
[e.g., HIV, tuberculosis], people involved with the 
criminal justice system, racial/ethnic minorities, 
rural populations, women [including those who are 
pregnant], adolescents, and people experiencing 
homelessness/unstable housing) and consider their 
possible medical complications or other medical 
effects when developing patient-centered case 
conceptualizations and treatment plans. 
Cardiovascular Efects 
Cardiovascular complications are a leading 
cause of death among people who use MA. 
Hypertension, aortic dissection, acute coronary 
syndromes, pulmonary hypertension, and 
cardiomyopathy (heart muscle dysfunction) 
are frequently observed (Paratz et al., 2016; 
Paulus & Stewart, 2020). MA use damages the 
cardiovascular system via multiple mechanisms, 
including triggering surges in catecholamine 
(e.g., dopamine, norepinephrine) release, which 
cause vasoconstriction; direct toxicity to cardiac 
and vascular tissue; and infammation of tissue 
and vessels (Kevil et al., 2019; Paratz et al., 2016). 
Hypertension and tachycardia are common and 
largely attributable to acute catecholamine release 
(Richards & Laurin, 2020). Vasoconstriction also 
triggered by catecholamine release can cause 
acute coronary syndromes and stroke. Damage to 
cardiac and vascular tissue, such as the endothelial 
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cells, by molecular mechanisms triggered by MA 
causes aortic dissection, dilated cardiomyopathy, 
arrythmia, and pulmonary hypertension (Kevil 
et al., 2019). Infammation triggered by MA 
contributes to functional and structural changes 
in the cardiovascular system, such as fbrosis and 
atherosclerotic plaque formation (Kevil at al., 2019; 
Paulus & Stewart, 2020). 
Cocaine has been linked with many forms of 
heart disease, including different forms of 
arrhythmias, hypertension, coronary vasospasm, 
arteriosclerosis, myocardial infarction, hypertrophic 
cardiomyopathy, and sudden cardiac death 
(Kim & Park, 2019). Arteriosclerosis is seen in 
younger-age individuals who take cocaine, as well 
as in individuals with co-occurring cardiovascular 
risk factors (Kim & Park, 2019). Myocardial 
infarction can occur with both low-dose and 
high-dose cocaine use (Kim & Park, 2019). Studies 
on the association between cocaine use and 
cardiovascular mortality have produced conficting 
results (Kim & Park, 2019). This may be due to 
variations in populations, as well as to study design 
issues, such as how studies control for other risk 
factors known to affect cardiovascular mortality, 
like cigarette smoking and depression. Some 
research suggests that individual factors may play 
a strong role in whether a person using cocaine 
experiences cardiovascular consequences (Kim & 
Park, 2019). 
Life-threatening acute conditions like myocardial 
infarction and aortic dissection require emergency 
response to stabilize the patient. Treatment for 
these and other cardiac conditions, such as heart 
failure and stroke, should follow consensus-based 
guidelines from experts in cardiology (Havakuk et 
al., 2017). Sedation through benzodiazepines is 
a recommended treatment for cardiotoxicity and 
agitation (Richards & Le, 2020). 
Prescription stimulants have been associated with 
increased resting heart rate and blood pressure 
(Torres-Acosta, 2020). In children and adolescents 
specifcally, prescription amphetamine has been 
linked to increased diastolic and systolic blood 
pressure and heart rate, whereas methylphenidate 
in this population has been linked to increased 
systolic blood pressure (Hennissen et al., 2017). 
In some cases, prescription stimulants have 
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also been associated with cardiac arrhythmias, 
cardiomyopathy, and sudden death (Torres-Acosta, 
2020). Adults with long-term use of prescription 
stimulants have increased risk of transient ischemic 
attack and sudden death due to ventricular 
arrhythmia, but children or adolescents with 
chronic use have not been observed to have 
increased risk (Westover & Halm, 2012). 
Pulmonary Efects 
Shortness of breath and chest pain can be 
either cardiac or pulmonary in origin. Wheezing, 
coughing, dark or discolored sputum, and 
hemoptysis (coughing up blood) can be symptoms 
of acute or chronic lung injury due to cocaine or 
MA use (Akwe, 2017; McCarthy & McClaine, 2019). 
Barotrauma is a complication of cocaine use 
and also occurs with MA (Guck & Munyon, 
2018; Restrepo et al., 2007). Barotrauma is 
caused by spasmodic or violent coughing 
following smoke inhalation, or increased airway 
pressure due to mouth-to-mouth drug delivery 
or Valsalva maneuver (Akwe, 2017; Kloss et al., 
2010). Barotrauma can cause alveolar rupture 
and the release of air into the chest cavity, 
the area surrounding the heart, and even the 
subcutaneous tissues of the chest wall and neck. 
The amount of free air is usually small and resolves 
spontaneously under observation. Alveoli can be 
damaged without associated rupture and air leak. 
Alveoli can lose structural integrity, resulting in 
emphysema. Blood vessels can also be damaged 
causing affected patients to cough up blood and 
experience bleeding into the lungs (Akwe, 2017; 
Mégarbane & Chevillard, 2013). 
The alveoli, blood vessels, and other lung tissue 
can be damaged in other ways as well. Mechanisms 
of injury to the lungs due to stimulant use include 
the introduction of foreign bodies or contaminants, 
triggering allergic or other infammatory immune 
responses. Pulmonary granulomatosis, excessive 
bronchial reactivity or bronchospasm, and 
hypersensitivity pneumonitis are all possible 
manifestations of these types of lung injury 
(Akwe, 2017; Mégarbane & Chevillard, 2013). 
People with asthma are more likely to experience 
bronchospasm with stimulant use (Akwe, 2017). 
Bronchiolitis and pneumonia are common 
complications of cocaine use (Akwe, 2017; 
Restrepo et al., 2007). People who smoke cocaine 
can experience acute alveolitis (also known as 
“crack lung”), which presents with severe chest 
pain, diffculty breathing, and high fever but 
normal-appearing lung X-rays. Alveolitis requires 
supportive care and, in some cases, high-dose 
steroids. Recovery typically takes 2 weeks, but 
the patient may experience long-term respiratory 
effects (Mégarbane & Chevillard, 2013). 
MA has been classifed as a “likely” risk factor for 
pulmonary arterial hypertension—a potentially 
fatal condition—with the amphetamine derivatives 
fenfuramine and benfuorex classifed as “defnite” 
risk factors (Ramirez et al., 2018a). However, only 
certain subsets of people who use MA appear 
to develop the disease, raising questions about 
whether individual genetic factors confer additional 
risk (Ramirez et al., 2018a). One study of California 
hospital discharges from 2005 to 2011 showed 
an association with MA and both pneumonia and 
acute respiratory failure (H. Tsai et al., 2019). Use of 
amphetamine-containing diet pills has resulted in 
pulmonary arterial hypertension (Garg et al., 2017). 
Research on amphetamine derivatives in 
prescription stimulants and their association with 
pulmonary arterial hypertension is not readily 
available, although at least one case report of 
methylphenidate-related pulmonary arterial 
hypertension (which subsided after treatment was 
ended) has been published (Ramirez et al., 2018b). 
Cerebrovascular Efects 
Medical consequences of stimulant use are 
produced in the cerebrovascular system through 
vascular, neuroexcitatory, and neurotoxic 
mechanisms. Neurologic effects of cocaine use 
are wide ranging and include seizures, cerebral 
ischemia, cerebral hemorrhages, infarction, 
cerebral atrophy, cognitive impairment, and mood 
and movement disorders (Cunha-Oliveira et al., 
2014). Systemic hypertension can trigger stroke 
and hemorrhage within the brain tissue or between 
the brain and the protective layers around it. Two 
of the most catastrophic acute consequences 
of unhealthy stimulant use are damage to the 
blood vessels in the brain and vasospasm. MA 
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use has been linked to increased occurrence of 
hemorrhagic stroke in people younger than age 
45 (Lappin et al., 2017). Damage to the heart can 
cause inadequate perfusion of the brain, resulting 
in hypoxic brain injury and subsequent edema, 
which can also cause lasting impairment after 
resolution of the acute injury (Ciccarone, 2011). 
Headache associated with cocaine use is also 
triggered by vasoconstriction or infammation of 
cerebral vasculature (Farooque et al., 2020). 
Seizures are a well-known complication of stimulant 
use (Klega & Keehbauch, 2018) triggered by 
neuroexcitation. Seizures triggered by cocaine 
tend to be short tonic-clonic events that stop 
without intervention and have no residual effects, 
but repeat seizures are typically managed with 
intravenous benzodiazepines. Seizures that don’t 
stop on their own should be managed according 
to standard protocols for status epilepticus. Focal 
seizures should trigger an evaluation for stroke or 
hemorrhage (Zimmerman, 2012). 
Neuroexcitation can also cause movement 
disorders and dystonia (Asser & Taba, 2015). 
Movement disorders consist of repetitive 
behaviors. Dystonia is the involuntary contraction 
of muscles in the face, neck, limbs, or other body 
parts. Dystonia can be painful and distressing 
(Ciccarone, 2011). Symptoms of these 
disorders typically resolve within a few days of 
discontinuation of stimulant use, but movement 
disorders or psychomotor disturbances, like tics 
and problems with gait and fne motor skills, have 
been seen in people who use MA and may persist 
even after a year or more of abstinence (Lappin 
et al., 2018). Benzodiazepines or neuroleptics 
may be used to manage acute, distressing, or 
persistent symptoms that impair function (Asser & 
Taba, 2015). More data are needed regarding the 
long-term management of patients with persistent 
movement disorders secondary to stimulant use. 
Evidence from a small number of animal and 
human studies suggests that MA use may 
moderately increase the risk of developing 
Parkinson’s disease or parkinsonism, including 
possibly causing premature onset of Parkinson’s 
disease—especially when other risk factors are 
present (e.g., comorbid HIV infection, male gender; 
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Lappin et al., 2018). The potential increased risk 
of Parkinson’s disease specifcally has not been 
observed among people taking cocaine (Lappin et 
al., 2018). 
Acquired brain injury is another mechanism 
contributing to the cerebrovascular consequences 
of stimulant use. Cocaine induces lesions and 
atrophy, mostly in the prefrontal cortex and basal 
ganglia (Cunha-Oliveira et al., 2014). MA is known 
to induce damage to dopamine and serotonin axon 
terminals in the striatum, prefrontal cortex, and 
hippocampus (Halpin et al., 2014). Cocaine and 
MA use have both been associated with defcits 
in executive functioning (decision making) and 
processing speed, often due to problems with 
perseveration, inattention, and working memory 
diffculties (Hall et al., 2018). Cocaine use has been 
linked to worse verbal working memory than MA, 
whereas MA has been associated with poorer 
delayed contextual verbal memory and delayed 
visual memory than cocaine (Hall et al., 2018). 
Cognitive defcits observed in cocaine and MA 
use are also seen in brain aging and dementia and 
may indicate premature brain aging, possibly due 
to cerebral atrophy resulting from direct effect of 
stimulants or hypoxic brain injury in people with 
stimulant use disorders. 
Simultaneous alcohol and cocaine use produces 
cocaethylene, the ethyl ester of benzoylecgonine, 
and is also being researched further (A. W. Jones, 
2019). (For more on the hazards of combining 
these two substances, see the “Polysubstance Use” 
section later in this chapter.) Another unresolved 
issue is whether stimulants are causal factors in 
CNS vasculitis; however, CNS vasculitis induced by 
MA or cocaine use is rare (Younger, 2019). People 
who have taken cocaine or MA and complain of 
sudden headache should be evaluated for possible 
intracranial hemorrhage (Farooque et al., 2020). 
Case reports of current or past history of cocaine 
use have found an association with corneal or 
retinal nerve damage (Friedman et al., 2010; Stuard 
et al., 2017), and in some instances the damage 
may be similar to optic nerve damage found in 
people with diabetes (Stuard et al., 2017). 
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Although amphetamine-type substances have 
been hypothesized to increase the risk of stroke, 
a literature review of stroke incidence associated 
with prescription stimulant use found very little 
research on the subject and noted the need for 
additional, more robust research (Indave et al., 
2018). Additionally, some studies have indicated 
long-term use of prescription stimulants might 
increase the risk of transient ischemic attack, but, 
again, more research is needed to reach frm 
conclusions (Westover & Halm, 2012). 
People with ADHD are at an increased risk for
seizures, but current evidence strongly suggests
this is not due to stimulant medication (Wiggs et al.,
2018). In an analysis of more than 800,000 insurance
claims, ADHD medication use was associated with
lower odds of seizure (Wiggs et al., 2018). 
Muscular and Renal Toxicity 
Cocaine and MA may directly cause muscle 
degradation, and acute rhabdomyolysis has 
been diagnosed in people who did not have 
any of the previously associated risk factors (i.e., 
hyperthermia, agitation, seizures, hypotension, 
toxic delirium or coma, acute renal failure 
[A.D.A.M. Medical Encyclopedia, 2021; Lannett, 
2020]). Muscle necrosis may occur regardless of the 
route of drug administration, and the presence of 
rhabdomyolysis should be considered in patients 
with stimulant intoxication, particularly those 
presenting with myalgia, lower back pain, or 
muscle tenderness. 
Cocaine is known to induce acute kidney injury, 
possibly through rhabdomyolysis, vasculitis, 
infarction, thrombotic microangiopathy, or severe 
hypertension (Goel et al., 2014; Pendergraft et al., 
2014; Zimmerman, 2012). In the Healthy Aging in 
Neighborhoods of Diversity across the Life Span 
study (Novick et al., 2016), lifetime cocaine use 
was signifcantly associated with reduced renal 
functioning as measured by albumin-to-creatinine 
ratio (odds ratio = 1.8) and estimated glomerular 
fltration rate (odds ratio = 1.4). MA is associated 
with acute kidney injury, hyponatremia, and 
nontraumatic rhabdomyolysis (Pendergraft et al., 
2014). Patients with stimulant use disorders should 
be encouraged to hydrate and take rest periods 
to minimize the risk of the development of renal 
toxicity/rhabdomyolysis. 
Gastrointestinal Efects 
Some people who use stimulants experience 
abdominal pain, nausea, and vomiting, potentially 
indicating intestinal ischemia caused by vasospasm 
in the intestinal blood supply. Intestinal ischemia 
can lead to death of bowel tissue. Severe bowel 
infarction due to stimulant use has been reported 
(J. E. Anderson, Brown, et al., 2018; Attaran, 
2017; Choi et al., 2019). Severe bowel infarction 
causes bleeding, elevated white blood cell counts, 
and metabolic acidosis, and can lead to shock 
and death. Even in the absence of infarction, 
intestinal ischemia associated with cocaine use 
may carry a higher risk of death compared with 
intestinal ischemia not caused by cocaine use. In 
one study, the prevalence of in-hospital death was 
26 percent among people with cocaine-related 
intestinal ischemia versus 7.7 percent with non-
cocaine-related intestinal ischemia (Elramah et 
al., 2012). Obstruction, perforation, and infarction 
are associated with cocaine use by any route of 
administration (Zimmerman, 2012). Although 
less common, gastrointestinal hemorrhage and 
pancreatitis can also occur from cocaine use (Carlin 
et al., 2014). 
Reduced appetite is one of the most common 
adverse effects of prescription stimulants, with 
stomach ache, abdominal pain, dyspepsia, and 
weight loss also occurring (Cortese et al., 2015; 
Holmskov et al., 2017; Storebø et al., 2015). 
Infections 
As already noted, intravenous injection of cocaine 
or MA is associated with a variety of infectious 
diseases. Intravenous injection is not the most 
common method of misusing prescription 
stimulants, but it can and does occur. Individuals 
who inject prescription stimulants are at risk for 
the same injection-related infections as people 
who inject cocaine or MA. People engaging in 
injection drug use are at increased risk of infectious 
endocarditis, which accounts for 5 to 25 percent of 
hospitalizations for acute infection among people 
who inject drugs (Visconti et al., 2019). Increased 
HIV and hepatitis B and C transmission are likely 
consequences of stimulant use, particularly in 
individuals who inject intravenously and share 
equipment. HIV and other blood-borne pathogens 
may spread through communities of people 
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injecting drugs via shared injection equipment 
or unprotected sex. People who injected drugs 
accounted for 9 percent of all new cases of HIV 
diagnosed in 2017 (Centers for Disease Control 
and Prevention, 2021b). MA or cocaine use in the 
presence of HIV or hepatitis C virus can accelerate 
virus replication and impaired immunity, resulting 
in overall disease progression (NIDA, 2016c; 
Soontornniyomkij et al., 2016). 
MA is also implicated in a host of infectious 
diseases, such as skin infections (cellulitis, skin 
abscesses), methicillin-resistant Staphylococcus 
aureus (MRSA), sexually transmitted infections, and 
opportunistic fungi (e.g., Histoplasma capsulatum;
Salamanca et al., 2015). High-risk sexual behaviors, 
malnutrition, harmful effects of MA on immune 
system functioning, and infammation likely 
contribute to infectious disease risk. 
Cocaine use carries a signifcant increased risk of 
sexually transmitted infections such as syphilis, 
trichomoniasis, hepatitis C, HIV, and human 
papillomavirus and associated complications such 
as precancerous cervical abnormalities and pelvic 
infammatory disease, and invasive pneumococcal 
disease. Tuberculosis, bronchitis, pneumonia, 
injection site infections, and MRSA infection are all 
also more common among people who use cocaine 
(Butler et al., 2017). 
Improved access to treatment of HIV infection 
and prevention efforts can help address the 
elevated risk of HIV infection among people who 
use stimulants. Prevention of HIV infection may 
include screening and diagnosis of other bacterial 
or viral sexually transmitted infections, access to 
nonoccupational postexposure prophylaxis, and 
pre-exposure prophylaxis (PrEP; Nerlander et 
al., 2018; UNODC, 2019a; Workowski & Bolan, 
2015). Given the multimodal risk factors for 
acquisition, including injection drug use and sexual 
transmission, the current recommendation for PrEP 
should be the use of tenofovir disoproxil fumarate 
with emtricitabine (Mayer et al., 2017). FDA also 
approved emtricitabine with tenofovir alafenamide 
for PrEP in individuals having nonvaginal sex (FDA, 
2019). Multiple studies support the treatment of 
HIV as a prevention modality in patients using 
stimulants (Nerlander et al., 2018; UNODC, 2019a), 
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as even imperfect medication adherence may result 
in viral suppression and decrease the likelihood of 
transmission. 
Reluctance to get tested for HIV and fear of 
being stigmatized by healthcare personnel may 
result in delays of HIV diagnosis (UNODC, 2019a). 
Patients with MA use in particular may have a 
lower CD4 nadir and may meet the criteria for an 
AIDS diagnosis within 6 months of HIV diagnosis. 
Frequent low-barrier testing and immediate access 
to antiretroviral therapy may improve overall 
outcomes for patients with co-occurring HIV and 
stimulant disorder (UNODC, 2019a). 
Hypersexuality and lowered inhibitions for 
patients who use stimulants should warrant a 
comprehensive sexual health screen. Regardless 
of the patient’s identifed sexual orientation it may 
be prudent to offer multisite (i.e., vaginal, rectal, 
penile, pharyngeal) sexually transmitted infection 
testing to identify and treat bacterial infections 
early (UNODC, 2019a). Patients engaging in sexual 
activities with elevated risk for sexually transmitted 
infection should be screened for chlamydia, 
gonorrhea, and syphilis at least every 3 to 6 months 
or more frequently depending on their individual 
risk (Workowski & Bolan, 2015). 
Harm reduction strategies related to skin and soft 
tissue infections should focus on the processes 
for injection that require sterile technique and 
should identify substances that may produce 
increased risks for infection (Saldana et al., 2020). 
Providing access to items to cleanse the skin 
prior to injection, safer injection techniques, and 
postinjection care are all important aspects of 
preventing skin and soft tissue infections (Hartnett 
et al., 2019; Saldana et al., 2020). Furthermore, for 
patients injecting crack cocaine who require an acid 
pairing to neutralize the base pair for injection, 
education should be provided regarding safer 
acid pairings, like ascorbic acid (British Columbia 
Center for Disease Control, 2011). Increased fungal 
infections, including endophthalmitis, have been 
well described in patients who have used natural 
acids like lemon juice to neutralize the base for 
injection (British Columbia Center for Disease 
Control, 2011). 
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For patients engaging in vaginal or anal 
consumption of stimulants, there is an elevated 
risk for toxicity and in some cases overdose or 
death (P. Jones et al., 2014). Patients using MA 
intravaginally or intrarectally should be educated 
on safety procedures to avoid tearing of rectal or 
vaginal tissues that may result in fssure or other 
microscopic tearing. Dissolution of the crystalline 
substrate is imperative to reduce the risk of 
microtears and associated acquisition of sexually 
transmitted infections. 
Hepatotoxicity is a rare side effect of 
methylphenidate, but liver values should still 
be monitored throughout treatment (Tong et 
al., 2015). A review of the literature reveals few 
cases of methylphenidate-induced liver damage, 
and cases that do exist were generally mild in 
severity and resolved with discontinuation of 
methylphenidate (Tong et al., 2015). 
Efects on Reproductive Function and on 
Fetus/Newborn 
Chronic, high-dose stimulant use can affect 
reproductive and sexual functioning in both 
males and females. Men report gynecomastia 
(development of breasts), loss of sexual interest, 
impotence, and diffculty in maintaining an erection 
or ejaculating (Del Río et al., 2015; Longheu et 
al., 2016). Long-term stimulant use can lead to 
menstrual cycle irregularity (Shen et al., 2014). 
This may lead some women to believe they cannot 
become pregnant, which may not be true. Testing 
for pregnancy and regular use of birth control 
should be encouraged. 
Cocaine effects on pregnant women include 
high blood pressure, heart attack, kidney failure, 
decreased platelets, and stroke. Pregnancy may 
increase the cardiovascular toxicity of cocaine, 
resulting in cardiac morbidity and mortality in 
otherwise healthy pregnant women (Smid et al., 
2019). The constellation of cocaine effects— 
including high blood pressure, low platelets, 
swelling, protein in the urine, and seizure—can 
be mistaken for preeclampsia or eclampsia 
(Maagdenberg et al., 2006). Hypertension in 
pregnancy is often treated with labetalol or other 
beta blockers, but these drugs are associated with 
coronary vasoconstriction and end-organ ischemia 
when used concurrently with cocaine. 
Preterm birth, low (less than 2,500 grams) birth 
weight, and newborns that are small for gestational 
age are all adverse perinatal outcomes associated 
with cocaine use (Gouin et al., 2011). Smoked 
cocaine specifcally is associated with smaller head 
circumference (Dos Santos et al., 2018). There is 
a suggested association between increased risk 
of miscarriage, still birth, and placental abruption 
and cocaine use, with a somewhat more marked 
association between at least partial placental 
abruption and crack cocaine use specifcally (Dos 
Santos et al., 2018). 
There is uncertainty about the connection between 
cocaine use in fetal structural abnormalities, 
because of studies’ poor control of common 
confounding variables such as maternal age, 
poverty, stress, co-occurring psychiatric conditions, 
and the use of other substances such as tobacco 
and alcohol. Concern persists about a possible 
link between cocaine use and defects in the 
genitourinary systems, limbs, and heart (Hetea et 
al., 2019). 
Maternal cocaine use increases the risk of 
transmission of HIV and syphilis to the infant (J. 
A. Cook, 2011; Smullin et al., 2021). Problems 
of growth, cognition, language and motor skills, 
attention, affect, and neurophysiology have been 
described in children with prenatal exposure to 
cocaine (Smid et al., 2019). However, the evidence 
linking these fndings to prenatal exposure to 
cocaine is less compelling than the evidence 
for association with gestational age; caregiver 
psychiatric illness; other prenatal exposures such as 
tobacco, cannabis, and alcohol; or the conditions 
of the postnatal environment. 
Women who use MA are at substantially higher 
risk of death than those who do not (26 times 
higher rate of death) or men who use MA (9 times 
higher rate of death [Smid et al., 2019]). Reported 
lifetime use of MA is associated with pregnancy in 
adolescence (Smid et al., 2019). Pregnant women 
who use MA are more likely to be younger than 
24 years old and are more likely to have signifcant 
psychiatric disorders (Smid et al., 2019), including 
ADHD (Marraccini et al., 2017). 
Women who use MA during pregnancy are at 
higher risk of high blood pressure, heart attack, 
and cardiomyopathy (Smid et al., 2019). These 
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conditions produce more infant morbidity in 
pregnancies exposed to MA than in pregnancies 
exposed to cocaine. Cleft palate has a clear 
association with prenatal MA exposure, but the 
link with other birth defects is not yet established 
(Smid et al., 2019). Exposure to MA, a neurotoxin, 
may impact metabolism, chemical signaling such 
as with serotonin, and structure of the developing 
fetal brain (Smid et al., 2019). Gestational age and 
sex may be important considerations, whereas 
concurrent exposure to alcohol and tobacco are 
confounding variables (Smid et al., 2019). 
MA use in pregnancy is associated with low birth 
weight, lower than expected gestational age at 
delivery, and smaller head circumference (Wright 
et al., 2015). Using MA throughout all trimesters 
has been linked to insuffcient prenatal care, 
early delivery, and lower birth weight (Wright et 
al., 2015). Adverse perinatal outcomes including 
preterm birth, fetal growth restriction, and fetal 
death have been described, but studies have not 
been able to determine whether these outcomes 
are caused by MA or other factors such as 
contaminants, other drugs, cigarette smoking, 
or poverty. 
At birth, infants exposed to stimulants may 
manifest symptoms suggestive of withdrawal. As 
with other newborns with substance exposure, 
implementation of the Eat Sleep Console model 
of caring for the mother and infant as a dyad, 
focusing on nonpharmacologic care and treatment 
of the newborn, has produced positive results 
(Dodds et al., 2019). The most common presenting 
symptoms are lethargy, sleepiness, and poor 
feeding. Stimulant-exposed infants may have 
diffculty being consoled (Anbalagan & Mendez, 
2021); the action of consoling can increase crying 
because of damage to the infant’s nervous system. 
The interaction between this and the stimulant-
affected mother’s low frustration tolerance (due to 
protracted withdrawal) can interfere with bonding 
and create negative feedback, psychologically and 
neurologically. Congenital malformations rarely 
occur because of stimulant exposure; those that do 
tend to affect the heart (Huybrechts et al., 2018). 
Risk of sudden infant death syndrome may be 
heightened slightly. Any reduction in stimulant use 
is correlated with improved outcomes for the baby. 
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Few infants exposed to MA require intervention. 
For those that do, supportive feeding is often 
suffcient (Oei et al., 2012). A prospective study 
of MA-exposed mother–infant pairs matched 
with non-MA-exposed mother–infant pairs in 
New Zealand has provided valuable insights into 
infant and childhood development (L. M. Smith et 
al., 2015). Among MA-exposed pairs, this study 
has described increased anxiety, depression, 
and attention problems in children ages 3 to 5 
and poorer cognitive outcomes at 7.5 years old. 
Imaging studies have identifed sex-dependent 
structural brain changes, but the clinical and 
functional importance of these changes is not 
known. Of note, fetuses exposed to MA mixed 
with fentanyl may be at risk for opioid-related 
effects, such as poor fetal growth, preterm birth, 
stillbirth, specifc birth defects, and neonatal 
abstinence syndrome (Centers for Disease Control 
and Prevention, n.d.-a). 
Little is known about the impact of misuse of 
prescription stimulants on pregnancy, the fetus, 
or development. Existing knowledge is based 
on studies of therapeutic use of prescription 
stimulants. Exposure to prescription stimulants 
during the frst trimester has not been shown to 
be associated with congenital defects (Andrade, 
2018). Third-trimester exposure has been 
associated with some instances of intrauterine 
fetal death (Wright et al., 2015). However, a recent 
review of eight studies investigating the effects of 
ADHD medication use during pregnancy found no 
evidence linking this medication to negative effects 
on pregnant women or their children. The authors 
cautioned against drawing defnitive conclusions 
given the small number of studies included in the 
review (L. Li, et al., 2020). 
Dental Efects 
Missing and flled teeth, cavities, and gum disease 
are all more common among people who use 
drugs (Yazdanian et al., 2020). Cavities are the most 
common dental problem among people who use 
drugs (Shetty et al., 2010). 
People who use MA are 4 times as likely to have 
cavities and twice as likely to have untreated 
cavities compared with people who do not use 
drugs and have double the risk of decayed, 
missing, or flled teeth (Shetty et al., 2016). One 
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study of 552 people with MA use revealed that 
96 percent had cavities, 58 percent had untreated 
cavities, 29 percent had severe periodontitis, 
almost 60 percent were missing one or more teeth, 
7 percent were completely without their natural 
teeth, and only 23 percent still had all of their 
natural teeth (Shetty et al., 2015). 
Fewer studies are available on the oral health of 
people who use cocaine, but gum disease and 
cavities are both positively associated with cocaine 
use (Bahdila et al., 2020). Cocaine is also associated 
with problems of the oral cavity, including oral 
ulcers, nasal necrosis, palate perforation, and 
oral candidiasis (Maloney, 2010), particularly with 
oral consumption and nasal insuffation (Fratto 
& Manzon, 2014). Oral or nasal administration 
of cocaine has been associated with oral lesions, 
receding gums, and dental erosion (Fratto & 
Manzon, 2014). 
MA use was previously thought to have a 
direct chemical effect on the mouth and teeth 
that contributed to extensive dental disease. 
Comparison with National Health and Nutrition 
Examination Survey participants shows that 
elevated rates of dry mouth and regular 
consumption of one or more sugary beverages per 
day to compensate for it, along with poor dental 
hygiene and lack of preventive dental care over a 
prolonged period, underlie the problem (Clague 
et al., 2017). Longer history of substance use, 
polysubstance use, and concurrent tobacco use 
are all associated with worse oral health. Smoking 
MA was not more strongly associated with dry 
mouth or cavities than was snorting or injecting MA 
(Clague et al., 2017). Amphetamine use has been 
linked to broken or missing teeth, bruxism, gingival 
enlargement, cavities, and dry mouth (Fratto & 
Manzon, 2014). 
People who use stimulants should receive 
education about preventive oral hygiene and the 
role of sugary drinks in the widely recognized 
dental problems affecting this population. 
Engagement, prevention, and treatment programs 
should provide the education and resources 
needed for people who use stimulants to maintain 
oral hygiene (Shekarchizadeh et al., 2013). 
Preventive dental care may be available under 
some Medicaid plans, at a dental school, or in a 
community clinic. Strategies to reduce the negative 
effects of dry mouth should also be considered by 
treatment programs. Use of hard candy or chewing 
gum by patients with dry mouth or bruxism may 
help to alleviate some of the symptoms. 
A program should not make its efforts in this 
area contingent on someone with a stimulant use 
disorder deciding to enter treatment or achieving 
recovery. Poor dentition and oral health may also 
be associated with an increased risk for serious 
or life-threatening infections, including infective 
endocarditis or abscess. Prevention of periodontal 
disease should be viewed as a form of care for 
patients in active stimulant use. 
Peripheral Vascular and Nerve Damage 
Stimulants can damage the central nervous and 
cardiovascular systems regardless of the route of 
administration. Use of any substances by injection 
can be uniquely harmful to the peripheral nerves 
and vessels (Delaney et al., 2020; Raiker et al., 
2016). Peripheral nerves control muscle use and 
sensation outside of the brain and spinal cord. They 
are fragile and can be easily damaged if struck by 
a needle during injection drug use. The peripheral 
vascular system comprises all the arteries and veins 
outside of the chest and abdomen. Use of any 
drug by injection can damage veins and arteries 
(Delaney et al., 2020; Raiker et al., 2016). All of the 
problems associated with use of drugs by injection 
described below are exacerbated by the chemical 
properties of all stimulants. Cocaine and MA cause 
vasoconstriction, especially near the injection site 
(Raiker et al., 2016). When blood fow is restricted, 
tissue dies, making damage to vessels and nerves 
as well as skin and muscle more pronounced 
among people who use stimulants by injection. 
For patients who may use substances adulterated 
with levamisole, there is an elevated risk of 
levamisole-induced vasculitis (Abdul-Karim et al., 
2013; George et al., 2019). Quick recognition of 
the signs and symptoms of levamisole-induced 
vasculitis may help in the evaluation of patients 
with severe presentations, including leukopenia or 
agranulocytosis. Most studies indicate resolution 
of symptoms with cessation of cocaine/levamisole 
consumption, but other studies have used oral 
steroids with unclear benefts over cessation of 
use alone. 
























The repeated puncturing of veins during injection
drug use causes infammation (phlebitis), scarring,
and stiffening (Dunn & Gauthier, 2020). Injection drug
use can also damage the function of veins (Delaney
et al., 2020; Raiker et al., 2016). When valves in
veins are damaged, blood pools in the surrounding
tissues and in the venous system below the damaged
area. Accumulated damage to the veins may cause
venous insuffciency (Dunn & Gauthier, 2020). Venous
insuffciency causes swelling of the extremities and
discolored, thickening, scaling, and peeling skin. The
affected extremity can be painful, hot, or itchy. The
skin becomes fragile and heals poorly if at all and may
result in chronic, weeping wounds. Both phlebitis and
venous stasis increase the risk of formation of blood
clots in the damaged veins. Clots in the arms or legs
can break apart causing a thromboembolic event.
If pieces of a clot travel to the lungs or heart, death
may occur. A growing body of research has linked
cocaine use to increased odds of developing venous
insuffciency and venous thrombosis (Griffn & Cha,
2019; T. Sharma et al., 2019). 
Arteries are deeper and harder to reach, but 
people who inject drugs may accidentally inject 
into arteries instead of veins (Lokoff & Maynes, 
2019). Injecting into the artery is painful and can 
cause extensive bleeding. It also causes the drug 
to be delivered downstream into the extremities 
rather than to travel toward the lungs, heart, 
and brain. The extremities can become infamed 
due to immune response provoked by the drug. 
Injection into the artery carries a high risk of clot 
formation (Lokoff & Maynes, 2019). The pressure in 
the arterial system pushes a clot until it lodges in a 
narrower artery; this is called a thromboembolism. 
Tissue past the clot no longer receives oxygen-rich 
arterial blood and begins to die in much the same 
way heart muscle dies during a heart attack. Like 
a heart attack, arterial blood clots are a medical 
emergency. 
Like arteries, nerves are sometimes hit accidentally 
during injection drug use (Dunn & Gauthier, 2020). 
Hitting a nerve causes intense electric or burning 
pain both above and below the injection site 
(Dunn & Gauthier, 2020). After the injury, pain and 
abnormal sensations like burning or neuropathy 
(pins and needles) in the area served by the nerve 
can persist. Other forms of nerve damage also 
may occur with cocaine or MA use (e.g., nerve 
Treatment for Stimulant Use Disorders 
compression; Dunn & Gauthier, 2020). In a sample 
of more than 900 people with injection drug use 
(Colledge et al., 2020), nerve damage was the most 
commonly reported injection-related injury and 
disease, occurring in 19 percent of the sample. 
Injection drug use can lead to a loss of vein 
functioning (venous sclerosis) and vein scarring, 
which in turn can increase the risk of vascular 
disorders, like deep vein thrombosis (formation of 
a blood clot within the vein, which can then travel 
to other parts of the body, like the lungs) and skin 
and soft tissue infections (Ciccarone & Harris, 2015; 
Raiker et al., 2016). People at risk for injection drug 
use should have access to a sterile syringe for each 
use. Reusing a syringe—even one’s own—increases 
the risk of infection. Dull or damaged needles tear 
and abrade delicate veins, increasing the risk for 
venous complications. Thorough, nonjudgmental 
education in phlebotomy techniques, including 
identifying appropriate sites for injection, rotating 
injection sites, and sterilizing injection equipment, 
should be provided. People who use injection 
drugs should be trained to recognize potentially 
life- or limb-threatening complications and apply 
frst aid to common complications. Opportunities 
for wound assessment and care should be a 
standard part of outreach, prevention, and harm-
reduction services for people who use drugs. 
Identifcation and Management
of Mental Complications 
Stimulant-Induced Psychosis 
Initially described by D. Young and Scoville in 
1938, amphetamine-induced psychosis usually 
is a brief and spontaneously remitting paranoid 
state that is frequently accompanied by intense, 
fear-evoking altered perceptions of reality and 
hallucinations, but with clear consciousness and a 
relatively intact formal thought process (McKetin, 
2018). Stimulant-induced psychosis occurs while 
the person is intoxicated, but may recur when 
a patient is in withdrawal or has been abstinent 
for many months (McKetin, 2018). The condition 
is not rare or idiosyncratic but typically follows 
chronic, high-dose use of amphetamines, MA, 
or cocaine and a lack of sleep. However, this 
drug-induced psychosis is seen more frequently 
with amphetamine and MA use than cocaine use 
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(Henning et al., 2019), probably because the short 
half-life of cocaine means that accumulating and 
sustaining high plasma concentration levels of that 
drug is diffcult. Stimulant-induced psychosis has 
been reported after acute intoxication in relatively 
naïve people and occasionally after low doses. 
Original reports of the condition describe onset of 
psychosis following typically high doses (i.e., 100 to 
300 mg of amphetamine; Henning et al., 2019). 
The prevalence of stimulant-related psychosis is
unclear, with studies on MA-induced psychosis
reporting estimates ranging from 7 to 76 percent
(Lecomte et al., 2018). A review of the literature
suggests an overall rate of 36.5 percent among
people using MA, with rates somewhat diverging
based on whether MA use was lifetime (42.7%) versus
current (22.1%; Lecomte et al., 2018). Fear regarding
the stigma associated with psychotic symptoms and
the persecutory nature of the altered perceptions of
reality likely contribute to the inconsistent description
of stimulant-induced psychosis. 
The prevalence of psychosis induced by 
prescription stimulants is low. In adolescents and 
young adults taking prescription methylphenidate 
or amphetamine for ADHD, psychosis has been 
reported in approximately 1 in 660 patients, 
with amphetamine carrying a greater risk than 
methylphenidate (1.78 per 1,000 people per year 
versus 2.83 per 1,000 people per year; Moran 
et al., 2019). Although these rates are low, FDA 
added a warning label to these medications in 
2007 that reads “stimulants may cause treatment-
emergent psychotic or manic symptoms in patients 
with no prior history” (Moran et al., 2019, p. 1,129). 
This is especially true when prescription stimulants 
are injected or snorted. 
The presence of stimulant-induced psychosis has 
implications for determining the appropriate level 
of care. Patients with stimulant-induced psychosis 
may require more acute psychiatric care, where 
there are staff to ensure patient safety. (Learn 
more about determining levels of care by reading 
Chapter 5.) 
Development of stimulant-induced psychosis 
Some researchers and clinicians describe the 
development of stimulant-induced psychosis as 
an evolving process, dividing presentations of 
stimulant-induced psychosis into three major 
categories: acute MA psychosis, chronic or 
persistent MA psychosis, and schizophrenia 
(Bramness et al., 2012; Deng et al., 2012). Acute 
stimulant-induced psychosis is directly related to 
the amount of substance used and lack of sleep 
of a specifc binge. Persistent MA psychosis is 
related to the chronic use of MA, and patients 
tend to demonstrate more profound hallucinations, 
including visual, auditory, and tactile hallucinations. 
Schizophrenia is a separate diagnosis from 
stimulant-induced psychosis, as the former is a 
substance-independent psychotic disorder. But 
a presentation of psychosis after simulant use 
would warrant consideration of schizophrenia 
in the differential diagnosis to determine 
whether a stimulant use disorder–schizophrenia 
comorbidity exists. Use of stimulants in people 
with schizophrenia or schizoaffective disorder will 
likely exacerbate their psychosis; thus, patients 
may have a psychotic disorder like schizophrenia 
or schizoaffective disorder and stimulant use 
disorder simultaneously. Some patients may have 
co-occurring schizophrenia and present with 
positive and negative symptoms of schizophrenia 
after MA use, though this requires further study to 
determine the pattern of correlation. 
Assessment of acute versus chronic stimulant-
induced psychosis may be diffcult and will likely 
require patients to engage in multiple treatment 
sessions. Patients should be evaluated after they 
have been able to sleep and regain some level of 
normal life functioning to differentiate between 
acute and chronic stimulant-induced psychosis. 
Patients who continue to experience hallucinations, 
altered perceptions of reality, and persecutory 
cues from their environment may be exhibiting 
chronic stimulant psychosis and may require 
longitudinal psychiatric intervention. Additionally, 
these patients may warrant diagnostic evaluation 
for a schizophrenia-spectrum illness. Persistent 
MA psychosis may occur with ongoing MA use, 
however, and requires medication treatment similar 
to that for schizophrenia (e.g., neuroleptics). 
At frst, people who use a moderately high amount 
of MA may experience intense curiosity about 
the world around them. This enthusiasm about 
“discoveries” changes, with time and increasing 





























doses, from “watching the world” to feelings of 
being watched. Behaviors become more fxed and 
stereotypic, culminating in intense suspiciousness 
and, in psychotic reactions, paranoid thinking 
and persecutory perceptions that misinterpret 
environmental cues. Visual hallucinations may be 
overreactions to barely glimpsed and recognizable 
objects in one’s peripheral vision or may be 
described as shadows of people or things. Auditory 
hallucinations similarly begin with hearing simple 
noises and usually progress to hearing others speak 
about oneself, typically derogatorily. In later stages 
of psychosis, the individual may have a persistently 
altered perception of reality and overwhelming 
feelings of being unsafe. 
Manifestations of stimulant-induced psychosis 
Although the symptoms of stimulant-induced
psychosis mirror those of independent psychotic
disorders (like schizophrenia), and heavy use
of cocaine/amphetamines may precipitate
schizophrenia, stimulant-induced psychosis and
primary psychosis are distinct conditions (APA, 2013).
DSM-5 criteria describe a substance-/medication-
induced psychotic disorder as the presence of altered
perceptions of reality (delusions) and/or hallucinations
that occur during or soon after intoxication or
withdrawal from a substance or shortly following
exposure to a medication (APA, 2013). The symptoms
cannot be part of a psychotic disorder and do not
occur only during delirium. The substance must have
the potential to cause altered perceptions of reality
or hallucinations that result in clinically signifcant
impairment. Per DSM-5, psychosis in the presence
of substance use is considered a primary disorder 
when (APA, 2013): 
• Symptoms substantially exceed what would 
be expected given the amount and type of 
substance taken. 
• The individual has had previous non-substance-
induced psychotic episodes. 
• The onset of psychosis precedes the substance 
use. 
• The psychosis lasts for at least 1 month after 
cessation of intoxication or withdrawal. 
Presentation usually includes auditory and tactile 
hallucinations, paranoid thoughts, ideas of 
reference, and protective behaviors associated 
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with paranoia, all of which may lead to diffculties 
with social and occupational functioning (Glasner-
Edwards & Mooney, 2014). Other often-reported 
psychotic symptoms include persecutory delusions, 
perceptions of jealousy, concerns of mind-
reading, irritability, visual hallucinations, invasive 
thoughts, thought broadcasting, derealization, and 
depersonalization (Fluyau et al., 2019). Another 
common manifestation is stereotypy. As chronic, 
high-dose stimulant consumption continues, most 
people also withdraw from all social interactions 
and initiate other antisocial behaviors before 
intensive drug use culminates in paranoia or other 
symptoms of psychosis with limited insight. 
Experimental studies in which participants received
amphetamine or MA with variable doses/dosing
schedules and with different routes of administration
showed that, across all participants, only some
people developed psychotic symptoms, the
threshold dose was inconsistent, and the most
common psychotic symptom was paranoia with ideas
of reference (Glasner-Edwards & Mooney, 2014). 
Risk factors for stimulant-induced psychosis include 
presence of ADHD, cognitive impairment, and 
certain neurobiologic factors (e.g., dysfunctions 
in the brain’s GABA systems; Bramness & Rognli, 
2016). A family history of psychotic disorders (e.g., 
schizophrenia) may also be a risk factor. 
The role of drug sensitization 
Several issues pertaining to stimulant-induced 
psychosis are unresolved. There is some 
disagreement about the role of drug sensitization 
(kindling) in precipitating more frequent psychotic 
reactions at smaller doses than previously required 
and sooner after drug use is reinitiated following a 
period of abstinence (Rolland et al., 2011). There 
is also disagreement about the role of sensitization 
in deepening postwithdrawal depression. The 
mechanisms for this “reverse tolerance” are not 
fully understood. 
Duration of stimulant-induced psychosis 
Symptoms of acute stimulant-induced psychosis 
usually abate spontaneously with cessation of 
substance use. Symptoms of chronic or persistent 
psychosis may occur for 6 months or longer 
(Glasner-Edwards & Mooney, 2014), particularly 
among patients with a long history of severe MA 
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use. Hallucinations may stop within 24 to 48 hours 
of cessation of substance use, and paranoia and 
altered perceptions of reality decrease over the 
next week to 15 days. Clinicians also report that 
drug-induced psychosis dissipates more quickly 
for cocaine use—usually in 1 to 3 days—compared 
with up to 2 to 3 weeks for MA use. Resuming or 
continuing stimulant use, using other substances 
(including alcohol, when used heavily), and 
experiencing stress or lack of sleep can all trigger 
recurrence of psychosis after symptoms have 
resolved and after prolonged periods of abstinence 
(Glasner-Edwards & Mooney, 2014). 
The duration of stimulant-induced psychosis is 
somewhat in dispute. Typically, uncomplicated 
psychosis induced by stimulants resolves rapidly 
unless more of the drug is taken. However, 
observational studies from Japan and Thailand 
suggest that MA-induced psychosis can persist 
well beyond the 1-month cutoff in DSM-5 and 
may become a more chronic condition, even in 
individuals without a previous psychiatric history 
(Glasner-Edwards & Mooney, 2014). 
Treatment of stimulant-induced psychosis 
Treating a patient who presents with stimulant-
induced psychosis entails rapid, systematic visual 
assessment, deescalation of agitated or paranoid 
behavior, continued observation and monitoring, 
and symptom management. All unnecessary 
stimulation should be reduced, but complete 
sensory deprivation should be avoided. Ideally, 
the patient should be moved to a quiet hospital 
room with moderate lighting and suffcient 
space and staff should talk in a subdued manner 
and without rapid or unexpected movements. 
The clinician should try to calm the patient and 
provide reassurance that he or she is safe (Glasner-
Edwards & Mooney, 2014; Holmwood & Gowing, 
2019). Deescalation using the AGRO+ model 
may help engage the patient in a conversation, 
decreasing the patient’s persecutory perceptions, 
and increasing the sense of safety and well-
being (Holmwood & Gowing, 2019; Overdose 
Response Strategy, New England High Intensity 
Drug Traffcking Area, & Boston Medical Center 
Offce Based Addiction Treatment Training and 
Technical Assistance, 2020). (See Exhibit 3.8.) It 
may be prudent to medicate patients who are 
nonresponsive to destimulation and deescalation 
using benzodiazepines and, if patients are 
unresponsive to initial benzodiazepine doses, 
antipsychotic medications. In rare instances, 
ketamine or similar medications may be 
appropriate in treating the patients’ symptoms. 
EXHIBIT 3.8. AGRO+ Method for Deescalation With Aggressive Patients 
DEESCALATION 
A G R O + 
Assess 
what triggered 
the agitation by 
calmly talking with 




your feelings about 
the situation. 
Be mindful that 
your verbal and 
nonverbal cues 




calmly yet frmly to 
the patient. Stand 
at a safe distance 





the patient’s verbal 
and nonverbal 












something, like a 
glass of water or a 
snack. 
Source: Adapted with permission from Hanieh et al. (2013). 
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Chronic/persistent stimulant-induced psychosis 
warrants referral for psychosocial intervention, 
like cognitive–behavioral therapy, SUD treatment 
to initiate abstinence and promote recovery, 
and the use of antipsychotic agents to treat the 
persistent symptoms of psychosis (Braunwarth 
et al., 2016; Glasner-Edwards & Mooney, 2014). 
Individuals with co-occurring stimulant use disorder 
and schizophrenia (or other psychotic disorder) 
may also beneft from case management and 
comprehensive care to address a broader range 
of potential service needs, like those pertaining 
to housing and vocational rehabilitation (Glasner-
Edwards & Mooney, 2014). 
The antipsychotics olanzapine, haloperidol, 
aripiprazole, risperidone, and quetiapine each 
may be useful in treating stimulant-induced 
positive and negative psychotic symptoms 
(Bramness & Rognli, 2016; Fluyau et al., 2019). 
Each medication carries unique side effects (e.g., 
metabolic syndrome caused by second-generation 
atypical antipsychotics, extrapyramidal symptoms 
[medication-induced movement disorders] caused 
by haloperidol). Prescribing decisions should be 
based on each patient’s risk–beneft profle and 
reevaluated throughout the course of treatment 
(Fluyau et al., 2019). 
Differential diagnosis of acute confusional states 
should include the possibility of head injury, 
intracranial hemorrhage, electrolyte imbalances, 
infection or medical comorbidity, acute trauma 
response, or thyrotoxicosis. Information from family 
and signifcant others is helpful, and toxicology 
testing may also help confrm a diagnosis (Glasner-
Edwards & Mooney, 2014). Assessment tools 
like the Diagnostic Interview Schedule and the 
Composite International Diagnostic Interview 
can help differentiate between primary and 
stimulant-induced psychosis (Glasner-Edwards & 
Mooney, 2014). 
Acute stimulant-induced psychosis should generally 
be managed in a hospital psychiatric department 
or similar facility. Minor psychotic episodes with 
low-grade symptoms that respond readily to 
neuroleptic medications may, on some occasions, 
be managed in a well-staffed, freestanding offce-
based addiction treatment program if suffcient 
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personnel with training and experience in treating 
co-occurring disorders are readily available. Urine 
testing is recommended to confrm a diagnosis 
of stimulant-induced psychosis because the 
syndrome can closely mimic other disorders that 
may have psychotic symptoms, such as medical 
comorbidities, schizophrenia, mania, depression, 
other substance intoxication states, or catatonia. 
The criteria for placement should refect the 
persistence of the condition, the competence and 
training of personnel, and the drug taken. People 
with MA use who have accumulated high plasma 
concentration levels from longer binges and larger 
doses of stimulants with longer half-lives may 
be more prone to protective behaviors during 
psychosis. This is especially likely if psychotic 
symptoms include paranoia about attempts to 
medicate them, which could lead to aggressive 
behavior and diffculty following medication 
instructions after release from the hospital. 
Aggression and Violence 
A potential problem associated with MA use is the 
risk of sudden and intense violence. Reports by 
law enforcement offcials, psychiatrists, and people 
using these substances themselves link stimulants 
to aggression and unprovoked assaults. A causal 
link between aggression in humans and use of 
stimulants has yet to be consistently established 
(Kuypers et al., 2020). But research has shown a 
robust association between MA use and increased 
risk of violent behavior or being a victim of violence 
(Foulds et al., 2020; McKetin et al., 2020; Richards 
et al., 2019; Stoicescu et al., 2019). MA use and 
psychopathy traits and behaviors (e.g., aggression, 
violence, criminal acts) may be associated with 
corticostriatal abnormalities consistent with 
decision-making defcits, increased impulsivity, and 
addictive behavior (W. F. Hoffman et al., 2020). 
Research suggests MA may be associated with 
aggression. Of individuals with MA use and with 
past violent behavior, 33 percent reported initiating 
MA use before frst engaging in violent behaviors, 
and 12 percent frst engaged in violent behavior 
during the same year they started using MA (Brecht 
& Herbeck, 2013). A study from New Zealand 
(Foulds et al., 2020) examined patients throughout 
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the life course and found an increased risk of both
violence perpetration and violence victimization
among people who used MA, suggesting that
the population associated with violence is also a
population that is disproportionately victimized. 
Compared with MA, fewer studies have examined 
aggression and violence resulting from cocaine 
use (Kuypers et al., 2020). Cocaine may have some 
infuence on impulsivity, but evidence for this is 
largely from animal studies, and human studies 
have been too inconsistently designed to yield 
frm conclusions (Kuypers et al., 2020). Among 
the small number of human studies reporting a 
link between aggression and cocaine use, acute 
cocaine use has been associated with violence 
resulting in injury (Chermack et al., 2010), youth 
violence (Stoddard et al., 2015), and—in women 
who inject drugs—violent criminal behavior (Butler 
et al., 2017). 
Because drug-induced psychoses can increase 
the potential for violence in response to 
perceived persecution and resulting paranoia, 
sound behavioral management techniques to 
prevent this negative and dangerous response 
are essential. 
For more information about how to manage 
violent behaviors in people with SUDs (with or 
without psychosis), see the Substance Abuse 
and Mental Health Services Administration’s 
(SAMHSA) Treatment Improvement Protocol (TIP) 
25, Substance Abuse Treatment and Domestic 
Violence (https://store.samhsa.gov/product/ 
TIP-25-Substance-Abuse-Treatment-and-Domestic-
Violence/SMA12-3390); TIP 36, Substance Abuse 
Treatment for Persons with Child Abuse and 
Neglect Issues (https://store.samhsa.gov/product/ 
tip-36-substance-abuse-treatment-for-persons-with-
child-abuse-and-neglect-issues/SMA12-3923); and 
TIP 44, Substance Abuse Treatment for Adults in 






People with stimulant use disorders are likely 
to have one or more coexisting or preexisting 
disorders and conditions that can make differential 
diagnosis challenging or complicate treatment. 
Preclinical studies and some surveys seem to 
indicate that neurologic defcits associated with 
ADHD, neuroanatomical abnormalities, alcohol 
use disorder, posttraumatic brain lesions, and 
posttraumatic stress disorder (PTSD) may be 
correlated with increased vulnerability to stimulant 
use disorders. 
People with MA use can experience co-occurring 
psychotic symptoms (e.g., paranoia, hallucinations), 
depressive disorders, anxiety disorders, 
polysubstance use (especially involving cannabis, 
benzodiazepines, and hypnotics), ADHD, gambling 
disorder, compulsive sex, sleep disorders, and 
eating disorders (Rawson, Ling, & Mooney, 2015). 
Cocaine use has been similarly linked to multiple 
psychiatric disorders, including ADHD, PTSD, 
bipolar disorder, antisocial personality disorder, 
eating disorders, insomnia disorder, and anxiety 
disorders (Butler et al., 2017; SAMHSA, 2020l). 
The following sections describe some of the most 
common premorbid and co-occurring disorders 
and conditions among individuals who use 
stimulants, with some comments on treatment 
precautions. 
Polysubstance Use 
Concomitant use of a variety of other licit and illicit 
psychoactive substances is a common correlate of 
stimulant use. In a latent class analysis of more than 
700 adults with past-month use of stimulants, four 
notable patterns of polysubstance use emerged: 
(1) high use of MA and cannabis but moderate use 
of alcohol and nonprescribed opioids; (2) high use 
of crack cocaine and alcohol but moderate use of 
cannabis; (3) high use of powder cocaine, alcohol, 
and cannabis but moderate use of crack cocaine; 
and (4) high use of crack cocaine, powder cocaine, 
nonprescribed opioids, alcohol, and cannabis but 
moderate use of MA, prescribed opioids, and 
Chapter 3 67 
TIP 33 Treatment for Stimulant Use Disorders 
nonprescribed tranquilizers (Timko et al., 2018). 
Concomitant use of cocaine with benzodiazepines 
to blunt the dysphoric effects of the latter is also 
common. 
Speedballing or goofballing—simultaneous use of 
an opioid and cocaine or other stimulant—is still 
prevalent in many places because the combination 
is perceived to smooth the effects of each drug. 
From 2011 to 2017, the number of people seeking 
opioid treatment who reported past-month MA 
use increased from nearly 19 percent in 2011 to 
43 percent in 2017 (M. S. Ellis et al., 2018). From 
2015 to 2017, the number of people with past-
month heroin use who reported also using MA 
tripled from 9 to 30 percent, refecting what some 
have termed a “twin epidemic” of opioid and MA 
addiction (Strickland et al., 2019). 
In the 2009 to 2014 National Health and Nutrition 
Examination Survey, polysubstance use was 
common among people with current cocaine use 
(30 percent reported using one other substance, 
almost 31 percent reported using two, and 19 
percent reported using three or more; Bahdila et 
al., 2020). Typically used substances were alcohol 
(almost 68%), tobacco (47%), cannabis (43%), 
prescription opioids (13%), MA (6%), and heroin 
(nearly 5%). 
The combination of cocaine and alcohol is 
particularly dangerous. Researchers have 
established that cocaethylene, the ethyl ester of 
benzoylecgonine, forms in the liver when a person 
uses these two substances together. The person 
may experience more intense pleasure than if 
using either substance alone, but he or she is also 
exposed to the combined toxicities of cocaine and 
the even more potent cocaethylene (da Silva Maia 
et al., 2017; A. W. Jones, 2019; Liu et al., 2018). 
Because cocaethylene has a longer half-life (2 
hours) than cocaine (about an hour; A. W. Jones, 
2019), the cumulative and additive effects found 
in the combination increase the incidence of 
lethal heart attacks and stroke (18 times higher 
risk of sudden death than with cocaine alone). 
Cocaethylene appears to prolong the duration of 
cocaine-related increases in blood pressure and, 
in turn, to increase the likelihood of small-vessel 
cerebral infarct or intracerebral hemorrhage. 
Cocaethylene is particularly toxic to the liver 
and may be associated with increased risk of 
intensive care unit admission (Wiener et al., 2010). 
Cocaethylene has been detected in cases of 
cocaine-related sudden deaths that were attributed 
to drug toxicity as well as cocaine-related cases 
of violent death (i.e., gunshot wound, motor 
vehicle accident, suicide by hanging; Pilgrim et 
al., 2013). Fatalities involving cocaethylene may 
also be due to cerebral hemorrhage, stroke, other 
cardiovascular events, or hyperthermia (A. W. 
Jones, 2019). For people with chronic cocaine use, 
cocaethylene also increases the risk of experiencing 
panic and anxiety attacks, especially attacks that 
persist for some time. 
The popularity of cannabis among people who 
use stimulants is explained by its pharmacologic 
properties. Because cannabis induces vasodilation 
of nasal mucosa, it attenuates the vasoconstriction 
of cocaine so that absorption is increased. Thus, 
co-use of cannabis and stimulants enhances 
their euphoric effects and, in MA use, decreases 
subjective dysphoric effects (Porcu & Castelli, 
2017). 
“Chemsex,” or the use of multiple substances 
to enhance sexual pleasure, is a potential health 
threat in polysubstance use with stimulant 
use (Giorgetti et al., 2017; Hammoud et al., 
2018; Stevens et al., 2020; Torres et al., 2020). 
In particular, concomitant use of gamma-
hydroxybutyric acid, alcohol, amyl nitrates, erectile 
dysfunction medications, and/or ketamine may be 
popular enhancements to the sexual experience, 
and each contributes differently to the potential for 
emergency intervention for patients. 
Psychiatric Disorders 
Research suggests that most people who use 
stimulants have concurrent mental disorders. 
Identifed anxiety, phobias, ADHD, and antisocial 
personality disorder typically precede chronic 
cocaine use, whereas alcohol use disorder, 
depression, and paranoia generally follow stimulant 
use. For MA use, people appear more likely to 
have non-substance-induced, preexisting lifetime 
depressive, anxiety, or psychotic disorders than to 
have MA-induced depressive, anxiety, or psychotic 
disorders (Salo et al., 2011). 
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Differentiating co-occurring psychiatric 
disorders from stimulant-related disorders can 
be challenging. Acute or chronic stimulant 
intoxication can elicit symptoms of anxiety that 
are indistinguishable from phobias, obsessive 
compulsiveness, panic, and generalized anxiety. 
The parallels between symptoms of stimulant-
induced psychosis and schizophrenia are discussed 
in the section “Stimulant-Induced Psychosis” 
earlier in this chapter. Withdrawal from stimulants 
can cause symptoms similar to major depression, 
resulting in symptoms like sad mood, fatigue, 
increased sleepiness, and thoughts of self-harm 
(UNODC, 2019b). 
The prognosis for SUDs is worsened by the 
presence of other untreated psychiatric disorders 
(or polysubstance use). Patients with co-occurring 
SUDs and mental disorders need treatment for 
both; the psychiatric problems may or may not 
improve with reduction in use. Antidepressant and 
neuroleptic medications with low anticholinergic 
and sedative properties are preferred because 
of their low potential for addiction. Sedative– 
hypnotics and benzodiazepines must be used 
with caution in high-risk populations (e.g., older 
adults, people consuming alcohol, people with a 




People with stimulant use disorders also 
frequently experience other mental disorders or 
psychiatric symptoms, such as depression and 
anxiety. Patients with stimulant use disorder and 
any co-occurring psychiatric illness or symptoms 
should have both disorders treated concurrently 
rather than wait to address the mental health 
issue until after they are in recovery. Most mental 
disorders can be treated while the person is 
pursuing recovery. If clinicians delay in treating 
those co-occurring symptoms or disorders, it 
can put at risk the person’s chances of achieving 
and staying in recovery from their stimulant use 
disorder. 
Preexisting Medical Conditions 
Any preexisting acute or chronic physical 
conditions are also likely to be complicated and 
exacerbated by the stress of stimulant intoxication 
and withdrawal. Particularly dangerous coexisting 
medical conditions include any history of seizures, 
coronary heart disease and other cardiac problems, 
thyroid problems, hypertension, or respiratory and 
pulmonary disease. Hypertension, renal failure, and 
possibly diabetes mellitus, which are risk factors for 
stroke, can be exacerbated by cocaine use (Goel et 
al., 2014). 
Patients who are already taking medications for 
other medical conditions may be at heightened 
risk for serotonin syndrome when stimulants 
are combined with certain antidepressants or 
neuroleptics. Additional cardiovascular risk exists 
for patients prescribed beta-blockers who continue 
to use stimulants, particularly cocaine. 
Traumatic Injury 
People who use stimulants may be at an increased 
risk of traumatic injury. A review of studies 
looking at amphetamine-type substance use and 
associations with traumatic injury or death from 
motor vehicle accidents found a mixed association 
in terms of traumatic injury but a moderately 
positive association with death (Hayley et al., 2016). 
In one sample of more than 2,500 trauma patients 
admitted to a Level II trauma center between 2005 
and 2015, 6.5 percent tested positive for MA and 5 
percent for cocaine (Neeki et al., 2018). Traumatic 
brain injuries appear to be prevalent in people with 
cocaine and MA use disorder (Duong et al., 2018; 
Yeung et al., 2013) and should be managed with 
appropriate interventions based on the cognitive 
defcits identifed in a neurologic evaluation 
(Ramesh et al., 2015). 
Patients appearing in hospital EDs following mild 
to severe traumas may use stimulants and may 
have been involved in physical altercations or 
accidents. Among men reporting to the ED with 
traumatic injuries (Armenian et al., 2019), those 
who used stimulants had 2.9 increased odds of 
experiencing any violent injury and 3.3 increased 
odds of experiencing a penetrating injury (i.e., 
gunshot or stab wound). 
Chapter 3 69 
TIP 33
 
Treatment for Stimulant Use Disorders 
Stimulant use may be associated with not just 
an increased risk of traumatic injury but worse 
traumatic injury-related outcomes, such as mortality 
and healthcare resource use. A lifetime history of 
an SUD is associated with a signifcantly elevated 
mortality rate following inpatient discharge for 
traumatic injury (compared with people without 
lifetime SUDs); cocaine in particular has a 1.1 to 
1.6 increased risk of all-cause mortality following 
discharge (Dezman et al., 2020). In individuals who 
sustain burn injuries, stimulant use is associated 
with longer hospital length of stay and a higher 
need for skin grafts, both of which suggest 
stimulant use may result in greater healthcare 
resource use (Hulsebos et al., 2020). In a survey 
of nurses, residents, and other faculty at a Level I 
trauma center, respondents largely agreed not only 
that patients who used MA tended to need more 
hospital resources and have a longer length of stay 
in the ED, but also that they required more effort 
on behalf of staff to treat and were perceived by 
staff to be more violent than patients who had not 
taken MA (Richards et al., 2019). 
Sexual assault is also reported by an increasing 
number of both men and women who report 
stimulant use (Kittirattanapaiboon et al., 2017; 
Lutnick et al., 2015). Sexual assault while using 
stimulants is particularly problematic for women 
engaged in sex work for acquisition of the 
substance. Additionally, studies have examined the 
increased risk for intimate partner violence among 
both men and women who engage in regular 
stimulant use (Crane et al., 2014; Foulds et al., 
2020; P. H. Smith et al., 2012). Clinicians should be 
familiar with appropriate places to which to refer 
patients to help them cope with trauma associated 
with sexual assault and intimate partner violence. 
Linking Treatment Programs and
Medical Facilities 
Because the ED may be the frst point of 
contact with the medical system and potential 
treatment for people with stimulant use disorders, 
hospitals need to give attention to establishing 
and supporting a continuum of care in which 
appropriate linkages among all necessary services 
and programs for these patients are present. The 
task of developing and encouraging these linkages 
among treatment components cannot fall to 
hospital staff alone; all providers and staff should 
be encouraged to cooperate in the effort. If not 
connected to the treatment system, people who 
use cocaine or MA will likely return repeatedly to 
the ED and other hospital departments for care of 
more and more serious health and mental health 
problems. Stimulant use disorders, like all SUDs, 
are lifelong, relapsing conditions that require 
ongoing management and support. 
Hence, treatment programs should take primary 
responsibility for developing linkages with 
hospitals, using several approaches. The best 
approach is to have an SUD treatment practitioner 
or trained nurse/social worker visit the hospital 
and other medical facilities regularly to identify, 
screen, encourage, and follow up with patients 
who have stimulant-related and other substance 
use problems and need access to the ongoing 
treatment continuum. Peer recovery support 
specialists also can be found in hospital settings 
and can help link patients with acute SUD crisis 
to longer-term SUD services outside the hospital 
(see the text box “Connecting Patients to Peer 
Recovery Support Specialists”). A face-to-face visit 
by an outreach specialist or peer recovery support 
specialist is particularly effective in supporting the 
crisis-precipitated motivation to enter treatment, 
especially if the patient is hospitalized for some 
time. Because a crisis creates an intervention 
opportunity, the patient may be unusually receptive 
to considering lifestyle changes and the need for 
longer term treatment. 
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CONNECTING PATIENTS TO PEER
RECOVERY SUPPORT SPECIALISTS 
Medical providers can facilitate the recovery 
process for people taking stimulants by 
connecting them with a peer recovery support 
specialist. Also called a recovery coach, a peer 
recovery support specialist is an individual (or 
in the case of a family peer specialist, a close 
friend, family member, or other loved one of an 
individual) with lived experience with an SUD and 
recovery. These individuals carry out a wide range 
of recovery-related activities, such as mentoring 
or coaching people just entering recovery, 
facilitating and leading recovery groups, and 
connecting people just entering recovery to other 
recovery resources. 
Research suggests that placing peer recovery 
support specialists in hospital settings is feasible 
and effective. For instance, Rhode Island’s 
AnchorED program links patients presenting to 
the ED for opioid use disorder with peer recovery 
support specialists who provide naloxone kits and 
overdose education and who can connect these 
patients with more extensive community-based 
peer recovery support services as needed (Waye 
et al., 2019). Regardless of the type of setting 
in which a peer recovery support specialist 
works (e.g., hospitals, outpatient clinics, SUD 
treatment programs), use of peer recovery has 
been associated with improved outcomes, such 
as a greater likelihood of completing medically 
supervised withdrawal, reduced substance use, 
an increased likelihood of attending mutual-help 
programs (e.g., Narcotics Anonymous), reduced 
hospitalizations, fewer inpatient psychiatric or 
substance use-related readmissions, increased 
self-effcacy, and improved quality of life (Eddie et 
al., 2019). 
Not all medical facilities employ peer recovery 
support specialists. But if such individuals are 
available, medical personnel should become 
familiar with who they are, what they do, and how 
to connect them with patients. 
It also may be realistic for hospital staff to provide 
patients with stimulant use a list of available 
treatment facilities for stimulant use disorders 
and/or other SUDs that is developed by the 
hospital’s SUD treatment staff. However, patients 
in crisis may struggle to self-refer related to the 
fatigue, exhaustion, and depression associated 
with stimulant withdrawal and the persecutory 
perceptions of reality associated with acute 
stimulant use. 
Some educational literature on stimulant use 
might also be helpful—particularly regarding 
withdrawal symptoms, stimulant-induced psychosis, 
and medical complications—if the patient or a 
signifcant other is willing to read it. Because 
hospital medical staff must know about the 
addiction process to understand patients whom 
they see every day, cross-training in the feld of 
SUD treatment is vital for learning about and 
actively supporting the development and use of 
linkages and referral mechanisms. At least one-
fourth of people treated in hospitals are thought to 
have some type of substance use-related problem. 
Motivation for change is often diffcult to 
determine in the individual. Health problems 
may, however, motivate an individual to move 
from contemplation to action (Prochaska et al., 
1992). Healthcare personnel working with a 
patient hospitalized for an acute drug episode 
should emphasize strategies to keep the patient 
safe even when he or she is using substances. 
Motivational interviewing focuses on exploring and 
resolving ambivalence and centers on motivational 
processes within the individual that facilitate 
change. This evidence-based practice builds on 
the patient’s strengths, which may be the most 
important component for patients to be able to 
initiate treatment for their stimulant use disorder 
(SAMHSA, 2020m). 
Hospitals often deal with people with frequent, 
revolving use of hospital EDs or inpatient 
hospital beds because of medical or psychiatric 
complications resulting from their substance 
use. The fnancial burdens can be severe for 
these patients and, if the patients lack insurance, 
hospitals’ costs of care may be unrecoverable. 
Collaborative arrangements between hospitals and 
local treatment facilities can allow for door-to-door 
SUD treatment. 
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Obtaining Consent for Treatment 
In obtaining the patient’s consent for treatment, 
gathering information from others about the 
patient’s history of substance use, making referrals 
for continuing care, or seeking reimbursement from 
insurance carriers, hospital staff must be familiar 
with the provisions of special federal laws and 
regulations for protecting confdentiality of SUD 
patient records as set forth in 42 U.S.C. §290dd-2 
and 42 C.F.R. Part 2, as well as any applicable state 
laws and regulations. Patients who are intoxicated 
or psychotic may have diminished capacity for 
providing informed consent to treatment. If 
consent is obtained, even temporarily, from a 
relative, this may be considered a “disclosure of 
identifying information” and be subject to federal 
guidelines. In referring a patient from a hospital 
to an outside treatment program and making an 
appointment, staff are also making a disclosure and 
will ordinarily need a written consent form from the 
patient containing specifed information. 
Special exceptions apply to disclosing information 
in SUD patient records when medical personnel 
need this information to treat a medical 
emergency. However, the Part 2 regulations require 
that the SUD treatment provider document in 
the patient’s record the nature of the emergency, 
what information was released, the name of the 
Treatment for Stimulant Use Disorders 
person making the disclosure, and the date and 
time. For additional information about consent 




Patients who use cocaine or MA or who misuse 
prescription stimulants are at risk for multiple 
medical complications—some of which can 
have severe, long-lasting, or possibly even 
fatal consequences. The various routes of 
administration and pharmacokinetics of stimulants 
also play a role in the development of medical 
complications, as well as in the intoxication and 
withdrawal processes. Even SUD treatment 
providers who do not have medical training 
can beneft from knowledge about the medical 
risks of and treatments for cocaine use, MA 
use, and prescription stimulant misuse. These 
clinicians can play an important part in identifying 
symptoms and helping to connect patients with 
healthcare providers in a timely manner. Further, 
educating patients about the health consequences 
of stimulants might also help increase their 
motivation for engaging in and completing SUD 
treatment. (Chapter 4 discusses options for the 
nonpharmacologic treatment of stimulant use 
disorders in further detail.) 
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KEY MESSAGES 
During the early and mid-1980s, various 
unconventional remedies for substance use 
disorders (SUDs), including health foods, amino 
acids, hot tubs, electronic brain tuners, and other 
“New Age” treatments, emerged and disappeared. 
Research efforts to develop scientifcally based 
treatments during this period often focused on 
behavioral techniques like contingency contracting 
(Anker & Crowley, 1982). Since these early efforts, 
an entire stimulant use disorder treatment literature 
has developed. 
This chapter reviews the current state of 
knowledge on the treatment of people with 
stimulant use disorders, beginning with the 
approaches that have the most rigorous empirical 
support: contingency management (CM), 
cognitive–behavioral therapy (CBT)/relapse 
prevention (RP), community reinforcement, and 
motivational interviewing (MI). Other approaches 
with less support in the scientifc literature are 
presented later in the chapter. These are physical 
exercise, the Matrix model, family or couples 
therapy, and mindfulness meditation. 
Although at the time of this writing there are 
no Food and Drug Administration-approved 
medications with demonstrated clinical effcacy, 
an ongoing research program sponsored by the 
National Institute on Drug Abuse (NIDA) holds 
great promise for important treatment advances 
for stimulant use disorders. 
• Despite an increase in research into psychosocial
treatments for people with stimulant use
disorders, currently the only treatment
with signifcant evidence of effectiveness is
contingency management (CM). 
• Other psychosocial treatments that have some 
support (especially if used in combination with 
CM) are cognitive–behavioral therapy/relapse 
prevention, community reinforcement, and 
motivational interviewing. 
• There currently are no Food and Drug 
Administration-approved medications for 
stimulant use disorders, making it even 
more important that behavioral health and 
healthcare service providers understand 
and offer (or offer referrals for) CM or other 
psychosocial treatments. 
• Other nonpharmacologic treatment approaches
and strategies may also be useful for supporting
recovery and improving health and well-being,
including physical exercise, the Matrix model of
neurobehavioral treatment, family or couples
therapy, and mindfulness meditation. 
• Clinicians need to promote harm reduction 
(e.g., through educating about needle 
exchange programs, offering naloxone, 
encouraging the use of fentanyl test strips) to 
people with stimulant use disorders who are 
not interested in formal treatment, because 
harm reduction techniques can help save lives. 
• Many clinical management strategies have 
been developed to deal with clinical issues 
common in people with stimulant use 
disorders, like cognitive problems, intoxication 












































Treatment for Stimulant Use Disorders 
ACCELERATING THE DEVELOPMENT OF STIMULANT USE DISORDER
PHARMACOTHERAPIES 
There currently are no Food and Drug Administration (FDA)-approved pharmacologic treatments for patients
with stimulant use disorders. However, the National Institute on Drug Abuse’s (NIDA) Division of Therapeutics
and Medical Consequences (DTMC) helps advance such research through three programs targeted at SUD
pharmacotherapies. DTMC supports the conduct of all clinical trial phases as well as assists with clinical trial
design, trial implementation, and regulatory paperwork. Its pharmacotherapy programs are: 
• The Pharmacotherapies Development Program: This program supports the development of novel
medications and conducts safety and effcacy trials; stimulant use disorders involving cocaine and
methamphetamine are high-priority areas given the lack of FDA-approved treatments for these conditions. 
• The Addiction Treatment Discovery Program: Through preclinical testing, this program identifes, 
evaluates, and recommends potential medications as treatments for the medical management of SUDs. 
• Regulatory Affairs Assistance for Medications Development Program: This program provides consultation on
medication development regulatory requirements and strategies to federal agencies, NIDA grantees, and
others. It also coordinates with FDA, fling the necessary regulatory documentation (like Investigational New
Drug applications and Drug Master Files) as new medications enter or complete clinical studies. 
For more on DTMC, including contact information for these programs, visit https://www.drugabuse.gov/ 
about-nida/organization/divisions/division-therapeutics-medical-consequences-dtmc/research-programs. 
How To Measure Efectiveness 
This chapter reviews effective treatments for 
people with stimulant use disorders. To be judged 
effective, a treatment must have been tested and 
demonstrated to be effective in a randomized 
controlled trial (RCT). Many psychosocial and 
pharmacologic treatments have been investigated 
in such trials. Several psychosocial treatments for 
stimulant use disorders have proved effective, 
although no reliably effective pharmacologic 
treatments have been found to date. What has 
been learned so far about the use of psychosocial 
treatments for stimulant use is summarized below. 
RCTs are the best available method for determining
whether an intervention improves health. An RCT is
a prospective study comparing the effect of some
intervention against a control intervention in patients
who are randomly assigned to the intervention group
or the control group (Bhide et al., 2018). 
In such trials, patients from a particular population
sample (e.g., all admissions to clinic X during 2018
meeting a particular list of inclusion and exclusion
criteria) who consent to participate are randomly
assigned to the intervention under study or to
a control condition. Random assignment helps
ensure against possible bias in assigning particular
kinds of patients to the different groups and helps
distribute evenly between the groups any participant
characteristics that might infuence outcomes. 
Prospective means that researchers study 
the groups from the start of the intervention, 
as opposed to retrospectively compiling the 
information after the intervention is completed. 
Retrospective observations are not RCTs but are
still commonly used approaches to research. For
instance, they are often used in studies relying on
administrative claims and electronic health records
databases. These studies tend to be less accurate
because relevant information is not always available
or may be distorted through reliance on people’s
recall. Having a comparison or control group is
essential because most problems have some level
of variability (i.e., they wax and wane over time) and
because many health problems resolve over time
without any formal treatment. The most effective way
to determine whether any observed changes are due
to the treatment being investigated rather than to
natural variability is by comparing against a similar
group of patients who either received no treatment
or received a standard treatment. 







Chapter 4—Approaches to Treatment 
Some of the alternatives to RCTs common in 
the SUD treatment feld can provide useful 
information but have serious limitations that must 
be recognized. For example, following a group 
of patients who received a particular treatment 
in the absence of a comparison group can be 
informative in terms of characterizing what has 
happened to them (e.g., percentage who returned 
to use, percentage who received additional 
treatment, amount of change from pretreatment 
to posttreatment). However, such observations do 
not permit making any scientifcally valid inferences 
about the role of the treatment provided in 
bringing about any of the changes observed during 
follow-up. For that purpose, a comparison group 
is necessary. Any changes observed might have 
occurred in the absence of treatment. Without a 
comparison group, there simply is no way to rule 
out that possibility. 
Similarly, when patients themselves select group 
membership, as opposed to being assigned by 
the researcher, one cannot make valid inferences 
about the role of treatment in the outcome. For 
example, comparing treatment completers to 
dropouts is common and may be informative in 
terms of characterizing how the groups fared, but it 
is not scientifcally valid to infer that any differences 
observed between them were due to the different 
amounts of treatment received. Some other factor 
(e.g., differences in the amount of other demands 
on their time) could have been responsible both 
for the differential retention rates and for the 
subsequent differences observed at follow-up. 
THE IMPORTANCE OF TEACHING HARM REDUCTION 
Many people with stimulant use disorders will not be interested in formal treatment. But that doesn’t mean 
that clinicians can’t help them. Abstinence does not have to be the only goal for people with stimulant use 
disorders. Harm reduction techniques can teach people how to stop using stimulants or how to use them 
in a way that will reduce the risk of injury or death. Also, people can change their minds, and by “meeting 
patients where they are,” rather than being argumentative and trying to force them into treatment, 
clinicians may fnd that patients who initially refuse treatment eventually become open to it. 
Although harm reduction is not treatment, it can still help someone with a stimulant use disorder stay alive. 
Clinicians should never turn someone away from help simply because that individual isn’t interested in 
entering formal treatment or pursuing abstinence. 
Examples of harm reduction strategies that clinicians can use or share with patients are: 
• Educating them about or helping connect them to needle and syringe exchange programs. People 
who use injectable drugs and who have reliable and trusted access to clean needles and syringes through 
a confdential exchange program may be less likely to share and reuse needles (Clarke et al., 2016). 
Exchange programs also help reduce the transmission of HIV (Des Jarlais, 2017). 
• Describing safer injection practices. Teaching people who inject stimulants about proper injection 
techniques, handwashing and other basic hygiene, vein and wound care, and how and when to use 
antibacterial treatments can help reduce the risk of infection and other medical complications. 
• Distributing and educating on naloxone. Naloxone is an FDA-approved opioid antagonist that reverses 
opioid overdose by helping people breathe normally (Offce of the Surgeon General, 2018). Naloxone is not 
for stimulant overdose; it is an antidote to opioid overdose. But for people who use both stimulants and 
opioids, it can save their lives. Naloxone is not addictive and can be taken by injection or nasal spray. 
• Encouraging the use of fentanyl test strips. Fentanyl, which can be deadly, may be added to drugs as 
a cheap fller. Fentanyl test strips allow individuals to determine before using drugs whether they have 
been mixed or cut with fentanyl. Use of the strips can reduce the risk of overdose. 
• Teaching patients HIV risk-reduction techniques, like safer sex practices. People who inject stimulants 
are at risk for HIV and other blood-borne infections. Reducing risky sexual practices can help decrease 
their chances of contracting HIV and other sexually transmitted infections. As noted above, needle 
exchange programs also can help stop the spread of HIV. 







The psychosocial interventions demonstrated to 
date to be effcacious in RCTs and other high-
quality studies with people with stimulant use 
disorders share a common feature of incorporating 
well-established psychological principles of 
learning. Currently, these psychosocial approaches 
to treating people with stimulant use disorders 
have the most research support: CM, CBT/ 
RP, community reinforcement approaches, and 
MI. Many studies look at combinations of these 
treatments. Thus, in making treatment decisions, 
clinicians should consider whether one of these 
approaches alone versus a combination of two 
might be best for a given patient. 
It is impossible to quantify all aspects of 
psychosocial treatment or to account for all 
factors that affect patient outcomes. However, 
given that effective treatments and associated 
manuals are available, using them is prudent and 
helps ensure that patients receive the services 
that research has shown to be effective. An often-
stated but unsubstantiated belief is that using a 
manual will limit or eliminate clinicians’ fexibility 
and ability to exercise clinical judgment. A carefully 
prepared manual recognizes the importance of 
clinical judgment and fexibility in addressing the 
individual needs of patients and incorporates 
those features. 
Contingency Management 
CM is a well-known behavioral intervention 
designed to increase desired behaviors by 
providing immediate reinforcing consequences (in 
the form of incentives) when the target behavior 
occurs, and withholding those incentives when 
the target behavior does not occur. CM has been 
used with considerable effectiveness in treating 
individuals with a variety of SUDs and is very useful 
for treatment planning because it sets concrete 
short- and long-term goals and emphasizes positive 
behavioral changes (Benishek et al., 2014; Minozzi 
et al., 2016). 
A meta-analysis found that CM had small and 
medium-sized effects on stimulant use at 3-month 
follow-up but not at 6 months (Sayegh et al., 
2017). In a network meta-analysis of almost 7,000 
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participants across 12 different psychosocial 
interventions for cocaine and/or amphetamine use 
disorder, the combination of CM and community 
reinforcement approach was the most effcacious 
and most acceptable treatment in both the short 
and long term (De Crescenzo et al., 2018). 
AshaRani and colleagues (2020) found that, across 
44 studies of nonpharmacologic interventions for 
methamphetamine (MA) use, CM interventions 
showed the strongest evidence favoring the 
outcomes assessed, although tailored CBT alone or 
with CM was also effective in the target population. 
Finally, H. D. Brown and DeFulio (2020) found that, 
across 27 studies looking at CM for MA use, nearly 
all (26 of the 27) reported reduced MA use. 
Other positive outcomes across studies included 
longer retention in treatment, greater number 
of therapy sessions attended, higher utilization 
of medical and other services, reduced high-risk 
sexual behavior, increased positive affect, and 
decreased negative affect. 
When considered collectively, CM interventions 
have by far the greatest amount of empirical 
support for their effcacy in promoting therapeutic 
behavioral change among people with stimulant 
use. In fact, interventions other than CM have 
demonstrated weak or nonspecifc effects on 
stimulant use disorder-related problems (Farrell et 
al., 2019). People who use stimulants are sensitive 
to systematically applied CM interventions. 
Like the other psychosocial interventions discussed 
in this chapter, CM may also be effectively used 
with other treatment approaches. In a review 
of 50 RCTs on 12 psychosocial interventions 
for cocaine or amphetamine use, CM plus 
community reinforcement was the only approach 
to result in increased rates of abstinence by the 
end of treatment, at short-term follow-up, and 
at long-term follow-up (De Crescenzo et al., 
2018). This combination was also more effective 
than CBT alone, CM alone, CM plus CBT, and 
12-Step programs plus noncontingent incentives. 
Treatment dropout rates were also lower with CM 
plus community reinforcement. These fndings 
are consistent with those from other reviews that 
support CM (alone and in combination) as being 
highly effective for stimulant use disorders (Ronsley 
et al., 2020). 
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The size of the incentive may be important in 
generating positive outcomes, with higher-value 
cash incentives generally leading to more positive 
behavior changes (such as abstinence) than lower-
value cash incentives (Stitzer et al., 2020). However, 
some research has found no difference in outcomes 
based on magnitude of incentive. For instance, 
Petry and colleagues (2015) studied differences in 
outcomes from standard-sized cash prizes (about 
$300 on average) versus larger-sized cash prizes 
(about $900 on average) in a CM program for 
people with cocaine use disorder and maintained 
on methadone. The two prize groups had no 
differences in drug-negative urine samples or 
duration of abstinence. 
Pregnant women are an important subgroup for 
CM research. For instance, a study of women 
with cocaine use disorder who were pregnant or 
had young children found that CM is associated 
with longer cocaine abstinence and more 
cocaine-negative urine tests compared with use 
of noncontingency vouchers (Schottenfeld et al., 
2011). For more information about stimulant use 
disorders in women who are pregnant, see 
Chapter 6. 
Another population vulnerable to SUDs are 
individuals with serious mental illness (SMI). For 
SMI and stimulant use disorders specifcally, 
McDonell et al. (2013) found that CM plus 
treatment as usual (mental health, SUD treatment, 
housing, and vocational services) was associated 
with fewer days of stimulant use and alcohol use 
and lower rates of injection drug use compared 
with treatment as usual. Researchers have also 
found CM added to usual treatment to be cost-
effective (Murphy et al., 2016). 
A WARNING ABOUT REIMBURSEMENT FOR CONTINGENCY MANAGEMENT 
CM has the greatest weight of evidence supporting its use for the treatment of people with stimulant use 
disorders. However, Medicare and Medicaid currently limit the amount of money that can be used as an 
incentive in CM programs to a maximum of $75 (Glass et al., 2020). Some states also have laws limiting CM 
payments. For instance, in Washington State, state-funded health insurance plans limit CM incentives to no 
more than $100 (Glass et al., 2020). (Note, however, that CM incentives do not have to be monetary. Some 
programs use tokens, nonmonetary coins, or food, for example.) 
Although some research in which CM has been successful has used much higher incentives—sometimes 
$400 to $500 per participant over the course of the study (Glass et al., 2020)—other studies have indicated 
CM effectiveness even when incentives were smaller (Hartzler & Garrett, 2016; López-Nuñez et al., 2016). 
Clinicians should be aware of current laws regarding CM payments and be prepared to offer other 
psychosocial interventions and services as needed. 















Treatment for Stimulant Use Disorders 
WHAT CLINICIANS SHOULD KNOW ABOUT IMPLEMENTING CONTINGENCY
MANAGEMENT 
CM has a strong evidence base of support for treatment of people with SUDs generally, and stimulant use 
disorders specifcally. But not all clinicians know or have been trained in CM and how to implement it. A 
walkthrough of this approach is beyond the scope of this Treatment Improvement Protocol, but the points 
below give important basic information about CM to help clinicians become more familiar with how to use 
it. The resources at the bottom of this text box offer more detailed guidance on this intervention. 
• CM uses stimulus control plus positive incentives to achieve behavior change. This means as patients 
control their use of stimulants, they receive positive incentives (e.g., money) as incentives for their 
behavior. The common outcome targeted by the incentives is a stimulant-negative urine drug screen. 
• Incentives come in the form of vouchers, points, or tokens that can then be exchanged for money, prizes, 
or privileges (like earning take-home doses of methadone for people in an opioid treatment program). 
• Incentives can be administered regularly (called a fxed schedule), like every time the patient achieves 
a target behavior (e.g., remaining abstinent as documented by a negative urine screen), or they can be 
given intermittently (called a variable schedule; Kirby et al., 2016). 
• Incentives can also be disbursed on an escalating schedule, with the incentive gradually increasing every 
time a target behavior is achieved. If a target behavior is ever not achieved, the incentive value “resets” 
back to the original value, and the escalating schedule begins again. 
• A fshbowl procedure (also called variable magnitude of reinforcement) can be used to provide incentives 
on a variable schedule. In this approach, slips of paper are placed in a fshbowl—half indicating that 
an incentive has been won and half offering a reinforcing statement, such as “Good job!” This method 
prevents patients from predicting when they will and will not get an incentive. 
• Some research suggests that people with SUDs respond better to CM that uses both immediate and 
delayed incentives, wherein patients earn an incentive right after meeting a target behavior but then 
also win the opportunity to potentially earn an even larger incentive in the future as the target behavior is 
continually met (Regier & Redish, 2015). 
• Additionally, some research suggests that people with SUDs respond better to receiving concrete 
incentives—like an actual prize or money—rather than a voucher or token, which is only an incentive in 
the abstract and is not in itself valuable (Regier & Redish, 2015). 
• To help maintain target behaviors, the longer a patient maintains a target behavior, such as remaining 
abstinent, the greater the incentive should be (Kirby et al., 2016). For example, a patient could earn more 
draws from the fshbowl for sequential stimulant-negative urine drug screens. 
• Clinicians can work with patients to determine the schedule for giving incentives, such as right away or 
following a brief delay (e.g., giving vouchers that can be exchanged for prizes as soon as they have been 
earned, rather than at the end of the week) (Kirby et al., 2016). 
Learn more about the major components of CM and how to implement it by reviewing: 
• The Substance Abuse and Mental Health Services Administration’s Addiction Technology Transfer Center 
(ATTC) Network online course Contingency Management for Healthcare Settings (https://attcnetwork.org/ 
centers/northwest-attc/news/new-online-course-contingency-management-healthcare-settings). 
• The Motivational Incentives Suite—a collection of tools and other resources to help organizations 
understand and implement CM (https://collaborativeforhealth.org/bettertxoutcomes/). 
• The ATTC Network’s guidance on the founding principles of CM (https://attcnetwork.org/centers/network-
coordinating-offce/contingency-management-part-2-founding-principles). 
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Cognitive–Behavioral Therapy/
Relapse Prevention 
Despite the increase in research on CBT for 
stimulant use disorders over the past two decades, 
its effectiveness is still unclear (De Crescenzo et 
al., 2018; Ronsley et al., 2020). Nonetheless, many 
clinicians and researchers fnd CBT to be helpful. A 
Cochrane review from 2018 found mixed outcomes 
for CBT (including some positive fndings, like 
an increase in percentage of abstinent days over 
a 90-day period and a reduction in symptoms). 
However, the review authors concluded that many 
CBT studies are small in size or poorly designed, 
making it diffcult to have full confdence in their 
fndings (Harada et al., 2018). 
CBT in combination with CM may be especially 
helpful (De Crescenzo et al., 2018). One study 
reported that adding CM to CBT enhanced CBT’s 
positive outcomes (e.g., cocaine-negative urine 
specimens) among people with cocaine use 
disorder (Carroll et al., 2016). Other researchers 
have found that CBT can have delayed positive 
effects on cocaine use disorder, with improvements 
appearing after study treatment has ended 
(Ronsley et al., 2020). 
RP is a form of CBT that teaches patients 
strategies, skills, and lifestyle adaptations to help 
them change their thoughts and behaviors related 
to substance use. RP emphasizes (Hendershot et 
al., 2011): 
• Ways to cope with substance craving. 
• Substance refusal and assertiveness skills. 
• General coping and problem-solving skills. 
• Strategies to prevent a full-blown return to use 
should an episode of substance use occur. 
Carroll and various colleagues have adapted RP 
for cocaine use and demonstrated the effcacy 
of the adapted approach (Carroll, Rounsaville, 
& Gawin, 1991; Carroll, Rounsaville, Gordon, 
et al., 1994; Carroll, Rounsaville, & Keller, 1991; 
Carroll, Rounsaville, Nich, et al., 1994). In an 
initial study, RP was compared with interpersonal 
psychotherapy (IP), which teaches strategies for 
improving social and interpersonal problems 
(Carroll, Rounsaville, & Gawin, 1991). Retention 
was better with RP than IP, and trends suggested 
cocaine abstinence may have been as well, but that 
difference was not signifcant. 
Using as a sample more than 300 individuals who 
had completed outpatient SUD treatment for 
people with stimulant use disorders, Farabee, 
McCann, and colleagues (2013) assessed 14 
RP strategies designed to help with abstinence 
maintenance at baseline and 3-month and 
12-month follow-up. They found avoidance 
strategies to be the most effective predictor of 
drug-free urines at all time points assessed. The 
strategies signifcantly correlated with negative 
urine screens at all time points were: 
• Reducing use of other drugs. 
• Avoiding friends with active drug use. 
• Avoiding places where drugs are available. 
Participating in 12-Step meetings signifcantly 
predicted negative urines at baseline and 
12-month follow-up. (For more information about 
12-Step and other mutual-help programs, see 
Chapter 5.) 
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THE PREVENTION AND TREATMENT OF PRESCRIPTION STIMULANT MISUSE 
Prescriptions for stimulant medication for attention defcit hyperactivity disorder (ADHD) have been 
increasing over the last two decades, likely in part because ADHD diagnoses in children and adolescents 
have been increasing (Colaneri et al., 2017; Visser et al., 2014). As rates of stimulant prescriptions have 
increased over the last 20 years, so too have rates of prescription stimulant misuse, including diversion (Holt 
et al., 2020). Adolescents and college-aged young adults are particularly at risk for behaviors like feigning 
ADHD symptoms to acquire a prescription, taking ADHD medication to improve academic performance, 
or giving away their prescribed medication to others (Colaneri et al., 2017; Weyandt et al., 2016). However, it 
is not just adolescents and college students who are at risk for prescription stimulant misuse. Adults older 
than 19 years received more than half (55%) of all U.S. stimulant prescriptions in the last decade (Arria & 
DuPont, 2018). Although most people prescribed stimulant medications do not misuse them and a much 
smaller percentage have a diagnosable stimulant use disorder, misuse can and does occur (Arria & DuPont, 
2018) and can have serious health and legal consequences (L. Y. Chen et al., 2016; Colaneri et al., 2017). 
Clinicians should ensure that patients meet the established criteria for ADHD in the ffth edition of the 
Diagnostic and Statistical Manual of Mental Disorders (DSM-5) to avoid writing unnecessary prescriptions 
for stimulant medications. If the patient meets DSM-5 criteria for ADHD and a prescription stimulant 
is deemed an appropriate treatment, the prescribing provider should cross-reference the prescription 
information with available data in state-run prescription drug monitoring programs. This step should be 
completed each time a prescription is provided. 
In the absence of published randomized controlled trials or randomized clinical trials on the treatment 
of prescription stimulant misuse, treatment should follow the same path as for cocaine use or MA use. 
That is, patients with prescription stimulant misuse should be offered CM, if available. Research into CM 
for youth with SUDs shows these interventions can help increase the chances of abstinence in the short 
term (Stanger & Budney, 2019). Such interventions may be particularly helpful given that most people with 
past-year prescription stimulant misuse are younger than 26 (SAMHSA, 2020g). However, there is a lack 
of long-term research showing whether substance-related outcomes persist over time and which factors 
might help improve short- and long-term effcacy (Stanger & Budney, 2019). If CM is not available, evidence-
based treatments such as CBT/RP, community reinforcement, and MI can be offered to patients misusing 
prescription stimulants. 
Research has examined the effectiveness of social infuence resistance strategies to help prevent diversion 
of stimulant medication in young adults. Holt et al. (2020) surveyed more than 1,500 college undergraduates 
to learn whether students found such strategies useful. The strategies consisted of students directly 
refusing to divert their stimulant medication, coming up with excuses to avoid diverting (“I don’t have any 
[medication] with me right now”), coming up with an alternative to diverting their medication (e.g., offering 
the person an energy drink instead), attributing their unwillingness to divert to an internal source (“I am not 
comfortable sharing my medication”), and blaming their unwillingness to divert on an external source (“My 
parents keep track of my prescription because they send it to me, so I can’t share any”). 
In the study, 19 percent of the students said they had engaged in nonmedical use of prescription stimulants 
(i.e., prescription stimulant misuse) at some point during their time in college (Holt et al., 2020). Internal and 
external strategies were perceived as being the most helpful, and the use of excuses was rated the least 
helpful. Students who had previously engaged in diversion found the strategies overall to be less effective 
than did students at low risk for diversion. Clinicians working to prevent diversion in their patients not 
already diverting medication—as well as clinicians helping patients who are already diverting learn how to 
stop—might want to emphasize teaching refusal skills based on internal and external blaming strategies. 
Using these strategies may prove more effective than simply telling patients that they need to “learn to say 
‘no’” when approached by someone wanting them to divert their medication. 
Continued on next page 
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Clinicians can also help reduce diversion by checking prescription drug monitoring databases and checking 
urine drug screens. Other stimulant diversion prevention techniques include (Colaneri et al., 2017): 
• Developing medication contracts that include the risks and benefts of the stimulant medication, the risks 
of misusing the medication, an agreement that the patient will only take the medication as prescribed, 
conditions for determining adherence (e.g., pill counts), and consequences of the patient violating the 
contract. 
• Providing materials that educate patients about the dangers of misusing prescription stimulants (e.g., the 
risk of potentially harming people with preexisting heart disease or cardiac structural abnormalities). 
• Prescribing a smaller number of pills. 
• Prescribing long-acting formulations rather than short-acting formulations. 
• Conducting periodic pill counts. 
• Learning about and prescribing nonstimulant medications instead of stimulants. 
Clinicians should also build linkages with local SUD treatment providers (including ones specializing in 
working with adolescents and young adults), so they can refer patients in need of formal treatment and 
services. Finally, clinicians should be sure to conduct SUD assessments for patients who are prescribed 
stimulants (even if the patient is not misusing the prescription stimulant) and refer patients for SUD 
treatment as needed. People taking prescription stimulants—even lawfully and as prescribed—are 
vulnerable to tobacco, cannabis, cocaine, hallucinogen, and opioid use (Arria & DuPont, 2018; Compton et al., 
2018). (See Chapter 2 for more information about stimulant use disorder assessment.) 
Community Reinforcement Approach 
Community reinforcement is an individualized 
treatment designed to promote key lifestyle 
changes that are conducive to successful recovery 
(see Meyers & Smith, 1995; Sisson & Azrin, 1989): 
• Patients with partners/spouses who do not 
use stimulants are offered marital therapy to 
improve the quality of their relationships in a 
reciprocal and rewarding manner. 
• Patients who are unemployed, employed in jobs 
that are high risk for substance use, or need 
vocational assistance for some other reason 
receive help in that domain. 
• Patients are counseled and assisted in 
developing new social networks and 
recreational practices that promote and support 
recovery. Mutual-help group participation is 
not mandatory but is often used as an effective 
means of developing a new social network. 
• Various types of skills training are provided 
depending on individualized patient needs, 
including substance refusal and associated 
skills, social skills, time management, and mood 
regulation. 
• Patients with alcohol use disorder (AUD) and no 
medical contraindications are offered a program 
of disulfram therapy coupled with strategies to 
support medication compliance. 
Very few recent studies have examined community 
reinforcement alone, so it is unclear whether this 
approach delivers better substance use outcomes 
than other psychosocial approaches or usual care 
(Ronsley et al., 2020). One study of community 
reinforcement did fnd increased treatment 
retention and abstinence and decreased addiction 
severity after 24 weeks (De Giorgi et al., 2018). 
More recently, research on community 
reinforcement has focused on the effectiveness 
of adding it to CM (Ronsley et al., 2020). When 
used together, these treatments appear to (De 
Crescenzo et al., 2018): 
• Do a better job than usual care at retaining 
individuals in treatment. 
• Do a better job than noncontingency-based 
approaches (either used alone or with 12-Step 
programs) at helping people achieve abstinence. 
• Have better patient acceptance than treatment 
as usual. 
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In one review, community reinforcement combined 
with noncontingent vouchers was less effective 
at achieving abstinence from cocaine than was 
community reinforcement combined with CM 
(Schierenberg et al., 2012). 
Motivational Interviewing 
MI has been found to be an effective evidence-
based, group- or individual-based treatment for 
people with SUDs, especially AUD (SAMHSA, 
2019). MI and motivational counseling, as applied 
to SUDs, have been associated with decreased 
substance use, improved SUD treatment retention, 
lower rates of relapse, and better adherence to HIV 
risk-reduction behaviors (SAMHSA, 2019). 
Recent studies of MI alone for stimulant use 
disorders show mixed results, with some fnding 
no beneft and others fnding improvements 
in reducing the number of days of cocaine use 
(De Giorgi et al., 2018). Intensive MI designed 
specifcally for MA use disorder demonstrated 
no different outcomes in MA use or in anxiety 
compared with an education control group that 
also received MI, although it was nonintensive 
(Polcin et al., 2014). A Cochrane review of 
psychosocial interventions for stimulant misuse 
(Minozzi et al., 2016) included fve studies 
comparing MI with no intervention. In these 
studies, receiving any psychosocial treatment 
(including MI) was associated with better treatment 
retention and greater abstinence than no treatment 
at all. However, the authors noted a fair amount of 
bias and study design problems across all of the 
studies in their review, including those pertaining 
to MI. Thus, results should be interpreted with 
caution. 
Recent studies on combining MI with other 
treatment approaches were either inconclusive or 
had unreported results. One review noted that MI 
combined with CBT has yet to demonstrate reliable 
improvements over other treatments (De Giorgi et 
al., 2018). However, some individual studies have 
reported good results from adding MI to CBT. 
In a sample of military veterans with SUDs, MI 
combined with CBT or combined with CBT and 
continuing care both showed signifcant decreases 
in substance use (including cocaine use) and 
reductions in aggression compared with treatment 
as usual (Chermack et al., 2019). MI added to CBT 
tailored to the unique needs of gay and bisexual 
men who are HIV positive was associated with 
lower MA use, better HIV medication adherence, 
and reduced risky sexual behavior (i.e., having sex 
without condoms) over the course of 12 months 
(Parsons et al., 2018). 
THE ROLE OF TELEHEALTH IN TREATING STIMULANT USE DISORDERS 
Technology use continues to grow as more people rely on smartphones and other electronic devices for 
access to information, social connection, and work-related activities. Telehealth is the use of technology to 
support and enhance healthcare delivery. Telehealth includes online education materials and treatments, 
mobile applications, and synchronous audiovisual services. 
Research has shown that telehealth can be a useful and cost-effective tool for people with SUDs (Dallery 
et al., 2019; Murphy et al., 2016; Tait et al., 2015). Although more research is needed on the use of telehealth 
for people with stimulant use disorders specifcally, research on telehealth for SUDs in general or other 
substances specifcally can still provide useful insight into how these innovative tools and approaches may 
be effective and benefcial for patients. 
Examples of ways that telehealth can help clinicians and their patients include: 
• Supporting formal treatment. 
- Self-guided web-based interventions using techniques from CBT and motivational enhancement 
have shown promise in increasing help-seeking and reducing role impairment for people using 
amphetamine-type stimulants (Tait et al., 2015). 
Continued on next page 
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- In 2017, a mobile application, reSET, became the frst prescription-based digital therapeutic cleared by 
FDA. The program is based on the community reinforcement approach model and allows physicians to 
prescribe an 84-day access period by providing a code required for download. A multisite clinical trial of 
more than 500 adults with an SUD (including stimulant use disorder) who were engaged in outpatient 
treatment and who used the reSET application had lower dropout rates and higher abstinence rates 
(FDA, 2017). 
- Posttreatment telephone contact, whether structured or directive, is associated with perceived 
decreases in life events that contribute to substance use among people who use stimulants (Farabee, 
Cousins, et al., 2013). High dropout rates during treatment for stimulant use disorders suggest there 
may be utility to using telephone contact during treatment to encourage retention as well (Lappan et 
al., 2020). 
• Reaching rural and underserved communities. 
- Telehealth can address barriers to receiving substance use treatment in rural communities, such as 
privacy concerns, lack of provider availability, and lack of evidence-based, culturally appropriate services 
(Lin et al., 2020; SAMHSA, 2016). Although promising, clinicians should be aware that patient-level 
barriers, such as reliable access to the Internet and devices that support audiovisual conferencing or 
mobile applications, may affect telehealth implementation (Hser & Mooney, 2021; Kleykamp et al., 2020). 
- Studies of people with alcohol, tobacco, and opioid use disorders show that telehealth can effectively 
promote treatment engagement and retention, perceived support from providers, and substance 
use reduction through increased access (Kruse et al., 2020; M. C. Mahoney et al., 2018; Weintraub et al., 





Physical activity is an area of robust and fast-growing
research for therapies for stimulant use disorders.
Aerobic exercise has been an increasing focus of SUD
treatment studies broadly (as an add-on therapy, not
as the lone treatment), including studies on stimulant
use disorders (Sanchez et al., 2017). A review of
physical activity interventions for people with MA
use (Morais et al., 2018) found that, compared with
nonexercise intervention controls, improvements
were observed for: 
• Aerobic performance. 
• Muscle strength and endurance. 
• Body composition. 
• Heart rate variability. 
• Depression. 
• Anxiety. 
• MA use. 
• MA cravings. 
• Inhibitory control. 
Other researchers have similarly found that 
structured aerobic exercise and resistance training 
help reduce depression and anxiety in MA use 
disorder (Morris et al., 2018; Rawson, Chudzynski, 
Gonzales, et al., 2015), which may be useful in 
helping patients remain in treatment and sustain 
abstinence. 
A study by Rawson, Chudzynski, Mooney, et 
al. (2015) found that participants with a lower 
severity of MA use assigned to an exercise 
intervention reported fewer days of drug use and 
had fewer positive urine screens, compared with 
participants with a lower severity of MA use who 
received a health education intervention. In the 
STimulant Reduction Intervention using Dosed 
Exercise (STRIDE) study (Trivedi et al., 2017), a 
12-week dosed exercise intervention in residential 
SUD treatment settings was associated with a 
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 signifcantly higher percentage of days abstinent 
compared with a health education intervention. 
(Both interventions were add-ons to treatment 
as usual.) 
Benefts of physical exercise to people who use 
stimulants may include enhanced antioxidant 
mechanisms, reduced oxidative stress, and 
decreased reward-seeking behaviors (Morais et 
al., 2018). Evidence from human trials of exercise 
for stimulant use indicates an improvement in 
neurotransmitter systems that become deranged 
with cocaine or MA exposure (especially 
dopaminergic systems; Morais et al., 2018). 
Exercise by people using MA may help increase 
their striatal D2/D3 receptor availability (Morais et 
al., 2018). Preliminary data suggest that exercise 
for MA use disorder may also lead to better MA-
related outcomes by increasing dopamine receptor 
binding in the brain (Robertson, Ishibashi, et al., 
2016). 
The Matrix Model 
The Matrix model (originally referred to as 
the “neurobehavioral model”) is a manualized 
outpatient treatment approach that was developed 
during the mid-1980s for the treatment of 
individuals with cocaine and MA use disorders 
(NIDA, 2018a). The model integrates treatment 
elements from a number of specifc strategies, 
including RP, MI, psychoeducation, family therapy, 
and 12-Step program involvement. The approach’s 
basic elements consist of a collection of group 
sessions (early recovery skills, RP, family education, 
and social support) and individual sessions, along 
with encouragement to participate in 12-Step 
activities (NIDA, 2018a; Rawson, 2010). 
In seven research projects evaluating the treatment 
model, application of the model was shown to be 
associated with signifcant reductions in cocaine, 
MA, and other substance use (Rawson et al., 1993; 
Shoptaw et al., 1994). Treatment participation in 
the Matrix model has also been demonstrated to 
be associated with a signifcant improvement in 
psychological symptoms and signifcant reduction 
in risky sexual behaviors associated with HIV 
transmission (NIDA, 2018a). Adaptations of the 
Matrix model are available to address the unique 
treatment needs of women with stimulant use 
Treatment for Stimulant Use Disorders 
disorders in such areas as trauma, pregnancy 
and parenting, body image, and sexuality 
(SAMHSA, 2012). 
Family and Couples Therapy 
People with SUDs often have extensive marital, 
relationship, and family problems. Stable marital 
and family adjustment is associated with better 
treatment outcomes. Including family members 
in treatment is based on the view that they can 
provide important support for the patient’s efforts 
to change and offer additional information about 
the patient’s substance use and other behavior. 
Interventions directed at improving marital and 
family adjustment have therefore been judged to 
have the potential to improve treatment outcomes. 
Studies with people with AUD have supported 
this hypothesis, at least in part (Klostermann et al., 
2011). Few studies have focused on stimulant use, 
however. 
Research on family and couples therapy for 
stimulant use disorders is scant, but outcomes 
appear promising. In a study of women with SUDs 
who have children, family systems therapy was 
associated with a reduction in both likelihood 
of cocaine use and frequency of use over time, 
and, compared with control participants, a faster 
decrease in frequency of cocaine use over time 
(Slesnick & Zhang, 2016). 
For more information about providing family 
and couples therapy for people with SUDs, see 
SAMHSA’s Treatment Improvement Protocol 
(TIP) 39, Substance Use Disorder Treatment and 





Mindfulness-based interventions have gained 
popularity as potential tools to help prevent 
return to use by people with SUDs (Chiesa & 
Serretti, 2014). Mindfulness-based psychotherapy 
for people with cocaine use disorder (Dakwar & 
Levin, 2013) resulted in a 73-percent treatment 
completion rate and a 55-percent abstinence rate. 





Chapter 4—Approaches to Treatment 
Among people with stimulant use disorders who 
received 12 weeks of CM, concurrent use of 
mindfulness-based RP was associated with greater 
reductions in depressed mood, greater reductions 
in Addiction Severity Index score, and lower odds 
of stimulant use compared with a health education 
control group (Glasner-Edwards et al., 2017). 
Close to half the sample had major depressive 
disorder (43%), and approximately one-quarter had 
generalized anxiety disorder (24%). Compared with 
CM plus health education, CM plus mindfulness RP 
was associated with lower scores of negative affect, 
greater reductions in depression severity and 
psychiatric symptom severity, and—among people 
with depressive and anxiety disorders—decreased 
stimulant use (Glasner-Edwards et al., 2017). 
A residential mindfulness-based intervention 
for women with SUDs (most of whom had 
amphetamine/MA use) similarly showed greater 
chances of treatment completion compared with 
the control condition. Also, program attendance 
signifcantly correlated with improvements in 
mindfulness, distress tolerance, and mood (D. S. 
Black & Amaro, 2019). 
Mindfulness-based RP combined with a single dose 
of ketamine was associated with longer cocaine 
abstinence than mindfulness plus midazolam in 
a 2019 study by Dakwar and colleagues. The 
mindfulness-ketamine participants were also 
53 percent less likely to return to use and had 
signifcantly lower scores on craving. 
Case Management and 
Coordinated Care 
Case management and coordinated care are 
SUD treatment approaches with strong support, 
especially in terms of their ability to link people 
with SUD treatments and services and to retain 
patients in treatment (Vanderplasschen et al., 
2019). These approaches are person centered and 
help ensure that care delivery is organized and 
includes all needed interventions and services, to 
the extent possible. 
A small but promising line of research has looked at 
case management or coordinated care specifcally 
among people with stimulant use disorders: 
• In a pilot study, a strengths-based case 
management intervention for people with HIV 
who used injection drugs or smoked crack 
cocaine was associated with a decrease in 
detectable viral load (Kral et al., 2018). 
• A study of women who used crack cocaine 
found case management was associated with 
improvements in drug and alcohol use (i.e., 
lower frequency of use), mental and emotional 
health (e.g., less depression or anxiety), and 
employment (Corsi et al., 2010). 
• Men and women who were receiving public 
assistance and had a long history of substance 
use (including cocaine use) benefted from 
a coordinated care management approach 
designed to help link patients to SUD treatment, 
provide them with SUD-related services, and 
help them fnd employment (Morgenstern et 
al., 2009). Compared with the usual care group, 
women (but not men) in the program saw an 
increase in employment over time. 
Vocational services are an important part of case 
management and coordinated care approaches; 
they can help people with SUDs, including 
stimulant use disorders, reintegrate into the 
workforce, learn valuable skills, and earn wages. 
Employment is an important aspect of long-term 
recovery and is associated with successful SUD 
treatment completion and 6-month abstinence 
(Sahker et al., 2019). Case management and 
coordinated care that incorporate vocational 
training or employment assistance may improve 
patients’ chances of stopping stimulant use and 
staying in recovery following treatment. 
For instance, the Compensated Work Therapy 
(CWT) program is a Department of Veterans 
Affairs clinical vocational rehabilitation service 
that supports veterans in fnding and retaining 
employment. CWT interventions have been 
combined with CM to help veterans with SUDs 
not only improve employment outcomes but 
reduce substance use (Cosottile & DeFulio, 2020). 
Employment-based CM programs have been 
particularly successful for patients with cocaine 
use and opioid use disorders (OUDs; Cosottile & 
DeFulio, 2020). 
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 For more information about vocational 
services, see SAMHSA’s TIP 38, Integrating 
Substance Abuse Treatment and Vocational 
Services (https://store.samhsa.gov/product/ 
TIP-38-Integrating-Substance-Abuse-Treatment-
Vocational-Services/SMA12-4216), and SAMHSA’s 
Advisory, Integrating Vocational Services Into 




Although case management and care coordination 
is still a growing area of research, these positive 
fndings, along with the research showing support 
for case management and coordinated care 
for SUDs in general, suggest that using these 
approaches, when possible, can help patients 
beneft further from treatment, even in non-SUD 
outcomes (like employment and HIV status). 
Other Interventions With
Supportive Research 
Evidence on transcranial magnetic stimulation 
(TMS) suggests this could be a safe and effective 
treatment for people with SUDs, although this 
research area needs further study. TMS involves 
nonsurgical stimulation of the brain through 
magnetic electrodes placed on the scalp. It is 
painless and noninvasive. It is thought to work on 
SUDs in part by increasing dopamine delivery to 
certain parts of the brain (e.g., the limbic system) 
and by reducing impulsivity/increasing self-control 
mechanisms in the prefrontal cortex network. 
Repetitive TMS (rTMS) has been shown to be 
effective in reducing cravings in AUD (De Sousa, 
2013). A review of six studies looking at rTMS for 
cocaine use disorder found a reduction in cravings 
and an increase in cocaine-free urine screens but 
noted that the evidence is still preliminary and 
needs to be replicated in larger studies (Bolloni 
et al., 2018). Data also suggest that only high-
frequency rTMS (rather than low frequency) is 
effective in reducing cocaine, amphetamine, or MA 
craving (Ma et al., 2019). 
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Other Models of Psychosocial
Treatment 
Network Therapy 
Network therapy is based on the theory that 
people can recover from SUDs if they have 
a stable social network to support them in 
psychotherapeutic treatment. In this model, 
a patient receiving individual psychotherapy 
develops a network of stable, nonsubstance-using 
support people, such as family, a partner, and close 
friends. These support people learn strategies from 
the clinician to support the therapeutic process 
for the individual being treated. They may interact 
regularly with the clinician, participate in treatment 
sessions with the patient (SAMHSA, 2020k), and 
be involved in setting up treatment plans for the 
patient. 
Inpatient (or Hospital-Based) Treatment 
“Inpatient treatment” is a broad term 
encompassing the highest levels of medical care 
for patients who may be experiencing acute 
medical or psychiatric needs secondary to recent 
use of substances or acute withdrawal. Specifcally, 
acute treatment services may involve 24-hour 
medical management or medical monitoring, 
particularly in instances where stimulant use has 
led to life-threatening medical problems, such as 
rhabdomyolysis, signifcant electrolyte imbalances, 
or severe cases of sleep deprivation. 
Historically, inpatient treatment began in the 1800s 
for patients experiencing severe AUD in an attempt 
to reduce the community-level concerns related to 
uncontrolled alcohol consumption. Programs like 
the Washingtonian Home in the city of Boston were 
specifcally designed to help patients detoxify from 
alcohol and return to society (White, 2004). Over 
time, these programs shifted to hospital-based or 
medically monitored care to reduce the morbidity 
and mortality associated with alcohol withdrawal. 
Inpatient treatment for AUD traditionally consisted 
of a 28-day stay in a hospital or residential 
treatment facility, during which daily activities such 
as group psychotherapy and relaxation practice 
were provided in a structured format. Generally 
supportive and sometimes confrontational 
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in nature, inpatient treatment was aimed at 
detoxifying patients, combating their denial, and 
beginning the process of engaging with mutual-
help programs. 
The 28-day standard treatment regimen also 
became common for patients experiencing other 
SUDs. It was especially widespread in the early 
1980s, when the numbers of patients seeking 
treatment for cocaine use disorder began to rise 
dramatically. Most of these inpatient programs for 
treating cocaine use were adapted with few or no 
modifcations from the alcohol regimens and with 
little input from empirically based research. Such 
inpatient programs were called into question by 
insurance providers, and subsequently, their use 
steadily declined (Malcolm et al., 2013). 
Today, acute treatment programs, colloquially 
referred to as “detoxes,” may admit patients for 
between 3 and 10 days for observation during 
initial cessation of substance use and restoration of 
physiologic homeostasis (the body’s natural ability 
to maintain critical functions, like normal core 
temperature and normal blood glucose levels) after 
signifcant periods of severe substance use. Acute 
treatment services vary greatly in the amount of 
recovery support available to patients and the 
number of medical staff onsite for the care and 
monitoring of patients. 
Patients with signifcant medical or psychiatric 
comorbidity may be voluntarily admitted to 
medically or psychiatrically managed SUD care, 
often referred to as “Level 4 facilities” after the 
level that is assigned in the American Society 
of Addiction Medicine’s (ASAM) levels of care 
(ASAM, 2015b; K. Hartwell & Brady, 2018). These 
hospital-based residential programs are capable 
of accommodating the highest acuity patients and 
are used for acute stabilization of medically or 
psychiatrically complex patients. 
Clinical stabilization programs, or transitional 
support services, are inpatient programs for 
patients with fewer medical or psychiatric 
comorbidities. These programs typically offer more 
recovery services for patients, including mutual-
help groups, therapeutic communities (TCs), 
education or therapy groups, individual counseling, 
a therapeutic milieu, and other integrated 
psychosocial services (ASAM, 2015b). These 
programs may last anywhere from 2 to 4 weeks 
(and often longer) and because of their extended 
nature may be the most benefcial in monitoring 
patients in early recovery from stimulants. 
Special considerations should be made in 
treatment plans for patients experiencing stimulant 
withdrawal in inpatient settings (Braunwarth 
et al., 2016). Given the profound fatigue and 
excessive sleeping that can occur, considerations 
for exemptions from therapeutic sessions and 
educational services should be considered. 
Nutritional support for patients recovering from 
SUDs is vital (Szydlowski & Amato, 2017). Increased 
access to high-calorie foods and foods with 
increased nutritional value may help in augmenting 
patients’ weight and correcting electrolyte 
imbalances (Braunwarth et al., 2016). Programs 
should consider consultation with appropriate 
nutrition or dietary specialists when necessary. 
Additionally, given the possibility of increased 
depressive symptoms throughout acute withdrawal 
from stimulants, patients should be assessed for 
changes to risk for self-injury or self-harm regularly 
while in the inpatient unit, and safety plans should 
be in place in case patients develop thoughts of 
self-harm or self-injury. Suicide has been shown to 
be a signifcant cause of mortality for individuals 
who misuse stimulants (Butler et al., 2017; Farrell et 
al., 2019; Marshall & Werb, 2010). 
Legislation regulating involuntary commitment 
to inpatient treatment settings (also known as 
mandated treatment) for SUDs varies throughout 
the United States. Many states have enacted 
legislation that allows clinicians or, in some 
instances, family members to fle petitions for 
involuntary assessment of SUDs when patients 
are unable to adequately care for themselves or 
they pose serious risks to themselves or others. 
A judge may dismiss the petition or issue a court 
order for SUD treatment. Patients can choose to 
refuse treatment and ignore court orders, which 
may result in undesirable legal consequences. For 
patients admitted for involuntary treatment, special 
consideration should be given to identifying the 
reason for the involuntary commitment and the 
best strategy to mitigate that condition. 
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Involuntary treatment may be confrontational 
initially, and staff generally use MI techniques 
to elicit change talk and capitalize on patients’ 
mandated treatment status. In the setting of 
involuntary treatment, it is vital to establish referral 
partners for when the patients have completed 
their requisite amount of time in SUD treatment. 
Inpatient treatment varies in both insurance 
coverage and credentialing of staff. It is important 
to understand the nuances of different inpatient 
treatment programs, especially the duration of 
treatment, the medical/psychiatric credentials of 
the staff, and the program’s ability to collaborate 
with outpatient treatment partners (Offce of the 
Surgeon General, 2016). Given that stimulant 
use disorders are chronic, relapsing conditions, 
treatment should not end once patients leave an 
inpatient setting. These patients should always be 
“stepped down” into outpatient care. 
In the past two to three decades, more patients 
have received primary SUD care in outpatient 
settings rather than inpatient treatment facilities. 
As this shift continues, inpatient treatment will 
remain reserved for patients experiencing the most 
severe forms of an SUD, with the highest risk of 
morbidity or mortality related to their medical or 
psychiatric presentation while using or stopping 
their use. 
Residential Treatment 
Residential treatment may be indicated for people 
with SUDs who need more structured support for 
a specifc period of time in early recovery. The 
structure of residential treatment allows positive 
changes and stabilization in patients’ attitudes and 
lifestyles. The duration of residential treatment 
varies. Some treatment may be as short as 30 days, 
whereas other treatment may last up to 1 year. 
TCs, a common type of long-term residential 
treatment, typically use group activities directed 
toward effecting signifcant changes in the 
residents’ lifestyles, attitudes, and values. They 
emphasize prosocial behavior and strengths-based 
strategies for improved decision making (NIDA, 
2015). Many referrals to TCs take place through 
the court system. In fact, TCs were originally 
Treatment for Stimulant Use Disorders 
designed for patients with heroin use disorder, 
low socioeconomic backgrounds, and long-term 
histories of criminal involvement. 
Halfway Houses 
Halfway houses (also known as sober living 
environments or facilities) provide transitional 
support for people who have completed residential 
treatment and are still attending formal treatment, 
like outpatient care (Polcin et al., 2010), but would 
beneft more from increased structure or support 
than from solitary community living. Halfway-house 
program requirements usually include specifed 
community involvement (e.g., employment or 
enrollment in school), and abstinence from mood-
altering substances. Evening group activities are 
structured around residents’ work schedules. 
Programs generally require out-of-pocket 
expenses and have limited insurance coverage or 
reimbursement. 
PATIENT PLACEMENT: AVOIDING THE
COOKIE-CUTTER APPROACH 
Long-term residential treatment can be 
enormously helpful for many patients. But not 
all people with stimulant use disorders need 
this level of care right away or even ever. A one-
size-fts-all approach to choosing a treatment 
setting—such as sending everyone to residential 
treatment for 60 days—should not be used. 
Rather, clinicians should consider each patient’s 
needs, preferences, and life circumstances 
individually. Using patient placement criteria, 
such as those from ASAM, or clinical assessment 
can help clinicians and patients make informed, 
tailored decisions. 
Clinical Issues To Consider 
Clinicians should be prepared to take into 
account a number of clinical challenges when 
doing treatment planning with patients. Exhibit 
4.1 summarizes the most common clinical issues 
encountered and strategies to manage them 
(Rawson et al., 2021). 
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An individual may use multiple 
substances to enhance the 
physical or psychological effects 
of each drug, to counteract the 
effects of one or more drugs, to 
prolong a drug’s effects, or to 
experience a new effect. 
One who uses stimulants often 
also uses: 
• Alcohol. 




• Assess individuals using opioids for opioid use 
disorder (OUD) and treat with medications for OUD.* 
• Assess individuals using alcohol for alcohol use 
disorder (AUD) and treatment with AUD medications, 
including naltrexone.* 
• Assess individuals using benzodiazepines for 
dependence, and, if needed, provide medical 
withdrawal assistance. 
• Offer motivational interviewing (MI) and other 
evidence-based behavioral strategies. 
Overdose 
risk 
Much of the cocaine and 
methamphetamine (MA) that is 
now available contains fentanyl 
and heroin. 
Individuals using stimulants 
that include fentanyl have an 
increased risk for overdose. 
Current supply of MA is very 
potent and can create MA 
overdose, including seizure, 
stroke, very high temperature, 
and heart attack. 
• Assess patient awareness of dangers from fentanyl 
and educate about risks. 
• Encourage patients to use fentanyl test strips to 
determine whether stimulants have been mixed or 
cut with fentanyl. 
• Train staff, patients, and family members on naloxone 
use and make naloxone available to patients, their 
families, and the community. 
• Monitor patients closely for opioid overdose 
symptoms from fentanyl (or heroin) mixed with MA or 
cocaine. 
• Train staff in use of MA overdose strategies, including 
how to address stroke and hyperthermia. 




• Increased locomotor activity. 
• Agitation. 
• Psychotic symptoms, including 
paranoia and hallucinations. 
• Dilated pupils (National 
Institute on Drug Abuse, 2021b; 
Yasaei & Saadabadi, 2021). 
• Try to calm the patient down (i.e., create a soothing 
environment). 
• Consider pharmacologic treatment (e.g., 
benzodiazepines, antipsychotics) for patients who 
exhibit severe symptoms of intoxication. 
• Note: No medications are currently available to 
reverse MA overdose. 
• Note: Cocaine intoxication typically lasts 2–4 hours, 







One of the challenges clinicians 
face is making a distinction 
between independent psychiatric
disorders, psychiatric disorders as 
a result of the stimulant use, and 
psychiatric symptoms that arise 
from intoxication and withdrawal.
• Consider integrated treatment options, regardless of 
the underlying cause of the co-occurring diagnosis. 
• Lack of adequate treatment for either disorder may 
interfere with overall recovery; coordinate services 
between SUD clinicians and mental health service 
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Issue Clinical Consideration Management Strategy 
Psychosis Stimulant use can cause psychotic symptoms 
(e.g., auditory and visual hallucinations, 
paranoia). Mania also may occur. Stimulant-
induced psychosis is generally transient; but 
persistent MA psychosis can resemble psychosis 
in schizophrenia. 
• Consider an antipsychotic medication 
to address acute symptoms. 
• Consider continuation of antipsychotic 
medications for long-term 
management of persistent psychosis. 
Violence MA use increases the risk of violent behavior 
(McKetin et al., 2014). 
• Understand the relationship between 
stimulant use and violence, and be 
aware of the consequences of violence 
for individuals using stimulants, 




Stimulant misuse leads to attention and memory 
problems that can interfere with an individual’s 
ability to engage in treatment approaches 
that involve learning. Stimulant misuse can 
also lead to executive dysfunction, including 
diffculties with problem-solving, planning and 
organization, and reasoning (C. Ellis et al., 2016; 
Wilens et al., 2017). 
• Inform patients about cognitive 
defcits and use strategies that 
provide repetition of information and 
do not depend on optimal memory. 
• Reserve treatments that require more 
complex cognitive functioning until a 
patient’s cognition is restored after a 
period of abstinence from stimulants. 
• Assess for cognitive defcits and teach 
staff to be aware of any defcits. 
Stimulant 
withdrawal 
Stimulant withdrawal symptoms comprise 
severe fatigue, cognitive impairment, feelings 
of depression and anxiety, anergia (lack of 
energy), confusion, and paranoia. Most patients 
experiencing acute withdrawal/early-phase 
abstinence will have most of their symptoms 
resolve in 2–10 days. 
• Suggest that patients rest, exercise, 
and eat a healthy diet, which is the 
best management approach for 
most people in withdrawal. Patients 
with heightened agitation and 
sleep disturbance may respond 
to pharmacotherapy, but acute 
depression and anhedonia associated 
with early abstinence generally 
resolve without intervention. Be 
aware of possible dehydration and 
hyperthermia. 
Individuals may experience cravings associated 
with specifc cues, such as objects (e.g., cash), 
people (e.g., relatives who use drugs), other 
substances (e.g., cannabis), places (e.g., areas 
where stimulants are sold or used), time periods 
(e.g., weekends, evenings), and emotional states 
(e.g., depression, boredom; A. R. Childress et al., 
1999). 
• Educate patients in treatment about 
the powerful impact of cue-induced 
cravings, and help them identify 
strategies to avoid situations in which 
there are “triggers.” 
Once acute withdrawal subsides and the 
person starts to feel better, they may experience
hypersexuality and impaired sexual functioning,
leading to mental distress (Rawson et al., 2002). 
• Educate patients about the possibility 
of changes in sexual function during 
later phases of recovery. 
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Severity of 
disorder 
and level of 
care 
Patients may receive treatment services at 
various levels within the continuum of care. 
Levels range from prevention and early 
intervention to inpatient and residential services. 
Assessing the required level of care for each 
patient based on the severity of the patient’s 
disorder is critical. Patient placement criteria, 
such as the American Society for Addiction 
Medicine’s, can be used to match severity to level
of care needed. 
• Ensuring access to care is a primary 
consideration given the potential 
for overdose. Evaluate the patient’s 
needs and try to match services at the 
appropriate level, and then step up to 
more intense treatment or down to 
less intense treatment as needed. 
• Engage peer recovery support 
specialists or case managers who 
can be helpful in continuing care, 
removing obstacles to recovery, and 
linking patients to specialty treatment. 
• Based on the risk of overdose, ensure 
availability of treatment and retention 
in treatment as primary goals for all 
programs working with people actively 
using stimulants. 
• Consider the presence of psychosocial 
stressors that may affect level of care 
needed, such as involvement in the 
criminal justice system or a lack of 
housing. 
 
* Because naltrexone is an opioid antagonist, patients who take opioids and are prescribed naltrexone for AUD or OUD 
must abstain from opioids for 7 to 14 days (depending on type of opioid) before starting naltrexone treatment. The 
purpose of this waiting period is to avoid precipitating opioid withdrawal (Substance Abuse and Mental Health Services 
Administration, 2020h, 2020o). 
Engaging and treating people who are actively 
using stimulants, in withdrawal, or in early recovery 
is challenging. Understanding the experience of 
the patients in conjunction with clinical concerns is 
essential for planning and implementing therapy 
practices to meet patient needs and preferences. 
Again, when working with these patients, keep in 
mind that the psychosocial approach with the most 
research support is CM, with CBT/RP, community 
reinforcement, and MI also being well-supported 
interventions. Moreover, mutual-help programs, 
such as Crystal Meth Anonymous and Narcotics 
Anonymous, can help individuals with stimulant use 
disorders manage relapses and enhance recovery. 
Summary 
Several empirically tested nonpharmacologic
treatments for stimulant use disorders are available,
with CM having the strongest weight of evidence.
CBT/RP, community reinforcement, and MI also have
good though less robust data to support their use to
treat stimulant use disorders. Less rigorously studied
yet still appropriate approaches, such as mindfulness
meditation and prescribed physical activity, can also
be used to supplement SUD care and potentially
help patients improve abstinence and other health
outcomes. Clinicians have a wide range of options to
help patients with stimulant use disorders reduce or
stop their substance use, improve their health, regain
functioning (e.g., obtain or return to work), and
achieve long-term recovery. 
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Chapter 5—Practical Application of 
Treatment Strategies 
KEY MESSAGES 
The Food and Drug Administration (FDA) has 
not—as of the publication date of this document— 
approved any medications for the treatment of 
individuals with stimulant use disorders. Therefore, 
Chapter 5 focuses on applying behavioral and 
psychosocial approaches to improving treatment 
outcomes for individuals with stimulant use 
disorders. Consensus panel recommendations 
for the Substance Abuse and Mental Health 
Services Administration’s (SAMHSA) original 
Treatment Improvement Protocol (TIP), which 
were augmented by feld review feedback, have 
been reviewed and updated. Whenever possible, 
the chapter presents treatment strategies that 
are supported by empirical evidence. However, 
because many stimulant use treatment issues have 
not been systematically researched, current clinical 
practice is also discussed. 
Individuals seeking help for stimulant use disorders 
can receive their treatment in a variety of settings. 
The strategies described in this chapter emphasize 
techniques used in outpatient substance use 
disorder (SUD) care. However, many, if not most, of 
these strategies and techniques can be integrated 
into other treatment settings across the continuum 
of care. 
This chapter describes the key aspects of stimulant 
use disorders in the order in which they typically 
unfold to provide clinicians with a roadmap for 
systematically addressing clinical issues as they 
emerge. 
This chapter assumes that structured outpatient 
treatment will be viewed as one interdependent 
component of a larger SUD treatment process and 
system. Many people with stimulant use disorders 
can experience the following: 
• Clinicians may begin engaging patients who
use stimulants before these patients have
any motivation to change their pattern of use.
Clinicians should use motivational interviewing
techniques to assess patients’ stage of change,
ambivalence to change, and motivators for change
as part of the initial assessment for treatment. 
• Strategies that clinicians can use to maximize
patient engagement include discussing
treatment expectations, offering multiple
treatment options, using a person-centered
and respectful approach, conveying empathy
and concern, identifying barriers to treatment
engagement or participation that would affect
success, and working collaboratively with
patients to develop a clear treatment plan and
framework that can be changed as necessary. 
• Clinicians should initiate treatment of new
patients by working with them to set treatment
goals, discussing reducing or discontinuing
all substance use, fully assessing their clinical
needs, and helping them manage stimulant
withdrawal. Clinicians should then focus on
helping these patients progress through the
continuum of substance use disorder care. 
• Clinicians can use several strategies to help
patients maintain progress in recovery, such as
teaching functional analysis of stimulant use;
reinforcing positive behaviors with incentives
(i.e., contingency management); offering
relapse prevention tools; teaching ways to
avoid high-risk situations; providing social
skills training; linking patients to vocational
counseling; and promoting connections to
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• Medical problems or emergencies 
• Psychiatric problems or crises 
• Social, legal, or employment problems 
Therefore, this chapter, while focusing on 
outpatient treatment of stimulant use disorders, 
acknowledges the critical importance of various 
settings and processes along the continuum 
of care. 
LEVELS OF CARE AND STIMULANT
USE DISORDER TREATMENT 
Chapter 3 describes the medical and mental 
health factors to consider to ensure the safe 
admission of patients into care settings. The 
American Society of Addiction Medicine (ASAM) 
Criteria establishes comprehensive guidelines to 
ensure that patients with SUDs enter treatment 
at the appropriate level of care, remain in care 
for the necessary duration, and are transferred to 
another level of care when they are ready. ASAM 
Criteria assesses six dimensions for individuals: 
1. Acute intoxication and/or withdrawal potential 
2. Biomedical conditions and complications 
3. Emotional, behavioral, or cognitive conditions 
and complications 
4. Readiness to change 
5. Recurrent or continued use or continued risk 
potential 
6. Recovery and living environment 
Clinicians can use ASAM Criteria to prioritize 
patients’ treatment needs and to identify the 
areas where patients are most likely to have a 
successful response to treatment (SAMHSA, 
2021c). Clinicians can also reference state-specifc 
placement criteria that satisfy requirements 
outlined in state statutes for SUD admissions (if 
available). 
Source: Mee-Lee D, Shulman GD, Fishman MJ, 
Gastfriend DR, Miller MM, eds. The ASAM Criteria: 
Treatment Criteria for Addictive, Substance-Related, 
and Co-Occurring Conditions. 3rd ed. Carson City, NV: 
The Change Companies®; 2013. 
People With Stimulant Use
Disorders Seeking Treatment 
To effectively meet the needs of people using 
stimulants, healthcare staff throughout the 
continuum of care must understand patients’ 
unique perspectives. For example, individuals with 
opioid use disorder (OUD) may initiate contact with 
the treatment system when they are experiencing 
opioid withdrawal. Taking FDA-approved 
medications for OUD that alleviate opioid 
withdrawal symptoms may be patients’ frst foray 
into formal SUD treatment. SUD care settings that 
can provide both OUD medication and behavioral 
support are better equipped to engage and retain 
patients in care. 
People with stimulant use disorders may approach 
the treatment system with a different set of 
priorities than do people with OUD. Although the 
priorities of people with stimulant use disorders 
and the assistance they seek vary, they often share 
several common pretreatment perspectives. 
“Bad Things Are Happening” 
Admission interviews with people who use 
stimulants may reveal that they are seeking 
treatment mainly because this use has resulted 
in negative consequences, such as legal, job-
related, medical, family/relationship, fnancial, and 
psychiatric problems (Herbeck et al., 2014; Pedrelli 
et al., 2015; Vayalapalli et al., 2011). Initially, these 
individuals may focus on receiving assistance to 
address these negative consequences rather than 
on reducing their stimulant use. This attitude 
is consistent with Maslow’s Hierarchy of Needs 
(Maslow, 1943), which states that individuals must 
meet their most basic needs (i.e., physiologic 
and safety needs) before they can pursue higher 
level needs (i.e., needs related to love and 
belonging, self-esteem, and self-actualization). By 
understanding patients’ motivations for seeking 
treatment, clinicians can better meet patients 
“where they’re at.” 
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“Life Is Out of Control” 
Patients engaging in treatment for stimulant use 
disorder may say, “My life is out of control.” They 
point to their excessive behaviors associated 
with obtaining, using, and recovering from using 
cocaine or methamphetamine (MA). These 
behaviors can lead to: 
• Financial instability and/or illegal activities 
(Cheng et al., 2010; Gizzi & Gerkin, 2010; 
Maiorana et al., 2021). 
• Lack of routine self-care (Nassar & Ouanounou, 
2020; Yasaei & Saadabadi, 2020); examples 
include insuffcient eating, sleeping, bathing, 
and oral hygiene. 
• Diverse or personally atypical sexual activities 
(Maiorana et al., 2021). 
• Strained familial and spousal relationships 
(Abdul-Khabir et al., 2014; Cheng et al., 
2010) resulting from, for example, spending 
subsistence money on drugs, failing to care for 
children, or engaging in marital infdelity. 
• Homelessness (McKenna, 2013; Walls & Bell, 
2011); examples include staying on a friend’s 
couch, staying in a car, and renting by the week 
at a motel. 
Emotional turmoil accompanies these 
developments, including (Ciccarone, 2011; J. C. 
Maxwell, 2014): 
• Cycles of euphoria and depression and 
heightened emotional lability. 
• Intense anxiety, fear, guilt, and shame 
over medical, fnancial, legal, and personal 
relationships. Patients can also experience these 
feelings when they are unable to determine 
whether recent behaviors or events that took 
place during a period of psychosis were real or 
imagined. 
• Anergia (lack of energy) and anhedonia (inability 
to feel pleasure) during periods of abstinence. 
• Anger, paranoia, and irritability during periods 
of use or abstinence. 
Patients who are in emotional turmoil may present 
with tangential (off-topic) or pressured speech or 
with slowed speech. 
Cognitive Impairment/Clinically 
Signifcant Paranoia 
Chapter 3 documents that the use of stimulants 
may produce signifcant cognitive impairment 
(Lappin & Sara, 2019; J. J. Mahoney, 2019; 
Wunderli et al., 2016) and may be accompanied 
by severe paranoia. Individuals have expressed 
concentration diffculties, impaired short-term 
memory, and a relatively short attention span. 
Patients using stimulants may also experience 
paranoia and altered persecutory perceptions 
of reality. To overcome these effects, clinicians 
must create a safe environment and gain patients’ 
trust while collaborating with them to establish a 
treatment plan and treatment goals. 
Ambivalence to Change/Skepticism 
About Treatment 
Clinicians new to working with individuals with 
stimulant use disorders may be frustrated and 
angered by what they perceive as their patients’ 
“lack of motivation” or “denial.” Ambivalence 
is part of the recovery process and is often 
associated with behavioral changes that lead to 
improved health outcomes. Clinicians need to 
remember that individuals receive some beneft 
from using stimulants. Addressing positive aspects 
of stimulant use allows for an open discussion 
about the negative consequences and motivations 
for change. Motivational interviewing (MI) can 
help clinicians understand and navigate patients’ 
ambivalence to change. For example, clinicians 
can ask questions such as “What is good about 
using stimulants?” and “What is not so good about 
using stimulants?” These questions can enhance 
engagement and prompt conversations about the 
reasons for behavior change. 
In addition, stimulant use is a byproduct not 
only of the neurobiology of craving, but also of 
dysregulated reward systems (see Chapter 2 for 
discussion). 
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Craving 
The experience of craving a substance 
characterizes almost all SUDs. However, the craving 
for stimulants may be more intense than any other 
cravings patients have experienced. Chapter 
2 describes research on the neurophysiologic 
correlates of stimulant craving. People who use 
stimulants have likely experienced craving but 
may have little understanding of the biologic 
underpinnings of this experience. 
The power and intensity of this craving response 
can make it exceptionally diffcult for people with 
stimulant use disorders to interrupt their pattern 
of use (Sinha, 2013), especially early in treatment. 
(This is especially true for those who use the rapid-
delivery routes of smoking or injection.) Some 
people cannot imagine how counseling or other 
forms of nonresidential treatment can help with this 
overwhelming sensation. 
Other Challenges Frequently 
Encountered in Treatment 
Clinicians treating patients with stimulant use 
disorders may also encounter: 
• Dysphoria (sad mood) that occurs upon 
discontinuing stimulant use (MacLean & 
Sofuoglu, 2018). 
• Compulsive sexual behavior (especially for those 
who use MA), which is often reported to be at 
least as diffcult to control as the stimulant use 
(Berry et al., 2020; Loza et al., 2020). 
• Discouragement given previous attempts in and 
outside of treatment to end stimulant use, only 
to experience return to even more severe levels 
of use. 
• Mental disorders that co-occur with or are 
induced by stimulant use disorders. (See 
the discussion on assessing for co-occurring 
mental disorders in this chapter’s “Complete 
Assessment of Clinical Needs” section and 
the Chapter 6 section “Individuals With Co-
Occurring Mental Disorders.”) 
These issues may interact in various ways and affect 
individuals in different ways, resulting in treatment 
experiences that are unique to individual patients. 
Treatment Needs of People
With Cocaine Use Versus
Methamphetamine Use Versus
Prescription Stimulant Misuse 
Limited empirical evidence exists for designating 
any one psychosocial approach as being 
differentially effective for these three stimulant 
groups: cocaine, MA, and prescription stimulants. 
Therefore, the treatment recommendations made 
in this chapter apply to people using cocaine 
and MA and misusing prescription stimulants. 




Make Treatment Accessible and Support 
Continued Participation 
Treatment services need to be highly accessible, 
because people with stimulant use disorders 
are seen in a broad range of settings. Research 
suggests that numerous factors can hinder access 
to SUD treatment, including provider-related 
factors, such as shortages of SUD treatment 
workers and stigmatizing attitudes they may have 
about SUDs; market and environmental factors, 
like Medicare and Medicaid reimbursement issues; 
and insurance factors, like the availability of in-
network clinicians in a geographic location (O’Brien 
et al., 2019). Several factors are vital to treatment 
engagement: 
• Accommodating patients’ schedules. Access 
to care is improved when treatment is provided 
during hours and days that are convenient for 
patients (i.e., not just during traditional 9 a.m. 
to 5 p.m. business hours). Daytime treatment 
programming may be helpful for patients 
who do not work and fnd boredom and lack 
of daytime activities signifcant contributors 
to substance use. Patients who work during 
the day may need to attend evening or 
weekend treatment sessions. Having a fexible 
treatment schedule allows clinicians to 
emphasize employment and other household 
responsibilities as protective factors in recovery. 
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WHY COORDINATED CARE IS SO CRITICAL 
Coordinated care encourages members of the treatment team to work collaboratively and in a person-
centered manner. Treatment occurs along a continuum that combines medical care with psychological 
and social interventions. Clinicians collaborate on treatment activities, which are tailored to each patient’s 
needs. To facilitate coordinated care, clinicians should obtain a signed release form for all of the patient’s 
care providers during the initial assessment. The patient may exit treatment quickly, so having a signed 
release form allows the treatment team to coordinate with other providers to help the patient reengage in 
treatment. 
People with SUDs typically have numerous health- and behavioral health-related issues that interact 
with one another (Radfar & Rawson, 2014). Clinicians cannot effectively address SUDs using a fragmented 
approach that ignores other problems their patients are coping with and may or may not be receiving 
services to address. This interaction is why coordinated care is so critical to ensuring successful SUD 
treatment outcomes for patients. 
Coordinated care models emphasize the engagement of multidisciplinary staff to fully address patients’
physical and mental health needs through open communication, shared knowledge and decision making,
individualized treatment plans, and the use of evidence-based best practices. For instance, a woman in
treatment for cocaine use disorder might beneft from seeing a drug and alcohol counselor to help her with
recovery and abstinence, a primary care provider to help monitor for any medical complications or conditions
(e.g., those that accompany stimulant withdrawal), a psychologist or licensed professional counselor to help
her better manage longstanding trauma symptoms and recent depressed mood, a psychiatrist to monitor her
antidepressant medication, a social worker to assist in navigating access to public assistance programs (e.g.,
Temporary Assistance for Needy Families), a peer recovery support specialist to share common experiences and
to serve as a mentor, and a case manager to help coordinate care. 
Coordinated care ensures that all members of the care team are equipped with accurate, current 
information about a patient’s diagnosis, history, treatments, and treatment goals. They work collaboratively 
to achieve those goals effectively, in a timely manner, and without redundancies. Coordinated care models 
have been scrutinized in research and deemed effective in the treatment of SUDs, particularly in primary 
care practices (LaBelle et al., 2016; Lagisetty et al., 2017; Pew Charitable Trusts, 2020). 
• Addressing concrete needs. Research has 
demonstrated the importance of addressing 
patients’ concrete needs, including 
transportation, housing, and fnances (Browne 
et al., 2016; Priester et al., 2016). Clinicians 
may need to establish protocols for rapidly 
addressing transportation barriers (e.g., by 
providing bus fare cards or cab/rideshare fare, 
using vans to drive patients to and from their 
appointments). Locating SUD care settings 
near public transportation and in areas viewed 
as safe for evening visits improves accessibility 
for patients. Individuals with disabilities may 
need special accommodations (e.g., wheelchair 
access ramps, electronic doors, elevators, 
assistive communication devices). Clinicians and 
organizations can seek philanthropic funds as 
well as federal and state grants to assist with 
addressing these particular needs. 
• Providing onsite services. Some logistical 
barriers can be overcome by providing 
onsite services, through agreements with 
subcontractors, or by referrals. These services 
can include providing onsite childcare, referrals 
to temporary shelters, vouchers for lunches, 
targeted fnancial assistance, and help with 
insurance paperwork or fling for disability. 
“Warm handoff” referrals where treatment staff 
personally contact personnel from other settings 
facilitate a successful referral process. 
• Reaching underserved populations. In rural 
areas, small satellite sites may be needed to 
bring treatment closer to patients (e.g., using 






space in primary care clinics or social service 
agencies). SUD care services should also offer 
telehealth technology—in place of or in addition 
to face-to-face treatment—for people with 
mobility or distance barriers. 
Respond Quickly and Positively to Initial 
Inquiries 
People who use stimulants may make their 
frst contact with the SUD treatment system by 
telephone, through email, or via online contact 
(e.g., the treatment center’s website, social media). 
They may drop by a clinician’s offce, an SUD care 
facility, or a campus health center. Some may make 
initial contact with treatment when they check 
in with their probation/parole offcer or engage 
with justice-involved staff. The manner in which 
the receptionist, intake worker, clinician, or other 
staff person handles the initial contact may affect 
whether the individual decides to enter treatment. 
Methods that promote successful treatment 
engagement include: 
• Answering telephone or online inquiries 
immediately for as many hours per day as 
possible (e.g., not placing people on hold, not 
requiring callbacks). 
• Using 24-hour hotlines to facilitate late-night 
and weekend inquiries. 
• Monitoring websites (including chat features) 
and social media accounts for new messages 
daily. 
Seeking SUD care can be a diffcult and painful 
process. Access to care improves when there is 
maximum fexibility in responding to all kinds of 
treatment inquiries. 
Schedule Initial Appointments With 
Minimal Delay 
An individual’s decision to seek help may last for 
only a brief period, so the initial interview should 
take place as soon as possible after frst contact. 
SUD treatment providers may not always have the 
resources to conduct thorough intake interviews 
immediately, and these interviews may not always 
be feasible (i.e., if the patient is in crisis and needs 
immediate intervention services for stabilization). 
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If possible, interim services should be provided 
until a more thorough intake can be completed, 
including any organization- or state-mandated 
health screenings. For example, a brief trauma-
informed interview or a partial intake session within 
24 hours of contact might identify acute needs 
that require immediate attention. SUD treatment 
providers can also hold orientation meetings in 
lieu of placing names on waiting lists. The use of 
telehealth can help clinicians stay connected to 
patients who are waiting for admission to higher 
levels of care. If a waiting list cannot be avoided, 
staff members can draw on the patient’s treatment 
readiness by telephoning to express concern 
about the patient’s well-being, conducting mini-
assessments, providing basic recommendations 
(e.g., attending a mutual-help group meeting), 
connecting patients to peer recovery support 
specialists, and working with the patient to locate 
other available treatment options within the same 
level of care. These efforts serve as a temporary 
bridge between the initial contact and a thorough 
interview and assessment. 
Assessment Procedures To
Enhance Treatment Engagement 
Use Brief Screening Tools 
Initial screenings that are brief, focused, and 
nonrepetitive enhance engagement. Free tools are 
available for clinicians to screen for SUDs, including 
stimulant use disorder and common co-occurring 
disorders, like alcohol use disorder and OUD. For 
example, clinicians can use the National Institute 
on Drug Abuse (NIDA) Quick Screen V1.0 to screen 
patients age 18 or older for general substance 
misuse. The NIDA-Modifed Alcohol, Smoking 
and Substance Involvement Screening Test 
(NIDA-Modifed ASSIST) V2.0 provides clinicians 
with additional questions to ask about recent and 
lifetime use of specifc substances. (For both tools, 
see https://www.drugabuse.gov/sites/default/fles/ 
pdf/nmassist.pdf.) 
Identify Patients’ Expectations and 
Provide a Service Orientation 
Identifying patients’ expectations—as well as 
their fears, concerns, and anxieties—is important. 
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For example, patients with previous treatment 
experiences may have anxieties about treatment 
failure or trauma associated with treatment. 
Clinicians should work to address patients’ worries 
through information and education about SUD care 
and the treatment process. This information can 
help decrease or eliminate fear of the unknown and 
create a safe space. A thorough, clear, and realistic 
orientation about stimulant use disorder treatment 
focuses on: 
• Basic treatment components and processes, 
including length of treatment and continuing 
care/recovery planning. 
• Rules of the SUD treatment provider. 
• The SUD treatment provider’s expectations 
about participation, such as the amount of 
time that is required and what happens at each 
phase. 
• The patient’s expectations of what the SUD 
services can do. 
• Completion criteria. 
• Expectations and possible treatment or care 
plan revisions if the patient continues to 
struggle with substance use. 
Clinicians may need to repeat this information, 
because patients with cognitive defcits secondary 
to prolonged stimulant use may have diffculty 
with memory or trouble following long and 
complex instructions and explanations. Clinicians 
can address this issue with simple and clear 
introductory information and instructions. Patients 
with and without cognitive defcits can beneft from 
also receiving brief handouts with this information 
written at an appropriate reading level. 
Ofer Options 
Motivation research demonstrates strongly and 
consistently that people are most likely to engage 
in an action when they perceive that they have 
personally chosen to do so. To perceive that one 
has a choice, alternatives must be available from 
which to choose (Köpetz et al., 2013; Miller, 1985). 
A fexible, trauma-informed, recovery-oriented 
approach to treating individuals with SUDs 
includes, where appropriate, seeking patient 
input into the type of treatment initiated and the 
treatment setting (World Health Organization 
[WHO] & United Nations Offce on Drugs and 
Crime [UNODC], 2020). This ethical, best practices 
approach to SUD treatment respects patients’ 
autonomy (WHO & UNODC, 2020), provides them 
with options, and encourages their collaboration 
on the treatment approaches and strategies that 
are the most acceptable to and promising for 
them. 
Involve Signifcant Others 
Whenever possible, clinicians should involve family 
members and signifcant others who support the 
goals of the treatment process—including the 
initial assessment and intake processes—provided 
patients give written consent for their inclusion. 
Patients who do not have close family relationships 
may wish to involve close friends whom they 
consider family. Signifcant others beneft from 
receiving information about the development 
of SUDs, SUD care, assessment results, 
troubleshooting concerns for continued use, and 
the next steps for themselves and their loved one. 
In the SUD care setting, clinicians can work with 
signifcant others to help them better understand 
their role in the SUD treatment process and their 
possibly complicated relationship with the person 
in treatment. Information on mutual-help groups 
for signifcant others, such as Nar-Anon and 
Al-Anon, should also be provided. 
Staf Skills To Enhance Treatment
Engagement 
Several basic therapeutic skills can enhance 
treatment engagement in people with stimulant 
use disorders: 
• Treating patients respectfully and calmly. 
Patients with stimulant use disorders may 
be frightened, disoriented, and cognitively 
impaired. Clinical and nonclinical staff members 
can alleviate fears about entering treatment by 
offering positive feedback, answering questions 
honestly, and letting patients know that staff 
members want to help them. When people with 
stimulant use disorders are treated calmly and 
respectfully, trauma responses and protective 
behaviors are rare. 










• Conveying empathic concern. Clinicians who 
provide advice and recommendations in a 
friendly, engaging, empathic, straightforward, 
and nonjudgmental way can calm patients and 
increase the likelihood for positive treatment 
outcomes (Elliott et al., 2018). 
• Refraining from fghting resistance. 
Fighting resistance to change or treatment is 
counterproductive and can harm the therapeutic 
alliance. Patient-centered, nonjudgmental, and 
nonconfrontational approaches are effective 
at improving outcomes in people with SUDs 





People with SUDs may feel ambivalent about 
entering treatment or becoming abstinent, 
especially during the early stages of recovery 
(SAMHSA, 2019). Clinicians can use MI techniques 
to help patients with SUDs understand stages of 
change and resolve ambivalence toward behavior 
change by helping them directly confront and 
acknowledge their hesitation, while highlighting 
motivations or reasons to change (Lindson et al., 
2019; Searight, 2018). Harm reduction techniques 
should be introduced to people who are not 
ready to enter formal treatment, to minimize risks 
associated with continued misuse of stimulants 
and other substances. (See the Chapter 4 text box 
“The Importance of Teaching Harm Reduction.”) 
Treatment 
Treatment for individuals with stimulant use 
disorders involves procedures that address a series 
of clinical issues in a fairly predictable sequence. 
To organize treatment strategies, it can be helpful 
to view the treatment process as consisting 
of engagement, initiation, stabilization, and 
maintenance with a long-term support plan. These 
are not discrete or sequential phases of treatment; 
in some instances, they occur simultaneously or 
in a different order. For example, some patients 
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engage in treatment and initiate abstinence at the 
same time; others may need to be stabilized prior 
to treatment initiation. 
At the beginning of treatment, patients may feel 
overwhelmed and may struggle with motivation 
in the context of cravings and triggers. Treatment 
plans must give patients a clear framework for 
their treatment experience. This framework sets 
up specifc expectations and provides patients 
with the benchmarks they need to plan their 
treatment participation and measure their 
progress. Treatment plans should include SMART 
goals: Specifc, Measurable, Achievable, Relevant, 
and Time Bound. Setting SMART goals at the 
beginning of treatment can help patients achieve 
small gains toward recovery and keep them 
motivated to engage in further treatment. 
Strategies for Engagement 
Stimulant use withdrawal symptoms, specifcally 
fatigue, dysphoric mood, and lack of motivation, 
may make initial engagement with SUD treatment 
clinicians diffcult. Some patients continue to use 
stimulants initially. For this reason, the goal of 
patient interaction in this frst phase may strictly be 
for the patient and clinician to initiate a therapeutic 
relationship that engages the patient in services. 
Clinicians can reference level-of-care tools such 
as the American Society of Addiction Medicine 
(ASAM) Criteria to determine the appropriate 
level and duration of care for individuals with 
stimulant use disorders who are entering 
treatment. The ASAM Criteria provides guidance 
about multidimensional assessment and 
recommendations for placement in the continuum 
of care. 
Several immediate priorities can encourage 
treatment engagement in the frst weeks of 
treatment: 
• Establish treatment attendance. 
• Discontinue or reduce use of stimulants and 
secondary substances of misuse. 
• Complete assessment of clinical needs. 
• Resolve immediate crises. 
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Establish Treatment Attendance 
Initiating a routine of treatment attendance 
involves giving patients: 
• A clear expectation of when and where they 
should be attending treatment. 
• A detailed explanation of what happens during 
treatment sessions. 
• Reinforcement when they attend treatment on 
schedule. 
• Reminders when they miss treatment. 
• Guidance, if they need it, on how they will travel 
to treatment sessions. 
During the initial weeks, patients may be early or 
late for their scheduled appointments or may show 
up under the infuence. They may frequently be in 
crisis or a state of confusion. Patients may come to 
the treatment setting only when it is convenient. 
Some patients may need a higher level of care 
or another assessment. However, patients should 
rarely, if ever, be discharged from services under 
these circumstances. 
Engagement with SUD care offers clinicians an 
opportunity to develop a trusting relationship with 
patients and to encourage appropriate behavior 
by reinforcing the importance of attendance. 
Engagement at this time is critically important 
because of the high dropout rates of this patient 
population at the start of treatment. Clinicians 
should highlight successes when patients attend 
treatment and celebrate those who reengage in 
treatment after taking a break from it. 
Patients with stimulant use disorders need to 
hear that they should participate in and return 
to SUD care, even if they are using stimulants or 
other substances. Participation is enhanced with 
reminder cards, fyers, and schedules with the 
message that patients are expected to return for 
their appointments and that they will always be 
welcomed back. Agencies should have a policy 
regarding patients attending treatment while using 
substances. Clinicians need to communicate with 
patients about this policy. 
Use incentives to reinforce treatment 
participation 
A powerful strategy for increasing treatment 
involvement and establishing treatment 
engagement is to provide immediate positive 
consequences for desired behaviors to incentivize 
progress in treatment (Kirby et al., 2013). These 
incentives will differ among patient populations. 
Some patients prefer gift cards for retail items 
or meal coupons; others appreciate clothes 
for themselves or their children or rebates for 
payments. Some SUD treatment providers hold 
brief graduation ceremonies or present certifcates 
of completion. Kirby and colleagues (2013) 
demonstrated the effectiveness of incentives 
for substance-free urinalyses through the use of 
vouchers that could be traded for prizes (e.g., gift 
certifcates). Research has shown that contingency 
management (CM) approaches demonstrate 
improved treatment attendance and retention 
(McDonell et al., 2013). Establishing what the 
incentives are, how they are obtained, and how 
the tasks associated with the incentives are verifed 
should be discussed and provided in writing for 
patients to review. 
See the “Contingency Management” section in 
Chapter 4 for more information. 
Reach out to no-shows 
Staff members should contact patients who fail to 
show up for scheduled visits to encourage their 
participation and inquire about possible crises that 
prevent them from fully engaging. Staff can send 
a letter, write an email, or phone or text patients 
to remind them that their participation is missed. 
This is also an opportunity to partner with peer 
recovery support specialists. Having peer recovery 
support specialists initiate contact with patients 
after no-shows can feel less threatening, and the 
patients may be more responsive. Policies and 
procedures for reaching out to no-shows should 
also be developed. Such policies and procedures 
need to conform to all applicable confdentiality 
requirements. 
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Create a positive environment 
Research demonstrates that positive 
environments—ones that promote growth and 
well-being—improve mental health and social 
functioning (Corral-Verdugo & Frias-Armenta, 
2016). Patients with stimulant use disorders may 
feel that they do not belong in treatment because 
they: 
• Do not see themselves as having a disorder. 
• Do not like the physical SUD care setting or 
location. 
• Perceive that they do not need SUD care to 
address their stimulant use. 
• Think they cannot relate to other patients. 
• Think that prescription stimulant misuse isn’t as 
serious or dangerous as using illicit substances. 
Rather than attribute these beliefs to defense 
mechanisms, SUD care workers should take steps 
to improve patients’ comfort level and experiences 
with the service. Administrative staff who answer 
the phone or greet patients at the front desk can 
set the tone by being welcoming. 
Clinicians should work to create a trauma-informed 
safe environment for all patients. For example, 
SUD treatment providers can establish connections 
between new patients and peer recovery support 
specialists who are trained to dispel fears and 
concerns about SUD care and the treatment 
process. Peer recovery support specialists can use 
their lived experiences to help patients who have 
recently initiated treatment relate to patients who 
are already established in treatment. 
Discontinue or Reduce Use of Stimulants 
and Secondary Substances of Misuse 
Encourage abstinence or reductions in use 
immediately 
After an initial assessment interview, clinicians 
should ask patients to agree to a trial period 
of abstinence or, if abstinence is not possible, 
reductions in substance misuse. The frst interview 
can end with a specifc plan for making these 
changes, such as abstaining from or reducing 
substance misuse until the next SUD care visit. 
Strategies to help patients initiate abstinence or 
reductions in substance misuse include preparatory 
group therapy that involves motivational 
enhancement techniques (Miller & Rollnick, 1991). 
These therapy sessions are brief but frequent (e.g., 
three to fve times per week) and can include urine 
testing. 
Individuals may be at a different stage of readiness 
for change (Prochaska et al., 1992) for each 
substance they use. For example, they may have 
decided to stop using stimulants but are still 
contemplating whether to stop drinking alcohol. 
Using MI strategies in individual and group 
therapy settings may move such patients from the 
contemplation phase to decision and action phases 
with regard to alcohol use. 
Establish a daily schedule 
Planning and scheduling are important ways to 
deter individuals with stimulant use disorder from 
spending a lot of time alone or having big blocks of 
time without planned activities. Typically, the daily 
routine of individuals with stimulant use disorders 
revolves around seeking, using, and recovering 
from the effects of stimulants. To break this 
pattern, patients are taught to use daily schedules 
to structure their lives and to help them monitor 
their actions. Using schedules is particularly critical 
during treatment initiation and stabilization. 
Clinicians can work with their patients to create 
simple daily and weekly schedules. Schedules 
should include time for: 
• SUD care visits. 
• Mutual-help meetings (e.g., 12-Step meetings, 
Self-Management and Recovery Training 
[SMART Recovery] meetings). 
• Healthy meals. 
• Healthy social activities. 
• Exercise, recreation, and leisure. 
• Medical and mental health appointments. 
Initiate a urinalysis schedule 
Establishing a regular urine drug screening 
protocol with patients at the onset of treatment 
helps alleviate fears about surveillance. There is 
a difference between supportive and surveillance 
urine toxicology screenings: Supportive urine 
toxicology screening can be a useful tool to 
assess the treatment plan and determine whether 
treatment is working. When discussing urine 
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toxicology results, the clinician should emphasize 
that the results refect the effectiveness of 
treatment and are not meant to identify patient 
failures. The clinician should use nonjudgmental 
language, such as “The results indicate a return 
to use,” and avoid value-laden terms like “clean” 
and “dirty.” 
Typically, urine toxicology testing tapers as 
treatment progresses, patients stabilize, and 
the clinical relevance of the tests become less 
important. Tests are spaced to ensure that results 
from the previous test are available before the 
next test is conducted and to avoid exceeding 
the sensitivity limits of standard laboratory testing 
methods, which generally means spacing tests no 
more frequently than every 3 days. More frequent 
testing generally provides little information 
of clinical relevance. However, if the patient 
appears intoxicated or has admitted to misusing 
substances, testing may need to be repeated to 
establish a baseline. SUD treatment providers also 
conduct random testing, although it is advisable to 
test on days that closely follow periods of high risk, 
such as holidays, paydays, and weekends. 
Urine collection should be conducted in a trauma-
informed way. Strategies for this process include 
the following: 
• Provide patients with information about the 
urine collection process so they know what to 
expect (Scoglio et al., 2020). 
• Allow patients to voice concerns about the urine 
collection process, and respond in an empathic 
manner (Scoglio et al., 2020). 
• Acknowledge that the urine collection process 
can trigger uncomfortable feelings for patients 
who have experienced trauma. 
• Allow patients to make choices about the urine 
collection process, when possible. For example: 
- Give patients several different options for 
what time of day the collection will take 
place. 
- Allow patients to choose which trained staff 
member will collect the specimen. 
• Offer the patient assistance from a peer 
recovery support specialist throughout the urine 
collection process. 
• Refrain from direct observation of specimen 
collection. Rather, collection should be 
supervised by a staff member. This entails 
requiring patients to leave their belongings 
outside the bathroom and to collect their 
sample without fushing the toilet. 
To learn more about trauma-informed urine 
collection strategies, see Trauma Informed 




After the specimen has been collected, laboratory 
assistants or clinicians collecting urine samples use 
temperature strips or other methods if specimen 
tampering is a concern. Urine samples that staff 
suspect have been tampered with are not sent to 
the lab for testing. Instead, clinicians or other staff 
should repeat the urine collection, using the same 
trauma-informed process. 
Encourage participation in mutual-help 
groups 
Involvement in mutual-help groups should be
encouraged throughout the continuum of care.
Patients can be given a schedule of in-person
meetings that are easily accessible to them, as well as
information about online meetings. Although mutual-
help participation has been shown to be associated
with positive treatment outcomes (Carroll et al.,
2012) and to be helpful for many, it is not a necessary
condition for all patients to succeed. 
Complete Assessment of Clinical Needs 
Assess for co-occurring mental disorders 
People with stimulant use disorders, especially 
people who use MA, may enter treatment 
exhibiting symptoms of mental disorders. However, 
not all these patients have a co-occurring mental 
disorder. Although these symptoms generally 
subside over several days (for cocaine use) or 
several weeks (for MA use), some individuals do 
have a co-occurring disorder. 
Psychiatric comorbidity in patients using stimulants 
is dynamic and should be reassessed throughout 
the continuum of care. Clinicians need to initiate 
appropriate treatment, including medication, when 
patients are experiencing psychiatric symptoms, 
including psychotic features. 

























































Expressions of suicidal ideation must be taken 
very seriously. The patient should be monitored 
for thoughts of self-harm and, when appropriate, 
provided with immediate intervention to ensure 
the patient’s safety. After the crisis has passed, the 
clinician and the patient work together to develop 
a patient-centered safety plan that includes steps 
the patient can take if suicidal thoughts recur, 
methods for limiting access to lethal means, coping 
strategies the patient can use to reduce distress, 
and contact information for individuals who can 
help in a crisis (e.g., the patient’s clinician, a family 
member, a close friend, hotlines). (Chapter 6 
provides more information on treating co-occurring 
mental disorders.) 
Assess for stimulant-associated compulsive 
behaviors 
Research demonstrates an association between
stimulant use disorders and a variety of compulsive
sexual behaviors (Berry et al., 2020; Loza et al.,
2020). These behaviors may include unprotected
anal or vaginal intercourse, transactional sex,
compulsive self-stimulation, compulsive seeking and
viewing of pornographic material, and more diverse
sexual activities and partners than the patient may
have engaged in/with previously. Clinicians should
screen for the presence of compulsive sexual
behaviors in patients with stimulant use disorders. 
Patients with stimulant use disorders can have
tremendous concerns and anxieties about the
compulsive sexual behaviors they engage in while
using stimulants. Chemsex is a sexual encounter that
is coupled with the use of mind-altering substances
during intercourse (Giorgetti et al., 2017).
Hypersexuality, sexual assault, and diverse sexual
behaviors and partners in the context of stimulant
use may result in concerns about sexual identity
(Lyons et al., 2010; Ritchwood et al., 2016). When
present, these feelings may be barriers to treatment
engagement and retention. 
Discussions on sexuality with this population must
be conducted in a nonjudgmental and caring
tone. Clinicians can discuss sexual risk reduction
strategies, including initiation of nonoccupational
postexposure prophylaxis (nPEP) or pre-exposure
prophylaxis (PrEP) for HIV, condom use, serosorting
(Centers for Disease Control and Prevention [CDC],
2020a) or seropositioning with partners of an
unknown HIV serostatus or serodiscordant partners,
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and the need for regular sexually transmitted
infection testing of both genital and extragenital
(e.g., throat, rectum) sites. 
Exhibit 5.1 includes key terms discussed in this
chapter. 
EXHIBIT 5.1. Key Terms 
Serodiscordant: Having a different HIV infection
status from that of one’s partner. 
Seropositioning: The act of choosing a sexual
position based on HIV status, such that the partner
without HIV is insertive during anal intercourse. 
Serosorting: The act of choosing partners with the
same HIV status. 
Serostatus: An individual’s HIV infection status
(positive or negative). 
Sources: CDC (2020a); Philip et al. (2010). 
Studies suggest a link between gambling behaviors
and stimulant use, particularly cocaine use, in adults
and adolescents (Dufour et al., 2016; Ethier et al.,
2020; Geisner et al., 2016). Among a sample of
more than 6,000 high school students (Richard et
al., 2019), 16.9 percent who reported past-year
stimulant use or prescription stimulant misuse were
identifed as having at-risk/problem gambling. In
addition, students who had used any stimulant drug
in the past year were 2.7 times as likely to engage
in at-risk/problem gambling as those who had not
used stimulants. Students with crack cocaine use
were 7.2 times as likely, and students with MA
use were 8.3 times as likely, to engage in at-risk/ 
problem gambling as those who had not used 
stimulants in the past year. 
Some researchers have suggested that overlap 
exists between neuroanatomic pathways altered 
with cocaine use and with gambling behaviors, 
such as pathways linked to motivation, inhibition, 
reward processing, decision making, craving, and 
habit formation (Lorenzetti, 2018). 
Resolve Immediate Crises 
Patients may enter treatment in physical or emotional
crisis. During early treatment sessions, clinicians
should reassure patients that SUD services can
provide or secure immediate attention to critical
















































Chapter 5—Practical Application of Treatment Strategies 
medical and mental health issues. Providing patients
with lists of community and mutual-help resources is
helpful. These materials should include the names,
addresses, telephone numbers, websites, and
descriptions of mutual-help groups and resources,
medical clinics, social service agencies, food
assistance programs, trauma-informed services or
services for victims of violence or abuse, temporary
housing and shelters, women’s shelters, and children’s
resources. A peer recovery support specialist or case
manager can help gather such information and work
with patients to follow through. 
FOCUSING ON TREATMENT
RETENTION 
Treatment engagement is critical to getting 
people into SUD care, but treatment retention 
is equally critical. Simply put, people are less 
likely to die when in treatment than when not 
in treatment. Clinicians should not turn away 
individuals—even those considered likely to drop 
out from treatment—except in very rare cases. 
Any amount of time people with stimulant use 
disorders remain in treatment is an opportunity 
for them to stay alive and improve their health. 
The dropout rate of people in treatment for 
stimulant use disorders is high (Kampman, 2019). 
For instance, pharmacotherapy studies of people 
with amphetamine use disorder report a 40- to 
50-percent dropout rate (Lee et al., 2018). People 
with other SUDs, such as OUD, who also misuse 
stimulants may be at higher risk for treatment 
dropout than people with SUDs who do not also 
misuse stimulants (Tsui et al., 2020). 
Using CM may retain people in treatment better 
than using other psychosocial therapies because 
it offers them an incentive to stay, such as money 
or vouchers (Ronsley et al., 2020). But many trials 
of medication and nonmedication treatments 
have failed to show a difference in treatment 
retention between the medication or therapy 
in question and a placebo or other comparator 
(Ronsley et al., 2020). 
Strategies for Treatment Initiation 
During the frst several weeks of treatment,
individuals may stop or at least reduce their use of
stimulants. They may also maintain their use at the
same level during this period. However, these frst
few weeks can be considered successful if patients
have engaged in treatment and taken initial steps
to reduce stimulant misuse. Achieving abstinence
becomes the focus of treatment engagement after
the frst 1 or 2 weeks. Although no clear delineation
exists between those patients initiating abstinence
and those maintaining abstinence, the initiating
period begins 2 weeks into treatment and lasts
through 6 weeks of treatment, roughly speaking. 
During treatment initiation, the goals are to: 
• Identify and break the cycle of compulsive, 
repetitive stimulant use. 
• Initiate a period of abstinence from all substance 
use. 
• Encourage the establishment of behaviors that 
support abstinence and an abstinent social 
support network. 
• Initiate changes in attitude, behavior, and 
lifestyle that help maintain abstinence. 
The immediate priorities for facilitating treatment 
initiation are to: 
• Alleviate stimulant withdrawal symptoms. 
• Establish structure and support. 
• Address secondary substance use. 
• Establish contingencies. 
• Address compulsive behaviors associated with 
stimulant use. 
Alleviate Stimulant Withdrawal 
Symptoms 
The initial period of stimulant abstinence is
characterized by symptoms of depression,
concentration diffculties, poor memory, irritability,
fatigue, craving for the substance, and paranoia
(especially for people with MA use disorder). Among
patients who use MA, craving can be present for
many weeks or months after achieving abstinence,
putting them at high risk for recurrent use in the frst
few weeks of treatment (Courtney & Ray, 2014). 
The severity of these symptoms vary with the severity
of use and the route of administration. During the
frst several weeks of treatment, patients learn that
they need proper sleep and nutrition to allow the
brain to recover. Giving patients “permission” to


































sleep, eat, and gradually begin a program of exercise
helps establish behaviors that have long-term utility.
Engaging in these behaviors helps patients begin to
think more clearly and feel some beneft from their
initial efforts in treatment. 
Clinicians should continue to encourage abstinence
from all illicit psychoactive substances. 
ALLEVIATING WITHDRAWAL:
CHALLENGING BUT POSSIBLE 
Alleviating stimulant withdrawal symptoms is
diffcult, and withdrawing from stimulants carries
a risk of harm to self or others. Fatigue, increased
appetite, anxiety, paranoia, and insomnia commonly
occur. Medication may provide some symptom
relief (particularly for anxiety and sleep disturbance),
highlighting the importance of including a
psychiatrist or other prescribing professional in
the patient’s treatment. Rest, relaxation, exercise,
and a healthy diet are also “prescribed” to aid in
preventing or reducing symptoms. 
Other steps clinicians can take to help patients
overcome diffculties with withdrawal include
(Grigg et al., 2018): 
• Alerting patients of symptoms to expect and
designing a plan to effectively manage these
symptoms. 
• Speaking with patients about how to stay
motivated throughout the process. 
• Monitoring and assessing on an ongoing basis
for new or worsening symptoms, including
physical symptoms requiring medical attention. 
• Treating co-occurring medical and mental
health issues as well as polysubstance use;
these issues can complicate the withdrawal
process. 
• Offering supportive care during and after the
withdrawal process so that patients receive
emotional support and help with maintaining
motivation. 
• Optimizing sleep hygiene practices. 
See the section “Management of Stimulant 
Withdrawal” in Chapter 3 for additional information. 
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Establish Structure and Support 
Initiating abstinence from stimulant use is not 
a mental exercise. It requires a specifc plan to 
encourage changes in behavior. The plan provides 
a basic structure and daily routine to replace the 
lifestyle dominated by seeking and using drugs 
and then recuperating from them. Structure, 
stability, and predictability come from a simple 
daily plan that patients follow and that is built on 
the patients’ participation in SUD care. This plan 
includes: 
• Setting short-term goals. Reasonably 
achievable, short-term goals are established 
immediately. One such goal is complete 
abstinence from all substances for 1 week. To 
address binge use, a comparable goal is to 
achieve a period of abstinence approximately 
twice as long as the usual period between 
binges. Brief, frequent counseling sessions can 
reinforce the short-term goal of immediate 
abstinence and establish a therapeutic alliance 
between the patient and the clinician. During 
each session, events of the past 24 hours 
are reviewed, and the clinician works with 
the patient to identify goals and provide 
recommendations for navigating the next 24 
hours. Having the patient set up a social support 
system and undergo urine toxicology screening 
also contributes to establishing structure, 
support, and accountability. 
• Maintaining a daily schedule. Daily scheduling 
remains an extremely important organizing 
strategy during treatment initiation. Proactively 
planning time is a direct counterpoint to the 
impulsivity people with stimulant use disorder 
previously experienced. With the clinician, 
patients review their successes and struggles 
with the schedule they prepared in the previous 
session and develop a schedule for the next 
week. Some patients fnd this task diffcult 
and resist this “regimentation” of their time. 
Clinicians may counteract this reticence by 
creating a strengths-based schedule that 
celebrates patients’ accomplishments for 
completing daily tasks. 
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• Participating in urine testing. Urine testing 
is not presented or used as an investigative 
tool or as a method to test patients’ honesty. 
Rather, it is presented and used as a way to 
support initiating and maintaining abstinence. 
SUD treatment providers conduct urine testing 
for the primary stimulant and for secondary 
substances during clinic visits. During treatment 
initiation, urine testing takes place no less than 
once a week. 
Address Secondary Substance Use 
People with stimulant use disorders commonly use 
other substances, such as alcohol or cannabis. They 
often do not perceive their use of a secondary 
substance as problematic. Indeed, for many 
patients, their secondary substance use may not 
have been associated with adverse consequences 
or compulsive use. As a result, patients need help 
connecting any use of other substances to their 
stimulant use disorder. Patients learn that: 
• Using another substance (e.g., alcohol; Staiger 
et al., 2013) increases the likelihood of recurrent 
use of the primary substance and treatment 
nonparticipation (Wang et al., 2017). 
• Combining secondary substances of choice, 
such as opioids or benzodiazepines, with 
injection drugs (including stimulants) can lead to 
accidental overdose (Riley et al., 2016). 
• Using alcohol with cocaine may increase an 
individual’s perception of euphoria. Some 
research appears to show that the combination 
of alcohol and cocaine may be more reinforcing 
than either substance alone. This combination 
produces a toxic metabolite—cocaethylene— 
that can harm the liver and heart (A. W. Jones, 
2019; Liu et al., 2018). (For more information 
about cocaethylene, see Chapter 3.) 
• Using low doses and infrequently using 
secondary substances can have disinhibiting 
effects, serve as cues for stimulant use, and 
evoke potent conditioned responses that 
negatively affect treatment outcomes and 
retention (Wang et al., 2017). 
• Helping patients understand why they use 
secondary substances can promote behavior 
change. For example, some patients may use 
benzodiazepines, alcohol, or opioids as “landing 
gear” after a particularly intense stimulant 
binge. The depressant nature of the secondary 
substance allows the patient to relax and sleep 
after several days of prolonged use (Walley, 
2013). 
Patients are sometimes ready for treatment for 
their primary substance of choice but are not 
ready to address their secondary substance use. 
Thus, secondary substance use is common during 
treatment initiation. Although clinicians should 
promote abstinence from all psychoactive drugs, 
patients who use a secondary substance are not 
discontinued from treatment solely because of 
this use. Rather, they receive treatment strategies 
to decrease the likelihood of using in the future. 
Patients struggling with more than one SUD need 
more help, not less. 
Establish Contingencies 
As described in Chapter 4, CM reinforces desired 
behavior by providing immediate incentives. It can 
be used to improve treatment outcomes, including 
abstinence. It sets concrete goals and emphasizes 
positive behavior changes. 
CM targets a specifc behavior, such as providing 
stimulant-free urine samples. The behavior should 
be easily and objectively measured. Each time 
patients accomplish this target behavior they 
receive a specifc and desirable contingency or 
incentive. The link between the target behavior 
and the incentive is specifed. A written contract 
documents the agreement and the duration, the 
mechanism for verifying task completion, and any 
changes over time in contingencies. Controlled 
research studies show that CM interventions for 
stimulant use behaviors are effective in helping 
people who use cocaine achieve and sustain 
abstinence through the end of treatment at least 
(De Crescenzo et al., 2018; Ronsley et al., 2020). 
Address Compulsive Behaviors 
Associated With Stimulant Use 
As noted above in the section on assessing for 
stimulant-associated compulsive behaviors, 
some patients with stimulant use disorders 














develop signifcant compulsive behaviors, such as 
compulsive sexual behaviors (Berry et al., 2020; 
Loza et al., 2020) and gambling (Szerman et al., 
2020). For these patients, interventions such as 
cognitive–behavioral therapy (CBT) or mindfulness 
meditation can be conducted that will decrease the 
likelihood of both the compulsive behaviors and 
recurrent stimulant use. Clinicians should provide 
a safe environment for such patients to talk about 
these behaviors, either in group sessions or in 
individual counseling. 
Compulsive sexual behavior 
Clinicians help patients address compulsive sexual 
behavior by: 
• Helping patients recognize that sexual feelings, 
thoughts, and fantasies are very high-risk 
triggers that will be acted upon if they are not 
talked out. For people who have this problem, 
even normal, routine sexual thoughts and 
contacts can quickly become major triggers. 
• Discussing safer and unsafe sexual behavior in 
the context of preventing recurrent behaviors. 
• Providing specifc and clear recommendations 
on strategies to identify partners who are 
low risk for recurrent compulsive behavior 
(e.g., looking for a partner with no history of 
substance use, avoiding anonymous sexual 
encounters). 
• Addressing fears (e.g., sex without drugs will 
be boring or impossible). Many avoidance 
strategies used with psychoactive substances 
can be employed for patients in relation to 
sexual cues as well. For patients engaging in 
regular or binge patterns of chemsex, the sexual 
behavior (i.e., seeking a partner, engaging 
in intercourse, and recuperating) may be as 
reinforcing as, or more reinforcing than, the 
stimulant. 
• Reminding patients to stay away from people, 
places, and things related to compulsive 
sexual behavior. Patients may also need 
to be reminded to avoid visiting certain 
neighborhoods where sex workers are located 
and using the Internet or dating apps to connect 
with others for sex. 
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• Providing education about reciprocal behaviors, 
in which one compulsive behavior is inextricably 
involved with another, and therefore engaging in 
the behavior associated with one condition can 
cause one to act out the behavior associated 
with the other condition. 
• Collaborating with patients to reach the 
consensus that patients will abstain from sex 
with other people for 2 to 4 weeks. 
Compulsive gambling 
Patients with compulsive gambling are likely to 
respond best to CBT, with some research indicating 
support for cognitive therapies and MI as well 
(Potenza et al., 2019). Participating in Gamblers 
Anonymous provides patients with ongoing 
support from sponsors and other individuals with 
similar compulsions. 
Harm reduction strategies may be useful for 
people who are not ready to enter treatment and 
abstain from gambling. These strategies teach 
how to engage in gambling with potentially fewer 
destructive consequences (e.g., limiting time spent 
in casinos, setting betting limits; Potenza et al., 
2019). No FDA-approved medications exist for 
compulsive gambling. 
Strategies for Stabilization 
People with stimulant use disorders may be able to
discontinue the use of cocaine or MA for periods
without treatment. Abstaining from stimulants is the
warm-up act; sustaining abstinence is the main event. 
Categorizing strategies as being either for 
achieving abstinence or for maintaining abstinence 
is somewhat artifcial and arbitrary, because many 
of the same principles apply and many of the same 
techniques are used over the course of treatment. 
Several important issues affect stabilization. 
After achieving initial cessation of stimulant use, 
patients need support and strategies to stabilize 
their lives without the substance. Strategies for this 
include the following: 
• Educate patients about managing subacute and 
protracted withdrawal symptoms. 
• Educate patients about avoidance strategies. 
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• Provide patient education on factors that 
contribute to stimulant use. 
• Teach basic conditioning. 
• Identify cues and triggers. 
• Develop action plans for cues and triggers. 
• Enlist family participation. 
• Help patients establish social support systems. 
• Predict scenarios for return to use. 
• Establish new activities. 
• Respond to early slips. 
Educate Patients About Managing 
Subacute and Protracted Withdrawal 
Symptoms 
Once a patient discontinues stimulant use and 
develops healthier sleeping and eating habits, 
most symptoms collectively described as the 
“crash” typically lessen. (Chapter 3 provides more 
information about the crash concept in relation to 
withdrawal.) But the resolution of crash symptoms 
does not signal that the brain has returned to 
normal. Clinical observations show that signifcant 
biologic and psychological symptoms continue 
to hamper functioning 90 to 120 days after 
discontinuation of stimulant use, a phenomenon 
sometimes referred to as “the wall.” Symptoms 
described include mild dysphoria, diffculty 
concentrating, anhedonia, lack of energy, short-
term memory disturbance, and irritability. 
The duration of these subacute (between acute and 
chronic) and protracted (long-lasting) withdrawal 
symptoms has been a subject of debate. Positron 
emission tomography scans have provided 
observable evidence of signifcant changes in 
brain functioning, such as decreased glucose 
metabolism, during protracted abstinence (Parvaz 
et al., 2011). Although caution about specifying 
the precise cause or time course of this syndrome 
is still warranted, neurophysiologic evidence 
appears to support this phenomenon. Clinicians 
should educate patients about the subacute 
and protracted withdrawal symptoms they may 
experience and when these symptoms may occur. 
Clinicians can encourage patients to continue using 
good coping skills to manage these symptoms, 
including stress management techniques, good 
sleep hygiene, and healthy eating habits. 
Educate Patients About Avoidance 
Strategies 
The process of identifying cues and triggers is 
dynamic and ongoing and changes over time. 
For example, as patients learn more about the 
associations between specifc emotional states 
and stimulant cues, they may become increasingly 
able to identify, avoid, and defuse potential 
triggers. Several strategies can be introduced early 
in the treatment process to help patients avoid 
certain external or environmental cues that can be 
potent triggers for stimulant cravings and urges 
(Kampman, 2019): 
• Discarding drugs, drug paraphernalia, and 
materials related to substance use. Patients 
fnd and remove all substances (including 
alcohol) and drug-related paraphernalia. 
Clinical oversight is imperative to determine 
the healthiest time to introduce this strategy 
(i.e., not in the middle of the worst withdrawal 
symptoms). Patients are encouraged to 
accomplish this task with the help of a treatment 
and recovery advocate such as a family member 
who does not misuse substances, an abstinent 
friend, a 12-Step sponsor, or a peer recovery 
support specialist. In addition, they discard 
materials associated with drug use, such 
as contact information of people who deal 
drugs and engage in sex work, pornographic 
materials, containers used to hold drug supplies, 
mirrors or special tables used to cut stimulants, 
spoons, straws or straw-type objects such as 
pens, razor blades, small or extra-small metal 
screens, ligatures, syringes not used for medical 
purposes, and weighing scales. Clinicians should 
discuss with patients how technology may 
remind them of past drug use behaviors, and 
why removing drug-specifc content from their 
computers, mobile devices, and social media 
can therefore be a good idea. This effort may 
require an honest discussion with the individual 
assisting the patient, especially if this individual 
is not aware of the culture of use the patient was 
involved in or the patient’s unique patterns and 
norms (e.g., drug hiding spots, pattern of use at 
home). 












• Breaking off contact with people who deal 
and use drugs. Patients develop plans to stop 
contact with dealers and other people who 
use stimulants, including removing contact 
information and deleting call histories from 
mobile devices. They also develop plans to 
assertively encourage family members and 
close friends who use stimulants to seek help. 
It may be diffcult to break off contact with 
people dealing and using drugs, because they 
could be family members or friends. Because of 
substance use, patients’ healthy supports may 
no longer be in their life and the only supports 
they have may be people who use and deal 
drugs. 
• Avoiding high-risk places. Patients identify 
places they strongly associate with stimulant use 
and come up with strategies for avoiding them. 
Strategies include taking different routes home 
from work, avoiding certain locations at certain 
times, and using a buddy system when going 
to a high-risk area. These high-risk places are 
sometimes living environments, neighborhoods, 
or work situations patients cannot avoid. 
• Developing basic refusal skills. Patients learn 
to handle encounters with acquaintances and 
friends who still use stimulants by immediately 
leaving the situation after an encounter. They 
also prepare specifc drug-refusal statements 
that they can make during encounters. Patients 
practice these statements in individual therapy 
sessions and with fellow group members. 
Provide Patient Education on Factors 
That Contribute to Stimulant Use 
Many factors, including cognitive changes, 
traumatic experiences, and weight gain, may 
affect patients’ memory or perception of 
their stimulant misuse. Patients may require 
education to understand the conditioning factors 
associated with stimulant use. Similarly, they 
need information about the impact of stimulants 
and other substances on the brain and behavior, 
such as cognitive impairment and forgetfulness. 
Information about stimulant-induced behavior 
helps explain episodes of mood lability, altered 
perceptions of reality, protective behaviors, sexual 
compulsivity, and impulsivity. 
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Clinicians provide patients, especially those with 
MA use disorder, with education about acute 
withdrawal symptoms. Patients should also: 
• Learn how other substances they may use have 
an important role in recurrent stimulant use. 
• Receive education about the biopsychosocial 
processes of SUDs, treatment, and recovery. 
• Discuss with their clinicians the stages of 
treatment and recovery, as well as specifc tasks, 
goals, and pitfalls of each stage. 
• Receive education about co-occurring mental 
disorders and their impact on SUDs, treatment, 
and recovery. 
Teach Basic Conditioning 
Although patients with stimulant use disorders may 
present with poor retention of information and 
other cognitive defcits early in treatment (Gould, 
2010), they should be able to understand basic 
information about cues and triggers. Patients can 
be taught that: 
• Conditioning factors elicit drug cravings and 
urges. 
• These cravings and urges are a natural part of 
early recovery and are due to the neurologic 
changes that occurred from substance misuse. 
• Methods are available to deal with these 
cravings and urges. 
Clinicians should provide basic education about 
this conditioning process and how it applies to 
stimulant use disorders. 
Identify Cues and Triggers 
Stimulant (and other substance) use may become 
strongly associated with certain people, places, 
objects, activities, behaviors, and feelings (Rawson 
et al., 2021). Because patients with stimulant 
use disorders may have engaged in stimulant 
use hundreds or thousands of times, their daily 
life contains numerous reminders or cues—any 
stimuli (e.g., friends who use substances, intimate 
relationships, locations associated with substance 
use, drug paraphernalia, seasonal changes, 
holidays, moods, smells related to the trigger, sex-
related websites, stress from increased educational 
demands) repeatedly paired with substance use 
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over the course of patients’ SUDs. These cues 
can trigger stimulant cravings and stimulant use. 
Although patients often have some of the same 
cues and reminders (e.g., seeing the drug or the 
dealer), the specifc type, strength, and number of 
cues differ widely from patient to patient. Clinicians 
should help patients identify and acknowledge the 
cluster of cues unique to their lives. 
The primary tasks are to teach patients how cues 
are developed, how they trigger drug craving and 
use, and how cues and triggers can be identifed. 
Cues can be unique to each patient. Patients need 
to be vigilant about identifying and managing their 
specifc cues. 
Develop Action Plans for Cues and 
Triggers 
External and internal cues can be present in 
every aspect of life for people with stimulant use 
disorders. To combat these cues, patients can 
develop action plans with specifc behavioral and 
cognitive steps to prevent cues from becoming 
triggers. Patients learn to avoid, wherever possible, 
external cues that are strong reminders of stimulant 
use and to leave situations that make them think 
about stimulants or experience cravings. They 
include these steps in their action plans and call 
on specifc techniques to stop drug thoughts from 
becoming intense drug cravings. 
Strategies that can immediately mitigate stimulant 
cravings that lead to drug use are vital to sustaining 
abstinence during stabilization. These strategies 
include: 
• Leaving situations or events that are reminders 
of stimulant use. 
• Using visualization techniques that help “turn 
off” thoughts about stimulant use. 
• Calling a sponsor, recovery ally, or abstinent 
friend. 
• Engaging in activities that promote healthy 
behaviors (e.g., taking a walk, exercising, using 
relaxation techniques). 
• Using imagery to assist with developing 
responses to high-risk situations. 
• Recognizing and managing sensory experiences 
that serve as cues and trigger cravings. 
• Maintaining a gratitude list of what has been 
restored and gained from recovery. 
Enlist Family Participation 
Clinicians should encourage families and 
signifcant others to participate in treatment 
when appropriate and after receiving patient 
consent. As part of this participation, families 
should receive education about SUD care and their 
possible role in treatment and recovery processes. 
Family members also need information about the 
effects of stimulants on the brain and behavior to 
understand stimulant-induced actions. By receiving 
a primer on the conditioning aspects of stimulant 
use disorders, they can come to understand 
craving as a conditioned response. 
Family members may beneft more from clear 
and simple information than from concepts. 
The ideal format is a group psychoeducational 
session consisting of a brief instruction session 
and a group discussion. This process elicits 
discussions and examples of family members’ 
experiences. Family participation is an opportunity 
for staff members to informally review available 
SUD care in case other family members need 
additional services or referrals. Family members 
may beneft from Community Reinforcement and 
Family Training (CRAFT), which is an approach 
that teaches family members and concerned 
signifcant others strategies for encouraging 
the family member who is misusing substances 
to change his or her substance use behaviors 
through positive reinforcement and enter 
SUD treatment (SAMHSA, 2020k). For more 
information about CRAFT, see SAMHSA’s TIP 39, 





For patients who are actively working on building 
their recovery and who have a stable marriage 
or relationship with someone who is not using 
stimulants, involving the spouse or partner in family 
and couples therapy can be valuable. 











This strategy can improve communication skills 
and the relationship. Research shows that marital 
and relationship counseling has positive effects 
on treatment outcomes for individuals with 
alcohol use disorder (O’Farrell & Clements, 2012). 
However, few studies have focused on stimulant 
use. Clinicians should screen for intimate partner 
violence (IPV) before initiating relationship 
counseling. Behavioral couples therapy is generally 
appropriate when (SAMHSA, 2020k): 
• The partner does not have active problems with 
substance use (except for nicotine). 
• There is no indication of active or acute risk for 
IPV. The clinician should use clinical judgment 
and consult state laws on mandatory reporting 
requirements when evaluating IPV and 
considering whether to recommend behavioral 
couples therapy. 
• Neither partner has a signifcant co-occurring 
mental disorder. 
• The partners are married or living together. 
(See also the “Family and Couples Therapy” 
section in Chapter 4.) 
Help Patients Establish Social Support 
Systems 
Patients with stimulant use disorders typically 
have low frustration tolerance and are sometimes 
restless in the therapeutic process, especially 
during initiation and stabilization. Nevertheless, 
these patients should be introduced to a structured 
and therapeutic group process as soon as possible 
(generally within a few days). These groups provide 
a preexisting support network and a forum for 
openly talking about problems associated with 
early recovery. 
At the same time, participating in mutual-help 
meetings, such as Cocaine Anonymous, Celebrate 
Recovery, Crystal Meth Anonymous, Narcotics 
Anonymous, SMART Recovery, and Wellbriety, 
should be strongly encouraged. Some patients 
beneft from short-term goals associated with 
attending 12-Step meetings, such as participating 
in 90 meetings in 90 days. Participating in 
these meetings reinforces the importance of 
implementing daily structure, immersing in 
treatment, and creating healthy habits. 
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Also, patients should be encouraged to reestablish 
relationships with friends and family who are 
not using substances and, perhaps, to seek out 
recovery allies who can be mentors/sponsors. 
These allies could be 12-Step sponsors whom 
patients can call during crises to discuss shared 
experiences in recovery. An abstinent social 
support network can be a useful tool for patients 
who need additional support throughout recovery. 
Predict Scenarios for Return to Use 
Research literature describes several predictors for 
recurrent stimulant use by patients who are trying 
to maintain abstinence (Brecht & Herbeck, 2014; 
Sánchez-Hervás & Llorente del Pozo, 2012): 
• Continued or other drug use leading to 
recurrent stimulant use and treatment 
nonparticipation. Several studies have reported 
a relationship between alcohol use and recurrent 
cocaine use, and other studies support this 
same pattern with alcohol and cannabis for MA 
treatment nonparticipation (Staiger et al., 2013; 
Wang et al., 2017). 
• Return to networks of people actively 
using substances. The clinical experiences 
of TIP consensus panel members suggest 
that returning to networks of people who use 
substances is a primary reason for an individual’s 
recurrent use. 
• Sexual behavior associated with stimulant 
use. Particularly for men, chemsex experiences 
and sexual behaviors associated with stimulant 
use (e.g., having sex with sex workers, viewing 
pornography or sexualized videos of people 
using substances) are an important contributor 
to recurrent stimulant use (Berry et al., 2020; 
Loza et al., 2020). 
• Craving triggered by external and internal 
stimuli. People who use stimulants report that 
conditioned cues have a powerful infuence on 
the production of craving and contribute to a 
return to stimulant use (Tolliver et al., 2010). 
• Negative affective states. Emotional states 
can be important antecedents to recurrent 
substance use (Kober, 2014). People who use 
stimulants typically fnd anger, depression, 
loneliness, frustration, and boredom diffcult to 
manage. These feelings can initiate a behavioral 
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sequence that ends in stimulant use. However, 
celebratory and positive emotions associated 
with using can also be consequential if they are 
not identifed. 
• Academic demands. Studies have shown a 
relationship between prescription stimulant 
misuse and academic demands among college 
students (Weyandt et al., 2016), particularly 
when they have experienced academic 
impediments or grade strain during the previous 
academic year (Norman & Ford, 2018). Students 
who return to school at the beginning of a new 
academic year and continue to experience 
academic diffculties may return to misusing 
prescription stimulants. 
Establish New Activities 
People with stimulant use disorders typically have 
spent a considerable amount of time leading up to 
treatment entry on getting stimulants, using them, 
and recuperating. During the initial 6 to 12 months 
of abstinence, patients may not know what to do 
with the time that they once devoted to substance 
use. They likely have few social and recreational 
outlets. Finding and participating in new, positively 
reinforcing activities and interests are important 
parts of stabilization and imperative to sustaining 
recovery. The community reinforcement approach 
presented in Chapter 4 is an intervention that helps 
patients reorganize their social lives and engage in 
new activities. 
Respond to Early Slips 
Patients may return to stimulant use sporadically 
throughout stabilization. Patients should be told 
that substance use could occur during this time, 
despite their hard efforts to abstain, and that even 
small treatment accomplishments and successes 
should be celebrated. Substance use is a part of 
the disorder and could be a sign that the treatment 
plan needs to be changed or that the treatment 
approach is not working and other treatment 
options should be explored. 
During stabilization, substance use is not a 
sign of poor motivation but instead refects 
multiple factors, including cues and triggers and 
neurochemical imbalance. Slips can be thought 
of as a behavioral indicator of confict and 
ambivalence about stopping. When explaining this 
to patients, clinicians need to clearly communicate 
that they are not giving patients permission to 
use, but rather, trying to keep patients engaged 
in treatment by immediately addressing the slip. 
Continued engagement in treatment throughout 
stabilization, even if a slip occurs, is the best way 
for patients to progress and succeed. 
Early slips are opportunities for adjusting the 
treatment plan and trying other strategies. In 
the process, patients gain an appreciation of 
the strength of cravings and triggers, learn 
new methods to manage and reduce them, 
and examine whether the treatment plan is 
adequate and appropriate or needs adjusting 
(e.g., increasing the frequency of contact with 
their treatment team, attending more mutual-help 
meetings, spending more time with their sponsor, 
volunteering). 
Early slips should be considered part of the 
learning process and not be thought of as failures. 
When slips occur, clinicians make a verbal or 
behavioral contract with patients regarding short-
term achievable goals. These goals include simple 
tasks such as not using psychoactive substances 
for the next 24 hours, attending a specifc number 
of clinic sessions over the next couple of days, 
and bringing a signifcant other or family member 
to the next treatment appointment. During this 
process, patients identify areas to address or 
improve. This focus on cues and triggers helps 
determine whether the treatment plan should 
be adjusted. Reviewing the past day, week, and 
possibly month of patients’ activities, behaviors, 
and emotions is a good therapeutic tool to identify 
signs that they were at high risk of substance use. 
Strategies for Maintenance 
The strategies for maintaining recovery draw 
primarily from the behavioral and cognitive– 
behavioral models described in Chapter 4. An 
overall theme of these models is that people 
require support even after stabilization to maintain 
success in treatment. 
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There are several immediate and long-term 
priorities for patients who are stable and want to 
maintain abstinence from stimulants: 
• Teach functional analysis of stimulant use. 
• Maintain positive reinforcement. 
• Teach relapse prevention techniques. 
• Provide psychoeducation about preventing a 
return to use. 
• Teach drug refusal skills. 
Teach Functional Analysis of 
Stimulant Use 
A functional analysis teaches patients how to 
understand their stimulant use so that they can 
engage in solving problems in a way that reduces 
the probability of future stimulant use. The core 
components of a functional analysis are: 
1. Teaching patients to examine the types of 
circumstances, situations, thoughts, and feelings 
that increase the likelihood that they will use 
stimulants. 
2. Counseling patients to examine the positive 
immediate, but short-term, consequences of 
their stimulant use. 
3. Encouraging patients to review the negative, 
and often delayed, consequences of their 
stimulant use. 
Maintain Positive Reinforcement 
Employing CM agreements can help sustain initial 
treatment gains. These agreements are detailed in 
a written behavioral contract and include specifc 
objective criteria such as urinalysis results and 
attendance at group therapy sessions. Systematic 
and consistent implementation of agreements is 
crucial. Reinforcement is delivered promptly when 
the contract is satisfed and withheld when it is 
not. Frequent, positive reinforcement of success is 
critical. Clinicians should always incentivize positive 
behaviors while trying to avoid punishing negative 
behaviors because positive reinforcement is a more 
effective way of shaping behavior than punishment 
(i.e., punishment can be counterproductive and 
can lead to avoidance). The goal of positive 
reinforcement is to encourage patients to continue 
growing their strengths in recovery rather than to 
emphasize their struggles. 
Teach Relapse Prevention Techniques 
Relapse prevention techniques help patients 
recognize high-risk situations for substance use, 
implement coping strategies when confronted with 
high-risk events, and apply strategies to prevent 
recurring use should an episode of substance use 
occur (Glasner-Edwards et al., 2017; S. Grant et 
al., 2017; Marlatt & Gordon, 1985). The techniques 
involve several cognitive–behavioral interventions 
that focus on skills training, cognitive reframing, 
and lifestyle modifcation. 
Relapse prevention techniques fall into several 
categories: 
• Acquiring, through psychoeducation, knowledge 
about the process of returning to substance use 
and how to interrupt it 
• Identifying high-risk situations and warning signs 
for a return to use 
• Enhancing self-effcacy in dealing with high-risk 
situations 
• Counteracting euphoric recall (i.e., pleasant 
memories of drug use) and the desire to test 
control over use 
• Developing a balanced lifestyle that includes 
healthy leisure and recreational activities 
• Responding safely to slips to avoid escalation 
into a full-blown return to use 
• Developing coping and stress management skills 
• Learning executive function skills 
• Learning educational enhancement skills, 
including time management, study skills, and 
test-taking strategies 
As reviewed in Chapter 4, a substantial body 
of literature exists on the use of prevention 
techniques for stimulant use. SAMHSA’s Matrix 
Manual (Center for Substance Abuse Treatment, 
2006) has a section on conducting prevention 
training in a group setting, along with handouts 
and instructions for their use. The following 
treatment themes are critical to the relapse 
prevention-based treatment strategies. 
Provide Psychoeducation About 
Preventing a Return to Use 
SUD treatment providers often deliver prevention-
related information in psychoeducation groups. 
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These groups consist of education, peer support, 
and recovery-oriented therapy. The group leader 
provides a brief discussion or shows a short video 
on a topic relevant to the group, then encourages 
group members to discuss the topic as it relates 
to them. The group leader also encourages group 
members to discuss their current problems, 
challenges, and successes. 
Topics typically discussed in a psychoeducation 
group for patients with stimulant use disorders 
include: 
• Understanding cravings and conditioning. 
• Managing protracted withdrawal. 
• Understanding stimulants’ effects on the brain. 
• Identifying and addressing high-risk situations. 
• Developing coping and stress-management 
skills. 
• Enhancing self-effcacy in dealing with high-risk 
situations. 
• Counteracting euphoric recall and the desire to 
test control over use. 
• Developing a balanced lifestyle. 
• Responding safely to slips to avoid escalation of 
substance use. 
• Establishing behavioral accountability. 
Some of these topics are explained below. 
Enhancing self-efcacy in dealing with high-
risk situations 
When patients are establishing abstinence, they 
work to acquire skills for negotiating high-risk 
situations for return to use. In particular, patients 
learn how to identify cues and triggers, develop 
action plans for cues and triggers, and manage 
withdrawal symptoms. 
Once patients learn to identify, manage, and avoid
high-risk situations for return to use, clinicians and
patients determine whether patients can confdently
use those skills in real-world situations. With clinician
guidance, patients evaluate their level of confdence
in using avoidance and refusal skills and determine
whether they need to work on their skills or develop
additional skills to manage specifc situations. Self-
effcacy should be therapeutically developed from the
start of treatment. 
Counteracting euphoric recall and the desire 
to test control over use 
Two important risk factors for return to stimulant 
use are euphoric recall and the desire to test 
control over stimulant use. “Euphoric recall” refers 
to remembering only the pleasures associated with 
stimulant use and not the adverse consequences. 
Euphoric recall is a potent risk factor for recurrent 
substance use because it minimizes patients’ 
perceptions of stimulants’ danger, promoting an 
ambivalence about quitting. “War stories” that 
include euphoric recall and selective memory act 
as powerful triggers. Clinicians should strongly 
discourage patients from retelling them in 
treatment and recovery groups, unless done in a 
therapeutic manner directed by the clinician. 
After beginning to feel healthier, more in control 
of their lives, and free of some of their stimulant- 
related problems, some patients feel ready to try 
a new approach to stimulant use. For example, 
some may believe that, if they are careful, they 
can use stimulants without losing control over 
their use. Others may think that this is a good 
time to try using stimulants “one last time” to 
fnd out whether they can do it without escalating 
into compulsive use and loss of control. Even the 
realization that they do not have money or are in 
debt may create a desire for “easy money,” and 
patients may think they can sell drugs without 
using them. Clinicians must explain to patients that 
urges to test their control over stimulant use are a 
powerful warning sign for return to use. Patients 
should reach out to their 12-Step or other mutual-
help group sponsor for support if they experience 
this warning sign. 
Developing a balanced lifestyle 
Treatment, recovery, and relapse prevention efforts 
should address biologic, psychological, social, 
and spiritual areas of life. Patients are taught the 
value of recreational and leisure activities and 
how to incorporate them into their recovery. 
Many recreational activities offer opportunities 
for patients to learn or practice social skills, such 
as cooperation, teamwork, healthy competition, 
and leadership. Patients may be experiencing 
anhedonia and depressed mood, which could 
make activities less enjoyable. Clinicians can 
provide psychoeducation that encourages patients 






to take small steps by gently pushing through 
the anhedonia and depressed mood as long as 
they are not associated with an untreated or 
undertreated co-occurring disorder. Clinicians 
should reinforce that, although it may be diffcult 
to initiate a recreational or healthy leisure activity, 
patients tend to feel better during and after active 
participation in the activity. 
Vigorous physical exercise helps patients feel 
good about themselves, decreases anxiety and 
depression, increases appetite, increases healthy 
cholesterol, stabilizes blood pressure, increases 
heart health, and helps patients sleep better. 
Clinicians inform patients about the value of 
regular exercise and how to incorporate it into 
their daily or weekly schedule. Studies on patients 
receiving MA treatment link structured aerobic 
exercise and resistance training to better mood 
outcomes (Morris et al., 2018; Rawson, Chudzynski, 
Gonzales, et al., 2015) and better overall outcomes 
(Rawson, Chudzynski, Mooney, et al., 2015). 
Patients in treatment for stimulant use disorders 
may have problems related to nutrition and diet 
(Wiss, 2019). Stimulants decrease appetite, leading 
to decreases in the intake of calories and nutrients. 
Patients with stimulant use disorders may eat 
impulsively and consume foods with negligible 
nutritional value. A professional nutritionist can 
conduct a formal nutritional assessment and 
provide patients with guidance on eating a healthy 
and balanced diet, eliminating infrequent and 
impulsive eating, and planning and preparing 
nutritious meals. Clinicians should screen patients 
for eating disorders when clinically necessary, 
as patients may use stimulants intentionally 
to facilitate disordered eating behaviors (e.g., 
suppressing appetite). 
Responding safely to slips to avoid 
escalation of substance use 
Slips and episodes of recurrent use are not failures, 
but they do indicate a need to adjust the treatment 
plan. After patients experience a slip, clinicians 
schedule a return-to-use-specifc session as soon 
as possible to reassure patients that they can get 
back on track. Clinicians and patients review the 
events leading up to the slip and identify warning 
signs. Patients consider the events of the previous 
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weeks, such as changes at work, at school, in social 
networks, or in family situations. Similarly, they 
closely examine events and issues that occurred 
in treatment, such as transitioning to different 
clinicians, moving from one phase of treatment 
to another, or learning about or observing events 
happening to another patient. 
Clinicians provide psychoeducation to patients 
and family members about each stage of change 
and how their specifc characteristics can affect 
treatment, relapse, and recovery. Clinicians help 
patients identify specifc steps to avoid future 
substance misuse if a similar set of circumstances 
recurs. Slips prompt revisions in the treatment plan. 
Revisions may include increasing attendance at 
mutual-help meetings, participating in individual 
counseling for a brief period, recruiting a 12-Step 
sponsor, developing additional positive coping 
mechanisms, or participating in more leisure 
activities. Patients should get recommendations 
and guidance to handle the negative thoughts and 
feelings caused by slips. 
Teach Drug Refusal Skills 
People in recovery from stimulant use may be 
surrounded by individuals who continue to use 
substances. The ability to refuse stimulants when 
offered requires a special type of assertiveness. 
Drug refusal training reminds patients that anyone 
offering them stimulants does not have their best 
interests in mind. Patients learn strategies to 
discourage others from offering them substances 
and to refuse offers of stimulants (Meyers et 
al., 2011). They also learn to reinforce their 
commitments to abstain from use and to feel good 
about themselves for not using. 
Patients should incorporate the following elements 
into their encounters with individuals offering them 
stimulants or inviting them into high-risk situations: 
• Say “No” immediately. 
• Tell the individual making the offer not to make 
such offers now or in the future. 
• Make eye contact; adopt an expression and 
tone that indicates the seriousness of the 
request. 
• Change the conversation to a different topic. 
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• Suggest healthy alternative activities (e.g., go 
for a bike ride or out for a meal), if the individual 
is someone the patient wants to be with. 
• Set boundaries with friends and family members 
before meeting with them by establishing 
that the patient is in recovery and will not use 
substances. 
The clinician conducts role-playing exercises with 
patients (Meyers et al., 2011) and guides them 
through scenarios involving specifc individuals, 
specifc times of the day, and specifc situations. 
Patients practice behaviors that they can use 
in real-life situations. Away from the treatment 
setting, patients should engage in additional 
role-playing exercises with family members and 
signifcant others to become more comfortable 
with these new behaviors. 
Other Strategies Useful in
Maintaining Abstinence 
Provide Relationship Counseling 
The overall goals of relationship counseling (i.e., 
couples counseling) are for couples to develop 
effective communication skills to help achieve 
and maintain abstinence, change their lifestyle, 
increase enjoyment in their relationship, and learn 
better ways to solve problems. Information about 
relationship counseling in the context of SUD 
treatment can be found in SAMHSA’s updated 
TIP 39, Substance Use Disorder Treatment and 




Provide Social and Recreational 
Counseling 
This counseling focuses on helping a patient 
develop new interests and participate in 
recreational and social activities that do not involve 
using stimulants or other substances. The clinician 
and the patient evaluate possible activities based 
on whether they involve others, how much time 
and expense they require, whether the patient 
is likely to enjoy them, and how much physical 
exertion they require. Potential coparticipants are 
identifed. Next, the steps required to engage in 
the activities are identifed (e.g., fnding out how to 
join a community basketball league). These steps 
should be incorporated into the treatment plan. 
Provide Social Skills Training 
Social skills training helps patients learn and 
practice skills that facilitate choosing nonsubstance 
alternatives for socializing, engaging in recreation, 
and coping with stressful interpersonal situations. 
The goal is to help patients experience more 
positive reinforcing effects and fewer negative, 
aversive effects from social interactions. The 
training is especially helpful for patients who 
have problems meeting nonsubstance-using 
peers or interacting with coworkers, or who feel 
uncomfortable in social settings. Clinicians can use 
role-playing to help patients learn social skills for 
use in various scenarios. 
Provide Vocational Counseling 
Vocational counseling and vocational rehabilitation 
services focus on helping unemployed patients 
locate jobs and on improving the employment 
situations of patients with unsatisfactory jobs 
or jobs that carry a high risk for recurrent use. 
Individuals with SUDs may have diffculty fnding 
gainful employment, which can negatively affect 
treatment-seeking and treatment outcomes 
(Miguel et al., 2019). In 2017, 31 percent of 
individuals in the United States admitted to 
treatment for any SUD were unemployed, 
compared with 3 percent of the general population 
(Center for Behavioral Health Statistics and Quality 
[CBHSQ], 2019). Among individuals who use 
stimulants, rates of unemployment ranged from 
37 to 43.5 percent (CBHSQ, 2019). Research has 
shown that acquiring employment during SUD 
treatment is associated with better treatment 
outcomes throughout the continuum of care 
(Miguel et al., 2019). 
Clinicians should connect patients to vocational 
rehabilitation services and supports, which 
can include assistance with job searching, job 
placement, on-the-job training and supports, costs 
of living, and other services required for obtaining 
and maintaining employment (e.g., occupational 
licenses, tools, equipment; Lusk & Veale, 2018). 
Ideally, vocational counseling or vocational 
rehabilitation services should begin as soon as 





possible in treatment. However, people in recovery 
from stimulant use disorders may experience 
psychotic symptoms and an inability to concentrate 
that could interfere with initiating vocational 
services. Vocational services can be initiated after 
patients’ psychotic symptoms have improved and 
their ability to focus has returned. 
For more information about vocational 
services, see SAMHSA’s TIP 38, Integrating 
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Provide Treatment and Services To Help 
Patients Manage Co-Occurring Disorders 
Having co-occurring substance use and 
psychiatric disorders can make achieving and 
sustaining recovery from stimulant use disorders 
more diffcult. Pharmacologic and psychosocial 
interventions are available to help patients 
with common co-occurring psychiatric illness, 
like depression and anxiety. Clinicians should 
encourage patients to receive behavioral health 
services as needed and provide referrals, resources, 
and support to enhance treatment engagement 
and retention. Additional treatment considerations 
for co-occurring disorders are presented in 
Chapter 6. 
Monitor Medications for Treatment of 
Co-Occurring Alcohol Use or Opioid Use 
Disorders 
When clinically indicated, clinicians use evidence-
based medications to treat patients with co-
occurring secondary SUDs. Clinicians consult 
with an experienced SUD treatment provider 
to determine the best course of pharmacologic 
treatment for patients based on current use, 
medical comorbidities, and patient preference. 
For patients with co-occurring alcohol use disorder, 
the FDA-approved pharmacologic therapies 
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are naltrexone, acamprosate, and disulfram. 
For patients with co-occurring OUD, the FDA-
approved pharmacologic therapies are methadone, 
buprenorphine, and naltrexone. For additional 
treatment considerations specifc to OUD, see 
Chapter 6. 
Recommend Mutual-Help Strategies 
Mutual-help strategies can be valuable 
components throughout treatment. These 
strategies, especially those that focus on substance 
use, are especially valuable as ancillary activities 
that support the treatment goals of maintaining 
abstinence. In general, mutual-help programs 
assist patients in developing appropriate social 
skills, creating healthy social networks, establishing 
healthy intimate relationships, and engaging 
in substance-free healthy activities. They also 
provide opportunities for patients to learn socially 
appropriate mores and norms, improve their 
ability to receive and give advice, and learn how 
to mentor others. 
The most frequently used and available mutual-
help strategy is the 12-Step approach. Most cities 
have many Alcoholics Anonymous group meetings 
every day, and most larger cities have numerous 
Cocaine Anonymous and Narcotics Anonymous 
meetings. Online meetings are also available. 
Clinicians or peer recovery support specialists 
provide patients with information on the 12-Step 
process, such as meeting format, the spiritual 
component, the basic content and meaning of the 
12 Steps, the role of the 12-Step sponsor, and the 
role of anonymity. 
Although SAMHSA’s TIP consensus panel 
recommends participation in a 12-Step group, 
clinicians should not require patients’ participation. 
Rather, clinicians encourage 12-Step participation, 
especially because 12-Step programs describe 
themselves as voluntary mutual-help programs of 
recovery. Similarly, patients’ family members should 
be encouraged to participate in mutual-help 
programs for family members, such as Al-Anon. 
Scheduling onsite meetings is a good way to 
encourage participation. Both patients and family 
members receive lists with the addresses and times 
of meetings, and programs provide transportation 
when necessary and possible. 
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Other mutual-help strategies that do not follow the 
12-Step approach are available. These programs 
include Save Our Selves, SMART Recovery, 
Wellbriety, and Women for Sobriety. Groups 
without a substance use focus, such as faith-based 
groups, cancer survivor groups, and domestic 
violence survivor groups, can also support patients’ 
progress in treatment. 
Next Steps 
Treatment maintenance ends only when patients 
achieve the treatment goals documented in their 
treatment plans and agree with their clinicians to 
stop ongoing treatment. 
The end of treatment maintenance is a good 
opportunity for patients to review their treatment 
experiences. Clinicians engage in activities 
and exercises that help patients examine their 
treatment successes, the areas where they 
experienced problems, and the ways in which they 
addressed these problems. Similarly, clinicians 
help patients evaluate the strength of their current 
recovery process and identify areas where they 
need strengthening. Through this process, the 
clinician and the patient develop a continuing care 
treatment plan that identifes remaining treatment 
needs and strategies that will be used to meet 
those needs. 
Treatment maintenance ends with a transition to 
a lower level of care, not a termination. Abrupt 
termination is avoided. SUD treatment facilities 
should have strategies that encourage patients to 
remain connected with care (i.e., using a recovery-
oriented system of care), because SUDs are chronic 
lifelong conditions that can have many pathways 
to recovery. Furthermore, clinicians should educate 
patients about the continuity of care available to 
them and encourage patients to engage with this 
care when they need it. SUD treatment facilities 
can help patients remain in contact by offering: 
• Continuing care group meetings that patients 
can attend weekly or more often as needed. 
• Individual counseling or psychotherapy that 
patients can participate in on an as-needed 
basis. 
• Family therapy that is available to patients and 
their families or to family members. 
• Alternative activities that focus on recreation, 
leisure, education, and social activities (e.g., 
dances, feld trips, barbecues and picnics, 
holiday events, lectures on topics not necessarily 
related to treatment or recovery). 
• SUD treatment alumni meetings that all 
graduates can attend. 
• SUD treatment alumni clubs that sponsor 
regional meetings and events (e.g., speakers on 
motivational and educational issues). 
• Peer mentoring programs in which SUD 
treatment alumni help new patients by sharing 
experiences, advice, and service expectations. 
• Surveys and newsletters that are sent to 
SUD treatment alumni as a way to collect 
posttreatment data, encourage participation in 
alumni activities, and motivate contact with SUD 
care staff, especially during times of need. 
For more information about recovery-oriented 
systems of care, see SAMHSA’s Recovery-Oriented 




Clinicians have multiple strategies that they 
can implement across the continuum of care to 
maximize patient engagement in treatment for 
stimulant use disorders. These strategies include 
discussing treatment expectations, offering 
multiple treatment options, using a person-
centered and respectful approach, conveying 
empathy and concern, and collaborating with 
patients to develop a clear, fexible treatment 
plan and framework. As patients transition to 
long-term recovery, clinicians can help them 
maintain treatment gains by teaching functional 
analysis of stimulant use, reinforcing positive 
behaviors with incentives (i.e., using CM), offering 
relapse prevention tools, teaching ways to avoid 
high-risk situations, providing social skills training, 
encouraging participation in mutual-help activities, 
and linking these patients to vocational counseling. 
Given that patients with SUDs typically have 
numerous health- and behavioral health-related 
issues, coordinated care models that include a 
wide range of multidisciplinary staff can enhance 
treatment implementation. 
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Chapter 6—Treatment Considerations for 
Special Populations 
KEY MESSAGES 
This chapter discusses stimulant use disorder risks 
and care considerations specifc to the following 
populations: 
• Racial/ethnic minorities 
• Women (including those who are pregnant) 
• Men who have sex with men (MSM) 
• Transgender and gender nonbinary (TGNB) 
community 
• Adolescents 
• People experiencing homelessness/unstable 
housing 
• Rural populations 
• People involved with the criminal justice system 
• People taking medication for opioid use 
disorder (OUD) 
• People who inject drugs (PWID) 
• People with or at risk for HIV/AIDS 
• People with or at risk for hepatitis 
• Individuals with co-occurring mental disorders 
If a patient with a substance use disorder 
(SUD) identifes with one or more of these 
groups, treatment must be informed by a solid 
understanding of the needs of the group or 
groups. 
Considerations for each special population include: 
• Location of treatment centers and community-
based organizations. 
• Availability of drop-in centers. 
• Availability of nonconfrontational programs. 
• Treatment approaches that include more time in 
the engagement phase prior to counseling. 
• Treatment that offers individualized approaches, 
encourages the establishment of safe 
relationships, allows time for trust to develop, 
and assesses the level of motivation for change. 
• Populations that experience health disparities
related to systems of care and engagement in
care may experience higher rates of stimulant use
disorder and increased issues with accessing care
for stimulant use disorders, and may be more likely
to experience secondary negative consequences
related to these vulnerabilities (e.g., trauma,
communicable diseases). 
• Clinicians should strive to understand the needs of
special populations, as well as the access-to-care
issues and treatment considerations they face.
In doing so, clinicians are more likely to provide
patient-centered, effective stimulant use disorder
care that maximizes rapport and treatment
engagement. 
• When possible, clinicians should tailor their
services to members of special populations to
accommodate a given population’s particular
needs. Examples include having gender-
responsive treatment programs for women or
programs specifcally designed for populations
that may experience xenophobia or racism within
the healthcare system. Clinicians may need to
seek guidance from experts in these special
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• Availability of clinicians trained to help patients 
identify their own ethnic issues. 
• Clinicians matched to patients by cultural 




One of the most important aspects of improving 
access and developing treatment options for 
diverse racial/ethnic minority populations is 
cultural responsiveness in providing care. Cultural 
responsiveness in the SUD care setting involves 
clinicians understanding and being responsive to 
the health beliefs, mores, practices, and values 
of diverse populations while simultaneously 
exploring the effects of ethnocentrism and racism 
on their caring process. For more information on 
cultural responsiveness, see the Substance Abuse 
and Mental Health Services Administration’s 
(SAMHSA) Treatment Improvement Protocol (TIP) 
59, Improving Cultural Competence (https://store. 
samhsa.gov/product/TIP-59-Improving-Cultural-
Competence/SMA15-4849). In addition, treatment 
providers need to understand the culture of their 
own organization and determine how it may or may 
not be welcoming to members of other cultures. 
Black/African American Populations 
This TIP uses the term “Black/African American” 
to broadly include all people who identify as 
African American and/or Black in the United States 
(Center for Behavioral Health Statistics and Quality 
[CBHSQ], 2020a). 
The 2019 National Survey on Drug Use and 
Health (NSDUH) found that, among Blacks/African 
Americans age 12 and older, an estimated 1.6 
percent (about 521,000) used cocaine and 0.2 
percent (about 81,000) used methamphetamine 
(MA; CBHSQ, 2020a). Compared with people from 
other racial/ethnic groups, Black/African American 
populations have had a disproportionately higher 
risk of cocaine use, cocaine use disorder, frequent 
cocaine use, and medical and social problems 
stemming from cocaine use (Palamar et al., 2015; 
Zapolski et al., 2016). However, rates of cocaine 
use among Black/African American adults age 
18 and older have been consistently declining in 
recent years (SAMHSA, 2020b). 
MA use has decreased signifcantly since 2017 
among Blacks/African Americans ages 18 to 25, 
but among those age 26 and older, it leveled 
off from 2016 to 2018 and then increased by 
about 24,000 in 2019 (SAMHSA, 2020b). About 
2.4 percent of Blacks/African Americans ages 18 
through 25 (about 111,000) reported past-year 
prescription stimulant misuse in 2019, compared 
with 0.5 percent (about 118,000) of Blacks/African 
Americans age 26 and older (CBHSQ, 2020a). 
The Black/African American community has a 
history of being arrested, prosecuted, convicted, 
and imprisoned for offenses involving cocaine (and 
crack specifcally) at higher rates than other racial/ 
ethnic groups and the general population. This 
is due in part to the 1980s’ and 1990s’ “war on 
drugs” approach to prohibiting illicit substances in 
the United States, which increased the percentage 
of Blacks/African Americans in state and federal 
prisons (Dumont et al., 2013). 
The strict sentencing laws passed during these 
decades largely targeted cocaine—and crack 
cocaine especially. Because crack was more 
accessible in urban areas than in suburban and 
rural communities, these stiff sentences resulted in 
more Blacks/African Americans being incarcerated 
for cocaine offenses compared with other racial/ 
ethnic groups (Murch, 2015). In fact, crack cocaine 
carried a federal mandatory minimum sentencing 
penalty that outweighed powder cocaine—more 
often used by White Americans—10 to 1 (Murch, 
2015). By 2015, the sentencing disparity between 
crack and powder cocaine was 18 to 1 (Palamar et 
al., 2015). 
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STRUCTURAL RACISM AND STIMULANT USE DISORDERS 
Beyond developing cultural responsiveness, clinicians also need to be aware of how structural racism, also 
called systemic racism (that is, racism embedded in social structures and institutions), may be affecting 
their racial/ethnic minority patients with stimulant use disorders. 
Aspects of structural racism and discrimination—like stigma, socioeconomic marginalization, and political 
bias—have been shown to affect the way healthcare and behavioral health service clinicians diagnose, treat, 
and interact with people of color (Bailey et al., 2017; Metzl & Roberts, 2014). For instance, the historically 
disproportionate rates of schizophrenia diagnosed in Black/African American men appear to refect 
discriminatory beliefs among clinicians who automatically labeled people with psychosis as aggressive, 
violent, combative, hostile, and emotionally unstable and who also tended to characterize Black/African 
American men this way (Metzl & Roberts, 2014). Further, unequal distribution of healthcare resources (e.g., 
clinics, providers) means people in low-income neighborhoods more often experience a lack of access to 
high-quality care—or a lack of access to any care—compared with people in higher income areas (Bailey et 
al., 2017). 
One of the most notable historical examples of structural racism affecting people with SUDs can be seen 
in the response to the crack cocaine epidemic of the 1980s. In the 1980s’ “war on drugs,” implementation 
of aggressive policing and harsh sentencing laws for the possession and distribution of crack cocaine 
differentially affected communities of color and intensifed existing social, legal, and healthcare inequalities 
between Whites and communities of color—notably Black/African American and Hispanic/Latino 
communities (Rosino & Hughey, 2018). This is in part because crack cocaine possession and distribution 
were more prevalent in urban neighborhoods—ones less likely to be populated by Whites. Notably, 
however, lengthier prison sentences are not associated with reduced self-reported drug use, drug overdose 
deaths, and drug arrests across states (Pew Charitable Trusts, 2018), suggesting that the harsh crack 
cocaine-related sentencing in the “war on drugs” was not an effective deterrent. 
Structural racism persists today within the SUD treatment system (Knight, 2020; Kunins, 2020; Metzl & 
Roberts, 2014; Rosino & Hughey, 2018). SUD treatment providers and SUD program staff need training not 
just in cultural responsiveness but in understanding structural racism and unconscious bias so they can 
better recognize and respond to the barriers facing patients of color (SAMHSA, 2014). Individually, clinicians 
must be willing to engage in open, nonjudgmental discussions with patients about their racial identities. 
Such discussions can help clinicians better understand whether and how bias and discrimination are 
affecting their patients’ SUDs and recovery. 
Clinicians need to remain present and undistracted during these conversations and be prepared to devote 
the necessary time and number of sessions to fully exploring issues of racism with their patients. Critical 
self-analysis is vital to helping clinicians become more aware of their own beliefs and attitudes toward race 
and the ways they can address structural racism in their own institutions and practices (SAMHSA, 2020i). 
On a macro level, clinicians can help transform systemic inequities in the healthcare and behavioral health 
service systems by (Evans et al., 2020): 
• Addressing workforce barriers (e.g., lack of people of color on staff). 
• Promoting research, grant-funding, and organizational efforts (e.g., making more of an effort to interview 
and hire people of color as faculty) for trainees/providers of color. 
• Openly recognizing the presence of structural racism and the inequities it has caused and continues to 
cause. 
Behavioral health service clinicians can learn more about structural racism and mental health services 
by visiting the website of the American Psychiatric Association’s (APA) Presidential Task Force to Address 
Structural Racism Throughout Psychiatry (https://www.psychiatry.org/psychiatrists/structural-racism-task-
force), which includes continuing medical education programs (for psychiatrists), recommended reading, 
and video recordings of town halls that address structural racism. 






















Clinicians working with Black/African American 
patients should be aware of and sensitive to 
this diffcult history. The “war on drugs” has 
contributed to the Black/African American 
experiences of historical trauma, racial bias, and 
discrimination (Conner, 2020). Black/African 
American patients may have unresolved grief, 
deep emotional pain, and strong mistrust related 
to these experiences, which can create hesitancy 
to engage with SUD treatment and speak openly 
about their current or past substance use. Black/ 
African American patients may express hesitancy to 
initiate treatment for SUDs because of fears about 
criminal prosecution. 
Certain protective factors may help reduce 
substance use among Blacks/African Americans 
(Sanders, 2015). Strategies that clinicians can use, 
as appropriate, to leverage these protective factors 
include: 
• Involving extended family members and 
nonrelatives with kinship-like ties to the patient 
in the patient’s recovery when needed and 
appropriate. 
• Incorporating spirituality and spiritual beliefs 
into treatment, such as using spiritually based 
coping skills or providing access to SUD 
treatment in spiritual settings (Jordan et al., 
2021). 
• Using humor when appropriate. 
A sense of belonging to a larger community and 
a concern for its well-being can also contribute 
to resilience in Black/African American patients 
(Sanders, 2015). Clinicians can help build rapport 
with Black/African American patients and improve 
their treatment engagement by: 
• Acknowledging and empathizing with the 
historical trauma of racism and discrimination 
experienced by Black/African American patients 
(Komaromy et al., 2021; Sanders, 2015). 
• Using trauma-informed techniques to manage 
distress associated with racial trauma that 
may be perpetuating substance use and 
impeding recovery, and connecting patients 
to treatment settings that have a lower risk of 
retraumatization (Komaromy et al., 2021). 
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• Being willing to talk about race and racism in 
sessions (Sanders, 2015). 
• Helping patients focus on their strengths 
and resilience (e.g., talents, support systems, 
instances from their life where they experienced 
success) in a system with signifcant structural 
racism (Sanders, 2015). 
• Giving patients choices and opportunities to 
make decisions, rather than dictating to them 
how treatment will go and what will happen 
(Sanders, 2015). 
• Remembering that there are many pathways 
to recovery, and the one that works best for a 
particular patient might be different than what 
works best for other patients (Sanders, 2015). 
To learn more about how to work effectively with 
Black/African American patients who have SUDs 
(including stimulant use disorders), see SAMHSA’s 
TIP 59, Improving Cultural Competence (https:// 
store.samhsa.gov/product/TIP-59-Improving-
Cultural-Competence/SMA15-4849), and 
NAADAC’s free webinar (https://www.naadac.org/ 
counseling-african-americans-with-substance-use-
disorders) on this topic. 
Hispanic/Latino Populations 
According to the 2019 NSDUH, 2 percent of
Hispanics/Latinos age 12 and older (about 970,000)
used cocaine in the past year, and 0.6 percent (about
288,000) used MA (CBHSQ, 2020a). Past-month
cocaine use was steady from 2016 to 2019 among
Hispanics/Latinos age 26 and older but increased
from 1.3 percent in 2018 to 1.6 percent in 2019
among those ages 18 to 25 (SAMHSA, 2020e). 
MA use in Hispanics/Latinos ages 18 to 25 declined
from 2017 (1.1%) to 2018 (0.7%) and remained
relatively unchanged in 2019. However, in Hispanics/ 
Latinos age 26 and older, MA use increased from
2017 (0.6%) to 2018 (0.8%) and then decreased
slightly in 2019 (0.7% [SAMHSA, 2020e]). 
Prescription stimulant misuse has been steadily 
decreasing since 2016 (from 5.2% to 3.4% in 2019) 
among Hispanics/Latinos ages 18 to 25 and has 
been relatively unchanged (around 0.7%) among 
those age 26 and older (SAMHSA, 2020e). 
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The treatment rate for Hispanic/Latino populations 
in need of SUD care is extremely low, with almost 
92 percent of the 3.2 million Hispanic/Latino 
people age 12 and older with an SUD in 2019 
receiving no treatment (CBHSQ, 2020a). There 
may be several reasons for this gap. Clinicians 
may not recognize that subgroups of Hispanic/ 
Latino populations—such as Mexicans, Puerto 
Ricans, Cubans, Central or South Americans, 
and Spanish individuals—are highly diverse and 
often differ in their substance use attitudes, 
behaviors, and ability to access treatment in the 
traditional medical setting. This heterogeneity 
is due in part to differences in these subgroups’ 
degree of acculturation, immigration patterns, 
and geographic location (Chartier et al., 2015; 
SAMHSA, 2014). These groups may also differ in 
their race, language, and indigenous ties. All of 
these subgroup differences might have an effect on 
treatment engagement, retention, and completion 
(Chartier et al., 2015). 
Language is another barrier for Hispanic/Latino 
engagement and retention in treatment for 
SUDs (SAMHSA, 2014). Where possible, SUD 
care should incorporate multilingual staff and 
offer culturally appropriate services (SAMHSA, 
2014). For example, bicultural care providers have 
demonstrated improved SUD treatment outcomes 
for Hispanic/Latino populations (SAMHSA, 2014). 
In a small qualitative study of treatment seeking 
among Hispanic/Latino individuals with SUDs, 
common reasons people gave for not seeking SUD 
care were (Pinedo et al., 2018): 
• Experiencing cultural barriers, such as feeling 
as though clinicians did not understand Latino 
culture or that seeking treatment itself was not 
acceptable in Latino culture. 
• Believing that treatment would not be effective 
or that clinicians did not have a lived experience 
with substance use problems and thus could not 
effectively help the patient. 
• Not wanting to pursue abstinence, but rather, 
harm reduction (e.g., limiting intake). 
• Feeling as though treatment was unnecessary 
because functioning did not seem impaired 
(e.g., no substance-related work absences, no 
signifcant family problems related to substance 
use). 
• Fearing stigma (e.g., being seen as “weak” by 
others for seeking treatment). 
• Lacking family support for treatment. 
• Experiencing logistical diffculties (e.g., no 
health insurance; long waits to be seen by a 
clinician). 
Clinicians can overcome some of these barriers and 
help improve treatment outcomes for Hispanic/ 
Latino patients by (Pinedo et al., 2018; SAMHSA, 
2014): 
• Learning about Hispanic/Latino culture and 
subcultures and understanding how substance 
use and accessing treatment are viewed within 
each. 
• Incorporating Hispanic/Latino cultural values 
and concepts into sessions, such as famialismo 
(valuing the family and its needs over that of any 
one individual) and respeto (showing respect to 
a person based on their age and gender). 
• Emphasizing the scope (and also limitations) 
of confdentiality. This might be especially 
important for a patient who is undocumented 
and who may worry that being open and honest 
about substance use could lead to deportation. 
• Being creative in service delivery to help the 
patient avoid stigma and to protect the patient’s 
privacy and anonymity. For instance, clinicians 
might want to offer web-based treatment 
when possible and appropriate, or consider 
integrating services within a primary care 
setting. 
• Including the patient’s family in sessions—with 
patient permission—when needed and 
appropriate. 
• Offering harm reduction and recovery-oriented 
services beyond those focused only on 
abstinence. 
Asian and Native Hawaiian and Other 
Pacifc Islander Populations 
In 2019, an estimated 1.1 percent (about 174,000) 
of U.S. Asians and 2.8 percent (about 31,000) 
of Native Hawaiians and Other Pacifc Islanders 
(NHOPI) age 12 and older engaged in past-year 
cocaine use; far fewer—0.1 percent of Asians 
(about 19,000) and 1.5 percent of NHOPI (about 
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16,000)—reported past-year MA use (CBHSQ, 
2020a). An estimated 1.0 percent (about 159,000) 
of Asians and 0.8 percent (about 9,000) of NHOPI 
age 12 and older engaged in past-year prescription 
stimulant misuse (CBHSQ, 2020a). 
Past-month use of cocaine in Asians and NHOPI 
ages 18 to 25 fell markedly from 2016 (about 
33,000) to 2017 (about 1,000) and then rebounded 
in 2018 and 2019 (to about 25,000 and 21,000, 
respectively). In Asians and NHOPI age 26 and 
older, past-month cocaine use decreased between 
2017 and 2019, down to about 52,000 in 2019 
(SAMHSA, 2020d). 
Regarding past-year MA use, a signifcant drop 
occurred from 2016 to 2017 (about 9,000 to less 
than 500) in the 18-to-25 age group, with rates 
stabilizing in 2018 and 2019 to around 9,000 and 
8,000, respectively (SAMHSA, 2020d). Asians and 
NHOPI age 26 and older reported less past-year 
MA use in 2019 (about 26,000) than in 2018 (about 
35,000 [SAMHSA, 2020d]). 
Past-year prescription stimulant misuse by Asians 
and NHOPI ages 18 to 25 increased from about 
81,000 in 2017 to 137,000 in 2018 and then 
dropped back down to 87,000 in 2019 (SAMHSA, 
2020d). For individuals age 26 and older, rates 
have been fairly consistent, staying somewhere 
between 60,000 and 101,000 from 2016 to 2019 
(SAMHSA, 2020d). 
Although the prevalence of substance use 
in general is low among Asians and NHOPI 
collectively, the annual SUD treatment admission 
rate of this group grew more than those of 
non-Asian and non-NHOPI populations from 2000 
to 2012 (Sahker et al., 2017). But for MA use 
specifcally, treatment admissions in this population 
increased by only 12 percent during this time, and 
rates for cocaine use treatment actually decreased 
by almost 51 percent (Sahker et al., 2017). 
Additionally, in 2019, only 7 percent of Asians/ 
NHOPI age 12 and older with any past-year SUD 
received treatment (CBHSQ, 2020a). Notably, a 
study found that Asians and NHOPI who use MA 
were less likely to complete treatment compared 
with Whites who use MA (Godinet et al., 2020). 
Collectively, these data suggest that greater efforts 
are needed to address SUD treatment access, 
engagement, retention, and completion in Asian 
and NHOPI populations—especially among those 
with MA or cocaine use disorders. 
ASIAN AND NHOPI POPULATIONS
AND STIMULANT USE DISORDER
STATISTICS 
It is important to recognize the diversity of Asian 
and NHOPI populations when considering the 
prevalence of stimulant use disorders. This is in 
part because the percentage of people in the 
United States who identify as Asian American 
(5.7%) is much larger than the percentage who 
identify as NHOPI (0.2%; U.S. Census Bureau, 
n.d.). Grouping Asian and NHOPI populations 
together can lead to interpretations of data that 
obscure the needs of NHOPI and underrepresent 
the impact of stimulant use and prescription 
stimulant misuse on NHOPI individuals. 
Asians are sometimes considered “model 
minorities,” referring to the false belief that a 
minority group largely possesses only positive 
qualities. This stereotype contributes to a 
misperception that Asians do not engage in 
substance use (Kim, 2021; Sahker et al., 2017). 
Consequently, individuals who are aware of this 
misperception—and feel pressure not to defy 
it—may hesitate to seek SUD treatment when 
needed. Also, clinicians may be less likely to look 
for substance problems in this population (Sahker 
et al., 2017). 
Other possible treatment barriers include (Masson 
et al., 2013): 
• Worry that SUD care will not be culturally 
tailored or linguistically appropriate. 
• Fear of stigma and losing face (in Asian 
and NHOPI cultures, one’s social standing, 
reputation, dignity, and honor) if people— 
especially family members—fnd out help was 
sought from “outside” rather than from within 
the family. 
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• A lack of support (emotional, fnancial, or 
tangible) from family members who may not 
believe that treatment is necessary and may 
even be using substances themselves. 
Additionally, Asians and NHOPI comprise 
numerous subgroups (e.g., Chinese, Japanese, 
Indian, Vietnamese, Hmong, Samoan) that 
have different attitudes toward and beliefs 
about substance use and treatment seeking 
(SAMHSA, 2014). Further, across these subgroups, 
individuals differ on level of acculturation and 
immigration status—two factors that have been 
linked to the presence of SUDs and their type. 
For example, higher degrees of acculturation 
have been linked to a greater risk of drug use 
disorders than have lower degrees of acculturation 
(Salas-Wright et al., 2015). Understanding these 
differences between and within subgroups can 
help clinicians better understand individual 
patients’ feelings and beliefs about substance 
use and SUD treatment. For more information, 
see SAMHSA’s TIP 59 (https://store.samhsa.gov/ 
product/TIP-59-Improving-Cultural-Competence/ 
SMA15-4849). 
The following strategies may further help Asian 
and NHOPI patients with stimulant use disorders 
initiate, participate in, and complete treatment 
(SAMHSA, 2014): 
• Culturally adapted SUD care (e.g., clinicians 
discuss presenting issues using patients’ 
culturally based explanations of them, rather 
than imposing views that could negatively 
affect patients’ attitudes toward treatment) and, 
where available, services in patients’ preferred 
language might help patients feel more 
understood by the clinician. 
• Shame can be a treatment barrier for Asian and 
NHOPI populations, so establishing warm and 
supportive clinician–patient relationships can 
help reduce feelings of embarrassment and 
encourage acceptance of treatment. 
• During the initial session, clinicians can help 
build patient confdence in their expertise by 
using their title, displaying diplomas and training 
certifcates, and discussing their experience 
working with other patients with stimulant use 
disorders. 
Clinicians working with Asian and NHOPI women 
with MA use should be especially mindful of 
screening for and addressing co-occurring 
disorders (CODs) as well as providing services 
or referrals to help with relationship issues and 
vocational challenges. This suggestion is based on 
a comparison of Asian/Pacifc Islander men and 
women in treatment for SUDs (Han et al., 2016) in 
which MA was the primary drug for more than half 
of the women in the study. Women in the study 
were more likely than male participants to report 
signifcant family/social relationship problems, 
employment diffculties, and mental health issues. 
American Indian and Alaska Native 
Populations 
An estimated 6.9 million people identify as 
American Indian or Alaska Native (AI/AN), and 
1.6 million AI/ANs are younger than age 18 (U.S. 
Government Accountability Offce, n.d.). AI/ANs 
have the highest rates of SUDs of any U.S. racial/ 
ethnic minority population, with 10.2 percent of AI/ 
ANs age 18 and older meeting criteria for an SUD 
(CBHSQ, 2020a). 
Recent NSDUH data show a decline in cocaine and 
MA use among AI/AN adults and a slight increase 
in prescription stimulant misuse among AI/AN 
adolescents and young adults (CBHSQ, 2020a). The 
rate of past-year MA and cocaine use in people 
age 12 and older (1.9% and 1.4%, respectively) 
remains high compared with other racial and ethnic 
groups (Baldwin et al., 2020; CBHSQ, 2020a; 
SAMHSA, 2018a). MA is the most prevalent drug 
seized from AI/AN communities, primarily owing 
to easy access and low prices associated with 
abundant distribution from large, well-organized 
drug traffcking organizations located in nearby 
border towns (To Protect and Serve, 2019). In a 
study examining prescription stimulant misuse in 
adolescent American Indians, nearly 7 percent of 
the sample had been prescribed stimulants and 
nearly 6 percent of the sample reported misusing 
stimulants to get high (Spillane et al., 2017). 












Awareness of the following considerations can 
assist clinicians in providing culturally responsive 
care for AI/ANs with stimulant use disorders: 
• Most AI/ANs believe that historical trauma,
including the loss of culture, lies at the heart of
SUDs within their communities (SAMHSA, 2018a). 
• Because of the diversity among AI/AN cultures, 
clinicians with AI/AN patients should consult 
with professionals who are experienced in 
working with members of the specifc tribes to 
which patients belong (SAMHSA, 2014). 
• Use of substances often begins at a younger age 
than it does in other major racial/ethnic groups 
(R. A. Brown et al., 2016; SAMHSA, 2018a). 
• Two-spirit individuals reported higher rates of 
illicit drug use, alcohol use, and mental health 
service use than their cisgender counterparts 
(“cisgender” refers to people who identify with 
the gender that matches their birth sex) in a 
small study conducted among urban AI/ANs 
(Balsam et al., 2004). “Two-spirit” is a pan-Indian 
term referring to AI/AN people combining 
activities of both men and women with traits 
unique to their status as two-spirit people, and 
who, in most tribes, were traditionally regarded 
as an alternative gender (Indian Health Service, 
n.d.). Among AI/AN people, the term can also 
be used to describe sexual orientation. 
• Increased rates of suicidal ideation and 
suicide attempts have also been reported in 
a study evaluating the impact of boarding 
school attendance on mental health issues 
and substance use among urban two-spirit 
individuals (Evans-Campbell et al., 2012). 
• There are multiple barriers to accessing SUD 
care in the AI/AN community, some of which 
include physical distance from service providers, 
concerns about maintaining anonymity, 
shame and prejudice, lack of childcare and 
transportation, a limited number of culturally 
competent AI/AN providers, and mistrust of 
government-funded social services (SAMHSA, 
2018a). A full list is available in SAMHSA’s TIP 
61, Behavioral Health Services for American 
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• AI/AN communities experience higher rates 
of trauma compared with other racial groups, 
especially among AI/AN women. Trauma 
exposure (including violent crime, intimate 
partner violence, child abuse, violence against 
two-spirit individuals, and injuries) increases 
the risk for substance use (Baldwin et al., 2020; 
Ehlers et al., 2013; SAMHSA, 2018a). 
• Resiliency factors in AI/AN communities are 
rooted in cultural traditions, family support, and 
cultural pride (LaFromboise et al., 2006). 
• Practice-based approaches (knowing what works 
through experience, clinical judgment, cultural 
knowledge, and patient feedback) are much 
better accepted in AI/AN communities than 
evidence-based practices are (SAMHSA, 2018a). 
Clinicians should also be mindful of patterns of 
urbanization among some AI/AN populations— 
especially patterns of forced migration into urban 
areas due to factors like land dispossession and 
natural disasters—and how this relocation might 
affect their patients. Some AI/AN populations 
living in urban areas—especially youth—may 
experience a weaker cultural identity, less cultural 
involvement, and more acculturative stress than AI/ 
AN populations living on reservations or in rural 
AI/AN communities. These experiences could 
negatively affect their mental health and substance 
use behaviors (R. A. Brown et al., 2016). Some 
AI/AN patients living in urban areas face unique 
challenges related to SUD care, such as limited 
access to Indian Health Service care and culturally 
appropriate SUD treatments (Tonigan et al., 2020; 
Whitesell et al., 2012). 
A national survey of urban and rural SUD 
treatment programs that provide services to AI/ 
AN populations (Rieckmann et al., 2016) found 
that rural programs had a higher mean number 
of years of staff experience, were more likely to 
offer open mutual-help recovery groups (e.g., 
Alcoholics Anonymous), and were less likely to 
have traditional healers and ceremonial providers 
among their staff, but were more likely to have 
elders working in their program. 
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Although clinicians should strive for cultural 
understanding, nontribal clinicians should not 
practice traditional healing when treating AI/AN 
patients of a given tribe. Rather, clinicians “should 
rely on the community and native tribal council 
(governance) to guide the selection of traditional 
practitioners and the integration of traditional 
healing practices across the continuum of care” 
(SAMHSA, 2018a, p. 8). Clinicians should frst ask 
AI/AN patients about their desire to incorporate 
cultural beliefs and practices into their treatment, 
as some may not have an interest in doing this 
(SAMHSA, 2014, 2018a). 
Examples of cultural responsiveness in practice 
include: 
• Addressing barriers to SUD care. Clinicians 
conduct needs assessments to identify and 
tailor services based on community strengths 
and resources, provide one-stop services, 
offer “warm-handoffs” to bridge referral gaps, 
develop outreach and community events 
that incorporate education and promote 
engagement, utilize telehealth services, and 
form partnerships between states and tribes 
(Baldwin et al., 2020; SAMHSA, 2018a). 
• Recognizing AI/AN communication styles, 
such as the use of (1) nonverbal messages to 
convey respect or displeasure, (2) humor to 
ease psychological pain or discomfort with 
diffcult topics, (3) indirect communication to 
avoid criticism of others and the appearance 
of being disloyal or disrespectful, and (4) 
stories to deliver personal messages (SAMHSA, 
2009). Clinicians can enhance communication 
by listening and respecting silence, adjusting 
eye contact, asking questions about nonverbal 
cues, anticipating laughter, determining and 
valuing linguistic preferences and abilities, and 
using hopeful language and avoiding labeling 
(SAMHSA, 2018a). 
• Addressing harmful narratives that result from 
historical trauma by offering AI/ANs the chance 
to explore the role of culture, history (including 
historical trauma), acculturation, discrimination, 
and bias in their stimulant use (SAMHSA, 
2018a). 
• Integrating holistic approaches that focus on 
mind, body, spirit, and context, particularly 
during the transition from adolescence to 
adulthood (Friesen et al., 2015). 
• Including AI/AN communities in research and 
program design, development, implementation, 
and dissemination to ensure that AI/AN-specifc 
issues are adequately represented in culturally 
sensitive interventions and prevention programs 
(Baldwin et al., 2009). 
Clinicians may fnd using a traditional, Western 
approach to SUD treatment is too individualistic 
and lacks a focus on concepts like belongingness 
and a sense of community identity, which tend to 
be highly valued in AI/AN populations (Walsh-Buhi, 
2017). Western treatment approaches may also 
fail to contextualize SUDs in this population in 
terms of their culture’s unique history, the presence 
of historical trauma, ongoing poverty and its 
effects, and the collective trauma experienced 
by this population as a whole (Walsh-Buhi, 2017). 
Neglecting these important contextual factors may 
make SUD treatment less effective for certain AI/ 
AN patients (Walsh-Buhi, 2017). 
For more information on culturally responsive 
SUD care for AI/AN patients and a list of culturally 
adapted SUD treatment approaches, see TIP 61, 
Behavioral Health Services for American Indians 
and Alaska Natives (https://store.samhsa.gov/ 
product/TIP-61-Behavioral-Health-Services-
For-American-Indians-and-Alaska-Natives/ 
SMA18-5070). See also the resources available 
through the SAMHSA-funded National American 
Indian & Alaska Native Addiction Technology 
Transfer Center (https://attcnetwork.org/centers/ 
national-american-indian-and-alaska-native-attc/ 
home). 




































Treatment for Stimulant Use Disorders 
THE IMPORTANCE OF THINKING ABOUT SOCIAL DETERMINANTS OF HEALTH 
Health is much more than just one’s physical condition. To truly understand why a patient is struggling with
a physical or behavioral health problem, such as a stimulant use disorder, a clinician needs to consider the full
picture of social and environmental factors that contribute to the formation and persistence of health issues. 
Social determinants of health (SDoH) have been defned as “the conditions in the environments where people
are born, live, learn, work, play, worship, and age that affect a wide range of health, functioning, and quality-
of-life outcomes and risks” (Healthy People 2030, n.d.), including risk for substance misuse and related health
consequences (Offce of the Surgeon General, 2016). 
Common examples of SDoH include (Andermann, 2016; Healthy People 2030, n.d.): 
• Poverty or income insecurity. • The air and water quality in one’s living 
• Homelessness or housing instability. environment. 
• Food insecurity. • The safety and stability of one’s neighborhood. 
• Racism and discrimination. • Access to healthcare and behavioral health 
services. • A history of childhood physical, sexual, or 
emotional abuse. • Access to education. 
• Joblessness. • Access to nutritious food. 
• Access to transportation. 
SDoH have been implicated in SUD formation and treatment access and completion (Sanner & Greene, 
2020). For instance, an analysis of data from the 2012 NSDUH found the presence of several SDoH 
signifcantly increased an adult’s odds of having lifetime MA use, including (King et al., 2019): 
• Having a family income of less than $20,000/year. 
• Not having had a job in the previous 12 months. 
• Having participated in a government assistance program in the previous 12 months. 
• Having a high school education or less. 
Clinicians need to ask patients about—and identify—possible SDoH that could be playing a role in their
substance use. Not doing so could make it diffcult—or even impossible—to get some patients to enter and
remain in recovery. And patients’ answers can reveal the need for “social prescribing” (Andermann, 2016)—that
is, linking the patient to social services or referrals for any SDoH in the patient’s life that are amenable to change
(e.g., referring the patient to vocational rehabilitation, coordinating care with a social worker who can help enroll
the patient in federal food or housing assistance programs). 
Some SDoH—like poor air and water quality, racism and discrimination, and neighborhood crime—are not
easily modifable by a clinician or any patient affected by them. But simply understanding that such factors are
present in a patient’s life can help a clinician adopt a more empathic and nonjudgmental approach to SUD care. 
Other strategies for clinicians include (Andermann, 2016): 
• Developing cultural responsiveness as a critical pathway to learning how to identify and talk with patients about
SDoH, particularly factors like racism, stigma, discrimination, immigration and acculturation, and inequities. 
• Taking a person-centered, trauma-informed approach to SUD care. This includes not just learning how to ask
patients about sensitive topics like abuse, violence, and other trauma but also about deeply personal topics
like job or housing loss, immigration concerns, or literacy diffculties. 
• Considering how to make treatment more accessible for all patients (e.g., offering evening hours, providing
bus vouchers for patients relying on public transportation). 
• Becoming advocates at the community, state, or national level to help enact social change, promote healthier
communities, and support health equity. 
For more information about SDoH and screening tools that can be used for assessment of SDoH, see the
Rural Health Information Hub’s Social Determinants of Health in Rural Communities Toolkit (https://www. 
ruralhealthinfo.org/toolkits/sdoh).
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Women (Including Those Who
Are Pregnant) 
Treating stimulant use disorders in women can 
be signifcantly more complicated than treating 
stimulant use disorders in men because of the 
complex social structures and biases that women 
experience in their daily lives. Roles associated 
with motherhood, such as childcare, pregnancy, 
breastfeeding, and care of elder family members, 
may increase the familial responsibilities of 
women with SUDs. Power structures that are 
patriarchal in nature may complicate a woman’s 
road to recovery through intimate partner violence, 
assault, and socioeconomic disenfranchisement. 
Additionally, data suggest that sexual minority 
women experience increased rates of stimulant use 
compared with their heteronormative counterparts 
(Philbin et al., 2020). 
In a study examining co-occurring SUDs and 
posttraumatic stress disorder (PTSD), women 
who used cocaine only or in combination with 
cannabis had increased rates of repeated traumatic 
exposures, including arrests, incarceration, and 
adult sexual assault compared with women 
who used cannabis only (Ruglass et al., 2017). 
Additionally, cocaine use among women is 
related to increased stress associated with family 
obligations for which they do not receive additional 
help (Preston et al., 2018). The risk for suicide 
among women veterans with cocaine use disorder 
is signifcantly higher than for men veterans, 
indicating the presence of CODs and further 
complicating treatment considerations (Bohnert et 
al., 2017). 
Although men and women use MA at similar 
rates, women often begin using MA at an earlier 
age and develop dependence more quickly than 
men (E. E. Hartwell et al., 2016). Additionally, 
women are more likely to obtain MA from a 
signifcant other and to use MA to assist with 
weight loss and enhanced energy (E. E. Hartwell 
et al., 2016). Women with MA use disorder have 
more psychiatric comorbidities (e.g., depression 
and anxiety), but tend to have longer treatment 
retention and better treatment outcomes (E. E. 
Hartwell et al., 2016). 
There are several indirect entry points into the SUD 
treatment system for women, including: 
• Pediatricians (mothers may take children to the 
doctor even when they do not go themselves). 
• Child protective services. 
• OB/GYN providers. 
• Social service agencies. 
• Primary care providers. 
• Criminal justice agencies. 
Barriers to effective evidence-based treatment 
are multifactorial for women. Access to care is 
a major barrier, particularly for women in rural 
settings. Among parenting women with SUD, 
women in rural settings had 90-percent lower 
odds of receiving treatment compared with urban 
women (Ali et al., 2020). Another study that 
considered women experiencing homelessness 
who were seeking services for their SUD found 
that a signifcant portion were highly motivated for 
treatment, but physical and transportation barriers 
remained an issue in accessing care (Upshur et 
al., 2018). Additionally, these women identifed 
feeling depressed as the primary barrier to seeking 
services. Given that women in treatment for 
stimulant use disorders have a higher risk for PTSD 
(Saunders et al., 2015), it is important to consider 
the role this comorbidity may play in decreasing 
engagement in care for women. Women who had 
been arrested in the last year were 3 times as likely 
to receive treatment for their SUD as were women 
who had not (Martin et al., 2020). 
Another barrier to effective care for women with a 
stimulant use disorder is the effect of self-stigma 
and previous traumatic medical experiences 
related to their SUD. Particularly among pregnant 
or parenting women, self-stigma related to their 
ability to parent or care for their children may 
cause them to avoid treatment situations that 
worsen feelings of shame or guilt (Cockroft et 
al., 2019; Frazer et al., 2019). SUD care should 
focus on engaging women and creating a safe 
and strengths-based treatment program to avoid 
further stigmatization of a vulnerable population. 























Treatment for Stimulant Use Disorders 
The fve core components of gender-responsive 
care are: 
1. Addressing women’s unique experiences. 
2. Using a trauma-informed approach. 
3. Using relational approaches. 
4. Addressing women’s needs in a comprehensive 
manner. 
5. Providing a healing environment. 
Treatment for women should use a holistic, gender-
responsive approach. Topics could include: 
• Relationships with family (after addressing social 
functioning, issues of homelessness/unstable 
housing, social isolation). 
• Treatment needs of children. 
• Intimate partner violence. 
• Parenting. 
• Life skills. 
• Education and vocational training. 
• Economic self-suffciency. 
• Reproductive health issues. 
• Education about long-term effects of using 
stimulants. 
• Mental health. 
• Self-esteem. 
• Independent living skills. 
• Nutrition. 
• Transportation. 
• Ethnic and cultural issues. 
• Day care and group counseling for children. 
Transactional/survival sex (sex offered in exchange 
for tangible goods or services, like money, drugs, 
food, or shelter) is not a phenomenon exclusive 
to women who use stimulants; it is a concept that 
providers need to understand and discuss with 
their patients. More than 40 percent of women 
with a cocaine use disorder who were in outpatient 
SUD treatment have engaged in transactional sex; 
more than 10 percent continue engaging in these 
behaviors even in the setting of abstinence from 
cocaine (Rash et al., 2016). 
Clinicians should address the specifc needs of 
women who engage in—or who have previously 
engaged in—transactional/survival sex using 
a trauma-informed approach to develop care 
plans. For women who continue to engage in 
transactional sex work, developing safety plans, 
avoiding cues and triggers related to substance 
use, and promoting health and reproductive 
autonomy may increase engagement and improve 
outcomes (Ditmore, 2013). 
Pregnant Women and Their Children 
National estimates of stimulant use among women 
of reproductive age show high rates of prescription 
stimulant misuse (617,000), followed by cocaine 
(540,000) and MA (317,000; CBHSQ, 2020a). The 
rate of stimulant use in the general population 
continues to rise and is mirrored in the rate of use 
among pregnant women (Smid et al., 2019). 
The prevalence of cocaine use during pregnancy 
has been diffcult to quantify but is estimated at 1.1 
percent at any point in pregnancy (Bhuvaneswar 
et al., 2008; Forray & Foster, 2015), with up to 
750,000 exposed pregnancies and births each 
year (Cain et al., 2013). Results from the 2019 
NSDUH showed that 0.2 percent of pregnant 
women reported past-month cocaine use (CBHSQ, 
2020a). Cocaine use is a major cause of antepartum 
hospitalizations related to substance use among 
pregnant women (Smid et al., 2019). 
Data on the prevalence of MA use in pregnancy 
also are limited, although national estimates range 
from 0.7 to 5.2 percent (Forray & Foster, 2015), and 
rates continue to rise, primarily in rural areas of the 
South, Midwest, and West. In a national sample 
of hospital deliveries occurring between 2004 
and 2015, approximately 82,000 deliveries were 
affected by maternal amphetamine use, reaching 
a peak of 2.4 per 1,000 amphetamine-related 
hospital deliveries between 2014 and 2015 (Admon 
et al., 2019). Stimulant use during pregnancy is 
underreported and selective screening based on 
race or socioeconomic status may miss patients 
and children that could beneft from more tailored 
interventions (Martin et al., 2020; Smid et al., 
2019). The prevalence of prescription stimulant 
misuse during pregnancy is not fully known. In 
2019, NSDUH data showed that between 1 and 
5.2 percent of reproductive-age women reported 
misuse of prescription stimulants (1.4% of women 
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ages 12 to 17, 5.2% of women ages 18 to 25, and 
1 percent of women age 26 and older; CBHSQ, 
2020a). 
Efects on Pregnant Women 
Stimulant use during pregnancy is associated with 
numerous harmful physical and psychological 
outcomes. Cocaine is toxic to multiple organ 
systems and can cause high blood pressure, 
heart attack, kidney failure, rupture of the liver, 
reduced blood fow to the heart and brain, strokes, 
seizures, and death (National Institute on Drug 
Abuse [NIDA], 2016b; Smid et al., 2019). As a 
result, cocaine toxicity can mimic preeclampsia 
(Cain et al., 2013). Cocaine use during pregnancy 
has a well-documented association with placental 
abruption (premature detachment of the placenta 
from the uterus) and preterm birth (Elkafrawi et 
al., 2020). Further, cocaine interacts with hormonal 
changes (e.g., increased progesterone) during 
pregnancy, which can worsen cardiovascular 
toxicity (Smid et al., 2019). Infection transmission is 
another risk of prenatal cocaine use, as women can 
transmit HIV, hepatitis, and syphilis to their fetuses. 
Women who misuse prescription stimulants during 
pregnancy can experience similar detrimental 
health effects, including high blood pressure, 
placental abruption, premature delivery, and 
postpartum hemorrhage (Worley, 2014). 
MA has similar physiologic effects on pregnant 
women and is strongly associated with poor 
oral health and increased risk for infectious 
diseases, such as hepatitis and HIV (Smid et 
al., 2019). Studies have shown increased risk 
for miscarriage, stillbirth, placental abruption, 
and uterine rupture due to MA use. Stimulant 
use during pregnancy also has psychological 
consequences. A longitudinal study examining 
physical and psychological outcomes of prenatal 
cocaine use found poorer perceptions of mental 
health, higher rates of PTSD, and higher rates 
of other substance use among pregnant women 
with cocaine use compared with pregnant women 
without such use (Minnes et al., 2012). The study 
also demonstrated that prenatal cocaine use 
strongly predicts perceived psychological distress 
up to 10 years postpartum (Minnes et al., 2012). 
Similarly, pregnant women who misuse prescription 
drugs including stimulants have an increased risk 
for psychosocial consequences, including poor 
judgment, impaired decision making, violence 
victimization, inadequate housing, involvement 
with the legal system, poor engagement in 
prenatal care, and co-occurring mental disorders 
(Worley, 2014). 
Perinatal, Neonatal, and Developmental 
Efects 
Cocaine can cross the blood–brain barrier and the 
placenta. Prenatal cocaine use increases the risk for 
(Dos Santos et al., 2018; Gouin et al., 2011; Smid 
et al., 2019): 
• Placental abruption. 
• Premature delivery. 
• Low birth weight. 
• Small-for-gestational-age infants. 
• Earlier gestational age at delivery. 
• Fetal growth restriction. 
Although studies documenting long-term 
outcomes of fetal cocaine exposure are limited, 
there is evidence showing effects on children that 
include problems with behavior (e.g., diffculties 
with self-regulation), growth, inhibitory control, 
attention, and information processing (NIDA, 
2016b; Smid et al., 2019). Cocaine can be passed 
to an infant through breastmilk; thus, breastfeeding 
is another source of exposure. 
MA use during pregnancy also has detrimental 
effects on fetuses, such as earlier gestational 
age at delivery, lower birth weight, and smaller 
head circumference (Smid et al., 2019). After 
birth, infants who were exposed to MA in utero 
can experience withdrawal symptoms, such as 
jitteriness, drowsiness, and respiratory distress 
(Smid et al., 2019). Neurotoxicity is much higher 
with prenatal MA use than prenatal cocaine 
use (Dinger et al., 2017), leading to a range of 
long-term neurodevelopmental problems in 
childhood. Prenatal exposure to MA is associated 




• Poorer motor performance. 

















• Lower IQ scores. 
• Increased likelihood of cognitive problems 
affecting academic achievement. 
• More problems with peers. 
Less is known about misuse of prescription stimulants
among pregnant women. However, studies of
pregnant women taking prescription stimulant
medications for attention defcit hyperactivity
disorder (ADHD) have shown small increased risks
for preeclampsia, premature delivery, and placental
abruption (Smid et al., 2019). 
Pregnant women should be screened for substance 
use, including stimulant use. Screening approaches 
can include brief self-report tools, brief intervention 
and referral to treatment screening methods, 
and urinalysis, following consent and appropriate 
counseling (American College of Obstetricians and 
Gynecologists [ACOG] Committee on Health Care 
for Underserved Women, 2011). Clinicians should 
be aware that many pregnant women are reluctant 
to admit or disclose stimulant use out of fear of 
losing custody of their children (A. O’Connor et al., 
2021), highlighting the need for showing empathy 
and building rapport. Additionally, clinicians should 
expect to encounter women with diagnosed ADHD 
that may or may not be treated and women with 
undiagnosed ADHD (Marraccini et al., 2017). 
Pregnant women who use stimulants require 
comprehensive prenatal care that is gender 
responsive and tailored to their needs (Chin & 
Bartholomew, 2020). This care should include 
nutritional assessment, testing for sexually 
transmitted infections and HIV, and access to 
social support services (ACOG, 2011). Given that 
stimulant use during pregnancy can impair fetal 
growth and increase the risk for pregnancy loss, 
pregnant women who use stimulants should have 
frequent ultrasounds and monitoring of fetal 
health throughout pregnancy, as clinically indicated 
(ACOG, 2011). Clinicians should ensure that these 
patients have established care with an OB/GYN 
and are connected to the appropriate ancillary 
services. 
Patients taking prescription stimulants for ADHD 
should discuss with their healthcare providers the 
risks and benefts of using these medications while 
pregnant. Continued use of prescription stimulants 
Treatment for Stimulant Use Disorders 
may be warranted in patients with severe ADHD 
symptoms that interfere with daily functioning 
(Marraccini et al., 2017). However, patients with 
milder forms of ADHD that do not signifcantly 
affect daily functioning may wish to discontinue 
their prescription stimulants while pregnant 
and engage in psychosocial treatments, such as 
cognitive–behavioral therapy (CBT). 
ACOG (2011) recommends that pregnant women 
who are unable to stop using MA or other 
stimulants seek SUD care. Given the importance 
of SUD treatment in the context of pregnancy, 
pregnant women should voluntarily seek care at 
a residential treatment center whenever possible. 
If residential treatment is not possible, outpatient 
therapy sessions should be frequent for at least 
90 days after treatment initiation. Treatment 
interventions should include: 
• Patient and family education about the dangers 
of stimulant use to both mother and fetus. 
• Motivational interviewing to assess readiness for 
change. 
• Contingency management (CM) with tangible 
incentives to encourage treatment initiation and 
retention and reduced stimulant use. 
• CBT, used in the Matrix model and trauma-
focused therapy. 
• Mutual-help support. 
• Drug testing to monitor drug use and treatment 
progress. 
Stressors and psychological distress during the 
postpartum period may increase the risk for 
relapse, necessitating close follow-up and support 
after delivery (ACOG, 2011; Smid et al., 2019). 
Clinicians should also help connect pregnant 
women with stimulant use disorders to peer 
recovery support specialists, where available. Peer 
recovery support specialists are individuals with a 
lived experience of SUD recovery who are specially 
trained, supervised, and often certifed to provide 
nonprofessional, nonclinical supportive services 
for other people with SUDs. The lived experience 
aspect is a critical piece of what helps make peer 
recovery support specialists effective in their work, 
as this experience conveys to patients a deep 
sense of understanding and empathy. Use of peer 
recovery support specialists has been linked to 
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many positive outcomes in SUD recovery, including 
increased abstinence, reduced substance use, 
better SUD treatment adherence and completion, 
and improved engagement in long-term recovery 
support, like mutual-help services and continuing 
care participation (Fallin-Bennett et al., 2020). 
Little research to date has focused on the use of 
peer services for pregnant women in recovery 
from SUDs. However, existing evidence suggests 
peer recovery support specialists likely can offer 
pregnant women with SUDs a sense of trust, 
support, understanding, and connectedness (Fallin-
Bennett et al., 2020; Paterno et al., 2018) that 
might help them later access and stay in recovery. 
For additional information on substance use issues 
in women’s health and pregnancy, see these 
SAMHSA publications: TIP 51, Substance Abuse 




Document for Supporting Women in Co-ed 
Settings (https://www.samhsa.gov/resource/ebp/ 
guidance-document-supporting-women-co-ed-
settings); Clinical Guidance for Treating Pregnant 
and Parenting Women With Opioid Use Disorder 
and Their Infants (https://store.samhsa.gov/ 
product/Clinical-Guidance-for-Treating-Pregnant-
and-Parenting-Women-With-Opioid-Use-Disorder-
and-Their-Infants/SMA18-5054); and Preventing 
the Use of Marijuana: Focus on Women and 
Pregnancy (https://www.samhsa.gov/resource/ebp/ 
preventing-use-marijuana-focus-women-pregnancy). 
Men Who Have Sex With Men 
Nationally representative data on MSM and their 
substance use patterns are not currently available. 
But based on individual studies, MSM may have 
a high rate of stimulant use. For instance, among 
MSM ages 16 to 20 surveyed from 2009 to 2013, 
6.2 percent reported lifetime use of cocaine 
and 3.3 percent reported recent cocaine use, 
whereas 1.1 percent reported lifetime MA use 
and 0.7 reported recent MA use (Newcomb et al., 
2014). Other researchers have estimated higher 
rates, particularly for MA use, which has ranged 
from about 21 to 27 percent in other studies of 
MSM (Anderson-Carpenter et al., 2019). Among 
a sample of 286 MSM who use MA, 31 percent 
reported a co-occurring cocaine use disorder 
(Fletcher et al., 2018). Using NSDUH data, a 2021 
study evaluating prescription drug misuse by sexual 
identity found that men who identifed as gay or 
bisexual had higher rates of past-year prescription 
stimulant misuse (5.1% and 6.4%, respectively) 
compared with men who identifed as heterosexual 
(2.3%; M. Diaz et al., 2021). 
MSM with HIV may be especially at risk for stimulant
use. In a study of 766 MSM with HIV, more than
one-third (35%) reported having used cocaine, crack,
crystal MA, amphetamine, and/or ecstasy in the
previous 3 months, and of these, 40 percent reported
using injection drugs (Teran et al., 2020). 
MSM may be at an increased risk for intimate 
partner violence, self-stigma/internalized 
homophobia, and trauma—all of which may be 
associated with negative health consequences, like 
depression, and could increase their likelihood of 
using substances (Batchelder et al., 2017; Duncan 
et al., 2018; Lopez-Patton et al., 2016; Moody et 
al., 2018). Some MSM—such as those experiencing 
homelessness or unstable housing—may engage 
in transactional sex, which has been linked to an 
increased risk of substance use and HIV infection 
and transmission (especially with casual as opposed 
to regular partners [Bauermeister et al., 2017]). 
In a study of MSM with and without HIV, among 
those who reported transactional sex, 60 percent 
reported using MA and 13 percent cocaine 
(Javanbakht et al., 2019). 
MSM are at an increased risk of HIV acquisition 
compared with the general population. In 2019, 
MSM made up 69 percent of new cases of HIV 
diagnosed in the United States (Department of 
Health and Human Services, 2021). Among the 
population of MSM, two factors affecting the risk 
of acquiring HIV are race and age. For example, 
from 2015 to 2019, MSM ages 25 to 34 accounted 
for the largest number of HIV diagnoses attributed 
to male-to-male sexual contact (Centers for 
Disease Control and Prevention [CDC], 2021a). In 
2019, the percentage of HIV infections caused by 
male-to-male sexual contact was somewhat higher 
in Black/African American (82%) and Hispanic/ 
Latino (87%) males compared to White males 
(73%; CDC, 2021a). Research has found that MSM 
who use stimulants are more likely to engage in 










condomless sex or to engage in other behavior— 
like forceful penetration that can lead to condom 
breakage—that increases the risk of transmission or 
infection with HIV (Vu et al., 2015; Yu et al., 2015). 
Sexual risk-taking often occurs under the infuence 
of substances. Sexual risk-taking within the 
context of substance use is hypothesized to occur 
because of the disinhibitory effects of the drug, 
learned patterns (especially between stimulant 
use and certain high-risk sexual practices), low 
self-esteem, altered perception of risk, lack of 
assertiveness to negotiate safer practices, and 
perceived powerlessness (Bourne & Weatherburn, 
2017; Ritchwood et al., 2015; Semple et al., 
2011; Thompson & Auslander, 2011). Substance 
use can reinforce risky sexual behavior through 
enhancement of sexual pleasure (Bourne & 
Weatherburn, 2017; Ritchwood et al., 2015). Young 
MSM report misusing prescription stimulants to 
increase sexual desire (Kecojevic et al., 2015). 
A wide range of factors, including sexual activities 
with an increased risk of HIV acquisition, likely 
contribute to the increased odds of HIV infection 
related to substance use among MSM (Edelman 
et al., 2016; Schneider et al., 2013). Other possible 
contributors to increased risks of HIV infection, 
especially among younger MSM, include 
(CDC, 2014): 
• Misinformation about HIV prevention strategies 
and diffculty in accessing highly effective forms 
of prevention and treatment, particularly among 
racially and ethnically diverse MSM (Mayer et al., 
2020; Ojikutu et al., 2018). 
• Lack of widespread, effective education about 
HIV prevention and treatments among MSM. 
• Missed opportunities for HIV testing to increase 
patients’ knowledge of their HIV serostatus and 
help them appropriately access and engage in 
care. 
• Lack of awareness among some MSM with HIV 
about their positive HIV status and about safe 
sexual practices to limit the spread of infection. 
• Feelings of rejection and loneliness among some 
MSM who may experience marginalization, 
bullying, harassment, and estrangement from 
family or friends, sexual victimization, or the 
intersectionality of homophobia and racism 
(CDC, 2014). 
Treatment for Stimulant Use Disorders 
There currently are no clear data on rates of SUD 
treatment seeking among MSM in the United 
States. An Internet survey conducted in 2008 found 
that only 3 percent of MSM surveyed had accessed 
drug or alcohol treatment in the past 60 days 
(Hirshfeld et al., 2015). A 2017 literature review 
that analyzed fndings from the United States, 
the United Kingdom, and Australia suggests that 
SUD treatment rates among MSM are likely much 
lower than they are among men who identify as 
heterosexual and do not engage in sex with other 
men (Bourne & Weatherburn, 2017). 
One treatment study looking at stimulant use in 
MSM is Project IMPACT, an HIV risk reduction 
and behavioral activation counseling intervention 
for MSM without HIV who are currently using 
stimulants (Mimiaga et al., 2018). Study researchers 
hope to determine whether 10 weekly sessions of 
education for HIV risk reduction, CBT for substance 
use reduction, and behavioral activation to improve 
mood, reduce substance use, and enhance 
motivation to engage in HIV risk reduction behavior 
will result in fewer instances of condomless anal sex 
without the protection of preexposure prophylaxis 
(PrEP), relative to a control group. Findings from 
the study have not yet been published. 
In the absence of data, it is diffcult to know 
for certain the barriers that prevent more MSM 
who need SUD treatment from seeking it, and 
thus how clinicians and treatment facilities can 
help overcome these barriers. A lack of specialty 
SUD care for MSM may be a major deterrent, 
as clinicians not trained in working with this 
population may not understand the unique 
challenges facing some MSM and the sociocultural 
issues that may contribute to substance use among 
them (Bourne & Weatherburn, 2017). 
SUD treatment clinics may fnd success in reaching, 
engaging, and retaining MSM patients by adapting 
strategies recommended for healthcare service 
delivery programs that address the specifc needs 
of MSM. These strategies include offering (United 
Nations Population Fund [UNFPA], 2015): 
• Flexible clinical hours and services (e.g., 
emergency medication pickups, walk-in 
services). 
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• Services that address specifc adversities facing 
MSM (e.g., sexual assault, intimate partner 
violence, physical assault, abandonment). 
• Referral to community-based and social services. 
• Welcoming, nonhostile tone toward MSM and 
their needs (staff training is key). 
The term “men who have sex with men” is 
an all-encompassing term to identify specifc 
behaviors rather than label someone’s sexual 
orientation. Recently, with changes in stigma 
toward the lesbian, gay, bisexual, transgender, 
queer, and intersex+ community, many patients 
feel comfortable sharing their gender identity 
and sexual orientation with clinicians or the 
outside world. Still, stigma persists, and fears of 
marginalization and homophobia—particularly 
in the healthcare setting—contribute to whether 
patients wish to disclose or self-identify their 
sexual orientation. Patients may choose to keep 
this information confdential or request that the 
information not be shared in the medical record, 
as they fear what could happen if they were ever 
“found out.” This may be an indicator of a larger 
need to address self-stigma or previous trauma 
with the medical system. 
Clinicians should understand that MSM may self-
identify in different ways, and that this is a diverse 
population. Some MSM may consider themselves 
gay, and others may identify as heterosexual or 
bisexual (UNFPA, 2015). Yet other MSM may not be 
comfortable self-identifying in any particular way. 
Stigma and fear of physical or emotional harm 
may keep some MSM from feeling comfortable 
discussing themselves and any struggles they may 
have encountered, which can be a challenge to 
getting them to enter SUD treatment (UNFPA, 
2015). When clinicians can help MSM feel 
comfortable sharing information about their 
self-identity and sexual behaviors, it may have 
positive effects in terms of reducing their risk of 
HIV. Among MSM, disclosure of same-sex practices 
to healthcare providers has been associated with 
an increased likelihood of undergoing HIV testing 
(Qiao et al., 2018). Healthcare settings in which 
MSM are more likely to disclose include ones in 
which physicians are perceived to be younger in 
age and nonhostile toward the gay community 
(Qiao et al., 2018). Specifc barriers to disclosure 
include: 
• Healthcare providers’ failure to ask patients 
directly about their sexual practices. 
• Patients’ fear of their confdentiality being 
violated. 
• Patients’ fear of stigma. 
Internalized homophobia and self-stigma can 
perpetuate ongoing substance use. Patients 
who have always associated same-sex contact 
with shame and guilt may use substances to 
pacify those feelings so that they can engage in 
the activity. Strategies to help patients through 
self-acceptance, and remittance of internalized 
homophobia, particularly for those who are not 
“out,” may be an important aspect of helping 
patients achieve recovery and minimize drug-
related problems (Moody et al., 2018). 
PWID make up only a small portion of positive 
cases of HIV in the United States. In 2018, of the 
more than 37,000 people newly diagnosed with 
HIV in the United States, about 10 percent were 
PWID (CDC, 2021b). However, injection drug use 
is still concerning because it can increase risk of 
HIV transmission or can be associated with sexual 
behaviors that could make HIV transmission 
more likely. For instance, a study of MSM with 
HIV who use MA showed that negative attitudes 
about condoms and higher levels of MA use are 
associated with higher levels of unprotected 
anal sex (Nakamura et al., 2011). Conducting risk 
assessment, including analyzing patients’ use to 
see how sex fts into their use patterns, is critical 
for clinicians and outreach workers to do. 
Clinicians should ask patients about their sexual 
activity and whether they are taking antiretroviral 
medication as PrEP. Research suggests that gay 
and bisexual men who indicate a willingness 
to adopt PrEP for HIV prevention may also be 
willing to engage in more risky sexual behavior, 
like decreasing or stopping condom use during 
anal sex (Brooks et al., 2012). However, among 
MSM specifcally, the relationship between PrEP 
use and increased risky sexual activity is not clear 
and requires further study (Freeborn & Portillo, 
2018). This underscores the importance of talking 
openly with patients about their use of PrEP 





and subsequent sexual behaviors and ensuring 
that they understand that having risky sex while 
adopting PrEP could negate the HIV-prevention 
benefts of PrEP by exposing them to other 
Treatment for Stimulant Use Disorders 
sexually transmitted infections. Patients should be 
both counseled on this risk and offered additional 
HIV risk reduction and prevention strategies (e.g., 
behavioral counseling, access to condoms). 
CHEMSEX AND STIMULANT USE DISORDERS 
Chemsex, also known as sexualized drug use, is a sexual encounter that is coupled with the use of mind-
altering substances before or during intercourse to facilitate, enhance, prolong, and sustain the sexual 
experience (Giorgetti et al., 2017; S. Maxwell et al., 2019). In addition, using substances to reduce cognitive 
inhibition during sexual encounters can increase perceptions of confdence and emotional connection 
(S. Maxwell et al., 2019). Despite these expected benefts, some research has shown that this disinhibition 
can increase risk-taking behavior and negatively affect psychosocial functioning, especially when multiple 
substances are used (Closson et al., 2018; S. Maxwell et al., 2019). 
Historically, cannabis, ecstasy, amphetamine, and cocaine were the substances most commonly used in 
chemsex; however, ɣ-hydroxybutyric acid (GHB) and congeners, mephedrone, MA, erectile dysfunction 
agents, alkyl nitrites, and ketamine have become increasingly used in sexual encounters (Giorgetti et al., 
2017; S. Maxwell et al., 2019). Using substances during sexual encounters can occur in a variety of settings 
(e.g., saunas, sex-on-premises venues, private homes). Phone applications and online platforms have made 
it easier for individuals to locate and connect with others who engage in chemsex. 
Among U.S.-based studies that have focused on chemsex and stimulant use, the prevalence of MA use 
ranged from 9 to 22 percent (S. Maxwell et al., 2019). International and U.S.-based studies have shown 
cocaine to be the least frequently used chemsex drug, with prevalence estimates ranging from 2 to 33 
percent (S. Maxwell et al., 2019). Studies with large samples of MSM found that between 1 and 9 percent 
reported injection drug use, with MA being the most commonly injected substance (S. Maxwell et al., 2019). 
Chemsex is well described among MSM (S. Maxwell et al., 2019). Research remains limited, and prevalence 
rates vary greatly by geographical location and culture (S. Maxwell et al., 2019). MSM who engage in 
chemsex are most likely to be White, identify as gay, and be between the ages of 32 and 42 (S. Maxwell et al., 
2019). 
The use of chemsex drugs during sex has been shown to increase engagement in high-risk sexual 
behaviors (e.g., condomless anal intercourse) in MSM, which, in turn, increases the risk of acquiring sexually 
transmitted infections and HIV (S. Maxwell et al., 2019). Studies examining the use of nPEP (nonoccupational 
postexposure prophylaxis) and PrEP among MSM who participate in chemsex remain extremely limited. 
Clinicians who work with individuals using stimulants can assess for chemsex-related behaviors by asking 
the following screening questions: 
• Have you ever thought about using substances when having sex? 
• When was the last time you had sex while using substances? 
• Have you ever felt guilty about what you have done under the infuence when having sex? 
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Transgender and Gender
Nonbinary Community 
In the United States, approximately 0.3 percent 
of adults identify as transgender (Stroumsa, 
2014). In a study of adults age 18 and older 
who self-identifed themselves as within the 
gender spectrum or gender variant, 45.2 percent 
identifed as neither male nor female, and 5.5 
percent identifed as both male and female 
(Kuper et al., 2012). Further, 72.3 percent of 
participants identifed with more than one current 
gender identity (e.g., male, female, genderqueer, 
transgender, transsexual, crossdresser, two-spirit, 
bigender, intergender), with a reported average of 
2.5 gender identities (Kuper et al., 2012). 
Exhibit 6.1 includes key terms discussed in this 
chapter. 
EXHIBIT 6.1. Key Terms 
Cisgender: A term that refers to individuals who 
do not identify as transgender. These individuals’ 
gender identities, expressions, and roles align 
with the sex assigned to them at birth and the 
culturally established categories of gender. 
Transfeminine: Individuals who were assigned 
male at birth but identify with the feminine side 
of the gender spectrum or as nonbinary. 
Transgender: An umbrella term for individuals 
whose gender identities, expressions, and roles 
occur on a continuum, often differ from the 
sex assigned to them at birth, and cut across 
culturally established categories of gender. 
Understanding of the transgender community 
continues to evolve. Therefore, some patients and 
health professionals may defne “transgender” 
slightly differently. 
Transmasculine: Individuals who were assigned 
female at birth, but who identify with the 
masculine side of the gender spectrum or as 
nonbinary. 
Sources: American Psychological Association (2015); 
Center for Substance Abuse Treatment (2012); Coleman 
et al. (2012); Human Rights Campaign (n.d.); Mayo 
Clinic (2017a); Scheim et al. (2017). 
Most substance use research with the TGNB 
population has focused on alcohol use. Signifcantly 
fewer studies have assessed the prevalence of illicit 
drug use. Results from these studies show cocaine 
and amphetamine use is somewhat more common 
among transgender people than cisgender people, 
with past-year cocaine use among transgender 
people an estimated 6.8 percent higher and 
past-year amphetamine use an estimated 1.3 
percent higher (Scheim et al., 2017). A study of 
SUD treatment programs in San Francisco, CA, 
demonstrates that transgender identity predicts 
MA and injection drug use in women (Flentje et al., 
2014). 
Benotsch and colleagues (2013) found that among 
transgender individuals who misused prescription 
drugs, 13.5 percent misused prescription 
stimulants. Prescription drug misuse has been 
shown to be more common among binary 
transgender men, nonbinary individuals assigned 
female at birth, and nonbinary individuals assigned 
male at birth compared with binary transgender 
women (Kidd et al., 2021). 
Stimulant use patterns differ between transgender 
and cisgender populations. Past-year cocaine 
use is higher among transmasculine individuals, 
and past-year amphetamine use is higher among 
transfeminine individuals compared with use 
among cisgender men and women (Scheim et al., 
2017). 
Substance use, particularly injection drug use, 
among the TGNB population increases the risk for 
transmission of blood-borne diseases such as HIV 
and hepatitis. A large multinational study of HIV 
infection rates among transgender women in the 
United States, Europe, Latin America, and the Asia-
Pacifc region showed the odds of being infected 
with HIV are 49 times higher among transgender 
women compared with all adults of reproductive 
age, regardless of race, culture, or socioeconomic 
status (Baral et al., 2013). The high rate of HIV 
infection among transgender women is concerning, 
given the barriers that TGNB individuals face in 
accessing care. 


















Transgender individuals with any lifetime 
treatment for substance use tend to be older and 
transfeminine, access gender-affrming health 
care, and have lower income levels (despite higher 
education levels). Seeking treatment for recent 
substance use is associated with a history of mental 
illness-related risk factors (e.g., being a victim 
of intimate partner violence and experiencing 
PTSD and depression) and with engagement in 
mental health services (Keuroghlian et al., 2015). 
Additionally, treatment for recent substance use is 
associated with participating in sex work, having 
unstable housing, and experiencing discrimination 
related to public accommodations (Keuroghlian et 
al., 2015). 
Several factors contribute to the development 
of SUDs and use of treatment services among 
TGNB people. People who identify as transgender 
have a higher risk for verbal, physical, and 
sexual victimization and frequently encounter 
interpersonal and structural discrimination 
(Keuroghlian et al., 2015). A national survey of 
transgender individuals found that 28 percent 
of individuals delayed medical care because of 
discrimination and barriers such as (J. M. Grant et 
al., 2011): 
• Refusal of care (19%). 
• Harassment in medical settings (28%). 
• Violence in medical settings, including physical 
assault in a doctor’s offce (2%). 
• A lack of provider knowledge about trans-
affrmative care (50%). 
Transgender individuals report using substances 
to cope with stigma and mistreatment (J. M. Grant 
et al., 2011), ultimately increasing the odds of 
alcohol, cannabis, or cocaine use by 3 to 4 times 
and, among transgender women, any drug use 
by 8 times (Nuttbrock et al., 2014). Co-occurring 
mental disorders (e.g., depression, PTSD) also can 
increase the risk for substance use and facilitate the 
underlying relationship between gender-related 
violence and substance use (Nuttbrock et al., 2014; 
Rowe et al., 2015). 
Data from several studies from the 2000s suggest
that approximately 50 percent of transgender
individuals with SUDs do not seek treatment because
of concerns about stigma (Matsuzaka, 2018). When
Treatment for Stimulant Use Disorders 
seeking inpatient SUD care, TGNB people encounter
structural barriers, such as gender-segregated
treatment facilities, institutional bias, and stigmatizing
attitudes among providers (Matsuzaka, 2018). 
Research on interventions for reducing problematic 
substance use in the transgender community 
remains scarce and has largely consisted of 
feasibility and acceptability studies conducted 
in the context of risky sexual behavior and HIV 
transmission (Glynn & van den Berg, 2017). But 
increased understanding of TGNB issues affecting 
general healthcare delivery has contributed to the 
American Psychological Association’s formulation 
of TGNB-specifc recommendations for mental 
health service and SUD care delivery. 
In 2015, the American Psychological Association 
recognized ongoing advancements in TGNB-
informed research and published practice 
guidelines to assist clinicians with providing 
culturally responsive, developmentally appropriate 
trans-affrmative care. When working with 
the TGNB population, clinicians should have 
foundational knowledge and awareness of the 
spectrum of gender diversity, cultural backgrounds, 
and life experiences (e.g., stigma, discrimination, 
violence victimization) of TGNB people to provide 
individualized, TGNB-specifc health care (American 
Psychological Association, 2015). Clinicians should 
help TGNB patients by (American Psychological 
Association, 2015): 
• Providing a safe environment to explore gender 
identity and expression, while recognizing 
their own attitudes and beliefs (e.g., asking 
for preferred pronouns, displaying TGNB-
affrmative resources, adapting paperwork that 
includes demographic information). 
• Learning about TGNB-specifc topics that affect 
care. 
• Acknowledging the existence of institutional 
barriers that can delay treatment engagement. 
• Remaining nonjudgmental. 
• Modeling acceptance. 
Learn more about clinical considerations when 
treating TGNB patients with SUDs in SAMHSA’s 
A Provider’s Introduction to Substance Abuse 
Treatment for Lesbian, Gay, Bisexual, and 
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Substance use among adolescents is of critical 
concern because of its associations with their 
physical and social development. Hormonal surges 
during puberty, especially in testosterone, support 
risk-taking behaviors, which can be negative 
(e.g., underestimating the danger of drinking and 
driving) or positive (e.g., trying out for a sports 
team or a role in a play). Adolescent years are also 
a time of expansive cognitive development (e.g., 
emergence of abstract reasoning, robust memory) 
and increased focus and specialization (Silvers et 
al., 2019). In essence, the adolescent brain is laying 
down a network of cognitive pathways that will 
shape and guide future brain development and, 
thus, adult thinking and behavior. 
Adolescence is a time of social maturation 
as well. Cultural expectations are that young 
adults emerge from adolescence with enhanced 
autonomy—ready to separate from their families, 
further their education or fnd employment, and 
begin to establish an independent existence. One 
aspect of this increased focus on the self can be, 
paradoxically, increased susceptibility to peer 
infuences, for good and ill. 
Because the brain is undergoing intense and 
rapid change during adolescence, it is particularly 
vulnerable to the effects of substance use. 
Substance use during adolescence is associated 
with abnormal brain development, including 
poor cognitive performance (Otten et al., 2019). 
Cocaine and MA use and amphetamine misuse 
during adolescence have been shown to rewire 
still-developing parts of the brain and alter the 
functioning of more mature parts (Salmanzadeh et 
al., 2020). 
Many substance misuse prevention and treatment 
efforts are directed at teenagers because 
intervention during adolescence can help 
prevent SUDs in later life. One of the strongest 
associations with substance use before age 15 is 
the development of SUDs in later adolescence and 
adulthood (Otten et al., 2019). Early substance use 
is also strongly associated with depression, suicidal 
ideation, and suicide attempts among adolescents 
(Marschall-Lévesque et al., 2017). 
Despite the negative effects that adolescent 
substance use has on physical and mental health, 
most problems with substance use resolve without 
any treatment as people enter adulthood (Cousijn 
et al., 2018). When considering the vulnerability 
of adolescents to substance use, it is helpful 
to remember that they also show remarkable 
resilience. The same plasticity that makes their 
developing brains particularly susceptible to the 
ill effects of substance use also seems to equip 
adolescents to learn and adapt. 
According to nationally representative data 
(CBHSQ, 2020a; University of Michigan, 2020): 
• More than one in three students (34.7%) in 
8th, 10th, or 12th grade have used an illicit 
drug, including cannabis. That fgure climbs to 
almost one in two (46.6%) if surveying only 12th 
graders. 
• Regarding cocaine use, 2.6 percent of 8th, 
10th, and 12th graders surveyed had ever used 
cocaine (including crack cocaine); 1.4 percent 
had used cocaine in the previous year. 
• Among people ages 12 to 17, an estimated 
75,000 engaged in lifetime MA use. 
• Among people ages 12 to 17, about 430,000 
engaged in past-year prescription stimulant 
misuse. 
Adolescent usage rates for cocaine, amphetamines, 
and MA have been dropping for two decades. In 
1999, nearly 1 in 10 high school seniors had tried 
cocaine (9.8%), 1 in 6 had used amphetamines 
(16.3%), and 1 in 12 had used MA (8.2%; Johnston 
et al., 2020). 
Despite declining use, stimulants warrant attention 
for at least two reasons. First, adolescents tend 
toward polysubstance use, estimated at 12 to 34 
percent among this group depending on age and 
setting (Kecojevic et al., 2017). Per NSDUH 2019 
data, people age 12 and older with past-year 
MA use are 4 times as likely to use cannabis, 2 
times as likely to drink heavily, 9 times as likely 
to misuse prescription opioids, and 17 times as 
likely to use cocaine as those with no past-year 
MA use (CBHSQ, 2020a). Second, they tend to 







use substances that are convenient to obtain; 
thus, rates of stimulant use are likely to be higher 
in areas with ample availability. Nationwide, when 
12th graders were asked about availability of 
various stimulants, more than a quarter (28.4%) 
said it was fairly or very easy to obtain cocaine; 
availability of powder and crack cocaine was 
roughly equal (18.3% and 16.5%, respectively; 
University of Michigan, 2020). 
Few adolescents who need treatment for stimulant
use disorder receive it. According to 2019 NSDUH
data, only 0.5 percent of adolescents receive
treatment for any SUD (CBHSQ, 2020a). By some
estimates, SUD treatment reaches less than 6 percent
of the adolescents who need it (Silvers et al., 2019). 
The advantages of identifying substance use 
problems in adolescents and intervening 
successfully are signifcant. Most people who 
develop an SUD will do so in adolescence or 
young adulthood (Saitz et al., 2021). Identifying 
adolescents who are using substances can help 
prevent those individuals from developing SUDs 
later in life. Drug and alcohol use are the primary 
preventable risks that contribute to some of the 
leading causes of death for adolescents—namely, 
accidents, homicide, and suicide. 
The American Academy of Pediatrics’ clinical 
report, Substance Use Screening, Brief 
Intervention, and Referral to Treatment (https:// 
pediatrics.aappublications.org/content/138/1/ 
e20161211) provides information about substance 
use screening and treatment for adolescents. 
Adolescents may be inclined to use prescription 
stimulants in a nonprescribed way or use another 
person’s prescription to try to improve cognitive 
and academic performance (Benson et al., 
2015; Weyandt et al., 2016). Stressors including 
college entrance exams, school assignments, and 
familial pressure may make misusing prescription 
stimulants appealing. All adolescents should be 
screened for stimulant use disorder regardless 
of academic performance or other perceived 
achievements. Notably, there is no evidence that 
taking stimulants prescribed by a medical provider 
for the treatment of ADHD in adolescence leads to 
the development of SUDs in adulthood (Quinn et 
al., 2017; Wilens et al., 2011). 
Treatment for Stimulant Use Disorders 
Risk-taking behaviors are not limited to substance 
use in adolescence. Increased sexual risk-taking 
behaviors can occur in adolescence more generally, 
especially when adolescents demonstrate high 
levels of sensation seeking and impulsive decision 
making (Charnigo et al., 2013). Clinicians caring 
for adolescent patients with stimulant use disorder 
should conduct a careful sexual health history 
to identify potential needs, including screening 
for sexually transmitted infections, PrEP/nPEP 
(nonoccupational postexposure prophylaxis ) 
referral, or additional education about safe sex 
practices. 
Evidence-based SUD treatment seems to be less 
effective for adolescents than for adults. This may 
be partly because many evidence-based treatment 
approaches are developed for and tested primarily 
on adult populations. A review of 29 studies of 
interventions to prevent adolescent substance use 
found that interventions that were successful in 
reducing or preventing illicit substance use were 
narrowly targeted (e.g., addressing only Asian 
American girls, eighth-grade girls in foster care, 
truant youth). Interventions that seemed to be 
more broadly successful were delivered in school 
settings and involved students’ families. Familias 
Unidas consists of 12 family-based sessions 
designed to improve family communication, 
develop positive parenting, and enhance parental 
monitoring to reduce risky substance use among 
Hispanic adolescents (E. O’Connor et al., 2020). 
Brief interventions in a primary care setting were 
found to be relatively ineffective at preventing 
substance use in young adults (Saitz et al., 2021). 
Adolescent substance use is often identifed 
in a primary care setting, where healthcare 
personnel may lack the training or skills to provide 
developmentally appropriate, evidence-based 
interventions (Hadland et al., 2021). Referrals often 
place young people in treatment settings more 
appropriate for adults. Because the SUD treatment 
system often focuses on adults, it can be hard to 
know where to refer adolescents for screening 
and assessment. Given the associations between 
risk-taking and substance use, adolescents with 
substance use problems often become involved in 
the juvenile justice system. The gaps in the SUD 
continuum of care for adolescents may help explain 
the diffculties in treating this population. 
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NIDA’S PRINCIPLES OF ADOLESCENT SUD TREATMENT 
A NIDA (2014b) research-based guide sets out these 13 principles of adolescent SUD treatment: 
1. Adolescent substance use needs to be identifed and addressed as soon as possible. 
2. Adolescents can beneft from a drug abuse intervention even if they are not addicted to a drug. 
3. Routine annual medical visits are an opportunity to ask adolescents about drug use. 
4. Legal interventions and sanctions or family pressure may play an important role in getting adolescents 
to enter, stay in, and complete treatment. 
5. SUD treatment should be tailored to the unique needs of the adolescent. 
6. Treatment should address the needs of the whole person, rather than just focusing on his or her drug 
use. 
7. Behavioral therapies are effective in addressing adolescent drug use. 
8. Families and the community are important aspects of treatment. 
9. Effectively treating SUDs in adolescents requires also identifying and treating any other mental health 
conditions they may have. 
10. Sensitive issues such as violence and child abuse or risk of suicide should be identifed and addressed. 
11. It is important to monitor drug use during treatment. 
12. Staying in treatment for an adequate period of time and continuity of care afterward are important. 
13. Testing for sexually transmitted diseases (e.g., HIV; hepatitis B and C) is important in drug treatment. 
For more on each principle, see NIDA’s Principles of Adolescent Substance Use Disorder Treatment: A 
Research-Based Guide (https://www.drugabuse.gov/publications/principles-adolescent-substance-use-
disorder-treatment-research-based-guide/principles-adolescent-substance-use-disorder-treatment). 
Behavioral treatments such as CM, CBT, and 
treatment regimens that mix the two approaches 
(e.g., the Matrix model) remain the best evidence-
based treatments for stimulant use disorder (NIDA, 
2019e). 
Because of their rapid cognitive development, 
adolescents are more adept than adults at 
incorporating new information and adapting their 
behavior to new social contexts (Davidow et al., 
2016). This tendency supports the use of behavioral 
approaches and those that involve family members 
in treatment of adolescent SUDs (Silvers et al., 
2019). Approaches that focus on parent training 
and family communication (e.g., Strengthening 
Families Program, Community Reinforcement and 
Family Training [CRAFT]) can enlist family members 
as a stabilizing infuence on adolescents. 
Peer-based SUD services may enhance other 
services such as screening, brief intervention, and 
referral to treatment (SBIRT) and help adolescents 
with SUDs engage in treatment when other 
support services are not readily available in the 
community (Winn et al., 2019). Peer services 
may also be particularly important for engaging 
adolescents in mutual-help programs, like 12-Step 
groups (Nash, 2020). (A 2016 review of case series 
studies yielded promising, although not defnitive, 
fndings that active participation in mutual-help 
groups by adolescents with substance misuse 
increases the likelihood that they will achieve 
abstinence [Bekkering et al., 2016].) 
Specifcally, peer recovery support specialists can 
aid adolescents with SUDs by (Nash, 2020): 
• Introducing them to sober activities. 
• Helping orient them to the philosophies and 
benefts of 12-Step groups. 
• Helping them resolve feelings of ambivalence or 
resistance to SUD treatment. 
• Serving as positive role models of recovery. 















Per the 2020 Annual Homeless Assessment Report 
to Congress, approximately 580,000 Americans were
homeless on any given night in 2020 (Department of
Housing and Urban Development, 2021). 
Some people experiencing homelessness or 
unstable housing also experience problems 
with stimulant use. Data from 12 SUD treatment 
programs in the National Drug Abuse Treatment 
Clinical Trials Network showed almost 32 percent 
of patients had unstable housing and nearly 6 
percent were experiencing homelessness (Pan et 
al., 2020). 
Compared with patients experiencing 
homelessness and those who were stably housed, 
patients with unstable housing had the highest 
prevalence of cocaine use (about 45%), opioid 
use (42%), and combination stimulant–opioid 
use (25%). In a primary care sample of people 
experiencing homelessness, 16 percent reported 
3-month cocaine use (Stringfellow et al., 2016). 
The 2005–2015 Treatment Episode Data Sets show 
that, among people experiencing homelessness 
who entered SUD treatment, 13 percent reported 
cocaine as their primary substance and 8.5 
percent reported MA (Famutimi & Thompson, 
2018). People using injectable drugs and currently 
experiencing homelessness who were surveyed 
as part of the 2015 National HIV Behavioral 
Surveillance System had a high rate of injecting 
MA (almost 72%) or injecting both MA and heroin 
(77%) in the previous year (Al-Tayyib et al., 2017). 
Adolescents and young adults who experience 
homelessness/unstable housing are also vulnerable 
to stimulant use. In a study of youth with a history 
of homelessness, nearly 22 percent reported 
using MA 20 times in the previous 30 days 
(Yoshioka-Maxwell et al., 2015). Additionally, 
a 2012–2013 survey of youth in California who 
were homeless revealed that nearly 11 percent 
misused prescription stimulants only, and about 21 
percent misused both prescription stimulants and 
prescription sedatives (Rhoades et al., 2014). 
Treatment for Stimulant Use Disorders 
The clinical picture of individuals who use 
stimulants and experience homelessness/unstable 
housing is diffcult to characterize because of 
the diversity of challenges these individuals face. 
Such challenges can include one or more of the 
following (Cox et al., 2017; Nyamathi et al., 2012; 
Torchalla et al., 2011): 
• Serious mental illness and other mental 
disorders 
• Chronic health conditions 
• A tendency toward injection drug use 
• A history of trauma (e.g., being a victim of 
sexual violence) 
• A history of emergency department visits 
• An elevated risk of engaging in transactional/ 
survival sex 
• Elevated rates of infectious diseases, like HIV or 
hepatitis C virus (HCV) 
• Elevated rates of polysubstance use (e.g., 
alcohol) 
Clinicians should recognize that, in patients 
who are using MA or cocaine and engaging in 
transactional/survival sex, the stimulant use may 
allow them to engage in sex work that provides 
them with a source of income. Such patients 
may have ambivalence about abstaining from 
stimulants. Walls and Bell (2011) describe the use 
of transactional/survival sex as common among 
youth and young adults experiencing homelessness 
who also have SUDs, including stimulant use 
disorders (especially ones involving MA and crack 
cocaine). The association between transactional/ 
survival sex and injection drug use is particularly 
strong. 
Stimulant use can also serve a functional purpose 
when people are evicted from housing. Individuals 
who are newly homeless may initiate or return 
to MA use because they perceive this as helpful 
in coping with the demands and stressors of 
their situation (Damon et al., 2019). In qualitative 
interviews of women experiencing homelessness 
and using stimulants, some women reported that 
stimulant use helped them stay awake and alert 
to protect themselves from physical harm or theft 
(McKenna, 2013). 
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Rather than shaming or stigmatizing patients for 
engaging in functional stimulant use, clinicians 
should be empathetic and try to understand 
the extent to which people with homelessness/ 
unstable housing sometimes engage in high-risk 
behaviors to protect themselves and survive. 
When working with patients with stimulant use 
disorders who are homeless or housing insecure, 
clinicians should: 
• Refer them to case managers who can help 
them navigate health and social support 
systems. 
• Teach them harm reduction strategies (especially 
ones related to sex work and HIV prevention). 
• Help connect them to available places to 
shower, use the toilet, and sleep. 
• Link them with social services that can provide 
basic hygiene tools and health products—like 
soap, toothbrushes, toothpaste, condoms, and 
menstrual products—and, for patients who 
inject stimulants, soap and water or alcohol-
based hand sanitizer or alcohol pads to cleanse 
the injection site and antibacterial ointment to 
heal injection sites. 
• Consider using Housing First approaches to 
treatment initiation (Baxter et al., 2019). (For 
more information on Housing First, see https:// 
www.hudexchange.info/resource/3892/housing-
frst-in-permanent-supportive-housing-brief/). 
Given the unique challenges and complex issues 
facing people experiencing homelessness or 
unstable housing, such patients may beneft from 
referral to a peer recovery support specialist, if 
available. Peer support in this population has been 
associated with reduced drug and alcohol use 
and lower rates of return to substance use (Barker 
& Maguire, 2017). Other non-substance-related 
outcomes of value associated with peer support 
among people with homelessness/unstable 
housing include improvements in quality of life and 
in social support (e.g., increase in certain types of 
social support, decrease in loneliness), an increase 
in mental health functioning and a reduction 
in psychiatric symptoms, a decrease in number 
of days homeless and lower risk of returning to 
homelessness, a decrease in number of criminal 
arrests, and improvements in self-effcacy and self-
esteem (Barker & Maguire, 2017). 
Harm reduction and supportive services like these 
can be especially helpful for patients who have 
stimulant use that serves a functional purpose, 
because these individuals might be unwilling to 
abstain from cocaine or MA use. 
For people who are interested in formal SUD
treatment, CM (see Chapter 4 for more discussion)
has demonstrated effectiveness in helping patients
with homelessness/unstable housing and SUDs
improve psychological and emotional distress,
abstinence, and treatment retention (Fletcher et al.,
2014; Rash et al., 2017). Supplementing CM with
nurse-led case management is also associated with
reduced drug use and reduced number of sexual
partners among sexual minorities (e.g., gay, bisexual)
experiencing homelessness and using stimulants
(Nyamathi et al., 2017; Zhang et al., 2018). 
For more guidance on providing SUD and 
mental health services for people who are 
homeless or experiencing unstable housing, 
see TIP 55, Behavioral Health Services for 





According to 2010 census data, approximately 20 
percent of the U.S. population lives in rural areas, 
with 704 counties or county statistical equivalents 
classifed as completely rural and 1,185 counties 
or county statistical equivalents classifed as mostly 
rural (Ratcliffe et al., 2016). Most of these counties 
are in Western states, where MA use is high. 
Rural areas offer drug manufacturers and dealers 
secluded areas in which to produce illegal 
drugs, including MA; access to major routes for 
transporting illegal drugs to other regions for sale 
and distribution; and a customer base. Illegal drug 
manufacturers and dealers can often operate in 
rural areas with minimal risk of discovery because 
of fewer local law enforcement resources. 
Prevalence in Rural Areas 
MA has the highest availability in the Western 
and Midwestern United States, with more than 70 
percent of local law enforcement agencies in these 








areas identifying it as the greatest drug threat 
(NIDA, 2019d). In nonmetro areas, an estimated 
8,000 adolescents ages 12 through 17 took part 
in past-year use of MA in 2019 (CBHSQ, 2020a). 
Similarly, an estimated 465,000 adults age 18 and 
older engaged in past-year use of MA in 2019 
(CBHSQ, 2020a). 
Rates of cocaine use in nonmetro areas were 
comparable to rates of MA use, with 10,000 
adolescents ages 12 through 17 and an estimated 
466,000 adults age 18 and older taking part in 
past-year use in 2019 (CBHSQ, 2020a). 
Results from the 2019 NSDUH also showed that 
48,000 adolescents ages 12 through 17 who were 
living in nonmetro areas engaged in past-year 
misuse of prescription stimulants (CBHSQ, 2020a). 
Further, 456,000 adults age 18 and older who were 
living in nonmetro areas engaged in past-year 
misuse of prescription stimulants (CBHSQ, 2020a). 
Treatment admissions for MA are highest in 
Western states. Data from the National Drug Early 
Warning System suggest 12 to 29 percent of sites 
located west of the Mississippi River reported MA 
as the primary substance for treatment admission, 
compared with less than 1 percent of sites east of 
the Mississippi River (NIDA, 2019d). 
In 2017, there were approximately 140,000 primary 
MA admissions among people age 12 and older 
in Western states, compared with approximately 
13,000 primary cocaine admissions in the same 
group (CBHSQ, 2019). Primary MA admission rates 
rose consistently in Southern and Midwestern 
states between 2011 and 2017 (CBHSQ, 2019). 
Challenges, Limitations, and Barriers to 
Treatment Services Faced by Rural Areas 
Many rural areas have no specialized SUD 
treatment at all. Often, only one multiservice 
provider is available, and that provider can be 
overwhelmed by the area’s various needs (L. B. 
Young et al., 2015). Additionally, rural areas have 
fewer formalized processes available to support 
and facilitate case management (Clary et al., 2020). 
Budget constraints limit SUD care, staff salaries 
(which contributes to high staff turnover), and 
the ability to provide support services such as 
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childcare or transportation. There are rarely any 
sources within the community from which to seek 
additional funding. 
Lack of SUD treatment providers and lack of 
public transportation in rural areas make accessing 
specialty SUD care diffcult for many rural patients 
(SAMHSA, 2016). Lack of privacy is another barrier 
to treatment. When a rural community has one or 
more SUD treatment providers, the comings and 
goings of patients can often be easily observed by 
people who know them (Clary et al., 2020; L. B. 
Young et al., 2015). This can contribute to concerns 
about stigma associated with seeking SUD services. 
Offering telehealth will not always overcome these 
barriers, as many rural households lack high-speed 
broadband Internet access (SAMHSA, 2021b). 
Lack of access to medical services and insurance 
is a major barrier in providing evidence-based 
treatment services for people using stimulants. 
Advocacy for expanded Medicaid programs and 
coverage of evidence-based treatments like CM 
is necessary to adequately address the needs of 
rural populations (Clary et al., 2020; Cucciare 
et al., 2019). 
Strategies To Provide Services in Rural 
Areas 
Using the following strategies can help provide 
treatment services to rural populations: 
• Partner with local agencies and stakeholders. 
Public safety and public health organizations 
can help create a coordinated response that 
streamlines the care of patients who use 
stimulants. 
• Partner with public and private schools to 
provide information about prescription stimulant 
misuse in youth. This includes educating middle 
and high school students about the dangers of 
prescription stimulant misuse and strategies for 
coping with academic demands. 
• Identify patients’ nontreatment needs, provide 
temporary case management, and make 
referrals to case managers for ongoing support. 
• Use telehealth to access experts who can 
provide specialty training for staff (e.g., Project 
ECHO; Browne et al., 2016; Zhou et al., 2016). 
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• Provide education about stimulant use disorders 
to local community members to raise awareness 
regarding treatment options. 
• Increase access to treatment by using one or 
more medical vans to take SUD services and 
other care to rural communities (Gibson et al., 
2014). 
• Provide safe, substance-free living arrangements 
for patients who do not reside nearby. Funds 
can be specially designated, solicited through 
recovery community networking, or obtained 
through donations. 
• Provide treatment services that are fexible 
in scope and structure (Browne et al., 2016; 
Timko et al., 2016). For example, an intensive 
outpatient (IOP) program might offer longer 
sessions on weekends instead of shorter, more 
frequent weekday sessions. 
• Maximize patient engagement by assigning 
homework, arranging phone check-ins, having 
drug testing done by outlying clinics, using 
online communication, and holding weekend 
workshops or retreats. 
• Use nontraditional sites and work arrangements 
to provide treatment services. If a treatment 
facility in a small rural community is not realistic, 
employ a part-time person who travels to 
satellite sites to provide outpatient services. 
• Increase access to care via telemedicine and 
virtual visits (SAMHSA, 2016, 2021b). Additional 
research is needed to evaluate whether 
methods of access affect treatment outcomes 
for individuals with stimulant use disorders. 
• Promote engagement in social–recreational 
activities beyond traditional mutual-help groups. 
Among rural people who use stimulants, 
increased engagement in social–recreational 
activities was associated with decreased 
substance use and decreased criminal recidivism 
(Timko et al., 2017). 
See this Rural Health Information Hub (https:// 
www.ruralhealthinfo.org/topics/substance-use) 
webpage on substance use in rural areas for 
resources and more information. 
People Involved in the Criminal
Justice System 
The number of people in state and federal prisons 
in the United States has been declining since its 
peak in 2008. Despite this decline, the United 
States still incarcerates a larger percentage of its 
population than any other country (Pew Research 
Center, 2020). According to the Department of 
Justice’s Bureau of Justice Statistics (BJS), 0.42 
percent of U.S. residents—1.43 million people— 
were in state or federal prison in 2019 (Carson, 
2020). 
The rate of imprisonment for Blacks/African 
Americans is at its lowest since 1989, before laws 
passed during the “war on drugs” imposed stiff 
mandatory jail sentences for drug-related crimes 
(BJS, 2020). Since 2006, the imprisonment rate 
for Blacks/African Americans has dropped 34 
percent. Over the same period, Hispanic and White 
Americans’ rates of imprisonment also dropped, 
by 26 and 17 percent, respectively. Even with the 
more rapid decline in their rates of incarceration, 
Blacks/African Americans are still imprisoned at 
a rate twice that of Hispanics and 5 times that of 
Whites (Pew Research Center, 2020). 
Substance use and criminal justice involvement are 
highly correlated. The manufacture, possession, or 
sale of a variety of drugs are criminal offenses; thus, 
many people are in prison for committing drug-
related crimes. Nearly 243,000 people nationwide 
are in state and federal prisons for drug offenses. 
As of May 2021, drug offenses accounted for 
almost half the inmates in federal prisons (46.3%, 
or more than 66,000 people; Federal Bureau of 
Prisons, 2021). In 2018, one in seven inmates in 
state prisons (14%, or more than 176,000 people) 
was serving time for a drug offense (Carson, 2020). 
About 21 percent of inmates in state prisons say 
they committed their crimes to obtain drugs or 
money to buy drugs (Bronson et al., 2017). Two 
out of every fve state prison inmates committed 
their crimes while on drugs. One in 6 was taking 
crack/cocaine; 1 in 10 was taking other stimulants, 
including MA (Bronson et al., 2017). Stimulant-
related offenses account for 75 percent of all 
federal drug crimes (CDC, 2019). 
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But beyond these connections, the link between 
substance use and criminal activity is correlational, 
not causal (Farabee, 2018). Precisely how many 
people in prison have SUDs is not known, but an 
estimated 65 percent of the prison population 
has an SUD (NIDA, 2020c). In some studies of 
limited prison populations, the fgure is as high 
as 87 percent (Proctor et al., 2019). According 
to BJS statistics, the incidence of SUDs among 
state prisoners is 14 times higher than among the 
general population not involved with the criminal 
justice system. Among state prisoners, 34 percent 
regularly used cocaine/crack and 23 percent 
regularly used other stimulants, including MA, with 
regular use defned as once a week for a month 
(Bronson et al., 2017). A study of 200 inmates in 
county jails found that, according to criteria in the 
ffth edition of Diagnostic and Statistical Manual of 
Mental Disorders (DSM-5), 34 percent met criteria 
for stimulant use disorder, the most prevalent SUD 
among study participants (Proctor et al., 2019). 
In 2018, fewer than one in four people in federal 
prison (about 23%) participated in SUD treatment 
(BJS, 2020). A large nationwide study found 
that 30 to 33 percent of people with criminal 
justice involvement in the previous year received 
treatment for SUDs (Saloner et al., 2016). For 
people who have been incarcerated, having 
cocaine use disorder was strongly associated 
with receiving SUD treatment, either during or 
after incarceration (J. Tsai & Gu, 2019). However, 
the researchers noted that despite the strong 
correlation, treatment usage rates were still low. 
The relative lack of treatment for people in 
prison represents a missed opportunity. Many 
are experiencing an extended period during 
which they are not using drugs and have available 
time and a structured environment in which to 
undertake treatment, yet access to evidence-
based treatments is limited. Treatment in prison 
often consists mainly of mutual-help groups like 
Alcoholics Anonymous and Narcotics Anonymous 
or psychoeducation (J. Tsai & Gu, 2019). Other 
therapeutic approaches available to prisoners 
include CM, therapeutic communities (TCs), CBT, 
motivational enhancement therapy, and counseling 
that includes vocational and life-skills instruction. 
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As with people who are not incarcerated, social 
support is a key aspect of SUD treatment for 
people in prison. Inmates who receive more 
visits and phone calls from family and friends and 
who are allowed furlough days are more likely to 
access treatment while incarcerated. Compared 
with Black/African American and Latino prisoners, 
Whites were more likely to receive such social 
support (Nowotny, 2015). 
Social support can also be particularly meaningful 
and effective when it comes from a peer recovery 
support specialist with a lived experience of 
incarceration and recovery from SUDs (Barrenger 
et al., 2019). A review of peer-delivered support 
services for SUDs among incarcerated individuals 
found evidence that peer services were associated 
with an increase in 30-day abstinence rates before 
release from incarceration, a greater likelihood of 
completing SUD treatment once released, and a 
decrease in future criminal justice charges (Bassuk 
et al., 2016). 
One example of how peer recovery support 
specialists can perform outreach in a criminal 
justice setting is providing recovery education to 
incarcerated individuals in the jail or prison. The 
incarcerated individual receives information about 
how to contact a peer recovery support specialist. 
Thirty days before release, the individual calls the 
peer recovery support specialist and they begin 
building a relationship. The peer recovery support 
specialist helps the individual get a head start 
on developing a recovery plan in preparation for 
returning to the community. 
Cos and colleagues (2020) looked at the use of 
peer recovery support specialists in an integrated, 
primary-care-based SUD treatment program in 
which all patients had a history of arrest with or 
without conviction, incarceration, or other criminal 
justice system involvement. Participation in the 
program was associated with a decrease in the 
percentage of patients using substances in the 
past 30 days, a reduction in number of days using 
alcohol, an increase in patient engagement in 
medical services after program enrollment, an 
increase in school enrollment, and an increase in 
rates of employment (Cos et al., 2020). 
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Therapeutic approaches that have been 
successful in treating stimulant use disorder in 
general populations (e.g., CBT, CM) have also 
shown success among criminal justice-involved 
populations, but much research into SUD treatment 
among prison populations has focused on TCs. TCs 
require long-term residence and center on peer 
group processes to promote behavioral change, 
making them ideally suited for incarcerated 
populations. A meta-analysis of therapeutic 
approaches used to treat SUDs in prison 
populations found that TCs were most effective at 
reducing recidivism and drug use after prisoners 
were released (Mitchell et al., 2012). 
Reentering society after imprisonment is a 
challenge for all prisoners. Those with SUDs 
face the additional challenge of being back in 
the environment in which they used substances. 
Research indicates that released prisoners who 
used MA and cocaine at the time they entered 
prison have higher rates of recidivism than other 
former inmates, with the exception of those with 
OUD (Cumming et al., 2020; Wimberly et al., 
2018). Follow-up care, in the form of telephone 
monitoring and counseling, in addition to IOP 
treatment, has been shown to decrease the odds 
of people with cocaine dependence having a 
criminal conviction for 4 years following release 
from prison, when compared with those who had 
only IOP treatment (Wimberly et al., 2018). 
Prisoners with stimulant use disorders who are 
reentering society should be referred to SUD care. 
Recovery support and other services they may 
beneft from include: 
• Continued interaction with peer recovery 
support specialists. 
• Connection to support services (e.g., 
reentry programs, vocational rehabilitation, 
transportation and housing assistance) in the 
community. 
• Multidisciplinary case management services for 
medical and psychiatric care. 
For more information on this topic, see 
these SAMHSA publications: Principles of 
Community-based Behavioral Health Services for 




A-Research-based-Guide/SMA19-5097); TIP 44, 
Substance Abuse Treatment for Adults in the 
Criminal Justice System (https://store.samhsa.gov/ 
product/TIP-44-Substance-Abuse-Treatment-for-
Adults-in-the-Criminal-Justice-System/SMA13-
4056); and After Incarceration: A Guide to Helping 




People Taking Medication for
Opioid Use Disorder 
People receiving OUD medication treatment may 
be prescribed one of the three Food and Drug 
Administration (FDA)-approved medications for 
OUD: methadone, buprenorphine, or naltrexone. 
All three may be offered by federally approved 
opioid treatment programs (OTPs). Buprenorphine 
treatment may be offered in other settings by 
healthcare professionals with the federal waiver 
required for prescribing buprenorphine, and 
naltrexone may be offered by any prescriber 
(SAMHSA, 2020h). 
Cocaine is among the nonopioid substances most 
frequently used by people taking medication 
for OUD. It was present among 24 percent of 
patients in one study of more than 19,000 OTP 
admissions from 2011 to 2013 (Fong et al., 2015). 
In a trial of 177 patients being treated with 
buprenorphine, 26 percent screened positive for 
DSM-IV-defned cocaine abuse or dependence 
(APA, 2000; Schottenfeld et al., 2014). And among 
791 pregnant women receiving methadone 
or buprenorphine, 21 percent had a history of 
cocaine use, whereas 1.4 percent had a history of 
amphetamine/MA use (Krans et al., 2016). 
Among patients entering OTPs for OUD between 
2012 and 2018, the prevalence of past-month 
MA use rose from almost 8 percent to about 21 
percent (Severtson et al., 2019). In 799 patients 
taking buprenorphine through the SAMHSA-
funded Washington State Medication Assisted 
Treatment–Prescription Drug and Opioid Addiction 




(WA-MAT-PDOA) program clinic between 2015 
and 2018, 30 percent reported past-month MA use 
and 15 percent past-month cocaine use (Tsui et al., 
2020). 
Clinicians treating patients for OUD should also 
make efforts to help patients stop or reduce 
any stimulant use. Regular cocaine use can 
decrease serum concentrations of methadone and 
buprenorphine and—in patients without HIV—may 
reduce peak concentrations of methadone (Tetrault 
et al., 2015). The potential effects of cocaine on 
the pharmacokinetics of opioid agonist therapy are 
important, because people taking opioid agonist 
medication and using cocaine at the same time 
may not experience the full clinical beneft of the 
medication, which could lead to poor treatment 
outcomes (Tetrault et al., 2015). Also of note, 
both cocaine and MA may increase the risk of 
cardiac arrhythmia in the presence of methadone. 
Therefore, patients with current or past stimulant 
use who are taking methadone for OUD should 
be assessed and monitored for risk of cardiac 
arrhythmias, specifcally a risk for prolonged 
QT interval. (For more information, see TIP 63, 




Some patients may report that methadone 
lengthens and mellows the effects of cocaine, 
presumably attenuating negative reinforcers 
associated with acute cocaine withdrawal. Patients 
taking buprenorphine or methadone for OUD who 
continue to use stimulants should not have their 
OUD medication stopped (American Society of 
Addiction Medicine, 2020). It is more appropriate 
to increase services and add adjuvant treatment, 
including CM, closer cardiac monitoring, and harm 
reduction education. 
Longitudinal data are lacking on whether and 
how OUD medication might affect co-occurring 
stimulant and opioid use disorders (Rawson, 2020). 
In the case of cocaine use while on medication 
for OUD, fndings thus far are mixed. In one 
study, cocaine use was associated with shortened 
duration of abstinence from opioids following 
methadone or buprenorphine/naloxone treatment 
(Zhu et al., 2018). But two other studies found no 
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effect of cocaine use on retention in buprenorphine 
treatment (C. O. Cunningham et al., 2013; 
Weinstein et al. 2017). Among OTP patients with 
baseline cocaine use who were randomized to 
either buprenorphine/naloxone or methadone, 
methadone was more effective at reducing number 
of days of opioid use, whereas the two medications 
were equally effective at reducing opioid use in 
patients without baseline cocaine use (Hser et 
al., 2016). Thus, in some OTP patients who have 
concurrent opioid and cocaine use, methadone 
might be more effective than buprenorphine/ 
naloxone in helping them achieve abstinence from 
opioids, but it is unclear which OUD medication 
would defnitively yield better results for patients 
with both opioid and stimulant use disorders. 
Compared with cocaine, there appears to be 
less research about the effects of MA on opioid 
medication, but what data are available suggest 
a negative relationship. In the WA-MAT-PDOA 
study, people with past-month MA use were in 
buprenorphine treatment for a signifcantly shorter 
length of time and were more likely to drop out 
or be terminated from treatment within the frst 3 
months, compared with people who did not report 
past-month MA use (Tsui et al., 2020). Past-month 
MA use in the same study was associated with 
more than 2 times the relative risk for treatment 
nonretention than not having past-month MA use. 
There appears to be very limited data from U.S. 
trials in humans on the effects of stimulants on 
naltrexone/extended-release naltrexone for 
OUD, making it hard to draw conclusions about 
whether cocaine and MA infuence outcomes with 
these medications specifcally. However, in some 
small samples, naltrexone has been associated 
with reduced cue-induced craving and subjective 
feelings of craving in people who use MA (Ray et 
al., 2015; Roche et al., 2017). 
In a very small qualitative, exploratory study of 25 
patients with current or recent stimulant use who 
were taking OUD medication, participants reported 
feeling that (Rawson, 2020): 
• Stimulants seemed, subjectively, to be more 
“addicting” than opioids. 
• Craving was a strong factor in their ambivalence 
about stopping stimulant use. 
150 Chapter 6 
TIP 33
 
Chapter 6—Treatment Considerations for Special Populations 
• Individual and group counseling was not helpful 
to their stopping stimulant use, but avoidance 
practices (e.g., not carrying cash, avoiding 
friends who use substances) were. 
In addition, the few people in the study who had 
previously participated in CM for stimulant use 
reported fnding it very helpful. (See Chapter 4 for 
more information about CM for stimulant use.) 
Peer recovery support specialists can play a role 
in helping people with OUD access medication 
treatment. Samuels et al. (2019) trained recovery 
coaches (another term for peer recovery support 
specialist) from a community-based recovery 
organization to approach patients treated and 
discharged from an emergency department 
following opioid overdose. Recovery coaches 
were trained to assess overdose risk factors 
and readiness to seek treatment and to provide 
individualized support and linkage to providers 
who could prescribe medication for OUD. The 
median number of days before starting OUD 
medication was shorter among the people given 
access to a recovery coach, compared with people 
discharged as usual. 
People Who Inject Drugs 
Injecting cocaine or MA, like injecting other drugs, 
poses a major public health problem because 
of potential HIV and hepatitis transmission. This 
transmission can occur when people who inject 
cocaine or MA share infected injecting equipment. 
Transmission can also occur when PWID with HIV 
or hepatitis have sexual contact, especially unsafe 
contact, with others. 
Prevalence of Injecting Drugs in People 
Who Use Stimulants 
An estimated 6.6 million people age 13 and older, 
representing 2.6 percent of the U.S. population, 
had injected drugs, including stimulants, as of 
2011 (Lansky et al., 2014). Among adults reporting 
past-year MA use between 2015 and 2018, 22.3 
percent injected MA (C. M. Jones et al., 2020). 
Many PWID have unmet healthcare service needs 
and poorer long-term outcomes, like experiencing 
homelessness or incarceration (Dasgupta et al., 
2020; Genberg et al., 2015; Linton et al., 2013; 
Robbins et al., 2010). 
Pattern of Use and the Consequences 
One factor that may increase risk of infection 
among PWID is their pattern of use. Cocaine is 
frequently used in intermittent cycles of repeated 
multiple uses known as binges (Vosburg et al., 
2010). This pattern of use, observed in human 
laboratory studies (Foltin et al., 2015; Vosburg et 
al., 2010), often leads to more frequent injections 
during a binge than are generally observed in 
people with opioid use disorder. 
This greater frequency of injection during a 
binge appears to have a greater likelihood of HIV 
infection. In a meta-analysis of global HIV risk 
among PWID (including in North America), the risk 
of HIV incidence was 3.6 times higher for people 
injecting cocaine and 3.0 times higher for people 
injecting amphetamine-type stimulants, compared 
with the risk for people who had not injected the 
drugs in the previous 6 months (Tavitian-Exley et 
al., 2015). 
Data from CDC suggest that PWID are about 16 
times more likely than people without injection 
drug use to develop invasive methicillin-resistant 
Staphylococcus aureus (staph) infections (Jackson 
et al., 2018). Another emerging medical issue 
related to injection drug use CDC has identifed 
is infective endocarditis (an infection in the heart; 
CDC, n.d.-e). Injection drug use is the main cause 
of infective endocarditis. Anywhere from 5 to 
10 percent of total deaths among PWID are due 
to this condition (Ji et al., 2012), which has an 
inpatient mortality rate of about 5 to 8 percent. 
The number of PWID younger than age 35 who 
died from infective endocarditis doubled from 
1999 to 2016 (Kadri et al., 2019). Staphylococcus 
aureus causes between 52 and 62 percent of cases 
of infective endocarditis in PWID (See et al., 2020). 
Reducing Injection Drug Use and Its 
Consequences 
A variety of interventions have been used to 
prevent the initiation of injection drug use (for 
a review, see Werb et al., 2013) and reduce the 
consequences of injection drug use (for reviews, 
see Jeal et al., 2015; MacArthur et al., 2014). These 
interventions are tailored to PWID in general. 
Beyond promoting cessation of injection drug use 
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through comprehensive SUD care, it is important to 
educate PWID regarding harm reduction principles 
and safer injection practices to avoid the negative 
consequences of injection drug use. 
Evidence shows that multicomponent HIV 
prevention programs—which provide antiretroviral 
medication, HIV testing, access to and education 
about condoms, and behavioral prevention skills 
training to people with HIV and their partners— 
reduce the risk of transmission over time (CDC, 
2016). 
Syringe access programs have been implemented 
in a wide variety of circumstances throughout the 
world (Des Jarlais et al., 2013; Nguyen et al., 2014). 
Research on syringe access programs show that 
they reduce the risk of HIV and hepatitis and do 
not lead to more injection drug use (Abdul-Quader 
et al., 2013; Bramson et al., 2015; CDC, n.d.-f). 
Furthermore, education on safer injection practices 
reduces the risk of skin and soft tissue infection 
among PWID (Baltes et al., 2020). To learn about 
recommendations and guidelines for safer injection 
practices (e.g., supplies, injection sites, injection 
processes), see the National Harm Reduction 
Coalition’s Getting Off Right: A Safety Manual for 
Injection Drug Users (https://harmreduction.org/ 
issues/safer-drug-use/injection-safety-manual/) 
and the Boston Public Health Commission’s 
Access Harm Reduction Overdose Prevention and 




Although research supports the use of syringe 
access programs (Platt et al., 2017) and safer 
injection education (Des Jarlais, 2017), barriers 
exist to using them for HIV and hepatitis risk 
reduction. For example, a study of adults who 
inject heroin identifed greater distance from 
syringe access programs, worries about potential 
arrest for possession of syringes, and lack of 
appropriate preparation (i.e., not having alcohol, 
alcohol wipes, or new syringes available) as barriers 
to use of sterile needles (Phillips, 2016). Further, 
perceived stigma from pharmacists and syringe 
access program staff can also affect engagement 
among PWID (Paquette et al., 2018; Rivera et al., 
2014). 
Prior to the implementation of syringe access 
programs, the 1995 report Preventing HIV 
Transmission: The Role of Sterile Needles and 
Bleach, produced by a panel organized by the 
National Research Council and the Institute of 
Medicine (IOM; now the National Academy of 
Medicine), states that bleach disinfection, when 
performed according to the guidelines provided by 
CDC and SAMHSA’s Center for Substance Abuse 
Treatment, is useful in preventing HIV infection 
for PWID who share injecting equipment. The 
IOM report recommends that PWID be trained 
in effective procedures and more research be 
conducted to identify the simplest effective 
disinfection procedures. Bleach disinfection is 
recommended in situations where alternative, 
effective interventions (e.g., syringe exchange 
programs) are not available. 
People Living With HIV/AIDS 
People who use stimulants are at higher risk for HIV 
acquisition, as they are more likely to (SAMHSA, 
2020j): 
• Engage in condomless sex. 
• Have multiple sexual partners. 
• Reuse or share injection drug equipment. 
People who inject stimulants may be at elevated 
risk for HIV acquisition compared with individuals 
who inject other substances, because of the 
frequency with which injection of stimulants 
occurs (Tavitian-Exley et al. 2015). Sexual activity, 
in particular being an anal receptive partner, 
and needle sharing are common routes of HIV 
acquisition for people who inject stimulants. Exhibit 
6.2 lists the probabilities of acquiring HIV from 
an infected source for various types of exposure. 
Providers need to address risk factors for HIV 
transmission with patients using stimulants. 
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EXHIBIT 6.2. Estimated Per-Act Probability of Acquiring HIV From an
Infected Source by Exposure Act* 
TYPE OF EXPOSURE RISK PER 10,000 EXPOSURES 
PARENTERAL (I.E., NONORAL) 
SEXUAL 
OTHER† 
Blood Transfusion 9,250 
Needle-Sharing During Injection Drug Use 63 
Percutaneous (Needle-Stick) 23 
Receptive Anal Intercourse 138 
Insertive Anal Intercourse 11 
Receptive Penile–Vaginal Intercourse 8 
Insertive Penile–Vaginal Intercourse 4 
Receptive Oral Intercourse Low 
Insertive Oral Intercourse Low 
Biting Negligible 
Spitting Negligible 
Throwing Body Fluids (Including Semen or Saliva) Negligible 
Sharing Sex Toys Negligible 
*Factors that may increase the risk of HIV transmission include sexually transmitted diseases, acute and 
late-stage HIV infection, and high viral load. Factors that may decrease the risk include condom use, 
male circumcision, antiretroviral treatment, and PrEP. None of these factors are accounted for in the 
estimates presented in the table. 
†HIV transmission through these exposure routes is technically possible but unlikely and not well 
documented. 
Sources: 
• Patel, P., Borkowf, C. B., Brooks, J. T., Lasry, A., Lansky, A., & Mermin, J. (2014). Estimating per-act HIV transmission 
risk: A systematic review. AIDS (London, England), 28(10), 1509–1519. 
• Pretty, L. A., Anderson, G. S., & Sweet, D. J. (1999). Human bites and the risk of human immunodefciency virus 
transmission. American Journal of Forensic Medicine and Pathology, 20(3), 232‒239. 
Source: Adapted from CDC (n.d.-b). Estimated per-act probability of acquiring HIV from an infected source, by 
exposure act (https://www.cdc.gov/hiv/risk/estimates/riskbehaviors.html). 
















Screening people with stimulant use disorders 
for HIV should be part of the standard of care 
provided by SUD treatment programs (SAMHSA, 
2020j). Patients may be reluctant to undergo an 
HIV test because they fear the results or because of 
stigma related to HIV/AIDS. Clinicians can help to 
increase both HIV testing uptake and engagement 
among patients who have a positive test by 
educating patients about effective treatments 
for HIV and the concept of “undetectable equals 
untransmittable” (U=U). The U=U slogan, which is 
part of the Prevention Access Campaign, conveys 
to patients that they cannot transmit HIV sexually 
if they are adherent to antiretroviral therapy (ART) 
and they do not have detectable levels of HIV in 
their blood for at least 6 months (Eisinger et al., 
2019). In the setting of highly active antiretrovirals, 
a durably suppressed HIV viral load truly is 
treatment as prevention. 
Many factors may delay a diagnosis of HIV 
in patients who use stimulants and it is more 
likely that patients using stimulants will have 
an AIDS diagnosis at the time of their positive 
HIV test (United Nations Offce on Drugs and 
Crime, 2019a). Patients living with HIV and using 
stimulants may have increased risk for progression 
to an AIDS diagnosis and increased all-cause 
mortality (Carrico et al., 2014). 
For patients who have a positive HIV screen, 
clinicians should confrm the diagnosis and link the 
patients to HIV care immediately for evaluation 
by a treatment provider (SAMHSA, 2020j). This 
may be overwhelming for patients, particularly in 
the setting of active substance use. Clinicians can 
avoid delays in linkage to care and promote patient 
safety by using a warm-handoff approach, in which 
the patient’s care is transferred between providers 
in the presence of the patient. 
Treating people living with HIV/AIDS (PLWHA) is 
another area in which program linkages become 
critical to successful treatment. It is helpful, where 
possible, to have medical staff skilled in both HIV 
and SUD care to provide patients convenient 
access to treatment for both chronic health 
conditions. Given the complex stigma patients face 
when living with HIV and SUD, it is imperative to 
seamlessly transition patients and refer them to 
appropriate care providers. 
Treatment for Stimulant Use Disorders 
Although ART has advanced signifcantly and new 
medication regimens like long-acting injectable 
products are on the horizon, daily medication 
adherence is still pivotal to having a durably 
suppressed viral load. In patients injecting 
stimulants, daily ART adherence is affected. 
Stimulant use is correlated with lower daily 
adherence, but does not necessarily correlate 
with increased levels of detectable HIV viral loads 
(Marquez et al., 2009). Additional research has 
found that positive affect intervention coupled 
with community-based CM may be effective in 
increasing viral suppression and limiting patients’ 
stimulant use (Carrico, Hunt, et al., 2019; Carrico, 
Neilands, et al., 2019). 
MA has been associated globally not only with higher
rates of HIV acquisition, but also with more diffculty
in patients reaching HIV viral suppression (Mastro
et al., 2020). Among people who use MA and are
living with HIV, there is an increased likelihood of
transmitted drug resistance (Cachay et al., 2007).
Multiple mechanisms of action have been indicated
for the worsening outcomes for PLWHA and using
MA, including infammation (Castillo-Mancilla et al.,
2016), increased viral replication (Mastro et al., 2020),
and immunologic dysfunction (Carrico et al., 2018)
related to substance use. 
One of the critical aspects of providing SUD 
treatment to PLWHA is the continuing education 
that clinicians need regarding the changing and 
complex array of medication regimens available 
to this population. Further, clinicians need an 
awareness of the compounded stigma that many 
PLWHA who use stimulants may face in seeking 
treatment in traditional medical systems (Brinkley-
Rubinstein, 2015; Pescosolido & Martin, 2015). 
Peer support may be crucial in helping PLWHA 
feel understood, encouraged, and supported in 
their recovery journey. In addition to facing SUDs, 
PLWHA may also be dealing with mental health 
issues and trauma, all of which make the recovery 
process particularly complex. Support from a peer 
can be powerful because of their understanding of: 
• The complexities of living with HIV/AIDS. 
• Accompanying substance-related, mental, and 
social needs. 
• Ways to access needed resources. 
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For more information on this topic, see 
SAMHSA’s publication Prevention and 
Treatment of HIV Among People Living with 





People With or At Risk for
Hepatitis 
Hepatitis is an infammation of the liver. It is often 
caused by viruses, the most common of which 
in the United States are hepatitis A virus (HAV), 
hepatitis B virus (HBV), and HCV. HCV is the most 
prevalent hepatitis virus in the United States (CDC, 
2021d). The primary mode of HCV transmission is 
injection drug use, particularly among young adults 
and rural populations (Harris et al., 2016; Iqbal 
et al., 2015; Page et al., 2013). Sexual contact is 
another common mode of transmission, particularly 
among PWID with sexual behavior with an elevated 
risk of tissue tearing (Tracy et al., 2014) or with 
co-occurring HIV infection (J. Chen et al., 2014). 
The prevalence of lifetime HCV infection among 
PWID ranges from 65 to 90 percent (Crawford 
& Bath, 2013; P. K. Nelson et al., 2011). HCV 
seropositivity is correlated with duration and 
frequency of injection (CDC, 2011). Among PWID 
who are also MSM and have HIV infection, the 
prevalence of detectable HCV infection is 40 
percent (Jordan et al., 2017). 
In a study of individuals who reported lifetime use 
of MA and who had susceptibility to HBV, 6.95 
percent had active HCV infection (Tressler et al., 
2020). People who use both MA and opioids have 
been shown to be almost twice as likely to have 
HBV or HCV compared with individuals who use 
opioids alone (Shearer et al., 2020). Another study 
found that among individuals who reported lifetime 
use of cocaine, 22 percent reported a history of 
HCV and 8 percent reported a history of HBV 
(Novick et al., 2016). 
HCV begins as an acute infection but may become 
chronic, which can lead to liver disease, other 
serious health consequences, and death (SAMHSA, 
2015). It is important to educate patients on the 
symptoms of acute HCV infection to increase the 
likelihood of screening and healthcare-seeking 
behaviors. One of the biggest barriers to medical 
treatment for HCV is that 65 to 75 percent of 
people with chronic HCV infection are unaware of 
their status because they are asymptomatic and 
likely will be until the disease advances (McGowan 
& Fried, 2012). It is also apparent from in vitro 
studies and animal data that stimulant use may 
promote HCV replication and in turn increase 
disease progression (Ye et al., 2008). 
Although no vaccine exists for HCV, effective and 
well-tolerated medications that can cure HCV are 
now available. The SIMPLIFY study demonstrated 
that stimulant use negatively impacts adherence to 
directly acting antivirals. However, the same study 
indicated that despite the issues with adherence 
related to stimulant use, patients continue to 
experience a functional cure with the completion of 
the therapeutic regimen (E. B. Cunningham et al., 
2018). 
Vaccines for HAV and HBV have existed for years 
(CDC, 2015), although HBV vaccination coverage 
among adults remains low, especially among PWID 
(Harris et al., 2016). Despite the availability of HAV 
and HBV vaccines, outbreaks of these infections 
have occurred in many states in the past decade. 
HBV outbreaks have been attributed in large part 
to injection drug use, and people who use drugs. 
Additionally, PWID are at increased risk for HAV, 
which is foodborne (CDC, 2021c; Foster et al., 
2019; Iqbal et al., 2015). 
SUD care providers can make a major contribution 
to public health, as well as their patients’ health, 
by screening for viral hepatitis or assisting patients 
in getting such screening. Exhibit 6.3 describes 
hepatitis risk and prevention for people who use 
stimulants. The U.S. Preventive Services Task 
Force (USPSTF) recommends screening for HBV 
in adolescents and adults at increased risk for 
infection, which includes PWID (USPSTF, 2020b). 
The USPSTF recommends HCV screening at least 
once for all adults, but periodically for people 
at continued risk for HCV, which includes PWID 
(USPSTF, 2020a). SUD care for people with 
stimulant use or at risk for stimulant use ideally 
should include a screening for viral hepatitis in the 
initial assessment. 
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WHY PEOPLE WHO USE 
STIMULANTS ARE AT RISK 
PREVENTION STRATEGIES 
HAV Fecal-oral MSM and people who use drugs 
have an increased risk for HAV 
infection (CDC, n.d.-c). 
Patients who use stimulants may 
be experiencing homelessness/ 
unstable housing or otherwise 
are living in situations that are not 
adequate for hygienically preparing 
food. This is a risk factor because 
the virus can be contracted through 
HAV-contaminated food and water 
(CDC, 2020b). 
Encourage patients to get their HAV 
vaccination (N. P. Nelson et al., 2020). 
Help patients with any personal 
hygiene needs and food preparation 
assistance (e.g., education about 
the dangers of eating uncooked 
food and how that might lead to 
HAV transmission; N. P. Nelson et al., 
2020). 
HBV Blood and body 
fuids 
Condomless sex with a partner 
living with HBV increases the odds 
of HBV transmission, particularly 
in the setting of dry mucosa 
and tissue tearing secondary to 
stimulant use. 
Encourage patients to get their HBV 
vaccination (Schillie et al., 2018). 
Offer patients access to condoms for 
anal and vaginal intercourse. 
HCV Blood-blood People who use stimulants may 
be injecting them, and injection 
drug use (including syringe 
sharing) increases the risk of HCV 
transmission among people using 
stimulants (Farrell et al., 2019). 
Stimulants can dry out body 
mucosa, increasing the risk for 
tissue tearing and transmission of 
HCV during sexual activities. 
People smoking or insuffating (i.e., 
snorting or inhaling) stimulants 
may share pipes or stems and 
have cracked lips, which could be 
a potential source of blood-blood 
transmission. 
People injecting stimulants may 
inject multiple times during a binge 
and may share injection equipment 
with others who are using injection 
drugs. 
Offer patients treatments and 
services to help them stop injecting 
drugs (Offce of Infectious Disease 
and HIV/AIDS Policy [OIDP], n.d.-b). 
Psychosocial treatments to stop 
stimulant use altogether also should 
be offered (Farrell et al., 2019). 
Teach patients about how to access 
and use safer injection equipment, 
and offer education about safer 
injection practices (Farrell et al., 2019; 
OIDP, n.d.-b). 
Educate patients about and 
encourage patients to practice safer 
sex while using stimulants (Farrell et 
al., 2019; OIDP, n.d.-b.). Offer patients 
access to condoms and lubrication 
for vaginal and anal sex. 
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Providers who conduct these screenings need to 
recognize that individuals may hesitate to answer 
questions about injection drug use, sexual history, 
or potential risk for hepatitis because of mistrust, 
stigma, and discrimination. Further, hepatitis 
infection may be misattributed to sexual contact 
among PWID who provide accurate responses 
about their sexual practices but do not admit to 
injection drug use (Klevens et al., 2012), putting 
them at future risk for reinfection if they do 
not receive SUD treatment or harm reduction 
education. 
SAMHSA’s Hepatitis C Screening in the Behavioral 
Healthcare Setting Advisory (https://store.samhsa. 
gov/product/Advisory-Hepatitis-C-Screening-in-
the-Behavioral-Healthcare-Setting/sma15-4917) 
provides an overview of how and why to conduct 
or make referrals for HCV screening, and also looks 
at the ways HAV, HBV, and HCV are transmitted. 
For additional information and resources, see the 
CDC Viral Hepatitis webpage (https://www.cdc. 
gov/hepatitis/index.htm). 
Clinicians should also integrate education on 
hepatitis into SUD care. Education should include 
information, as appropriate, about the health 
benefts of: 
• Participating in syringe services programs. 
• Using protection when engaging in sex. 
• Getting vaccinated against HAV and HBV. 
• Taking medication for HCV. 
SAMHSA’s comic book-style publication Take 
Action Against Hepatitis C: For People in Recovery 
From Mental Illness or Addiction (https://store. 
samhsa.gov/product/Take-Action-Against-
Hepatitis-C/sma14-4853) provides information 
directed to patients. 
Individuals With Co-Occurring
Mental Disorders 
A patient with CODs has a combination of two 
or more SUDs and mental disorders as defned in 
DSM-5 (SAMHSA, 2020l). Although a stimulant use 
disorder can coexist with any mental disorder, this 
section focuses on some of the mental disorders 
that are most often diagnosed in people with 
a stimulant use disorder: depressive disorders, 
bipolar disorder, anxiety disorders, PTSD, ADHD, 
and schizophrenia. 
Someone who displays symptoms consistent with 
a mental disorder does not necessarily have an 
organic mental disorder but may have a substance-
induced disorder or symptoms mimicking an 
organic mental disorder (per DSM-5). For example, 
people in withdrawal from stimulant use may 
show symptoms of depression, but they do not 
necessarily have a depressive disorder. Similarly, 
people who use MA may exhibit psychotic 
symptoms like those common in people with 
schizophrenia, but the psychotic symptoms are 
not conclusive evidence of schizophrenia and may 
resolve with cessation of substance use. 
Other symptom clusters commonly associated 
with specifc mental disorders are also frequently 
seen during the use of stimulants or during early 
abstinence. These symptom clusters include 
physical and psychological signs of anxiety, mood 
fuctuations, and antisocial behavior. 
Some people with stimulant use seek psychiatric 
care for symptoms related to their stimulant use 
before entering SUD treatment. Some patients may 
use substances to treat symptoms of their organic 
mental illness rather than seeking formal treatment. 
In both cases, stigma about mental health concerns 
and SUDs can make people reluctant to engage 
in care (Zwick et al., 2020), which can result in a 
delayed diagnosis and ineffective treatment plans 
for individuals with co-occurring stimulant use 
disorder and mental illness (National Academies of 
Sciences, Engineering, and Medicine, 2016). 
Someone with stimulant use who has previously 
received a psychiatric diagnosis or has symptoms 
typically associated with a mental disorder does 
not necessarily have CODs. Having CODs means 
both an SUD and a mental disorder are actively 
present, and the patient meets full criteria (rather 
than just symptoms) for both disorders. 
The accurate diagnosis of mental illness in an 
individual with stimulant use requires considerable 
diagnostic skill on the part of the mental health 
service provider (Warden et al., 2016). It is often 
necessary to make a provisional diagnosis, which 
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is modifed after additional data are collected. 
Additionally, for patients using stimulants like 
cocaine or MA, it is important to differentiate 
symptoms associated with an organic mental 
illness and symptoms of protracted withdrawal. 
For example, patients may have symptoms of 
depression and psychosis that accompany acute 
withdrawal symptoms, but they typically resolve 
within 1 week (Zorick et al., 2010). 
Another important element in the diagnosis of 
a co-occurring mental disorder is obtaining a 
careful history of the chronological relationship 
between the onset of psychiatric symptoms and 
the substance use history. An accurate chronology 
can help clinicians determine whether there is a 
co-occurring mental disorder or the psychiatric 
symptoms are induced by the substance. 
Clinicians should assess whether the outpatient 
setting is appropriate for evaluation of symptoms. 
Hospital admission allows for a more thorough 
evaluation of symptoms and factors that may 
contribute to the symptoms. Additionally, patients 
can be observed for resolution of particularly 
concerning symptoms, such as suicidal or homicidal 
ideation or psychotic symptoms that may affect 
individual or community safety (Kampman & 
Jarvais, 2015). 
Given the many challenges people with CODs face, 
linking them with peer recovery support specialists 
may be benefcial. In one study, a treatment group 
of people with SUDs and co-occurring serious 
mental illness who participated in a peer support 
program spent more time living in the community 
before needing rehospitalization and had fewer 
rehospitalizations overall than did a comparison 
group without program participation (Min et 
al., 2007). Helping patients with CODs connect 
with peer recovery support specialists (including 
mutual-help programs devoted to CODs) should 
be a part of discharge planning, continuous care, 
and may even be combined with ongoing clinical 
interventions (e.g., CBT, medication treatment) to 
maximize positive outcomes (SAMHSA, 2020l). 
Mutual-help programs for people with 
CODs—often called dual recovery mutual-help 
programs—are available to help patients fnd 
direction and support for recovery from both 
mental illness and SUDs. More information 
about accessing dual recovery mutual-help 
programs can be found in SAMHSA’s TIP 42, 
Substance Use Disorder Treatment for People 




Specialized Treatment Interventions 
Depressive disorders 
Past-year major depressive disorder occurs in 
about 10 percent of U.S. adults (Hasin et al., 
2018). Major depression appears to be about 
1.5 times more prevalent in women than in men 
(Hasin et al., 2018). Persistent depressive disorder 
(previously called dysthymia) is likely much less 
common, although current U.S. prevalence rates 
are unclear at this time. Data based on diagnostic 
criteria from DSM-IV show a 12-month persistent 
depressive disorder prevalence of 1.5 percent 
in U.S. adults (Blanco et al., 2010). Co-occurring 
persistent depressive disorder and episodes of 
major depressive disorder, known as “double 
depression,” have been shown to occur in 14 
percent of patients who seek treatment for SUDs 
(N. Diaz et al., 2012). In a sample of patients with 
any stimulant use disorder who were receiving 
residential treatment, 22.6 and 9.4 percent met 
diagnostic criteria for major depressive disorder 
and persistent depressive disorder, respectively 
(Warden et al., 2016). 
To screen for depressive disorders, clinicians can 
use an evidence-based screener such as the Patient 
Health Questionnaire (PHQ-9; Beard et al., 2016; 
Bentley et al., 2021). 
Key recommendations for clinicians working 
with patients who have co-occurring depressive 
disorders include (SAMHSA, 2020l): 
• Initiating medications as soon as patients 
engage in care (if feasible). It should be noted 
that for patients taking medications affecting 
serotonin (e.g., selective serotonin reuptake 
inhibitors), there may be an elevated risk for 
serotonin syndrome in the setting of continued 
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stimulant use. Patients should be educated 
about these signs and symptoms and advised 
on what to do should they experience them 
(Cooper & Sejnowski, 2013; Moss et al., 2019). 
• Using integrated CBT approaches that draw on 
functional analysis of the relationship between 
depression and substance use, incorporate 
cognitive training, and encourage behavioral 
activation. 
• Evaluating for the development of “double 
depression”—the occurrence of persistent 
depressive disorder and intermittent major 
depressive episodes. 
• Evaluating whether antidepressant medication is 
warranted for managing depressive symptoms 
or providing a referral for a medication 
evaluation. 
• Considering the temporal relationship between
depression and SUD, which can be unclear and
can affect treatment planning. Clinicians can avoid
making assumptions about what is causing and
maintaining depression or an SUD by using various
treatment approaches that address both CODs. 
Bipolar disorder 
About 2 percent of U.S. adults report a lifetime 
history of bipolar disorder (Blanco et al., 2017). 
Results from the National Epidemiologic Survey 
on Alcohol and Related Conditions–III, a large 
epidemiological study using DSM-5 criteria, show a 
strong positive association between past-year drug 
use disorder (i.e., an SUD excluding alcohol) and 
bipolar I disorder, with an odds ratio of 1.5 (B. F. 
Grant et al., 2016). Patients with SUDs and bipolar 
disorder have an increased risk for an unstable and 
more severe course of illness, violence, and suicide 
(Swann, 2010). A co-occurring bipolar disorder and 
SUD is also associated with worse clinical outcomes 
compared with clinical outcomes for bipolar 
disorder alone (Farren et al., 2012). 
Patients with bipolar disorder may use stimulants 
to self-treat depressive episodes. Additionally, 
given the elevated mood associated with stimulant 
use, it is not uncommon for patients using 
stimulants to experience manic symptoms while 
acutely intoxicated from stimulant use. Patients 
with bipolar disorder that is well managed by 
medication can be treated in traditional treatment 
settings. Therefore, medication management, 
specifcally daily adherence, is one of the most 
important issues in treating patients with bipolar 
disorder (Salloum & Brown, 2017). 
Anxiety disorders 
In 2019, one in six (15.6%) adults age 18 and 
older reported experiencing symptoms of mild, 
moderate, or severe generalized anxiety within 
the past 2 weeks (Terlizzi & Villarroel, 2020). 
Nearly 7 percent of U.S. adults report having 
had panic disorder in their lifetime (Kessler et al., 
2012). Patients with anxiety disorders and SUDs 
have greater symptom severity, more functional 
impairment, and poorer course of illness than 
patients with only an anxiety disorder or an SUD 
(Magidson et al. 2012; McHugh, 2015). In a sample 
of patients with any stimulant use disorder who 
were receiving residential treatment, 29.6 percent 
met diagnostic criteria for a co-occurring anxiety 
disorder, with generalized anxiety disorder (15.3%) 
and social phobia (10.6%) comprising the most 
common anxiety disorders (Warden et al., 2016). 
To screen for generalized anxiety, clinicians can 
use an evidence-based screener such as the 
Generalized Anxiety Disorder scale (GAD-7; 
Bentley et al., 2021; Rutter & Brown, 2017). 
Key recommendations for clinicians working with 
patients who have co-occurring anxiety disorders 
include (SAMHSA, 2020l): 
• Identifying patients with elevated anxiety early 
in SUD treatment, which can help address risks 
that contribute to treatment engagement and 
retention as well as posttreatment relapse. 
• Screening for elevated anxiety early in treatment 
to identify patients who may need additional 
skills to help them manage elevated distress 
related to stopping or decreasing their 
substance use. 
• Discussing reasons for treatment concerns when 
relevant, especially adherence interference from 
anxiety symptoms or anxiety-related avoidance. 
• Integrating a holistic approach to treatment, 
such as: 
- Providing psychoeducation about the nature 
of anxiety and its role in SUDs. 















- Teaching CBT techniques to recognize and 
manage symptoms of anxiety. 
- Discussing appropriate medication options, 
using motivational enhancement strategies. 
- Practicing mindfulness techniques. 
- Encouraging healthy lifestyle activities (e.g., 
diet, physical activity, sleep hygiene). 
• Exercising extreme care in prescribing 
benzodiazepines for anxiety disorders, because 
of their high addiction potential. 
Posttraumatic stress disorder 
A strong association exists between PTSD and 
SUDs (B. F. Grant et al., 2015; B. F. Grant et 
al., 2016; Hasin & Kilcoyne, 2012). The lifetime 
prevalence of PTSD in people with SUDs is thought 
to range between 26 and 52 percent, and rates 
of current PTSD between 15 and 42 percent 
(Vujanovic et al., 2016). 
People in treatment for a cocaine use disorder 
have double the odds of probable PTSD compared 
with people without cocaine use disorder, and the 
risk is greater for women than for men (Saunders et 
al., 2015). Among people who complete treatment 
for MA use disorder, PTSD is associated with more 
than 5 times greater odds of posttreatment MA 
use than not having PTSD (Glasner-Edwards et al., 
2013). Women who are likely to experience trauma, 
such as those with current or past experiences of 
domestic violence, sexual assault, or homelessness, 
may be vulnerable to MA use and the negative 
effects of MA (Kittirattanapaiboon et al., 2017). 
Clinicians need to obtain specialized training 
to work with individuals who have co-occurring 
SUD and PTSD. To screen for PTSD, clinicians 
can use an evidence-based screener such as the 
PTSD Checklist for DSM-5 (PCL-5; Blevins et al., 
2015; Keane et al., 2014; LeardMann et al., 2021). 
Specialized treatment issues include relapse 
triggers, timing of addressing issues in group 
sessions, and the tools and social skills necessary 
to facilitate a successful recovery. Trauma-informed 
care should be universal throughout treatment 
settings. Learn more about how to provide trauma-
informed care for patients with stimulant use 
disorders in SAMHSA’s TIP 57, Trauma-Informed 
Care in Behavioral Health Services (https:// 
store.samhsa.gov/product/TIP-57-Trauma-
Treatment for Stimulant Use Disorders 
Informed-Care-in-Behavioral-Health-Services/ 
SMA14-4816). 
Key recommendations for clinicians working with 
patients who have co-occurring PTSD include: 
• Acknowledging that disclosure is not the 
initial goal. Use a trauma-informed approach 
to help patients view the SUD care setting as 
a safe place at the beginning of treatment by 
using grounding exercises, treatment routines, 
safety-promoting behaviors, and safety plans. 
Be careful not to rush patients into discussing 
trauma and monitor the intensity and speed of 
the treatment for signs that patients are feeling 
overwhelmed (SAMHSA, 2020l). 
• Treating PTSD and stimulant use disorder 
concurrently, as PTSD symptoms can worsen 
during abstinence (SAMHSA, 2020l). 
• Implementing strategies to prevent 
retraumatization of patients, such as recognizing 
triggers and their cues, reacting to behaviors 
resulting from triggers in a sensitive manner, 
and teaching patients to identify and manage 
triggers (SAMHSA, 2020l). 
• Recognizing the cyclical relationship between 
trauma and substance use and providing 
education to patients about this relationship. 
Having an increased awareness of this 
relationship allows patients to develop and 
implement safeguards (SAMHSA, 2020l). 
• Referring patients to sexual assault and incest 
support groups as quickly as possible, as 
appropriate. 
• Offering group counseling in a gender-
responsive format that includes coaching on 
what to expect from dreams, fears, and sleep 
disruptions as a result of PTSD and withdrawal 
from stimulants. 
• Providing information on practical tools to 
combat nightmares and sleep disruption—such 
as exercise, night lights, herbal teas, and 
relaxation techniques—as well as information 
on relapse triggers (McHugh et al., 2014). Such 
information will help provide patients with 
reassurance and skills to get through this period. 
• Tailoring treatment to unique trauma-related 
symptoms and needs; the widely used Seeking 
Safety program is an example of such an 
approach (Berenz & Coffey, 2012; Lenz et al., 
2016; Ruglass et al., 2014). 
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• Evaluating whether medication is warranted 
for managing PTSD symptoms or providing a 
referral for a medication evaluation (Berenz & 
Coffey, 2012). 
Attention defcit hyperactivity disorder 
The prevalence of ADHD is estimated to be 9.4 
percent in children ages 2 to 17 (Danielson et al., 
2018). The prevalence of adult ADHD is about 2.5 
percent (Katzman et al., 2017). The co-occurrence 
of SUDs in people with ADHD is quite high, 
especially for cocaine, alcohol, nicotine, and 
cannabis (Klassen et al., 2012). Use of prescribed 
stimulant medication for children with ADHD is not 
associated with an increased risk of developing an 
SUD later in life (Klassen et al., 2012). Increasing 
numbers of young adults with ADHD are attending 
college, many of whom may be prescribed a 
prescription stimulant (Weyandt et al., 2013). 
Clinicians need to retrieve a clear longitudinal 
history of both substance use and symptoms 
of ADHD before formalizing SUD and ADHD 
diagnoses. Symptoms of stimulant withdrawal or 
intoxication can mirror some symptoms of ADHD 
(e.g., impulsivity, attention diffculties, restlessness, 
agitation; Kaye et al., 2013). However, stimulant-
related symptoms tend to disappear with time 
(when the patient is no longer in withdrawal or 
intoxicated). 
Generally, adults with ADHD also had the disorder 
when they were children (that is, new onset usually 
does not occur in adulthood), although it may 
not have been diagnosed as such (Ahmad et al., 
2019). An assessment of childhood symptoms 
should be part of completing the patient’s history. 
The presence of ADHD symptoms in childhood 
provides a reliability measure for the presence of 
the adult disorder. 
HOW TO TREAT ADHD IN PEOPLE WITH CO-OCCURRING STIMULANT USE
DISORDER 
Stimulant medications are widely used, highly effcacious, and very effective for treating ADHD in children 
and adults. How can providers in primary care and integrated care settings approach ADHD management 
for adults who have co-occurring stimulant use disorder and want to pursue abstinence? 
Not much research has been done on how best to treat patients with ADHD and co-occurring stimulant 
use disorder. The available studies have mixed fndings on treatment effectiveness (J. Cook et al., 2017). 
High-dose stimulant medication has been suggested as a potential aid in reducing both ADHD and illicit 
stimulant use (J. Cook et al., 2017), with robust research support among people who use cocaine (Levin 
et al., 2015). This strategy would have to be used with diversion prevention and compliance/monitoring 
approaches, such as (Colaneri et al., 2017): 
• Prescribing long-acting, rather than short-acting, stimulant formulations. 
• Using medication contracts. 
• Limiting prescriptions to a smaller number of pills. 
• Implementing pill counts. 
• Providing education about medications to patients. 
For patients who want to be completely abstinent from all stimulants, several safe and effective 
nonstimulant ADHD medications with low addiction potential are available, such as atomoxetine, 
guanfacine, and clonidine (Clemow & Walker, 2014). Although not approved by FDA for the treatment 
of ADHD, antidepressants like venlafaxine and bupropion have also shown some use in reducing some 
ADHD symptoms (Katzman et al., 2017). However, nonstimulant medication is not considered a frst-line 
pharmacotherapy for ADHD (Katzman et al., 2017). Pharmacotherapy should always be monitored closely 
for potential interactions with other drugs, side effects, or misuse, especially when prescribed to individuals 
with a history of SUDs. 
Continued on next page 
















































Treatment for Stimulant Use Disorders 
Continued 
Several nonpharmacologic treatments for ADHD have demonstrated effcacy and should be a core part of 
any ADHD treatment plan, regardless of whether medication is also prescribed. In patients with stimulant 
use disorder who want to remain abstinent, reliance on nonpharmacologic interventions becomes even 
more critical. Such interventions are (Katzman et al., 2017): 
• Psychoeducation (e.g., learning organizational skills, fnding resources and support groups). 
• Psychotherapy (e.g., CBT, interpersonal therapy). 
• Behavioral interventions (e.g., teaching patients how to manage their environment, helping patients 
make healthy lifestyle changes, such as getting more exercise or better sleep). 
• Social interventions (e.g., social skills training, anger management). 
• School/workplace accommodations (e.g., being given extra time to complete tests, being allowed to close 
one’s offce door to minimize distractions). 
Both conditions can be treated concurrently, but if the patient is destabilized because of stimulant use, 
the provider may need to address the SUD and stabilize the patient before pursuing ADHD treatment 
(Katzman et al., 2017). 
Schizophrenia 
Schizophrenia is very uncommon in the United States,
with somewhere between 0.3 and 0.7 percent of
U.S. adults developing the disorder in their lifetime
(APA, 2013). The prevalence of SUDs among people
with schizophrenia is estimated to be as high as 55
percent (Kerner, 2015). 
Key recommendations for clinicians working with
patients who have co-occurring schizophrenia
include: 
• Treating SUD immediately to allow time for the
medication for the mental illness to take effect.
Both conditions should be treated at once, as
substance use in schizophrenia can worsen disease
course and may reduce adherence to antipsychotic
medication (Werner & Covenas, 2017). 
• Providing psychoeducation about schizophrenia,
medication, and the importance of medication
adherence for symptom control (SAMHSA, 2020l). 
• Beginning treatment with deescalation and
treatment of the psychotic symptoms through
sleep, medications, and nutritional support. This is
recommended because continuous cocaine or MA
use, particularly in the setting of sleep deprivation,
may result in psychotic symptoms and in severe
cases may be completely indistinguishable from
paranoid schizophrenia (J. M. Wilkerson et al.,
2018). 
• Providing treatment for both schizophrenia and
stimulant use disorder with slight modifcations
after a stabilization period. 
• Teaching patients to detect early signs of relapse
for both schizophrenia and stimulant use or
prescription stimulant misuse (SAMHSA, 2020l). 
• Teaching patients to manage positive and
negative symptoms of psychosis, increase coping
skills, improve social skills (e.g., communication
with others), expand social networks, enhance
problem-solving abilities, build distress tolerance,
increase motivation, and set and achieve goals. 
• Modifying group counseling, so that groups are
smaller and more structured than in traditional
SUD treatment. Confrontational situations should
be avoided. To be effective, each group session
should focus on a particular skill or topic. For
patients with unstable schizophrenia currently
exhibiting uncontrolled positive symptoms,
deferment of group counseling and continued
individual counseling may be appropriate until
stabilization occurs. 
Learn more about treating patients with
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Summary 
Patients who belong to specifc populations with 
intrinsic vulnerabilities related to systems of care 
may have higher rates of stimulant use disorders 
and more diffculties engaging in care for these 
disorders. Factors that can infuence treatment 
engagement among these special populations 
include location and availability of SUD programs 
and culturally competent clinicians, clinicians’ 
ability to foster trust and safe relationships, 
and clinicians’ ability to apply individualized 
approaches. By understanding the needs of 
special populations with stimulant use disorders, 
as well as their care access issues and treatment 
considerations, clinicians can provide patient-
centered, effective care that maximizes rapport and 
treatment engagement. 
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Chapter 7—Resources 
Resources for Counselors,
Providers, and Programs 
Substance Abuse and Mental Health Services 
Administration (SAMHSA), Addiction 
Technology Transfer Center (ATTC) Network
(https://attcnetwork.org): The ATTC Network is 
a multidisciplinary resource for professionals in 
the substance use disorder (SUD) treatment and 
recovery services feld. The network’s 10 U.S.-
based centers, 2 national focus area centers (the 
National American Indian & Alaska Native ATTC 
[https://attcnetwork.org/centers/national-american-
indian-and-alaska-native-attc/home] and National 
Hispanic and Latino ATTC [https://attcnetwork. 
org/centers/national-hispanic-and-latino-attc/ 
home]), and Network Coordinating Offce provide 
news, tools and other resources, and free and 
low-cost training programs. The training includes 
a new series on contingency management (CM). 
Access the CM series at https://attcnetwork.org/ 
centers/northwest-attc/news/new-online-course-
contingency-management-healthcare-settings
for Part 1 and https://attcnetwork.org/centers/ 
network-coordinating-offce/contingency-
management-part-2-founding-principles for Part 2. 
SAMHSA, Lesbian, Gay, Bisexual, and 
Transgender (LGBT) Behavioral Health Equity
(https://www.samhsa.gov/behavioral-health-
equity/lgbt): This webpage provides information 
on SAMHSA’s programs related to the LGBT 
community and SAMHSA resources for providers 
and programs working with the LGBT population, 
as well as links to other federal initiatives that seek 
to expand services and improve behavioral health 
outcomes for these individuals. 
SAMHSA, Mental Health Technology Transfer 
Center (MHTTC) Network (https://mhttcnetwork. 
org): The MHTTC Network supports resource 
development and dissemination, training and 
technical assistance, and workforce development 
for the mental health feld. The network includes 10 
Regional Centers, a National American Indian and 
Alaska Native Center (https://mhttcnetwork.org/ 
sites/default/fles/2020-12/AIAN_MHTTC_Year2_ 
TwoPager%20edited.pdf), a National Hispanic 
and Latino Center (https://mhttcnetwork.org/ 
sites/default/fles/2020-12/NHL%20MHTTC%20 
Year%202_%202%20pager.pdf), and a Network 
Coordinating Offce (https://mhttcnetwork.org/ 
centers/mhttc-network-coordinating-offce/ 
network-coordinating-offce). These centers 
work with healthcare systems, organizations, and 
treatment practitioners involved in the delivery of 
mental health services to strengthen their capacity 
to deliver effective evidence-based practices to 
individuals. 
SAMHSA, Prevention Technology Transfer Center 
(PTTC) Network (https://pttcnetwork.org): The 
PTTC Network seeks to improve implementation 
and delivery of effective substance abuse 
prevention interventions and provides training 
and technical assistance services to the substance 
abuse prevention feld. The network is comprised 
of 10 Domestic Regional Centers; 2 National Focus 
Area Centers, one focused on American Indians 
and Alaska Natives (https://pttcnetwork.org/ 
centers/national-american-indian-alaska-native-
pttc/home) and another focused on Hispanic 
and Latino populations (https://pttcnetwork.org/ 
centers/national-hispanic-latino-pttc/home); and a 
Network Coordinating Offce (https://pttcnetwork. 
org/centers/pttc-network-coordinating-offce/ 
about-network-coordinating-offce). Together the 
network serves the 50 U.S. states, the District of 
Columbia, Puerto Rico, the U.S. Virgin Islands, 
and the Pacifc Islands of Guam, American Samoa, 
Palau, the Marshall Islands, Micronesia, and the 
Mariana Islands. 
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SAMHSA, Providers Clinical Support System 
(PCSS) (https://pcssnow.org): The PCSS program 
was created in response to the opioid overdose 
epidemic to train primary care providers in the 
evidence-based prevention and treatment of 
opioid use disorder (OUD) and treatment of chronic 
pain. A coalition of major healthcare organizations, 
including the American Academy of Addiction 
Psychiatry, the American Medical Association, 
and the American Psychiatric Association (APA), 
the PCSS program provides a variety of trainings 
and clinical mentoring, with the goal of increasing 
healthcare providers’ knowledge and skills in the 
prevention, identifcation, and treatment of SUDs, 
with a focus on OUD. 
SAMHSA, Recovery Support Tools and Resources 
(https://www.samhsa.gov/brss-tacs/recovery-
support-tools-resources): This webpage provides 
SAMHSA’s working defnition of recovery and links 
to information, tools, and video trainings relevant 
to shared decision-making, peer workers, and 
programs led by parents, families, and youth and 
young adults. 
SAMHSA/National Center on Substance 
Abuse and Child Welfare, Research on 
Methamphetamine (https://ncsacw.samhsa.gov/ 
resources/methamphetamine/literature-review. 
aspx): This webpage provides citations for 
peer-reviewed research on topical areas related 
to methamphetamine (MA), including prenatal 
exposure; children and family affected by MA use; 
prevalence, intervention, and treatment; criminal 
justice and legislation; and special populations and 
how they have been impacted by MA. 
APA Presidential Task Force to Address 
Structural Racism Throughout Psychiatry (https:// 
www.psychiatry.org/psychiatrists/structural-racism-
task-force): This resource provides psychiatric 
clinicians with information about structural racism 
and mental health services. It includes continuing 
medical education programs for psychiatrists, 
recommended reading, and video recordings of 
town hall gatherings that address structural racism. 
Association of Lesbian, Gay, Bisexual, 
Transgender Addiction Professionals and 
Their Allies (NALGAP) (www.nalgap.org): 
NALGAP’s mission is to confront oppression and 
discriminatory practices in the delivery of services 
to all people and to advocate for programs 
and services that affrm all genders and sexual 
orientations. NALGAP provides information, 
training, networking, and advocacy about addiction 
and related issues, and support for health 
professions and individuals in recovery. 






campaigns): The Colorado Meth Project seeks 
to reduce the use of MA through public service 
messaging, community outreach, and public policy. 
A key component of the program is MethProject. 
org, which features TV, radio, print, online, mobile, 
and social media campaigns that communicate the 
risks of MA use. 
Generation Rx, Educational Toolkits for Safe 
Medication Practices (https://generationrx.org/ 
toolkits/): The mission of Generation Rx is to 
educate people of all ages about the dangers 
of prescription medication misuse. Developed 
through a partnership between The Ohio State 
University College of Pharmacy and the Cardinal 
Health Foundation, the Generation Rx website 
provides open-source, ready-to-use resources 
designed to help educators and providers make 
presentations or develop prevention programs in 
communities or academic environments. 
Methamphetamine Research Center (MARC) 
(https://www.ohsu.edu/methamphetamine-
research-center): Part of the Oregon Health & 
Science University, MARC is funded by the National 
Institute on Drug Abuse (NIDA) to study genetic 
factors in human and animal responses to MA, 
with the goal of identifying new approaches to 
treatment. 













Motivational Interviewing Network of Trainers 
(MINT) (https://motivationalinterviewing.org):
MINT works to establish and promote good practice
in the use, research, and training of motivational
interviewing (MI). The MINT website provides users
with a library of MI publications, as well as references,
articles, videos, and links to training opportunities in
the theory and practice of MI. 
NAADAC, The Association for Addiction 
Professionals (https://www.naadac.org/resources): 
NAADAC provides free training and low-cost 
continuing education credits for SUD professionals. 
Topics covered include SUD treatment, supervision, 
workforce development, veterans, families, trauma, 
and peer recovery support. 
National Institute on Alcohol Abuse and 
Alcoholism (NIAAA), Professional Education 
Materials (https://www.niaaa.nih.gov/alcohols-
effects-health/professional-education-materials): 
This NIAAA webpage is for clinicians, physicians, 
social workers, and other providers who work with 
people who misuse alcohol. It offers access to 
screening, brief intervention, treatment planning, 
and general information. 




research-programs): This resource supports and 
conducts studies to evaluate the safety and effcacy 
of pharmacotherapies, behavioral therapies, and 
devices to treat SUDs. 




to-treatment): This NIDA webpage provides 
behavioral healthcare practitioners with access to 
motivational incentive tools for engaging clients in 
behavioral health therapy. 
NIDAMED, Clinical Resources (https://www. 
drugabuse.gov/nidamed-medical-health-
professionals): The NIDAMED website provides 
healthcare professionals with science-based 
information about the effects of substance 
misuse on clients’ health, such as how to identify 
substance use early and prevent it from turning 
into misuse or addiction. 
NIDA, Quick Screen V1.0 (https://www.drugabuse. 
gov/sites/default/fles/pdf/nmassist.pdf): Clinicians 
can use this tool to screen patients age 18 or 
older for general substance misuse. This resource 
also includes questions from the NIDA-Modifed 
Alcohol, Smoking, and Substance Involvement 
Screening Test V2.0 that inquire about recent and 
lifetime use of specifc substances. 
NIDA/SAMHSA, Motivational Incentives 
Suite (https://collaborativeforhealth.org/ 
bettertxoutcomes/): The Motivational Incentives
Suite is a collection of tools and resources to help
organizations understand and implement CM into
practice. 
Self-Management Resource Center (https:// 
www.selfmanagementresource.com/): The 
center’s website offers a range of small-group, 
self-management programs for chronic illness. 
Programs are available online or through licensed 
local organizations. In addition to the core program 
for groups with multiple chronic illnesses, several 
condition-focused programs are offered, including 
diabetes, chronic pain, and HIV. 
Trauma Informed Oregon, Trauma 
Informed Urine Drug Screenings (https:// 
traumainformedoregon.org/wp-content/ 
uploads/2019/05/Urine-Drug-Screen-tip-sheet. 
pdf): Urine drug screens (UDS) can be triggering 
experiences for some people, especially those 
with a history of trauma. This tip sheet can be 
used to inform the UDS procedure, with the 
goals of preventing re-traumatization of patients 
and facilitating their safety. Included are guiding 
considerations, tips, and examples offered by 
service users and experts in the substance use 
treatment feld. 








U.S. Department of Veterans Affairs (VA), 
National Center for PTSD (https://www.ptsd. 
va.gov/professional/index.asp): VA offers training 
materials, information, and tools to assess and treat 
trauma-related disorders. This website contains 
links to continuing education on posttraumatic 
stress disorder (PTSD), free training in prolonged 
exposure therapy for providers who treat veterans, 
and links to VA benefts. 
Publications 
SAMHSA Publications 
After Incarceration: A Guide to Helping Women 
Reenter the Community (https://store.samhsa. 
gov/product/After-Incarceration-A-Guide-To-
Helping-Women-Reenter-the-Community/ 
PEP20-05-01-001): This guide provides an 
overview of topics and resources for supporting 
women who are reentering the community after 
involvement with the criminal justice system. It was 
created for individuals who provide or coordinate 
reentry services (e.g., corrections staff, reentry 
organizations, substance use disorder and mental 
health treatment providers, reentry specialists, peer 
specialists). 
Advisory: Hepatitis C Screening in the Behavioral 
Healthcare Setting (https://store.samhsa.gov/ 
product/Advisory-Hepatitis-C-Screening-in-the-
Behavioral-Healthcare-Setting/sma15-4917): Part of 
SAMHSA’s Advisory series, this brief guide gives an 
overview of hepatitis C and discusses approaches 
to testing, treatment, and counseling. 
Advisory: Integrating Vocational Services Into 




Advisory is directed to programs serving clients 
who are unemployed, underemployed, or struggling
in workplace settings. It presents strategies and
resources for SUD treatment counselors and clinic
directors to improve outcomes for clients in recovery
by helping them fnd and keep employment and
manage workplace stressors. 
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Anger Management for Substance Use Disorder 
and Mental Health Clients: A Cognitive— 
Behavioral Therapy Manual (https://store.samhsa. 
gov/product/PEP19-02-01-001): This treatment 
manual describes the concept of cognitive— 
behavioral therapy (CBT) and its use of social 
learning theory for treating clients in a variety of 
clinical settings. CBT teaches clients with substance 
use and mental disorders how to control their 
anger and disrupt the aggression cycle. The manual 
may be used with the companion Participant 
Workbook (see entry below). 
Anger Management for Substance Use Disorder 
and Mental Health Clients: Participant Workbook 
(https://store.samhsa.gov/product/PEP19-02-01-
002): This workbook was developed for use with 
Anger Management for Substance Use Disorder 
and Mental Health Clients: A Cognitive–Behavioral 
Therapy Manual. Participants refer to the workbook 
during anger management group treatment and 
use it to complete homework assignments. 
Clinical Guidance for Treating Pregnant and 
Parenting Women With Opioid Use Disorder 
and Their Infants (https://store.samhsa.gov/ 
product/Clinical-Guidance-for-Treating-Pregnant-
and-Parenting-Women-With-Opioid-Use-Disorder-
and-Their-Infants/SMA18-5054): This guide 
recommends standard and feasible approaches to 
the care of pregnant and parenting women with 
OUD and their infants. These approaches can be 
adopted in a variety of care settings. 
Finding Quality Treatment for Substance Use 
Disorders (https://store.samhsa.gov/product/ 
PEP18-TREATMENT-LOC): This resource is for 
people seeking behavioral health services and 
treatment for SUDs. It provides guidance on how 
to fnd a quality treatment center and the steps to 
complete before accessing treatment. 
Guidance Document for Supporting Women in 
Co-ed Settings (www.samhsa.gov/resource/ebp/ 
guidance-document-supporting-women-co-ed-
settings): Most women in SUD treatment receive 
services in co-ed treatment and recovery centers 
where men outnumber women, yet women and 
men with SUDs differ in many ways. This guide 
explores the ways in which treatment providers 
can better understand these differences and meet 
women’s specifc treatment needs. 




In Brief: Rural Behavioral Health: Telehealth 
Challenges and Opportunities (https://store. 
samhsa.gov/product/SMA16-4989): This guide 
for behavioral healthcare providers describes the 
barriers associated with implementing telehealth 
services in rural and frontier communities and 
offers tips on how to overcome these challenges 
and improve patient outcomes. 
In Brief: Treating Sleep Problems of People in 
Recovery From Substance Use Disorders (https:// 
store.samhsa.gov/product/SMA14-4859): This 
publication explains how healthcare providers can 
help clients in recovery from SUDs who have sleep 
problems. It discusses the potential impact of poor 
sleep on recovery and offers recommendations on 
screening and treatment. 
Matrix Intensive Outpatient Treatment for 
People With Stimulant Use Disorders: Client’s 
Handbook (https://store.samhsa.gov/product/ 
SMA15-4154): This handbook contains checklists 
and other recovery tools based on the Matrix 
model, including tips for managing emotions, 
substance use triggers, and other impediments 
to achieving and maintaining recovery from 
stimulant misuse. 
Matrix Intensive Outpatient Treatment 
for People With Stimulant Use Disorders: 
Counselor’s Treatment Manual (https://store. 
samhsa.gov/product/SMA13-4152): This manual 
is one of fve components of the Matrix model’s 
intensive outpatient treatment package that 
provides structured, evidence-based treatment 
strategies for helping clients who misuse or are 
dependent on stimulant drugs, such as MA and 
cocaine. 
Preventing the Use of Marijuana: Focus on 
Women and Pregnancy (https://www.samhsa. 
gov/resource/ebp/preventing-use-marijuana-
focus-women-pregnancy): This guide examines the 
scientifc literature on the risk factors for, and the 
adverse health consequences of, marijuana use 
during pregnancy. It also discusses emerging and 
best practices to prevent or reduce this use. 
Prevention and Treatment of HIV Among 
People Living with Substance Use and/or 
Mental Disorders (https://store.samhsa.gov/ 
product/Prevention-and-Treatment-of-HIV-Among-
People-Living-with-Substance-Use-and-or-Mental-
Disorders/PEP20-06-03-001): This guide provides 
an overview of interventions for people living with 
substance use and/or mental health issues who are 
at risk for, or are living with, HIV. The interventions 
addressed are in alignment with the goals of the 
federal “Ending the HIV Epidemic: A Plan for 
America” initiative. 
Principles of Community-based Behavioral 
Health Services for Justice-involved Individuals: 




This guide, intended for behavioral health 
service providers in community settings, shares 
foundational principles for sound clinical practice 
and community-based case management when 
helping criminal justice-involved individuals with 
mental disorders and SUDs. 
A Provider’s Introduction to Substance Abuse 
Treatment for Lesbian, Gay, Bisexual, and 
Transgender Individuals (https://store.samhsa.gov/ 
product/Providers-Introduction-Substance-Abuse-
Treatment-Lesbian-Gay-Bisexual-Transgender/ 
SMA12-4104): This manual assists behavioral health 
clinicians in providing services that are sensitive 
to transgender and other clients from LGBT 
communities. 
Recovery-Oriented Systems of Care (ROSC) 
Resource Guide (www.samhsa.gov/sites/default/ 
fles/rosc_resource_guide_book.pdf): This resource 
guide explains what a ROSC is and the planning 
and implementation steps necessary to establish 
one. The guide also includes links to studies, white 
papers, presentations, manuals, practice guides, 
checklists, regulations, and other resources that 
can help with the formation of a ROSC. 
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SAMHSA and the National Association of State 
Alcohol and Drug Abuse Directors, Addressing 
the Substance Use Disorder (SUD) Service Needs 
of Returning Veterans and Their Families (https:// 
www.samhsa.gov/sites/default/fles/veterans_ 
report.pdf): This resource addresses the training 
needs of state alcohol and drug agencies and 
treatment providers responsible for administering 
behavioral health services to returning veterans 
and their families. It includes a collection of case 
studies, a discussion guide, and a list of provider 
resources organized by state. 
SAMHSA’s Concept of Trauma and Guidance for a 
Trauma-Informed Approach (https://store.samhsa. 
gov/product/SMA14-4884): This manual provides 
a working concept of trauma and key principles of 
a trauma-informed treatment approach that can 
be used by behavioral health workers and an array 
of service systems. It also suggests methods for 
implementing a trauma-informed approach. 
Take Action Against Hepatitis C (https://store. 
samhsa.gov/product/Take-Action-Against-
Hepatitis-C/sma14-4853): Using a comic book 
format and plain language, this publication covers 
basic information about what hepatitis is, how to 
reduce infection risk, and screening and treatment 
processes and options. 
Tips for Teens: The Truth About Cocaine (https:// 
store.samhsa.gov/product/PEP18-01): This 
resource is a concise presentation of cocaine’s 
harmful effects on the brain and body. It features 
a question-and-answer section on trend data 
and risks, the outward signs of cocaine use, and 
information on how to access treatment from 
SAMHSA. 
Treatment of Stimulant Use Disorders (https:// 
store.samhsa.gov/product/PEP20-06-01-001): This 
guide discusses effective practices to treat SUDs, 
clinical challenges associated with these disorders, 
and implementation strategies to address those 
challenges. 
SAMHSA Treatment Improvement 
Protocols (TIPs) 
TIP 26: Treating Substance Use Disorders in 
Older Adults (https://store.samhsa.gov/product/ 
treatment-improvement-protocol-tip-26-treating-
substance-use-disorder-in-older-adults/PEP20-02-
01-011): TIP 26 helps providers and others better 
understand how to identify, manage, and prevent 
substance misuse in older adults. It describes the 
unique ways in which the signs and symptoms of 
SUD manifest in older adults; drug and alcohol 
use disorder screening tools, assessments, and 
treatments specifcally tailored for older clients' 
needs; the interaction between SUDs and cognitive 
impairment; and strategies to help providers 
improve their older clients' social functioning and 
overall wellness. 
TIP 27: Comprehensive Case Management for 
Substance Abuse Treatment (https://store.samhsa. 
gov/product/SMA15-4215): TIP 27 describes case 
management as an interdisciplinary approach to 
SUD treatment that includes coordination of health 
care, substance use, mental health, and social 
services. It provides guidance and resources to 
keep clients engaged in treatment and moving 
toward recovery. 
TIP 31: Screening and Assessing Adolescents 
for Substance Use Disorders (https://store. 
samhsa.gov/product/SMA12-4079): TIP 31 
describes strategies, procedures, and screening 
and assessment instruments that are appropriate 
for the initial detection of substance use among 
adolescents, the comprehensive assessment 
of their problems, and subsequent treatment 
planning. It summarizes each instrument in the 
appendixes. 
TIP 34: Brief Interventions and Brief Therapies 
for Substance Abuse (https://store.samhsa. 
gov/product/SMA12-3952): TIP 34 documents 
the components of and criteria for using CBT, 
brief strategic and interactional therapies, 
brief humanistic and existential therapies, brief 
psychodynamic therapy, short-term family therapy, 
and time-limited group therapy. 
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TIP 35: Enhancing Motivation for Change in 
Substance Use Disorder Treatment (https:// 
store.samhsa.gov/product/PEP19-02-01-003): 
TIP 35 describes the elements of motivational 
interventions, the fve principles of MI, catalysts for 
changing behavior, and the stages of change that 
clients go through while working toward recovery 
from SUDs. 
TIP 38: Integrating Substance Abuse Treatment 
and Vocational Services (https://store.samhsa. 
gov/product/TIP-38-Integrating-Substance-Abuse-
Treatment-Vocational-Services/SMA12-4216): TIP 
38 offers practice guidelines and recommendations 
for integrating employment services into SUD 
treatment. It also provides information about 
funding, policy, and legal issues. 
TIP 39: Substance Use Disorder Treatment and 
Family Therapy (https://store.samhsa.gov/product/ 
treatment-improvement-protocol-tip-39-substance-
use-disorder-treatment-and-family-therapy/ 
PEP20-02-02-012): TIP 39 helps providers and 
administrators better understand how to include 
families in SUD treatment and services. 
TIP 42: Substance Use Disorder Treatment for 
People With Co-Occurring Disorders (https:// 
store.samhsa.gov/product/PEP20-02-01-004): TIP 
42 provides guiding principles and strategies for 
working with people who have co-occurring mental 
disorders and SUDs. 
TIP 44: Substance Abuse Treatment for Adults in 
the Criminal Justice System (https://store.samhsa. 
gov/product/SMA13-4056): TIP 44 addresses both 
clinical and programmatic areas of treatment for 
men and women involved in the criminal justice 
system. It guides counselors and administrators 
on best practices for intervening throughout the 
justice process. The 2017 Editor’s Note features 
legislative, literature, and clinical updates. 
TIP 51: Substance Abuse Treatment: Addressing 
the Specifc Needs of Women (https://store. 
samhsa.gov/product/SMA15-4426): TIP 51 
considers the complex and unique facets of 
women’s social, socioeconomic, cultural, and health 
needs that should be considered when providing 
treatment services for SUD. 
TIP 55: Behavioral Health Services for People 
Who Are Homeless (https://store.samhsa.gov/ 
product/SMA15-4734): TIP 55 focuses on proven 
approaches for providing screening/assessment, 
treatment planning, and continuing care to clients 
who are homeless or at risk of being homeless. 
Vignettes based on role-played interactions feature 
techniques that can be applied in a variety of 
settings. 
TIP 57: Trauma-Informed Care in Behavioral 
Health Services (https://store.samhsa.gov/product/ 
SMA14-4816): TIP 57 covers trauma awareness, the 
impact of trauma, trauma-informed screening and 
assessment, implementation of trauma-informed 
care, and development of a trauma-informed 
workforce. 
TIP 59: Improving Cultural Competence (https:// 
store.samhsa.gov/product/SMA15-4849): TIP 59 
provides an introduction to cultural competence 
in behavioral health services. The TIP is written for 
treatment counselors, clinical and programmatic 
staff, and program administrators and discusses 
racial, ethnic, and cultural considerations. 
TIP 60: Using Technology-Based Therapeutic 
Tools in Behavioral Health Services (https:// 
store.samhsa.gov/product/SMA15-4924): TIP 60 
introduces behavioral health service providers 
to technology-based treatment and prevention 
tools and interventions that can be used in various 
behavioral health service settings. The TIP includes 
guidelines for implementation, as well as ethical, 
programmatic, and regulatory considerations for 
counselors and administrators. 
TIP 61: Behavioral Health Services for American 
Indians and Alaska Natives (https://store.samhsa. 
gov/product/TIP-61-Behavioral-Health-Services-
For-American-Indians-and-Alaska-Natives/SMA18-
5070): TIP 61 provides guidance to behavioral 
health program clinicians and administrators about 
the importance of cultural awareness, cultural 
competence, and culture-specifc knowledge when 
working with American Indian and Alaska Native 
clients. 





TIP 63: Medications for Opioid Use Disorder 
(https://store.samhsa.gov/product/PEP20-02-01-
006): TIP 63 introduces the three U.S. Food and 
Drug Administration (FDA)-approved medications 
for OUD treatment and explains their use in 
general medical settings. It includes practical 
guidelines and clinical tools for OUD screening, 
assessment, diagnosis, treatment planning, and 
referral to recovery support services. 
Other Agency Publications 
American Academy of Pediatrics, Substance Use 
Screening, Brief Intervention, and Referral to 
Treatment (https://pediatrics.aappublications.org/ 
content/138/1/e20161211): This resource provides 
policy and clinical guidance to help pediatricians 
incorporate screening, brief intervention, and 
referral to treatment for substance misuse among 
adolescent patients. 
American Addiction Centers, How to Help 
a Meth Addict (https://drugabuse.com/ 
methamphetamine/how-to-help-an-addict/) and 
Meth Addiction, Abuse, and Treatment (https:// 
americanaddictioncenters.org/meth-treatment): 
These guides offer an overview of the nature 
and signs of MA misuse, discuss effective ways 
to approach a loved one who may be misusing 
MA, discuss the types of treatment available, and 
provide resources for individuals and families who 
are seeking help for SUD. 
Boston Public Health Commission’s Needle 
Exchange Program, Access Harm Reduction 
Overdose Prevention and Education (AHOPE), 
Program Participant Guide (https://www.bphc. 
org/whatwedo/Recovery-Services/services-for-
active-users/Documents/Client%20Manual%20 
FINAL.pdf): The AHOPE Needle Exchange 
Program was created to reduce the spread of 
infectious diseases like HIV/AIDS, hepatitis C, 
and tuberculosis among individuals who inject 
illicit drugs, as well as their sexual and drug use 
partners. The guide focuses on “safer” drug use 
and injection practices and provides information 
about the health risks of injecting illicit drugs, 
overdose prevention, and services available to 
people who use illicit drugs. 
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Centers for Disease Control and Prevention 
(CDC), Viral Hepatitis Webpage (https://www.cdc. 
gov/hepatitis/index.htm): This webpage provides 
a broad range of information on viral hepatitis, 
including a defnition of all strains (A through E), 
hepatitis trends in the United States, national and 
global prevalence statistics, and resources for 
treatment and prevention. 
Government of South Australia, SA Health, Acute 
Presentations Related to Methamphetamine 







statewide guideline aims to promote best practice 
management of adult patients who present to 
urgent care in an agitated state. It promotes the 
use of a standardized assessment for the possible 
use of MA or related substances, while using the 
AGRO+ approach for safely and respectfully de-
escalating the agitated behavior of the patient. 
National Harm Reduction Coalition, Getting Off 
Right: A Safety Manual for Injection Drug Users 
(https://harmreduction.org/issues/safer-drug-use/ 
injection-safety-manual/): This step-by-step guide 
to safer drug injection focuses on how to avoid 
disease, reduce accident and injury, and recognize 
and respond to overdose. It also covers the 
potential health complications of injecting drugs. 
Minnesota Department of Health, Opioids: 
Social Determinants of Substance Use & 
Overdose Prevention (https://www.health. 
state.mn.us/communities/opioids/prevention/ 
socialdeterminants.html): This webpage 
provides an overview of social determinants 
of health, and discusses the ways in which 
individual, interpersonal, community, and societal 
determinants can infuence an individual’s use or 
misuse of substances. 




NAADAC, the Association for Addiction 
Professionals: Counseling African Americans 
With Substance Use Disorders (https://www. 
naadac.org/assets/2416/2015-06-04_counseling_ 
african_americans_with_suds_webinarslides.pdf): 
This PowerPoint presentation showcases tools 
that can help practitioners work more effectively 
with African American clients who are dealing with 
chemical dependency and other SUDs. 
National Center on Substance Abuse and Child 
Welfare, Children Affected by Methamphetamine 
Program: Implementation Progress and 
Performance Measurement Report (https:// 
ncsacw.samhsa.gov/topics/methamphetamine. 
aspx): This page offers resources and guidelines for 
meeting the needs of parents and children affected 
by MA use, including this summary report for a 
grant program focused on providing services to 
children ages 0–17 and their families. 




Revised in October 2019, this report provides 
an overview of the latest scientifc fndings 
on MA, including short- and long-term health 
consequences, effects on pregnancy, and 
prevention and treatment options. 
NIDA, Mind Matters: The Body’s Response to 
Prescription Stimulants (https://teens.drugabuse. 
gov/teachers/lessonplans/mind-matters-bodys-
response-prescription-stimulants): This colorful 
booklet is designed for educators of ffth- through 
ninth-graders, to help teach students about the 
uses of prescription stimulants and the dangers of 
misusing these drugs. 
NIDA, Prescription Stimulant Medications 
(Amphetamines) (https://teens.drugabuse.gov/ 
drug-facts/prescription-stimulant-medications-
amphetamines): This publication provides an 
overview of prescription stimulants, how misuse of 
these drugs can occur, the risks of overdose, and 
how to fnd treatment for misuse, as well as links to 
resources for educators. 
NIDA, Prescription Stimulants DrugFacts (https:// 
www.drugabuse.gov/publications/drugfacts/ 
prescription-stimulants): This publication provides 
an overview of prescription stimulants, how they 
can be misused, the risks of overdose, and how to 
get treatment for misuse of these drugs. 
NIDA, Principles of Drug Addiction Treatment: 
A Research-Based Guide (Third Edition), 
Community Reinforcement Approach 






approach-vouchers): This resource describes the 
Community Reinforcement Approach (CRA) Plus 
Vouchers, an intensive 24-week outpatient therapy 
that combines counseling, vocational services, 
recreational and social activities, and material 
incentives to help patients maintain abstinence. 
NIDA, Principles of Drug Addiction Treatment: 
A Research-Based Guide (Third Edition), 
Contingency Management Interventions/ 
Motivational Incentives (Alcohol, 







resource briefy summarizes how to implement two 
approaches to CM, Voucher-Based Reinforcement 
and Prize Incentives CM. 
Oregon Post Adoption Resource Center, 
Parenting Children Who Have Been Exposed 
to Methamphetamine: A Brief Guide for 
Adoptive, Guardianship, and Foster Parents 
(https://www.ohsu.edu/sites/default/fles/2019-06/ 
Parenting-Children-Who-Have-Been-Exposed-to-
Methamphetamine.pdf): This guide provides an 
overview of MA and its pre- and postnatal effects 
on children. It also offers guidance to parents who 
are caring for children who were exposed to MA. 





Rural Health Information Hub, Substance Use 
and Misuse in Rural Areas Webpage (https:// 
www.ruralhealthinfo.org/topics/substance-use): 
This webpage answers frequently asked questions 
regarding substance use and misuse in rural 
areas, addresses prevalence and usage trends in 
these areas, and provides links to prevention and 
treatment resources. 
UCLA, Integrated Substance Abuse Programs, A 




clean.pdf): This online treatment manual describes 
how to implement a CM program for individuals 
who were recently paroled and are seeking SUD 
treatment in the community. 
United Nations Offce on Drugs and Crime, 
Treatment of Stimulant Use Disorders: 
Current Practices and Promising Perspectives
(https://www.unodc.org/documents/drug-
prevention-and-treatment/Treatment_of_PSUD_ 
for_website_24.05.19.pdf): This discussion 
paper describes the physical and behavioral 
consequences of using stimulants for both medical 
and illicit purposes, explains stimulant use disorder, 
and provides information on evidence-based 
treatment interventions. 
U.S. Department of Health and Human Services,
Facing Addiction in America: The Surgeon 
General’s Report on Alcohol, Drugs, and 
Health (https://addiction.surgeongeneral.gov/ 
sites/default/fles/surgeon-generals-report.pdf): 
This report alerts the American public about the 
burden of substance misuse in communities, the 
effects of government policies on prevention and 
treatment, and opportunities for increasing access 
to treatment for all those affected by SUDs. 
U.S. Department of Housing and Urban 
Development (HUD), Housing First in Permanent 
Supportive Housing Brief (https://www. 
hudexchange.info/resource/3892/housing-frst-in-
permanent-supportive-housing-brief/): This brief 
for supportive housing providers is a high-level 
summary of the Housing First approach and offers 
some initial steps for providers interested in 
adopting it. 
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U.S. Department of Justice/Drug Enforcement 
Administration, Drug Fact Sheet— 
Methamphetamine (https://www.dea.gov/sites/ 
default/fles/2020-06/Methamphetamine-2020_0. 
pdf): This fact sheet provides an overview of MA, 
including its origin, common names, effects on 
the brain and body, and the risks of misuse and 
overdose. 
HUD, The 2019 Annual Homeless Assessment 
Report (AHAR) to Congress (https://www.huduser. 
gov/portal/sites/default/fles/pdf/2019-AHAR-
Part-1.pdf): This report outlines key fndings of the 
2019 Point-In-Time count and Housing Inventory 
count, which provides national, state, and local 
estimates of overall homelessness and subgroup-
specifc data. 
World Health Organization, International 
Classifcation of Diseases, Clinical Modifcation 
(ICD–CM) (under “Coding” at https://www.cms. 
gov/Medicare/Medicare): Providers can use criteria 
from this publication to confrm patient diagnoses 
and to determine treatment codes for proper 
reimbursement. (The current version at the time of 
this TIP update’s publication was ICD-10-CM.) 
Yale University Psychotherapy Development 
Center, Contingency Management: Using 
Motivational Incentives to Improve Drug Abuse 
Treatment (http://lib.adai.washington.edu/ctnlib/ 
PDF/CMmanual.pdf): Research on the use of 
CM interventions shows the effcacy of providing 
tangible incentives to clients who are targeting 
distinct behaviors on their journey to achieving 
recovery from SUDs. This publication provides 
an overview of research fndings and guides 
practitioners on applying CM strategies across 
clinical settings. 
Treatment Locators 
SAMHSA’s Behavioral Health Treatment Services 
Locator (https://fndtreatment.samhsa.gov/): This 
confdential and anonymous information source 
is for people seeking facilities for treating mental 
disorders and/or SUDs in the United States or 
U.S. territories. It also offers information about 
treatment options and how to pay for treatment. 






SAMHSA’s National Directory of Drug and 
Alcohol Abuse Treatment Facilities, 2019 (https:// 
www.samhsa.gov/data/report/national-directory-
drug-and-alcohol-abuse-treatment-facilities-2019): 
This directory provides a comprehensive list of 
state-certifed substance use and mental disorder 
treatment facilities that responded to the 2018 
National Survey of Substance Abuse Treatment 
Services. It lists SUD agencies and individual 
treatment facilities by city and state. 
NIAAA Alcohol Treatment Navigator (https:// 
alcoholtreatment.niaaa.nih.gov/): This resource
provides information about treatment for alcohol
misuse and how to choose a high-quality treatment
provider, center, or program for alcohol use disorder. 
VA SUD Program Locator (https://www.va.gov/ 
directory/guide/SUD.asp): This webpage lets users 
search by state for VA medical centers that offer 
specialized SUD treatment. 
Client and Family Resources 
Organizations 
SAMHSA’s National Helpline (https://www.samhsa. 
gov/fnd-help/national-helpline; 1-800-662-HELP 
[4357]; 1-800-487-4889 [TTY]): This helpline 
provides free treatment referral and relevant 
information for individuals who need help dealing 
with substance misuse or mental illness. Phone 
lines are staffed 24 hours a day by information 
specialists who can respond in English or Spanish. 
All calls to the helpline are free and confdential. 
Anxiety & Depression Association of America 
(ADAA) (https://adaa.org): ADAA promotes 
awareness of anxiety disorders and depression 
and supports scientifc innovation in treatment. 
The website contains information and links to 
education, treatment, resources, and support for 
consumers, the public, and treatment providers. 
Association of Recovery Community 
Organizations (ARCO) (https:// 
facesandvoicesofrecovery.org/arco/): ARCO 
supports a growing network of local, regional, 
and statewide recovery community organizations 
(RCOs). It links RCOs with local and national allies 
and provides training and technical assistance to 
recovery groups. 
Attention Defcit Disorder Association (ADDA) 
(https://add.org): ADDA is an international 
nonproft organization founded to help adults with 
attention defcit/hyperactivity disorder (ADHD) 
lead better lives. ADDA brings together scientifc 
perspectives and lived experiences to generate 
hope, awareness, empowerment, and connections 
in the feld of ADHD. 
Defense Health Agency (DHA) (https://www. 
health.mil/About-MHS/OASDHA/Defense-Health-
Agency): DHA is a joint, integrated combat support 
agency and the healthcare delivery arm of the 
Military Health System (https://www.health.mil). It 
supports the delivery of integrated, affordable, and 
high-quality health services and manages a global 
healthcare network of military hospitals and clinics. 
Learn to Cope (https://www.learn2cope.org/): This 
secular mutual-support group offers education, 
resources, and peer support for families of people 
with SUDs, focusing on OUD. It maintains an online 
forum and convenes groups in several states. 
Legal Action Center (LAC) (https://www.lac.org): 
LAC offers information about the rights of people 
with criminal records, HIV/AIDS, and SUDs. 
Mental Health America (https://www.mhanational. 
org/): This nonproft, community-based 
organization aims to improve public knowledge 
of mental disorders and enhance prevention and 
treatment strategies. It is composed of more 
than 200 affliates in 41 states, 6,500 affliate staff 
members, and more than 10,000 volunteers. 
National Alliance on Mental Illness (NAMI) 
(https://www.nami.org/Home): NAMI is the largest 
grassroots educational, peer support, and mental 
health advocacy organization in the United States. 
Founded in 1979 by a group of family members 
of people with mental disorders, it has grown 
to become an association of hundreds of local 
affliates, state organizations, and volunteers. 
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National Coalition Against Prescription Drug 
Abuse (NCAPDA) (www.ncapda.org): NCAPDA is a 
nonproft, volunteer-based organization established 
to prevent prescription SUD and overdose deaths 
through community education and policy change 
at the local, state, and national levels. Its goal is 
to network with similar organizations and like-
minded agencies throughout the country to share 
best practices, develop and share useful material 
resources, and establish and implement a cohesive, 
nationwide education campaign around medication 
safety. 
National Council on Alcoholism and Drug 
Dependence of the Central Mississippi Area 
(NCADD) (https://ncaddms.org/): NCADD offers 
a variety of publications and resources and has a 
nationwide network of nearly 100 affliates. These 
affliates provide information and referrals to local 
services, including counseling and treatment. 
National Empowerment Center (https://power2u. 
org/): The center has an extensive resource list that 
includes a directory of consumer-run organizations, 
peer support, and webinars. 
National Suicide Prevention Lifeline (https:// 
suicidepreventionlifeline.org/; 1-800-273-8255): 
Funded by SAMHSA, this national network of local 
crisis centers offers free and confdential support 
to people in suicidal crisis or emotional distress 24 
hours a day, 7 days a week. 
Parents of Addicted Loved Ones (PAL) (https:// 
palgroup.org/): This organization provides secular 
support group meetings for parents who have a 
child with an SUD. PAL hosts in-person meetings 
in some locations, as well as online and phone 
meetings. 
Mutual-Help Programs 
Al-Anon Family Groups (https://al-anon.org/): 
Al-Anon meetings allow friends and family 
members of people who misuse substances to 
share their experiences and learn how to apply 
the principles of the Al-Anon program to their 
individual situations. 
Alcoholics Anonymous® (AA) (https://www. 
aa.org/): The AA website offers information about 
alcohol misuse and links to local resources that 
list AA meetings for people who misuse alcohol 
and want to stop. AA sponsors provide personal 
support from individuals with lived experience 
following 12-Step principles. 
Cocaine Anonymous® (CA) World Services, Inc. 
(https://ca.org/): CA is a mutual-help program for 
people with cocaine use disorder. It follows the 
12-Step principles and offers meetings worldwide. 
Crystal Meth Anonymous® (CM-Anon) (https:// 
www.crystalmeth.org/): CM-Anon is a fellowship 
program for people who use crystal meth and 
is based on the 12-Step principles. It includes a 
24-hour helpline and has a directory of online and 
in-person meetings worldwide. 
Emotions Anonymous (EA) (http:// 
emotionsanonymous.org/): EA is a 12-Step fellowship
based on AA principles for people with emotional
diffculties (not only clinical mental disorders). Groups
are located in more than 30 countries and are
available through Skype and phone meetings. 
Faces & Voices of Recovery, Mutual Aid 
Resources (https://facesandvoicesofrecovery.org/ 
resources/mutual-aid-resources/): Faces & Voices 
of Recovery offers information on mutual-help 
organizations in the following categories: 12-Step 
groups; alcohol use; co-occurring health conditions; 
faith-based organizations; family-, friend-, and 
youth-focused groups; gender-specifc meetings; 
medication-assisted treatment; and secular groups. 
Nar-Anon Family Groups (https://www.nar-anon. 
org/): Nar-Anon group meetings are for friends 
and family members of people misusing 
narcotics and other substances. Group members 
share their experiences and learn to apply the 
12-Step principles to their lives. Nar-Anon offers 
individualized support from experienced members 
acting as sponsors. 









Narcotics Anonymous (NA) World Services
(https://www.na.org/): NA is a global, community-
based organization with a multilingual, multicultural 
membership that supports SUD recovery via 
a 12-Step program, including regular group 
meetings. This ongoing support network helps 
participants maintain a drug-free lifestyle. 
National Mental Health Consumers’ Self-Help 
Clearinghouse (https://www.mhselfhelp.org/): This 
clearinghouse offers a resource kit featuring the 
names and contact information of treatment and 
mutual-help support services that address SUDs 
and cooccurring disorders. 
Partnership to End Addiction (https://drugfree. 
org/): Partnership to End Addiction is an online 
resource for families of individuals who use drugs, 
including stimulants. In addition to educational 
resources, the website includes a helpline, an 
online support community, peer-to-peer parent 
coaching, online skill-building courses, and a 
text message program that provides customized 
messages and resources. Resources are available in 
Spanish. 
Pills Anonymous World Service (https://www. 
pillsanonymous.org/): This 12-Step mutual-help 
fellowship holds regular meetings for individuals in 
recovery from SUDs involving medication. Meeting 
participants share their experiences, build their 
strengths, and offer hope for recovery to one 
another. 
Recoveries Anonymous (https://www.r-a.org/): 
This 12-Step mutual-help fellowship welcomes 
people with a broad range of problems, from 
SUDs to mental disorders to “problem behaviors” 
(e.g., compulsive spending, risk-taking, suicidal 
behaviors). 
Secular Organizations for Sobriety (SOS) (http:// 
www.sossobriety.org/): SOS is a nonproft network 
of autonomous, nonprofessional local groups 
whose focus is on using a secular approach to 
maintaining abstinence from alcohol, other drugs, 
or other types of addictive behaviors. 
SMART Recovery® (https://www.smartrecovery.org/):
The SMART Recovery website provides information
about the organization’s science-based and self-
empowering program, training opportunities, and a
searchable database of local and online meetings in
the United States and abroad. 
The Trevor Project (https://www.thetrevorproject. 
org): The Trevor Project provides crisis intervention 
and suicide prevention services to lesbian, gay, 
bisexual, transgender, and queer & questioning 
(LGBTQ) young people age 24 and younger. The 
organization offers no-cost, judgment-free, online, 
hotline, and chat/text services that are available 
24/7 to young people who want to socially 
network, are in crisis, or have questions about 
sexual orientation, gender identity, and other 
topics. 
Women for Sobriety (WFS) (https:// 
womenforsobriety.org/): WFS is a recovery 
program based on women’s unique emotional 
needs. It focuses on helping women with SUDs 
begin and maintain recovery. WFS has certifed 
moderators and chat leaders who facilitate mutual-
help groups online and in person, as well as phone 
volunteers available for one-on-one support. 
Laws and Regulations 
SAMHSA, Fact Sheet: SAMHSA 42 CFR Part 
2 Revised Rule (https://www.hhs.gov/about/ 
news/2020/07/13/fact-sheet-samhsa-42-cfr-part-
2-revised-rule.html): This resource provides a 
summary of changes to 42 CFR Part 2 (made in 
response to the opioid epidemic) pertaining to 
patient records in federally assisted SUD treatment 
programs. 
SAMHSA, Substance Abuse Confdentiality 
Regulations (https://www.samhsa.gov/about-us/ 
who-we-are/laws-regulations/confdentiality-
regulations-faqs): This webpage provides 
information about consent and confdentiality 
regulations pertaining to release of patient records 
for SUD, as codifed in 42 CFR Part 2 (revised). 
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CDC, Public Health Professionals Gateway, 
Health Insurance Portability and Accountability 




webpage explains HIPAA standards, which require 
healthcare providers to protect sensitive patient 
health information from being disclosed without 
the patient’s consent or knowledge. 
Comprehensive Addiction and Recovery Act 
of 2016 (https://www.congress.gov/bill/114th-
congress/senate-bill/524/text): This legislation 
authorizes grant programs designed to expand 
SUD (especially OUD) prevention, education, 
treatment, and recovery efforts. The Act includes 
provisions explicitly aimed at supporting such 
efforts in communities facing sudden increases in 
MA use. 
Drug Addiction Treatment Act of 2000 (https:// 
www.congress.gov/bill/106th-congress/house-
bill/2634): This legislation, as amended, allows 
healthcare professionals who meet certain 
qualifcations to offer FDA-approved narcotic 
medication treatment for OUD in settings other 
than opioid treatment programs. (At the time 
of this publication, buprenorphine is the only 
approved medication that meets the provisions 
of the Act.) This is relevant for patients with 
stimulant use disorder who are also using 
opioids and wish to initiate buprenorphine 
treatment. For statutory changes expanding 
buprenorphine prescribing, see https://www. 
samhsa.gov/medication-assisted-treatment/ 
statutes-regulations-guidelines. 
Fair Sentencing Act of 2010 (https://www. 
congress.gov/bill/111th-congress/senate-bill/1789): 
This Act reduced the 5- to 10-year “mandatory 
minimum” prison sentence for possession of 
low-level crack cocaine. It also removed the 
mandatory minimum for simple possession of 
cocaine. 
U.S. Department of Justice, Drug Enforcement 
Administration, Diversion Control Division, 
Combat Methamphetamine Epidemic Act of 
2005 (CMEA) (https://www.deadiversion.usdoj. 
gov/meth/index.html): This webpage interprets 
CMEA, the federal legislation that bans over-
the-counter sales of cold medicines containing 
ingredients that are commonly used in the 
manufacture of MA, such as pseudoephedrine. It 
also limits the amount of these products that can 
be purchased at one time and tracks purchasers. 
21st Century Cures Act: (https://www.congress. 
gov/114/plaws/publ255/PLAW-114publ255.pdf): 
Passed in 2016, this Act was intended to help 
increase the speed and effciency of the discovery, 
development, and delivery of medical cures. It 
provides U.S. research and healthcare delivery 
institutions, such as FDA and the National Institutes 
of Health, with funding to improve clinical trials, 
enhance data sharing, increase the recruitment of 
participants in clinical trials, and launch innovative 
research projects. It also established the State 
Targeted Response to the Opioid Crisis grant 
program. 
Additional Resources 
SAMHSA, Suicide Safe Mobile App (https:// 
store.samhsa.gov/product/suicide-safe): Based
on SAMHSA’s “Suicide Assessment Five-Step
Evaluation and Triage” (SAFE-T) card (https://store. 
samhsa.gov/product/SAFE-T-Pocket-Card-Suicide-
Assessment-Five-Step-Evaluation-and-Triage-for-
Clinicians/sma09-4432), the Suicide Safe mobile
app is designed to help providers integrate suicide
prevention strategies into their practice and address
suicide risk among their patients. The app offers tips
on how to communicate effectively with patients
and their families, determine appropriate next steps,
and make referrals to treatment and community
resources. The app is free and can be downloaded
from Google Play or the Apple App Store. 











American Journal of Psychiatry, Prevalence 
and Correlates of Prescription Stimulant Use, 
Misuse, Use Disorders, and Motivations for 
Misuse Among Adults in the United States
(https://ajp.psychiatryonline.org/doi/10.1176/ 
appi.ajp.2018.17091048): Published in the April 
2018 issue of The American Journal of Psychiatry, 
this article examines data from the 2015 and 
2016 releases of the National Survey on Drug 
Use and Health to establish prevalence rates of 
prescription stimulant use and misuse, motivations 
and demographics underlying stimulant misuse, 
and common sources (other than a legitimate 
prescription) that users access to acquire 
stimulants. 
Authentic Happiness (https://www. 
authentichappiness.sas.upenn.edu): Authentic 
Happiness is a University of Pennsylvania website 
developed by the Positive Psychology Center 
(https://ppc.sas.upenn.edu) to provide free 
learning resources about Positive Psychology, 
including readings, videos, research, conferences, 
questionnaires with feedback, and more. 
Positive Psychology is the scientifc study of the 
strengths and virtues that enable individuals and 
communities to thrive. 
DHA Solution Delivery Division, T2 Mood Tracker 
Mobile App: The T2 Mood Tracker mobile app 
allows users to monitor and track their emotional 
health. Developed as a tool for service members 
to record and review their behavior changes, 
particularly after combat deployments, it has 
become popular with civilian users, as well. The 
app allows users to record a range of emotions 
for anxiety, depression, head injury, stress, 
posttraumatic stress, and general well-being. An 
overview of the app is available from the DHA 
Solution Delivery Division’s “Web and Mobile 
Technology” menu (https://health.mil/About-MHS/ 
OASDHA/Defense-Health-Agency/Information-
Operations-J6/Solution-Delivery-Division), and 
the app is available for download from Google 
Play (https://play.google.com/store/apps/ 
details?id=com.t2.vas) or the Apple App Store 
(https://apps.apple.com/us/app/t2-mood-tracker/ 
id428373825). 
DHA Solution Delivery Division, Virtual Hope 
Box Mobile App: The Virtual Hope Box mobile 
app is designed for patients and their behavioral 
health providers as an accessory to treatment. 
The app contains simple tools to help patients 
with coping, relaxation, distraction, and positive 
thinking. Patients and providers can work together 
to personalize the app’s content on the patient’s 
smartphone according to the patient’s specifc 
needs. An overview of the app is available from the 
DHA Solution Delivery Division’s “Web and Mobile 
Technology” menu (https://health.mil/About-MHS/ 
OASDHA/Defense-Health-Agency/Information-
Operations-J6/Solution-Delivery-Division), and the 
app can be downloaded from Google Play (https:// 
play.google.com/store/apps/details?id=com. 
t2.vhb&hl=en&gl=US) or the Apple App Store 
(https://apps.apple.com/us/app/virtual-hope-box/ 
id825099621). 




This webpage discusses the use of prescription 
stimulants to manage ADHD, along with the clinical 
and personal reasons that may infuence a young 
person or adult to misuse these drugs. 
Psychiatric Times, Issues Pertaining to Misuse 
of ADHD Prescription Medications (https://www. 
psychiatrictimes.com/view/issues-pertaining-
misuse-adhd-prescription-medications): Published 
in September 2018, this article discusses the use 
of prescription stimulants to manage ADHD, the 
characteristics and co-presenting conditions in 
both young people and adults that may predispose 
them to substance misuse, and how these factors 
impact diagnostic and prescribing decisions. 





professional%20care): The PTSD Coach app can
help individuals learn about and manage symptoms
that often occur after trauma. Features include
reliable information on PTSD and treatments that
work, tools for screening and tracking symptoms,
convenient, easy-to-use tools to help manage stress
symptoms, and direct links to support and help.
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